

GenCore version 5.1.3
Copyright (c) 1993 - 2002 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 22, 2002, 07:41:51 ; Search time 2776 Seconds

(without alignments)
13817.543 Million cell updates/sec

Title: US-09-964-994-1
Perfect score: 1318
Sequence: 1 cagttcttcacatctgtaaca.....aaaaaaaaaaaaaaaaaaaa 1318

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 2054640 seqs, 14551402878 residues
1 number of hits satisfying chosen parameters: 4109280

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : GenEmbl:*
1: gb_ba:*
2: gb_htg:*
3: gb_in:*
4: gb_om:*
5: gb_ov:*
6: gb_pat:*
7: gb_ph:*
8: gb_pl:*
9: gb_pr:*
10: gb_ro:*
11: gb_sts:*
12: gb_sy:*
13: gb_un:*
14: gb_vi:*
15: em_ba:*
16: em_fun:*
17: em_hum:*
18: em_in:*
19: em_mu:*
20: em_om:*
21: em_or:*
22: em_ov:*
23: em_pat:*
24: em_ph:*
25: em_pl:*
26: em_ro:*
27: em_sts:*
28: em_un:*
29: em_vi:*
30: em_htg_hum:*
31: em_htg_inv:*
32: em_htg_other:*
33: em_htg_mus:*
34: em_htg_pln:*
35: em_htg_rod:*
36: em_htg_mam:*
37: em_htg_vrt:*
38: em_sy:*
39: em_htgo_hum:*
40: em_htgo_mus:*
41: em_htgo_other:*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	1318	100.0	1318	6	AX300012	AX300012 Sequence
2	1282.6	97.3	2859	9	AY040567	AY040567 Homo sapi
3	1280.4	97.1	1351	9	HSAB313162	AJ313162 Homo sapi
4	1094.4	83.0	2367	6	AX469514	AX469514 Sequence
5	1080.6	82.0	2763	9	AY040566	AY040566 Homo sapi
6	1078.4	81.8	1255	6	AX399654	AX399654 Sequence
7	1078.4	81.8	1255	9	HSAB313161	AJ313161 Homo sapi
8	1078	81.8	1618	9	AY044429	AY044429 Homo sapi
9	910	69.0	2271	6	AX469509	AX469509 Sequence
10	831.6	63.1	2149	6	AX151700	AX151700 Sequence
11	831.6	63.1	2149	6	AX179609	AX179609 Sequence
12	805.2	61.1	810	6	AX399656	AX399656 Sequence
13	730.6	55.4	2593	9	AY040568	AY040568 Homo sapi
14	669	50.8	775	9	HSAB297262	AJ297262 Homo sapi
15	588.4	44.6	696	6	AX193705	AX193705 Sequence
16	449.2	34.1	750	6	AX193682	AX193682 Sequence
17	449.2	34.1	750	6	AX399652	AX399652 Sequence
18	406	30.8	113811	9	HSJ503F13	AL050337 Human DNA
19	404.4	30.7	124324	2	AL158138	AL158138 Homo sapi
20	404.4	30.7	131227	2	AL136098	AL136098 Homo sapi
21	398.2	30.2	693	6	AX151702	AX151702 Sequence
22	398.2	30.2	693	6	AX193707	AX193707 Sequence
23	319.6	24.2	747	6	AX193684	AX193684 Sequence
24	269.8	20.5	526	6	AX193708	AX193708 Sequence
25	179.4	13.6	187075	2	AL445424	AL445424 Homo sapi
26	166.2	12.6	390	6	AX193710	AX193710 Sequence
27	120.4	9.1	139591	2	AC116231	AC116231 Rattus no
28	79.8	6.1	139591	2	AC116231	AC116231 Rattus no
29	75.4	5.7	1806	6	AX180177	AX180177 Sequence
30	75.4	5.7	1806	6	AX180677	AX180677 Sequence
31	69.6	5.3	52514	2	AC116551	AC116551 Dictyoste
32	68.8	5.2	124820	2	AC117073	AC117073 Dictyoste
33	68.6	5.2	105470	2	AC116306	AC116306 Dictyoste
34	67.2	5.1	97683	2	AC116548	AC116548 Dictyoste
35	67	5.1	1720	6	AX180193	AX180193 Sequence
36	67	5.1	1720	6	AX180693	AX180693 Sequence
37	67	5.1	1720	6	AX406502	AX406502 Sequence
38	67	5.1	1750	6	AX376330	AX376330 Sequence
39	67	5.1	1750	6	AX464054	AX464054 Sequence
40	67	5.1	1801	6	AX180163	AX180163 Sequence
41	67	5.1	1801	6	AX180663	AX180663 Sequence
42	67	5.1	1801	6	AX406496	AX406496 Sequence
43	67	5.1	3485	9	AF184971	AF184971 Homo sapi
44	67	5.1	3516	6	AX180151	AX180151 Sequence
45	67	5.1	3516	6	AX180651	AX180651 Sequence

ALIGNMENTS

RESULT 1
AX300012
LOCUS
DEFINITION AX300012 1318 bp DNA linear PAT 26-NOV-2001
ACCESSION AX300012
VERSION AX300012
KEYWORDS
SOURCE
ORGANISM human.
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Eaton,D.L., Fong,S., Goddard,A., Godowski,P.J., Grimaldi,C.J.,
Gurney,A.L., Tumas,D., Watanabe,C.K., Wood,W.I. and Zhang,Z.
TITLES Compositions and methods for the treatment of immune related

JOURNAL	diseases									
	Patent: WO 0166740-A 17 13-SEP-2001;									
	Genentech, Inc. (US)									
FEATURES	Location/Qualifiers									
Source	1. 1318									
	/organism="Homo sapiens"									
	/db_xref="taxon:9606"									
BASE COUNT	451	a	251	c	259	g	357	t		
ORIGIN										
Query Match	100.0%; Score 1318; DB 6; Length 1318;									
Best Local Similarity	100.0%; Pred. No. 9.8e-274;									
Matches 1318; Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;			
QY	1	CAGTTTCTCATCTGTAACTCAAAATGAATTAATATACCAATCTCCCTAGACTTCATAGA	60							
DB	1	CAGTTTCTTCATCTGTAACTCAAAATGAATTAATATACCAATCTCCCTAGACTTCATAGA	60							
QY	61	GGATTAAACAAAGACAAAATATGGGAAAAACATTAACATGGCGTCCCATTAATTAGATCT	120							
DB	61	GGATTAAACAAAGACAAAATATGGGAAAAACATTAACATGGCGTCCCATTAATTAGATCT	120							
QY	121	TATTAATTGACACTAAATGGCATTAATAATTACCAAAAGGAAGACAGCATCTGTTCCCTCT	180							
DB	121	TATTAATTGACACTAAATGGCATTAATAATTACCAAAAGGAAGACAGCATCTGTTCCCTCT	180							
QY	181	TTGGTCCCTGAGCTGGTTAAAAGGAACACTGGTTGCCCTGAACAGTCACACATTTGCAACCATG	240							
DB	181	TTGGTCCCTGAGCTGGTTAAAAGGAACACTGGTTGCCCTGAACAGTCACACATTTGCAACCATG	240							
QY	241	ATGCCCTAAACATTTGCTTTCTAGGCTTCCCTCATCAGTTTCTTCTTACTGGTGTAGCAGGA	300							
DB	241	ATGCCCTAAACATTTGCTTTCTAGGCTTCCCTCATCAGTTTCTTCTTACTGGTGTAGCAGGA	300							
QY	301	ACTCAGTCAACGCGATGAGTCTCTGAAAGCCTCAGAGGGTACAATTTCACTGCCGAAATTTT	360							
DB	301	ACTCAGTCAACGCGATGAGTCTCTGAAAGCCTCAGAGGGTACAATTTCACTGCCGAAATTTT	360							
QY	361	CACACATTTTGGCAATGGCAGCCTGGAGGGCAGTTACTGGCAACAGCAGTGTCTAATTTT	420							
DB	361	CACACATTTTGGCAATGGCAGCCTGGAGGGCAGTTACTGGCAACAGCAGTGTCTAATTTT	420							
QY	421	GTCAGTACAAATCATGTTCTCATGCGCATGAAGAGCTCTCACCGAAGCCAAAGTGA	480							
DB	421	GTCAGTACAAATCATGTTCTCATGCGCATGAAGAGCTCTCACCGAAGCCAAAGTGA	480							
QY	481	TGCTGGCAGCACATTTCTTGTAACTTCCAGGCTGCAGAACATTTGGCTAATATGAGCAG	540							
DB	481	TGCTGGCAGCACATTTCTTGTAACTTCCAGGCTGCAGAACATTTGGCTAATATGAGCAG	540							
QY	541	AGACAATGAAAAATTAAGACAGACTGTTGGGCTACTCAAGAACTCTTGTGACCTTACC	600							
DB	541	AGACAATGAAAAATTAAGACAGACTGTTGGGCTACTCAAGAACTCTTGTGACCTTACC	600							
QY	601	AGTGAACCTCAGACATACAGGAACCTTATTACGGGAGGGGTGAGGGCGGCTCGGCTGGG	660							
DB	601	AGTGAACCTCAGACATACAGGAACCTTATTACGGGAGGGGTGAGGGCGGCTCGGCTGGG	660							
QY	661	AGCTACTCAGAATGGAGCATGACGGCGGTTCACTCCCTGGTGGGAAAACAAAAATAGAT	720							
DB	661	AGCTACTCAGAATGGAGCATGACGGCGGTTCACTCCCTGGTGGGAAAACAAAAATAGAT	720							
QY	721	CCCTCAGTCATGAATATTAACCCCAAGTCAATGGCTCTTGTGGTAAATCTCCATGCTCCA	780							
DB	721	CCCTCAGTCATGAATATTAACCCCAAGTCAATGGCTCTTGTGGTAAATCTCCATGCTCCA	780							
QY	781	AATTTACCATATAGATACCAAAAGAAAAATGTATCTATAGAAGATTACTATGAACCTA	840							
DB	781	AATTTACCATATAGATACCAAAAGAAAAATGTATCTATAGAAGATTACTATGAACCTA	840							
QY	841	CTATACCGAGTTTTTATATTAACAATTCACCTAGAAAAGGAGCAAAAGGTTTATGAAGGG	900							
DB	841	CTATACCGAGTTTTTATATTAACAATTCACCTAGAAAAGGAGCAAAAGGTTTATGAAGGG	900							

[illegible]

RESULT 2	AY040567	2859 bp	mRNA	linear	PRI 19-AUG-2001
LOCUS	AY040567				
DEFINITION	Homo sapiens interleukin 22-binding protein CRF2-10L (IL22BP) mRNA, complete cds, alternatively spliced.				
ACCESSION	AY040567				
VERSION	AY040567.1	GI:15212827			
KEYWORDS					
SOURCE	Homo sapiens.				
ORGANISM	Homo sapiens				
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.				
AUTHORS	1 (bases 1 to 2859) Kotenko,S.V., Izotova,L.S., Mirochnitchenko,O.V., Esterova,E., Dickensheets,H., Donnelly,R.P. and Pestka,S.				
TITLE	Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity				
JOURNAL	J. Immunol. 166 (12), 7096-7103 (2001)				
MEDLINE	21286453				
PUBMED	11390454				
REFERENCE	2 (bases 1 to 2859) Kotenko,S.V. and Pestka,S.				
AUTHORS	Direct Submission				
TITLE	Submitted (15-JUN-2001) Molecular Genetics and Microbiology,				
JOURNAL	UMDNJ-Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, NJ 08854-5635, USA				
FEATURES	Location/Qualifiers				
source	1..2859				
	/organism="Homo sapiens"				
	/db_xref="taxon:9606"				
gene	1..2859				
	/gene="IL22BP"				
CDS	275..1066				
	/gene="IL22BP"				
	/note="secreted protein; long splice variant of CRF2-10/IL-22BP; alternatively spliced"				
	/codon_start=1				
	/product="interleukin 22-binding protein CRF2-10L"				
	/protein_id="AAK85715.1"				
	/db_xref="GI:15212828"				
	/translation="MMPKHCFLGFLISFILTGVAGTOSTHESLKPQRYVOFSRNFHNI LWMPGRALTGNSSVYFVQYKIMFSCSMKSSHOKPSCGWOHISCNFGCRTLAKYGOR QMKNKEDCWGTQELSCDLTSETSDIQEPYGRVRAASAGSYSEWSMTPTPTPWWETKI				

DPVPMNITQVNGSLVILIHAPNLPYRYQKEKNVSIEDYYELLYRVETINNSLEKEOKV
YEGAHRAVEIEALTPHSSYCVVAEIIYQPMIDRRSQSRSERCVEIP"
BASE COUNT 893 a 504 c 549 g 913 t
ORIGIN

Query Match 97.3%; Score 1282.6; DB 9; Length 2859;
Best Local Similarity 99.7%; Pred. No. 4.1e-266;
Matches 1285; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 CAGTTTCTCATCTGTAAACATCAATGAATAATATACCAATCTCTAGACTTCATAGA 60
Db CAGTTTCTCATCTGTAAACATCAATGAATAATATACCAATCTCTAGACTTCATAGA 97
QY 61 GGATTAACAAGACAAAATATGGGAAAAACATACATGGCGTCCCATTAATTATAGATCT 120
Db GGATTAACAAGACAAAATATGGGAAAAACATACATGGCGTCCCATTAATTATAGATCT 157
QY 121 TATTATTGACACTTAAATGGCATTTAAATTACCAAAAAGAGACATCTGTTCTCT 180
158 TATTATTGACACTTAAATGGCATTTAAATTACCAAAAAGAGACATCTGTTCTCT 217
QY 181 TTGGTCTGAGCTGGTTAAAGAGACACTGGTGGCTGAACAGTCACACTTGCAACCATG 240
Db TTGGTCTGAGCTGGTTAAAGAGACACTGGTGGCTGAACAGTCACACTTGCAACCATG 277
QY 241 ATGCCCTAAACATTCCTTTCTAGGCTTCTCATCAGTTTCTTCTTACTGTTAGCAGA 300
Db ATGCCCTAAACATTCCTTTCTAGGCTTCTCATCAGTTTCTTCTTACTGTTAGCAGA 337
QY 301 ACTCAGTCAACGCATGAGTCTCTGAAGCCTCAGAGGGTACAAATTTCAGTCCCGAATTTT 360
Db ACTCAGTCAACGCATGAGTCTCTGAAGCCTCAGAGGGTACAAATTTCAGTCCCGAATTTT 397
QY 361 CACAACATTTTGGCAATGGCAGCCCTGGAGGGCAGCTTACTGGCAACAGCAGTGTCTATTTT 420
Db CACAACATTTTGGCAATGGCAGCCCTGGAGGGCAGCTTACTGGCAACAGCAGTGTCTATTTT 457
QY 421 GTGCAGTACAAAATCATGTTCTCATGACATGAAGAAGCTCTCACAGAGCCCAAGTGA 480
Db GTGCAGTACAAAATCATGTTCTCATGACATGAAGAAGCTCTCACAGAGCCCAAGTGA 517
QY 481 TGCTGGCAGCACAATTTCTGTAACTTCCAGGCTGCAGAACATTTGGCTAAATATGACAG 540
Db TGCTGGCAGCACAATTTCTGTAACTTCCAGGCTGCAGAACATTTGGCTAAATATGACAG 577
QY 541 AGACAATGGAATAAAGAGACTGTGGGGTACTCAAGAACTCTCTGTGACCTTACC 600
Db AGACAATGGAATAAAGAGACTGTGGGGTACTCAAGAACTCTCTGTGACCTTACC 637
QY 601 AGTGAACCTCAGACATACAGGAACCTTATTACGGGAGGTGAGGGCGGCTCGGCTGG 660
Db AGTGAACCTCAGACATACAGGAACCTTATTACGGGAGGTGAGGGCGGCTCGGCTGG 697
QY 661 AGCTACTCAGATGAGCATGACGCGCGGTTCCTCCCTGGTGGAAACAAAATAGAT 720
Db AGCTACTCAGATGAGCATGACGCGCGGTTCCTCCCTGGTGGAAACAAAATAGAT 757
QY 721 CCTCCAGTCATGAATATAACCCCAAGTCAATGGCTTTGTGTAATCTCCATGCTCCA 780
Db CCTCCAGTCATGAATATAACCCCAAGTCAATGGCTTTGTGTAATCTCCATGCTCCA 817
QY 781 AATTACCAATATAGATACCAAAAAGGAAAAATGTATCTATAGAAGATTACTATGAACCTA 840
Db AATTACCAATATAGATACCAAAAAGGAAAAATGTATCTATAGAAGATTACTATGAACCTA 877
QY 841 CTATACCGAGTTTATTAATTAACAATTCATAGAAAAAGAGCAAAAAGGTTTATGAAGG 900
Db CTATACCGAGTTTATTAATTAACAATTCATAGAAAAAGAGCAAAAAGGTTTATGAAGG 937
QY 901 GCTCAGAGAGCGGTTGAATTTGAAGCTCTAACACCACTCCAGCTACTGTAGTGCT 960
Db GCTCAGAGAGCGGTTGAATTTGAAGCTCTAACACCACTCCAGCTACTGTAGTGCT 997

QY 961 GAAATATATCAGCCCATGTAGACAGACAGTCAAGAGAGTGAAGAGATGTGTGAA 1020
Db GAAATATATCAGCCCATGTAGACAGACAGAGTCAAGAGAGTGAAGAGATGTGTGAA 1057
QY 1021 ATTCCATGACTTGTGAATTTGGCATTCAGCAATGTGGAAATTTCTAAAGCTCCCTAGAA 1080
Db ATTCCATGACTTGTGAATTTGGCATTCAGCAATGTGGAAATTTCTAAAGCTCCCTAGAA 1117
QY 1081 CAGGATGACTCGTGTGGAAGGATCTTAAATTTGTTTGTATTTCTTAAAGCAA 1140
Db CAGGATGACTCGTGTGGAAGGATCTTAAATTTGTTTGTATTTCTTAAAGCAA 1177
QY 1141 TATTCACTGTTACACCTGGGACTTCTTTGTTTATCCATTCCTTATATTTTC 1200
Db TATTCACTGTTACACCTGGGACTTCTTTGTTTATCCATTCCTTATATTTTC 1237
QY 1201 ATTTGTAAACTATATTGAACGACATTCACCCCGGAAAAATTTGAATGTAAAGATGAGCA 1260
Db ATTTGTAAACTATATTGAACGACATTCACCCCGGAAAAATTTGAATGTAAAGATGAGCA 1297
QY 1261 GACAATAAAGTGTCTATGAATAAAAAA 1289
Db GACAATAAAGTGTCTATGAATAAAAAA 1326

RESULT 3
HSA313162
LOCUS
DEFINITION
Homo sapiens mRNA for soluble cytokine class II receptor, long isoform (CRF2-S1 gene).
ACCESSION
AJ313162
VERSION
AJ313162.1 GI:16304592
KEYWORDS
alternative splicing; CRF2-S1 gene; long isoform; soluble cytokine class II receptor.
SOURCE
human.
ORGANISM
Homo sapiens
REFERENCE
1 (bases 1 to 1351)
Gruenberg, B.H., Schoenemeyer, A., Weiss, B., Toschi, L., Kunz, S., Wolk, K., Asadullah, K. and Sabat, R.
A novel, soluble homologue of the human IL-10 receptor with preferential expression in placenta
Genes Immun. 2 (6), 329-334 (2001)
JOURNAL
MEDLINE
PUBMED
21518574
11607789
REFERENCE
2 (bases 1 to 1351)
Weiss, B.
Direct Submission
Submitted (06-JUN-2001) Weiss B., Genomics & Bioinformatics, Schering AG, Muellerstr. 178, Berlin, D-13342, GERMANY
COMMENT
Related sequence AJ313161: short isoform.
FEATURES
Location/Qualifiers
1..1351
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="6"
/map="6q241.-25.2"
/sex="female"
/tissue_type="placenta"
/dev_stage="adult"
/tissue_lib="Clontech Human Placenta #64024-1"
1..1351
/gene="CRF2-S1"
1..303
/gene="CRF2-S1"
304..1095
/gene="CRF2-S1"
/codon_start=1
/product="soluble cytokine class II receptor, long isoform"
/protein_id="CAC85635.1"
/db_xref="GI:16304593"

QY 290 GTGTAGCAGGAAGTCAAGCATGAGTCTGTGAAGCCTCAGAGGGGTACAAATTTTCAGT 349
Db 162 GTGTAGCAGGAAGTCAAGCATGAGTCTGTGAAGCCTCAGAGGGGTACAAATTTTCAGT 221
QY 350 CCCGAAATTTTCAACAATTTTGAATGGCAGCCCTGGGAGGCGACTTACTGGCAACAGCA 409
Db 222 CCCGAAATTTTCAACAATTTTGAATGGCAGCCCTGGGAGGCGACTTACTGGCAACAGCA 281
QY 410 GTGTCTATTTTGTGACAGTACAAATTCATGTCATGCAGCATGAAAGCTCTCACCAGA 469
Db 282 GTGTCTATTTTGTGACAGTACAAATTCATGTCATGCAGCATGAAAGCTCTCACCAGA 341
QY 470 AGCCAAGTGGATGCTGGCAGCAGCATTTCTGTAACTTCCAGGCTGCAGAACATTTGCTA 529
Db 342 GCCAAGTGGATGCTGGCAGCAGCATTTCTGTAACTTCCAGGCTGCAGAACATTTGCTA 401
QY 530 AATATGGACAGACATGGAATAAAGAGACTGTGGGGTACTCAAGACTCTCTT 589
Db 402 AATATGGACAGACATGGAATAAAGAGACTGTGGGGTACTCAAGACTCTCTT 461
QY 590 GTGACCTTACCAGTGAACCTCAGACATACAGGAACCTTATTACGGGAGGGTGAAGGCGG 649
Db 462 GTGACCTTACCAGTGAACCTCAGACATACAGGAACCTTATTACGGGAGGGTGAAGGCGG 521
QY 650 CCTCGGCTGGGAGCTACTCAGAAATGAGCATGACGCCGCGTTCACCTCCCTGGGCGAAA 709
Db 522 CCTCGGCTGGGAGCTACTCAGAAATGAGCATGACGCCGCGTTCACCTCCCTGGGCGAAA 581
QY 710 CAAAAATAGATCCTCCAGTCAATATTAACCCCAAGTCAATGGCTCTTGTGTATATTC 769
Db 582 CAAAAATAGATCCTCCAGTCAATATTAACCCCAAGTCAATGGCTCTTGTGTATATTC 641
QY 770 TCCATGCTCCAAATTTTACCATATAGATACCAAAAGGAAAAAATGTATCTATAGAGATT 829
Db 642 TCCATGCTCCAAATTTTACCATATAGATACCAAAAGGAAAAAATGTATCTATAGAGATT 701
QY 830 ACTATGAAGTCTATACCGAGTTTATTAATTAACAATTCAGTAAAGAGCAAAAGG 889
Db 702 ACTATGAAGTCTATACCGAGTTTATTAATTAACAATTCAGTAAAGAGCAAAAGG 761
QY 890 TTTATGAAGGGGCTCACAGAGCGGTTGAATTTGAAGCTCTAACACCACTCCAGCTACT 949
Db 762 TTTATGAAGGGGCTCACAGAGCGGTTGAATTTGAAGCTCTAACACCACTCCAGCTACT 821
QY 950 GTGTAGTGGCTGAATATATACGCCCATGTTAGACAGAGAAGTCAAGAGTGAAGAGA 1009
Db 822 GTGTAGTGGCTGAATATATACGCCCATGTTAGACAGAGAAGTCAAGAGTGAAGAGA 881
QY 1010 GATGTGTGAAATTCATGACTGTGGAATTTGGCATTCAGCAATGTGAAATTTCTAAAG 1069
Db 882 GATGTGTGAAATTCATGACTGTGGAATTTGGCATTCAGCAATGTGAAATTTCTAAAG 941
QY 1070 CTCCCTGAGAACAGGAGTCTGTTTGAAGGATCTTATTTAAATTTGTTTGTATTT 1129
Db 942 CTCCCTGAGAACAGGAGTCTGTTTGAAGGATCTTATTTAAATTTGTTTGTATTT 1001
QY 1130 TCTTAAAGCAATATTCACCTTTGAGGACTCTTGTTTATCCATCTTTATC 1189
Db 1002 TCTTAAAGCAATATTCACCTTTGAGGACTCTTGTTTATCCATCTTTATC 1061
QY 1190 CTTTATATTTTCAATTTGTAACCTATATTGAACGACATTCCTCCCGAATAATTTGAATGTA 1249
Db 1062 CTTTATATTTTCAATTTGTAACCTATATTGAACGACATTCCTCCCGAATAATTTGAATGTA 1121
QY 1250 AAGATGAGCAGAGAATAAGTGTCTATGAAAAAAA 1289
Db 1122 AAGATGAGCAGAGAATAAGTGTCTATGAAAAAAA 1161
RESULT 5
LOCUS AY040566 2763 bp mRNA linear PRI 19-AUG-2001
DEFINITION Homo sapiens interleukin 22-binding protein CRF2-10 (IL22BP) mRNA,

complete cds.
AY040566
AY040566.1 GI:15212825
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1. .2763
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="6"
/map="6q25.1"
1. .2763
/gene="IL22BP"
275. .970
/gene="IL22BP"
/function="neutralizes IL-22 activity by preventing the binding of IL-22 to the functional cell surface IL-22 receptor complex"
/note="CRF class II member 10; soluble receptor; IL-22BP; member of the class II cytokine receptor family"
/codon_start=1
/product="interleukin 22-binding protein CRF2-10"
/protein_id="AAK85714.1"
/db_xref="GI:15212826"
/translation="MMPKHCFLGLISFLLTGVAGTOSTHESLKPORVOFOSRNFHNI LQWQGRALTGNSVYFVQKIKYQGRQWKNKEDCWGTOELSCDLTSETSDIOEPIYGR VRAASAGSYLSWMTPTPTPMWETKIDPVMNITOVNGLVILHAPNLPYRYQKEKN VSIEDYVELLRVFTIINNSLEKEQKYEGAHRAVEIEALTPHSSYCVVAEIQPMLDR RSORSEERCEVEIP"
BASE COUNT 866 a 479 c 528 g 890 t
ORIGIN
Query Match 82.0%; Score 1080.6; DB 9; Length 2763;
Best Local Similarity 92.2%; Pred. No. 1.4e-222;
Matches 1189; Conservative 0; Mismatches 4; Indels 96; Gaps 1;
QY 1 CAGTTTCTTCATCTGTAACATCAATAATAATATACCAATCTCCTAGACTTCATAAGA 60
Db 38 CAGTTTCTTCATCTGTAACATCAATAATAATATACCAATCTCCTAGACTTCATAAGA 97
QY 61 GGATTAACAAGACAAATATGAGGAAAAACATACATGCGGCTCCCATTAATTAGATCT 120
Db 98 GGATTAACAAGACAAATATGAGGAAAAACATACATGCGGCTCCCATTAATTAGATCT 157
QY 121 TATTAATGACACTAAATATGCAATTAATAATACCAAAAGGAAGACAGCATCTGTTCCCT 180
Db 158 TATTAATGACACTAAATATGCAATTAATAATACCAAAAGGAAGACAGCATCTGTTCCCT 217
QY 181 TTGGTCTGAGCTGGTTAAAGGAACACTGGTGGCTGGAAGTCAACACTTGCAACCATG 240
Db 218 TTGGTCTGAGCTGGTTAAAGGAACACTGGTGGCTGGAAGTCAACACTTGCAACCATG 277
QY 241 ATGCCTAAACATTTCTTCTAGGCTTCTCCTCATCAGTTTCTTCTTACTGTGTAGCAGGA 300
Db 278 ATGCCTAAACATTTCTTCTAGGCTTCTCCTCATCAGTTTCTTCTTACTGTGTAGCAGGA 337

```
QY 301 ACTCAGTCAACGCATGACGTCCTCTGAAGCCTCAGAGGGTACAAATTTTCCAGTCCCGAAATTTT 360
DB 338 ACTCAGTCAACGCATGACGTCCTCTGAAGCCTCAGAGGGTACAAATTTTCCAGTCCCGAAATTTT 397
QY 361 CACACATTTTGCATATGCGACGCTGGAGGGCAGCTTACTGCGACACAGCAGTGTCTATTTT 420
DB 398 CACACATTTTGCATATGCGACGCTGGAGGGCAGCTTACTGCGACACAGCAGTGTCTATTTT 457
QY 421 GTGCGATGACAAATCATGTTCTCATGCGAGCATGAAAGCTCTCACCAGAGCCAAAGTGA 480
DB 458 GTGCGATGACAAATCATGTTCTCATGCGAGCATGAAAGCTCTCACCAGAGCCAAAGTGA 471
QY 481 TGCTGGCAGCACATTTCTTCTTAACCTTCCAGGCTGCAGAACATTGGCTAAATATGACAG 540
DB 472 -----ATATGACAG 481
QY 541 AGACAATGAAAAAATAAGAGACTGTTGGGTTACTCAAGAACTCTTGTGACCTTACC 600
DB 482 AGACAATGAAAAAATAAGAGACTGTTGGGTTACTCAAGAACTCTTGTGACCTTACC 541
QY 601 AGTGAACCTCAGACATACAGAACCTTATTACGGAGGCTGAGGGCGGCTCGGCTGG 660
DB 542 AGTGAACCTCAGACATACAGAACCTTATTACGGAGGCTGAGGGCGGCTCGGCTGG 601
QY 661 AGCTACTCAGAAATGAGCATGACGCGCGGCTTCACTCCCTGGTGGGAAACAAATAGAT 720
DB 602 AGCTACTCAGAAATGAGCATGACGCGCGGCTTCACTCCCTGGTGGGAAACAAATAGAT 661
QY 721 CCTCCAGTCATGAATATAACCCAGTCAATGGCTCTTGTGGTAAATTCCTCATGCTCCA 780
DB 662 CCTCCAGTCATGAATATAACCCAGTCAATGGCTCTTGTGGTAAATTCCTCATGCTCCA 721
QY 781 AATTACCATATAGATACCAAGAAAAATGTATCTATAGAGATTAATACTAATACTA 840
DB 722 AATTACCATATAGATACCAAGAAAAATGTATCTATAGAGATTAATACTAATACTA 781
QY 841 CTATACCGAGTTTATTAATTAACAATTAACAAGAGAGCAAAAGTTTATGAAGG 900
DB 782 CTATACCGAGTTTATTAATTAACAATTAACAAGAGAGCAAAAGTTTATGAAGG 841
QY 901 GCTCAGACAGCGGTTGAATTTGAAGCTCTAACACCACTCCAGTCTGTAGTGCGT 960
DB 842 GCTCAGACAGCGGTTGAATTTGAAGCTCTAACACCACTCCAGTCTGTAGTGCGT 901
QY 961 GAAATATATCAGCCCATGTGTAGACAGAGAGTCAAGAGAGTGAAGAGAGATGTGGAA 1020
DB 902 GAAATATATCAGCCCATGTGTAGACAGAGAGTCAAGAGAGTGAAGAGAGATGTGGAA 961
QY 1021 ATTCCATGACTTGTGGAATTTGGCATTTCAACAATGTGGAATTTCTAAAGCTCCCTGAGAA 1080
DB 962 ATTCCATGACTTGTGGAATTTGGCATTTCAACAATGTGGAATTTCTAAAGCTCCCTGAGAA 1021
QY 1081 CAGGATGACTGCTGTTGAAGGATCTTATTAATAATTTTGTATTTCTTAAGCAA 1140
DB 1022 CAGGATGACTGCTGTTGAAGGATCTTATTAATAATTTTGTATTTCTTAAGCAA 1081
QY 1141 TATTCACCTGTTACACCTTGGGACTCTTGTATTCATCTTTATCTTATATTTT 1200
DB 1082 TATTCACCTGTTACACCTTGGGACTCTTGTATTCATCTTTATCTTATATTTT 1141
QY 1201 ATTTGTAACATATATTTGAACGACATTCCTCCCGAAAAATTTGAATGTAAAGATGAGCA 1260
DB 1142 ATTTGTAACATATATTTGAACGACATTCCTCCCGAAAAATTTGAATGTAAAGATGAGCA 1201
QY 1261 GAGATAAAGTGTCTATGAAAAAATA 1289
DB 1202 GAGATAAAGTGTCTATGAAAAATTCAGAA 1230
RESULT 6
LOCUS AX399654 1255 bp DNA linear PAT 06-JUN-2002
DEFINITION Sequence 3 from Patent EP1191035.
```

```
ACCESSION AX399654
VERSION AX399654.1 GI:21335431
KEYWORDS
SOURCE
ORGANISM human.
REFERENCE
AUTHORS Weiss, B., Sabat, R., Assadullah, K. and Toshi, L.
TITLE Three members of the cytokin-receptor class II family
JOURNAL Patent: EP 1191035-A 3 27-MAR-2002;
SCHERING AKTIENGESELLSCHAFT (DE)
FEATURES
source
1. .1255
/organism="Homo sapiens"
/db_xref="taxon:9606"
BASE COUNT 402 a 251 c 246 g 356 t
ORIGIN
Query Match 81.8%; Score 1078.4; DB 6; Length 1255;
Best Local Similarity 92.4%; Pred. No. 4.1e-222;
Matches 1185; Conservative 0; Mismatches 1; Indels 96; Gaps 1;
QY 1 CAGTTTCTTCATCTGTATACATCAATGAATATATATACCAATCTCTAGACTTCATAAGA 60
DB 67 CAGTTTCTTCATCTGTATACATCAATGAATATATATACCAATCTCTAGACTTCATAAGA 126
QY 61 GGATTAACAAGACAAATATGGGAAAAACATAACATGCGGCTCCCATATATATAGATCT 120
DB 127 GGATTAACAAGACAAATATGGGAAAAACATAACATGCGGCTCCCATATATATAGATCT 186
QY 121 TATTAATGACACTAAATATGGCATTAATAATTACCAAAAGGAAGACAGCATCTGTTCTCT 180
DB 187 TATTAATGACACTAAATATGGCATTAATAATTACCAAAAGGAAGACAGCATCTGTTCTCT 246
QY 181 TTGCTCCTGAGCTGTTAAAAGAACACTGTTGCCCTGAACAGTCACTTGAACCATG 240
DB 247 TTGCTCCTGAGCTGTTAAAAGAACACTGTTGCCCTGAACAGTCACTTGAACCATG 306
QY 241 ATGCTTAACATTTGCTTTCTAGGCTTCTCATCAGTTTCTTCTTACTGTTAGCAGGA 300
DB 307 ATGCTTAACATTTGCTTTCTAGGCTTCTCATCAGTTTCTTCTTACTGTTAGCAGGA 366
QY 301 ACTCAGTCAACGCATGACGTCCTCTGAAGCCTCAGAGGGTACAAATTTTCCCGAAATTTT 360
DB 367 ACTCAGTCAACGCATGACGTCCTCTGAAGCCTCAGAGGGTACAAATTTTCCCGAAATTTT 426
QY 361 CACACATTTTGCATATGCGACGCTGGAGGGCAGCTTACTGCGACACAGCAGTGTCTATTTT 420
DB 427 CACACATTTTGCATATGCGACGCTGGAGGGCAGCTTACTGCGACACAGCAGTGTCTATTTT 486
QY 421 GTGCGATGACAAATCATGTTCTCATGCGACATGAAAGCTCTCACCAGAGGCCAAGTGA 480
DB 487 GTGCGATGACAAATCATGTTCTCATGCGACATGAAAGCTCTCACCAGAGGCCAAGTGA 500
QY 481 TGCTGGCAGCACATTTCTTGTAACTTCCAGGCTGCAGAACATTGGCTAAATATGACAG 540
DB 501 -----ATATGACAG 510
QY 541 AGACAATGAAAAAATAAGAGACTGTTGGGTTACTCAAGAACTCTTGTGACCTTACC 600
DB 511 AGACAATGAAAAAATAAGAGACTGTTGGGTTACTCAAGAACTCTTGTGACCTTACC 570
QY 601 AGTGAACCTCAGACATACAGGAACCTTATTACGGAGGTTAGGGGGCGGCTCGGCTGG 660
DB 571 AGTGAACCTCAGACATACAGGAACCTTATTACGGAGGTTAGGGGGCGGCTCGGCTGG 630
QY 661 AGCTACTCAGAAATGAGCATGACGCGCGGTTCACTCCCTGGTGGGAAACAAATAGAT 720
DB 631 AGCTACTCAGAAATGAGCATGACGCGCGGTTCACTCCCTGGTGGGAAACAAATAGAT 690
QY 721 CCTCCAGTCATGAATATAACCAAGTCAATGGCTCTTGTGTGTAATTTCTCATGCTCCA 780
DB 721 CCTCCAGTCATGAATATAACCAAGTCAATGGCTCTTGTGTGTAATTTCTCATGCTCCA 780
```

Db 691 CCTCAGTCATGATATATAACCCAGTCAATGCTCTTTGTTGGTAATTCTCCATGCTCCA 750
QY 781 AATTACCATATAGATACCAAAAGGAAAAAATGTATCTATAGAGATTACTATGACTA 840
Db 751 AATTACCATATAGATACCAAAAGGAAAAAATGTATCTATAGAGATTACTATGACTA 810
QY 841 CTATACCGAGTTTATTAATTAACAATCTACTAGAAAAAGGCAAAAGGTTTATGAAGGG 900
Db 811 CTATACCGAGTTTATTAATTAACAATCTACTAGAAAAAGGCAAAAGGTTTATGAAGGG 870
QY 901 GCTCAGAGCGGTTGAAATTTGAAGCTCTTAACACCACACTCCAGCTACTGTGTAGTGCGT 960
Db 871 GCTCAGAGCGGTTGAAATTTGAAGCTCTTAACACCACACTCCAGCTACTGTGTAGTGCGT 930
QY 961 GAAATATATCAGCCCATGTAGACAGAGAAGTCAAGAGAAGTGAAGAGAGATGTGGAA 1020
Db 931 GAAATATATCAGCCCATGTAGACAGAGAAGTCAAGAGAAGTGAAGAGAGATGTGGAA 990
QY 1021 ATTCATGACTTGTGGAATTTGGCATTCACCAATGTGGAATTTCTAAAGCTCCCTGAGAA 1080
Db 991 ATTCATGACTTGTGGAATTTGGCATTCACCAATGTGGAATTTCTAAAGCTCCCTGAGAA 1050
QY 1081 CAGGATGACTCGTGTGGAAGGATCTTAATTAATTTGTTTGTATTTCTTAAAGCAA 1140
Db 1051 CAGGATGACTCGTGTGGAAGGATCTTAATTAATTTGTTTGTATTTCTTAAAGCAA 1110
QY 1141 TATTCACCTGTACACCTTGGGACCTCTTGTATTCATCTTTATCCCTTATATTTTC 1200
Db 1111 TATTCACCTGTACACCTTGGGACCTCTTGTATTCATCTTTATCCCTTATATTTTC 1170
QY 1201 ATTTGTAACCTATATTTGAACGACATTCACCCCGAAAAAATTGAATGTAAAGATGAGGCA 1260
Db 1171 ATTTGTAACCTATATTTGAACGACATTCACCCCGAAAAAATTGAATGTAAAGATGAGGCA 1230
QY 1261 GAGAAATAAGTGTCTATGAAA 1282
Db 1231 GAGAAATAAGTGTCTATGAAA 1252

RESULT 7
HSA313161
LOCUS HSA313161 1255 bp mRNA linear PRI 21-OCT-2001
DEFINITION Homo sapiens mRNA for soluble cytokine class II receptor, short isoform (CRF2-S1 gene).
ACCESSION AJ313161
VERSION AJ313161.1 GI:16304590
KEYWORDS alternative splicing; CRF2-S1 gene; short isoform; soluble cytokine class II receptor.
ORIGIN human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 (bases 1 to 1255)
AUTHORS Gruenberg,B.H., Schoenemeyer,A., Weiss,B., Toschi,L., Kunz,S., Wolk,K., Asadullah,K. and Sabat,R.
TITLE A novel, soluble homologue of the human IL-10 receptor with preferential expression in placenta
JOURNAL Genes Immun. 2 (6), 329-334 (2001)
MEDLINE 21518574
PUBMED 11607789
REFERENCE 2 (bases 1 to 1255)
AUTHORS Weiss,B.
TITLE Direct Submission
JOURNAL Submitted (06-JUN-2001) Weiss B., Genomics & Bioinformatics, Schering AG, Muellerstr. 178, Berlin, D-13342, GERMANY
COMMENT Related sequence AJ313162: long isoform.
FEATURES
source location/Qualifiers
1..1255
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="6"
/map="6q24.1-25.2"
/tissue_type="mammary gland"

/clone_lib="Clontech Human Mammary Gland #7409-1"
/dev_stage="adult"
1..1255
/gene="CRF2-S1"
1..303
/gene="CRF2-S1"
304..999
/gene="CRF2-S1"
/codon_start=1
/product="soluble cytokine class II receptor, short isoform"
/protein_id="CAC85634.1"
/db_xref="GI:16304591"
/translation="MMPKHFLEFLISFLLTGAVGTOSTHESLKPORVQFOSRNFHNI LQWQGRALTGNSSVFVQYKIVGQKQWKNKEDCWGTQELSCDLTSETSDIQEPIYGR VRAASAGSYSEWSMTPRFTPWETKIDPVMNITQVNGSLVTLHAPNLPYRQKEKN VSIEDYVELLYRVFTINNSLEKEQKVEGAHRAVEIEALTPHSSYCVVAEIQPMLDR RSQRSEERCVETIP"
304..366
/gene="CRF2-S1"
367..996
/gene="CRF2-S1"
/product="soluble cytokine class II receptor, short isoform"
1000..1255
/gene="CRF2-S1"
BASE COUNT 402 a 251 c 246 g 356 t
ORIGIN
Query Match 81.8%; Score 1078.4; DB 9; Length 1255;
Best Local Similarity 92.4%; Pred. No. 4.1e-22;
Matches 1185; Conservative 0; Mismatches 1; Indels 96; Gaps 1;
QY 1 CAGTTTCTCATCTGTAAACATCAAAATGAATATAATACCAATCTCCTAGACTTCATAAGA 60
Db 67 CAGTTTCTCATCTGTAAACATCAAAATGAATATAATACCAATCTCCTAGACTTCATAAGA 126
QY 61 GGATTAACAAGACAAATATATGGGAAAAACATAACATGGCGTCCCATATATTAGATCT 120
Db 127 GGATTAACAAGACAAATATATGGGAAAAACATAACATGGCGTCCCATATATTAGATCT 186
QY 121 TATTATTGACACTAAATGGCATTAATAATTAACCAAAAGGAAAGACAGCATCTGTTCTCT 180
Db 187 TATTATTGACACTAAATGGCATTAATAATTAACCAAAAGGAAAGACAGCATCTGTTCTCT 246
QY 181 TTGGTCTGACCTGGTTAAAGGAACACCTGGTGCCTGAACAGTCACACCTTGCAACCATG 240
Db 247 TTGGTCTGACCTGGTTAAAGGAACACCTGGTGCCTGAACAGTCACACCTTGCAACCATG 306
QY 241 ATGCTTAACATTTGCTTTCTAGGCTTCCTCATGATTTCTTCTTACTGTTAGCAGGA 300
Db 307 ATGCTTAACATTTGCTTTCTAGGCTTCCTCATGATTTCTTCTTACTGTTAGCAGGA 366
QY 301 ACTCAGTCAACGCATGAGTCTCTGAAGCCTCAGAGGGTACAATTTCCGCAAAATTTT 360
Db 367 ACTCAGTCAACGCATGAGTCTCTGAAGCCTCAGAGGGTACAATTTCCGCAAAATTTT 426
QY 361 CACAACATTTTGGCAATGGCAGCCTGGGAGGGCACTTACTGGCAACAGCAGTGTCTATT 420
Db 427 CACAACATTTTGGCAATGGCAGCCTGGGAGGGCACTTACTGGCAACAGCAGTGTCTATT 486
QY 421 GTGCAGTACAAATCATGTCTCTCATGACGATGAAGAGCTCTCACCAGAGCAAGTGA 480
Db 487 GTGCAGTACAAAT-
QY 481 TGCTGGCAGACATTTCTTGTAACTTCCAGGCTGCAGAACATTTGGCTAAATATGACAG 540
Db 501 -----ATATGACAG 510
QY 541 AGACAATGAAAAATAAAGAAGACTGTTGGGCTACTCAAGAACCTCTGTTGACCTTACC 600
Db 511 AGACAATGAAAAATAAAGAAGACTGTTGGGCTACTCAAGAACCTCTGTTGACCTTACC 570

QY	601	AGTAAACCTCAGACATACAGAACCCTTATTACGGGAGGGTGAGGGCGCCCTCGGCTGGG	660
Db	571	AGTGAACCTCAGACATACAGAACCCTTATTACGGGAGGGTGAGGGCGCCCTCGGCTGGG	630
QY	661	AGCTACTCAGAATGGAGCATGACGCCGCGGTTCACCTCCCTGGTGGGAAACAATAATAGAT	720
Db	631	AGCTACTCAGAATGGAGCATGACGCCGCGGTTCACCTCCCTGGTGGGAAACAATAATAGAT	690
QY	721	CCTCCAGTCATGAATATTAACCAAGTCATGGCTCTTTGGTGGTAATTCCTCATGCTCCA	780
Db	691	CCTCCAGTCATGAATATTAACCAAGTCATGGCTCTTTGGTGGTAATTCCTCATGCTCCA	750
QY	781	AATTTACCATATAGATACCAAAAGAAAAAATGTATCTATAGAAGATTACTATGACTA	840
Db	751	AATTTACCATATAGATACCAAAAGAAAAAATGTATCTATAGAAGATTACTATGACTA	810
QY	841	CTATACCGAGTTTTTATTAATTAACAATTCCTAGAAAAGAACCAAAGGTTTATGAAGG	900
Db	811	CTATACCGAGTTTTTATTAATTAACAATTCCTAGAAAAGAACCAAAGGTTTATGAAGG	870
QY	901	GCTCACAGAGCGGTGGAATTTGAAGCTCTAACACCCACACTCCAGCTACTGTGTAGTGGCT	960
Db	871	GCTCACAGAGCGGTGGAATTTGAAGCTCTAACACCCACACTCCAGCTACTGTGTAGTGGCT	930
QY	961	GAAATATATCAGCCCCATGTTAGACAGAGAAGTCCAGAGAAAGTGAAGAGATGTGTGAA	1020
Db	931	GAAATATATCAGCCCCATGTTAGACAGAGAAGTCCAGAGAAAGTGAAGAGATGTGTGAA	990
QY	1021	ATTCCATGACTTGTGGAATTTGCCATTCCAGCAATGTGGAATTTCTAAAGCTCCCTGAGAA	1080
Db	991	ATTCCATGACTTGTGGAATTTGCCATTCCAGCAATGTGGAATTTCTAAAGCTCCCTGAGAA	1050
QY	1081	CAGGATGACTCGTGTGGAAGCATCTATTAAAAATGTTTTGTATTCTTAAAGCAA	1140
Db	1051	CAGGATGACTCGTGTGGAAGCATCTATTAAAAATGTTTTGTATTCTTAAAGCAA	1110
QY	1141	TATTCACCTGTTACACCCCTGGGCACTCTTTGTTTATCCATTTCTTATCCTTATATTTC	1200
Db	1111	TATTCACCTGTTACACCCCTGGGCACTCTTTGTTTATCCATTTCTTATCCTTATATTTC	1170
QY	1201	ATTGTAAACTATATTGGAACGACATTCCCCCGAAAAATGGAATGTAAGATGAGGCA	1260
Db	1171	ATTGTAAACTATATTGGAACGACATTCCCCCGAAAAATGGAATGTAAGATGAGGCA	1230
QY	1261	GAGAATAAAGTGTCTATGAAA	1282
Db	1231	GAGAATAAAGTGTCTATGAAA	1252
LOCUS	AY044429	1618 bp mRNA linear PRI 01-SEP-2001	
DEFINITION	Homo sapiens class II cytokine receptor (IL22RA2) mRNA, complete cds.		
ACCESSION	AY044429		
VERSION	AY044429.1 GI:15419022		
KEYWORDS			
SOURCE	Homo sapiens.		
ORGANISM	Homo sapiens.		
REFERENCE	Xu,W., Presnell,S.R., Parrish-Novak,J., Kindsvogel,W., Jaspers,S., Chen,Z., Dillon,S.R., Gao,Z., Gilbert,T., Madden,K., Schlutsmeyer,S., Yao,L., Whitmore,T.E., Chandrasekhar,Y., Grant,F.J., Maurer,M., Jelinek,L., Storey,H., Breder,T., Hammond,A., Topouzis,S., Clegg,C.H. and Foster,D.C. A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist Proc. Natl. Acad. Sci. U.S.A. 98 (17), 9511-9516 (2001)		
JOURNAL MEDLINE	21396522		
PUBMED	11481447		
REFERENCE	2 (bases 1 to 1618)		

AUTHORS	Xu,W., Presnell,S.R., Parrish-Novak,J., Kindsvogel,W., Jaspers,S., Chen,Z., Dillon,S.R., Gao,Z., Gilbert,T., Madden,K., Schlutsmeier,S., Yao,L., Whitmore,T.E., Chandrasekhar,Y., Grant,F.J., Maurer,M., Jelinek,L., Storey,H., Brender,T., Hammond,A., Topouzis,S., Clegg,C.H. and Foster,D.C.				
TITLE	Direct Submission				
JOURNAL	Submitted (09-JUL-2001) Bioinformatics, ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA 98102, USA				
FEATURES	Location/Qualifiers				
source	1. 1618				
	/organism="Homo sapiens"				
	/db_xref="taxon:9606"				
	/chromosome="6"				
	/map="6q24.1-q24.2"				
gene	1. 1618				
	/gene="IL22RA2"				
	/note="IL-22RA2"				
	237. .932				
CDS	/gene="IL22RA2"				
	/note="zcytor16"				
	/codon_start=1				
	/product="class II cytokine receptor"				
	/protein_id="AAK91775.1"				
	/db_xref="GI:15419023"				
	/translation="MMPKHCFGLISFELTGVAQTOSTHESLKPQVQFOSRNFHNI LQWQGRALTGNSVYEVQYKIYGQRQMKNEKDCWGTQLSCDLTSETSDIQEPIYGR VRAASAGYSSEWSMTPRFTPWMEETKIDPYMNITOVNGSLVILHAPNLPRYQKEKN VSIEDYELLIRVFLIINNSLEKEQKVYEGAHRAVEIEALTPHSSYCVVAEIIQPMIDR RSQRSEERCEVEIP"				
BASE COUNT	562 a	277 c	286 g	493 t	
ORIGIN					
Query Match	81.8%; Score 1078; DB 9; Length 1618;				
Best Local Similarity	92.2%; Pred. No. 5e-222;				
Matches 1187; Conservative	0;	Mismatches	5;	Indels	96; Gaps 1;
QY	2	AGTTCTTCATCTGTACATCAATGAATATATACCAATCTCCTAGACTTCATAAGAG	61		
Db	1	AGTTCTTCATCTGTACATCAATGAATATATACCAATCTCCTAGACTTCATAAGAG	60		
QY	62	GATTACAAAGACAAATATGGGAAAACATPACATGGCGTCCATPATTATAGATCTT	121		
Db	61	GATTACAAAGACAAATATGGGAAAACATPACATGGTGTCCCATTAATTATAGATCTT	120		
QY	122	ATTATTGACACTAAATGGCATTTAAATTACCAAAAGAGACAGCATCTGTTCCCTCT	181		
Db	121	ATTATTGACACTAAATGGCATTTAAATTACCAAAAGAGACAGCATCTGTTCCCTCT	180		
QY	182	TGGTCTGAGCTGTTAAAAGAACACTGGTTGCTGAACAGTCACACTTGCACACATGA	241		
Db	181	TGGTCTGAGCTGTTAAAAGAACACTGGTTGCTGAACAGTCACACTTGCACACATGA	240		
QY	242	TGCCTAACATTTGCTTCTAGGCTTCTCATCATGATTCTTCTTACTGGTGTAGACGAA	301		
Db	241	TGCCTAACATTTGCTTCTAGGCTTCTCATCATGATTCTTCTTACTGGTGTAGACGAA	300		
QY	302	CTCAGTCAACGCATGAGTCTCTGAAGCCTCAGAGGGGTACAAATTTCAGTCCCGAAATTTTC	361		
Db	301	CTCAGTCAACGCATGAGTCTCTGAAGCCTCAGAGGGGTACAAATTTCAGTCCCGAAATTTTC	360		
QY	362	ACAACATTTTGGCAATGGCAGCCCTGGGAGGGGACCTTACTGGCAACAGCAGTGTCTAATTTTG	421		
Db	361	ACAACATTTTGGCAATGGCAGCCCTGGGAGGGGACCTTACTGGCAACAGCAGTGTCTAATTTTG	420		
QY	422	TGCAGTACAAATCATGTTCTCATGACAGCATGAAAAGCTCTCACACGAAAGCCAAGTGGAT	481		
Db	421	TGCAGTACAAAT-----	433		
QY	482	GCTGGCAGACATTTCTTGTAACCTCCAGGCTGCAGACACATTTGGCTAAATATGACACAGA	541		
Db	434	-----ATATGGACACAGA	444		
QY	542	GACAATGAAAAATAAAGAAGACTGTTGGGGTACTCAAGAACTCTCTGTGTGACCTTACCA	601		

|||||
Db 445 GACAAATGGAATAAAGAGACTGTGGGGTACTCAAGAACTCTTGTGACCTTACCA 504
QY 602 GTGAACCTCAGACATACAGAACCTTATTACGGAGGTGAGGGCGCCCTCGGCTGGGA 661
Db 505 GTGAACCTCAGACATACAGAACCTTATTACGGAGGTGAGGGCGCCCTCGGCTGGGA 564
QY 662 GCTACTCAGAATGAGCATGACGCCGGGTTCACTCCCTGGTGGGAAACAAAATAGATC 721
Db 565 GCTACTCAGAATGAGCATGACGCCGGGTTCACTCCCTGGTGGGAAACAAAATAGATC 624
QY 722 CTCAGTCATGAATATAACCCAGTCATGGCTCTTGTGTGTAATTCCTCATGCTCCAA 781
Db 625 CTCAGTCATGAATATAACCCAGTCATGGCTCTTGTGTGTAATTCCTCATGCTCCAA 684
QY 782 ATTTACCATATAGATACCAAAAGGAAAAATGTATCTATAGAGATTACTATGAAGTAC 841
Db 685 ATTTACCATATAGATACCAAAAGGAAAAATGTATCTATAGAGATTACTATGAAGTAC 744
QY 842 TATACCGAGTTTATTATTAATTAACAATTCACCTAGAAAAAGAGCAAAAGTTTATGAAGGG 901
Db 745 TATACCGAGTTTATTATTAATTAACAATTCACCTAGAAAAAGAGCAAAAGTTTATGAAGGG 804
QY 902 CTCACAGAGCGGTTGAATTTGAAGCTCTAACACACACACTCCAGCTACTGTGTAGTGGCTG 961
Db 805 CTCACAGAGCGGTTGAATTTGAAGCTCTAACACACACACTCCAGCTACTGTGTAGTGGCTG 864
QY 962 AAATATATCAGCCCATGTATAGACAGAGAAGTCAGAGAAGTGAAGAGATGTGTGAAA 1021
Db 865 AAATATATCAGCCCATGTATAGACAGAGAAGTCAGAGAAGTGAAGAGATGTGTGAAA 924
QY 1022 TTCCATGACTGTGTGAATTTGGCATTCAGCAATGTGAAATTCCTAAAGCTCCCTGAGAAC 1081
Db 925 TTCCATGACTGTGTGAATTTGGCATTCAGCAATGTGAAATTCCTAAAGCTCCCTGAGAAC 984
QY 1082 AGGATGACTCGTGTGTTGAAGGATCTTATTTAAATTTGTTTGTATTTCTTAAGCAAT 1141
Db 985 AGGATGACTCGTGTGTTGAAGGATCTTATTTAAATTTGTTTGTATTTCTTAAGCAAT 1044
QY 1142 ATTCACTGTTACACCTTGGGACTTCTTTGTTATCCATCTTTTATCCTTATATTCA 1201
Db 1045 ATTCACTGTTACACCTTGGGACTTCTTTGTTATCCATCTTTTATCCTTATATTCA 1104
QY 1202 TTTGTAACATATATTGAACGACATTCCTCCCGGAAAAATTGAAATGTAAAGATGAGGCAG 1261
Db 1105 TTTGTAACATATATTGAACGACATTCCTCCCGGAAAAATTGAAATGTAAAGATGAGGCAG 1164
QY 1262 AGAATAAAGTGTCTATGAAAAA 1289
Db 1165 AGAATAAAGTGTCTATGAAATTCAAGAA 1192

RESULT 9
AX469509 2271 bp DNA linear PAT 16-JUL-2002
LOCUS AX469509 Sequence 5 from Patent WO0224912.
DEFINITION AX469509
ACCESSION AX469509
VERSION AX469509.1 GI:21901794
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Renauld,J.C. and Dumoutier,L.
AUTHORS Isolated nucleic acid molecules which encode a soluble il-tlf/il-22
TITLE receptor or binding protein which binds to il-tlf/il-22 and uses
thereof

JOURNAL Patent: WO 0224912-A 5 28-MAR-2002;
LUDWIG INSTITUTE FOR CANCER RESEARCH (US)
FEATURES Location/Qualifiers
source 1..2271
/organism="Homo sapiens"

BASE COUNT 709 a 400 c 444 g 718 t
ORIGIN
/db_xref="taxon:9606"
Query Match 69.0%; Score 910; DB 6; Length 2271;
Best Local Similarity 91.0%; Pred. No. 7.9e-186;
Matches 1019; Conservative 0; Mismatches 5; Indels 96; Gaps 1;
QY 170 CTGTTTCCTCTTTGGTCTCTGAGCTGGTTAAAGGACACACTGGTTCCTGAACAGTCACAC 229
Db 42 CAGTTTCCTCTTTGGTCTCTGAGCTGGTTAAAGGACACACTGGTTCCTGAACAGTCACAC 101
QY 230 TTGCAACCATGATGCCCTAAACATTGCTTCTAGGCTTCTCCTCATCAGTTTCTTCTTACTG 289
Db 102 TTGCAACCATGATGCCCTAAACATTGCTTCTAGGCTTCTCCTCATCAGTTTCTTCTTACTG 161
QY 290 GTGTAGCAGAACTCAGTCAACGCGATGAGTCTCTGAAGCCTCAGAGGGTACAAATTTCACT 349
Db 162 GTGTAGCAGAACTCAGTCAACGCGATGAGTCTCTGAAGCCTCAGAGGGTACAAATTTCACT 221
QY 350 CCCGAAATTTTCAACAACATTTTGCAATGGCAGCCCTGGAGGGCAGCTTACTGGCAACAGCA 409
Db 222 CCCGAAATTTTCAACAACATTTTGCAATGGCAGCCCTGGAGGGCAGCTTACTGGCAACAGCA 281
QY 410 GTGTCTATTTTGTGTCAGTACAAAATCATGTTCTCATGAGCATGAAAAGCTCTCACCAGA 469
Db 282 GTGTCTATTTTGTGTCAGTACAAAAT----- 306
QY 470 AGCCAAGTGCATGCTGGCAGCACATTTCTTGTAACTTCCCAGGCTGCAGAACATTGGCTA 529
Db 307 ----- 306
QY 530 AATATGACAGAGACAATGGAATAAAGAAAGACTGTTGGGTAATCTCAAGAACTCTCTT 589
Db 307 -ATATGACAGAGACAATGGAATAAAGAAAGACTGTTGGGTAATCTCAAGAACTCTCTT 365
QY 590 GTGACCTTACCAGTGAACCTCAGACATACAGGAACCTTATTACGGAGGGTGAGGGCGG 649
Db 366 GTGACCTTACCAGTGAACCTCAGACATACAGGAACCTTATTACGGAGGGTGAGGGCGG 425
QY 650 CCTGGCTGGAGCTACTCAGAAATGAGCATGACGCCCGGTTCACTCCCTGGTGGGAAA 709
Db 426 CCTGGCTGGAGCTACTCAGAAATGAGCATGACGCCCGGTTCACTCCCTGGTGGGAAA 485
QY 710 CAAAAATAGATCCTCCAGTCATGAATATAAACCAGTCAATGCTCTTGTGTAATTC 769
Db 486 CAAAAATAGATCCTCCAGTCATGAATATAAACCAGTCAATGCTCTTGTGTAATTC 545
QY 770 TCCATGCTCCAATTTTACCATATAGATACCAAAAAGAAAAAATGTATCTATAGAGATT 829
Db 546 TCCATGCTCCAATTTTACCATATAGATACCAAAAAGAAAAAATGTATCTATAGAGATT 605
QY 830 ACTATGAACTACTATACCGAGTTTATATTAATTAACAATTCACAGAAAGAGCAAAAGG 889
Db 606 ACTATGAACTACTATACCGAGTTTATATTAATTAACAATTCACAGAAAGAGCAAAAGG 665
QY 890 TTTATGAAGGGGCTCAGAGAGCGGTTGAAATTGAAGCTCTTAACACCACACTCCAGCTACT 949
Db 666 TTTATGAAGGGGCTCAGAGAGCGGTTGAAATTGAAGCTCTTAACACCACACTCCAGCTACT 725
QY 950 GTGTAGTGGCTGAATAATATACGCCCATGTTAGACAGAGAAGTCAAGAGTGAAGAGA 1009
Db 726 GTGTAGTGGCTGAATAATATACGCCCATGTTAGACAGAGAAGTCAAGAGTGAAGAGA 785
QY 1010 GATGTGTGAAATTCATGACTGTGGAATTTGGCATTCAGCAATGTGGAATTTCTAAAG 1069
Db 786 GATGTGTGAAATTCATGACTGTGGAATTTGGCATTCAGCAATGTGGAATTTCTAAAG 845
QY 1070 CTCCTGAGAACAGAGATGCTGTTTGAAGGATCTTAATTAATTTGTTTGTATTTT 1129
Db 846 CTCCTGAGAACAGAGATGCTGTTTGAAGGATCTTAATTAATTTGTTTGTATTTT 905
QY 1130 TCTTAAGCAATATTTCACTGTTACACCTTGGGAGCTTCTTGTATCCATTTCTTATC 1189

|||||
Db 906 TCTTAAGCAATATTCACCTGTACACCTTGGGACTCTTTGTTTATCCATCTTTATC 965
QY 1190 CTTTATATTTCAATTTGTAACCTATATTTGAACGACATTCCTCCCGAAAAATTGAATGTA 1249
Db 966 CTTTATATTTCAATTTGTAACCTATATTTGAACGACATTCCTCCCGAAAAATTGAATGTA 1025
QY 1250 AAGATGAGCAGAGAAATAAGTGTCTATGAAAAAAA 1289
Db 1026 AAGATGAGCAGAGAAATAAGTGTCTATGAAATTCAGAA 1065
RESULT 10
AX151700 2149 bp DNA linear PAT 22-JUN-2001
LOCUS Sequence 1 from Patent WO0140467.
DEFINITION AX151700
ACCESSION AX151700
VERSION AX151700.1 GI:14533639
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 (bases 1 to 2149)
AUTHORS Presnell,S.R., Xu,W., Kindsvogel,W. and Chen,Z.
TITLE Human cytokine receptor
JOURNAL Patent: WO 0140467-A 1 07-JUN-2001;
ZymoGenetics, Inc. (US)
FEATURES
source
1. 2149
/organism="Homo sapiens"
/db_xref="taxon:9606"
1. .696
/note="unnamed protein product"
/codon_start=1
/protein_id="CAC42591.1"
/db_xref="GI:14533640"
/translation="MMPKHCFLGLISFLLTGAAGTOSTHESLKPQVQFQSRNHNH
LWOPGRALTGNSVYFVQKIYQORQWKNKEDCWGTOELSDLTSETDIEPYGR
VRAASAGSYSEMSMTPRFTPMWETKIDPVMNITQVNSLLVILHAPNLPYRQKEKN
VSIEDYVELLYRVFIINNSLEKQKVEGAHRAVEIALTPHSSYCVVAEIYQPLDR
RSQRSEKVEIP"
BASE COUNT 685 a 381 c 421 g 662 t
ORIGIN
Query Match 63.1%; Score 831.6; DB 6; Length 2149;
Best Local Similarity 90.4%; Pred. No. 6.1e-169;
Matches 951; Conservative 0; Mismatches 4; Indels 97; Gaps 2;
238 ATGATGCCTAAACATTTGCTTCTAGGCTCTCATCAGTTTCTTCTTACTGGTGTAGCA 297
Db 1 ATGATGCCTAAACATTTGCTTCTAGGCTCTCATCAGTTTCTTCTTACTGGTGTAGCA 60
QY 298 GGAACCTCAGTCAACGATGAGTCTCTGAAGCCTCAGAGGGTACAAATTCAGTCCCGAAAT 357
Db 61 GGAACCTCAGTCAACGATGAGTCTCTGAAGCCTCAGAGGGTACAAATTCAGTCCCGAAAT 120
QY 358 TTTCACACATTTTGCATGCGAGCCTGGGAGGGCAGCTTACTGGCAACAGCAGTGTCTAT 417
Db 121 TTTCACACATTTTGCATGCGAGCCTGGGAGGGCAGCTTACTGGCAACAGCAGTGTCTAT 180
QY 418 TTGTGTCAGTACAAATCATGTCTCATGCAAGCATGAAAAAGCTCTCACCAGAACCAAGT 477
Db 181 TTGTGTCAGTACAAAT----- 197
QY 478 GGATGCTGGCAGCAGCATTTCTTGTAACTTCCAGGCTGCAGAACATTTGGCTAATATGGA 537
Db 198 -----ATATGGA 204
QY 538 CAGAGACAATGAAAAATAAAGAAAGCTGTGGGGTACTCAAGAACTCTTGTGACCTT 597
Db 205 CAGAGACAATGAAAAATAAAGAAAGCTGTGGGGTACTCAAGAACTCTTGTGACCTT 264

QY 598 ACCAGTGAACCTCAGACATACAGGAACCTTATTTACGGAGGGGTGAGGGCGGCTCGGCT 657
Db 265 ACCAGTGAACCTCAGACATACAGGAACCTTATTTACGGAGGGGTGAGGGCGGCTCGGCT 324
QY 658 GGGAGCTACTCAGAAATGAGCATGACGCCGCGTTCACCTCCCTGGTGGAAACAAAAATA 717
Db 325 GGGAGCTACTCAGAAATGAGCATGACGCCGCGTTCACCTCCCTGGTGGAAACAAAAATA 384
QY 718 GATCCTCCAGTCATGATATAACCCAGTCAATGGCTTTTGTGTGTAATCTCCATGCT 777
Db 385 GATCCTCCAGTCATGATATAACCCAGTCAATGGCTTTTGTGTGTAATCTCCATGCT 444
QY 778 CCAATTTACCATATATGATACCAAAAGGAAAAAATGTATCTATAGAAGATTACTATGAA 837
Db 445 CCAATTTACCATATATGATACCAAAAGGAAAAAATGTATCTATAGAAGATTACTATGAA 504
QY 838 CTACTATACCGAGTTTATTAATTAACAATTCACCTAGAAAAAGGCAAAAGTTTATGAA 897
Db 505 CTACTATACCGAGTTTATTAATTAACAATTCACCTAGAAAAAGGCAAAAGTTTATGAA 564
QY 898 GGGGCTCAGAGAGCGTTGAAATTGAAGCTCTAACACCACTCCAGCTACTGTGTAGTG 957
Db 565 GGGGCTCAGAGAGCGTTGAAATTGAAGCTCTAACACCACTCCAGCTACTGTGTAGTG 624
QY 958 GCTGAATATATCAGCCCATGTTAGACAGAAAGAGTCAAGAGAGAGATGTGTG 1017
Db 625 GCTGAATATATCAGCCCATGTTAGACAGAAAGAGTCAAGAGAGAGATGTGTG 684
QY 1018 GAAATTTCCATGACTGTGTGAATTTGGCATTCAGCAATGTGGAATTTCTAAAGCTCCCTGA 1077
Db 685 GAAATTTCCATGACTGTGTGAATTTGGCATTCAGCAATGTGGAATTTCTAAAGCTCCCTGA 744
QY 1078 GAACAGGATGACTCGTGTGTAAGGATCTTATTTAAATTTGTTTGTATTTCTTAAAG 1137
Db 745 GAACAGGATGACTCGTGTGTAAGGATCTTATTTAAATTTGTTTGTATTTCTTAAAG 804
QY 1138 CAATATTCACCTGTACACCTTGGGAGCTCTTGTGTTATCCATCTTTATCCTTATAT 1197
Db 805 CAATATTCACCTGTACACCTTGGGAGCTCTTGTGTTATCCATCTTTATCCTTATAT 864
QY 1198 TTCAATTTGTAACCTATATTTGAACGACATTCCTCCCGAAAAATTGAAGTGAAGATGAG 1257
Db 865 TTCAATTT-TAAACTATATTTGAACGACATTCCTCCCGAAAAATTGAAGTGAAGATGAG 923
QY 1258 GCAGAGAAATAAGTGTCTATGAAAAAAA 1289
Db 924 GCAGAGAAATAAGTGTCTATGAAATTCAGAA 955
RESULT 11
AX179609 2149 bp DNA linear PAT 06-AUG-2001
LOCUS AX179609
DEFINITION Sequence 32 from Patent WO0146422.
ACCESSION AX179609
VERSION AX179609.1 GI:15132038
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 (bases 1 to 2149)
AUTHORS Presnell,S.R. and Kindsvogel,W.
TITLE Cytokine zcyto18
JOURNAL Patent: WO 0146422-A 32 28-JUN-2001;
ZymoGenetics, Inc. (US)
FEATURES
source
1. 2149
/organism="Homo sapiens"
/db_xref="taxon:9606"
1. .696
/note="unnamed protein product"
/codon_start=1
/protein_id="CAC49975.1"

/db_xref="GI:15132039"
/translation="MPKHCHFLGFLISFLTGVAQSTHESLKPORVOFOSRNFHNI
LWQPGRALTGNSSVYFVQYKFIQGRQWKNKEDCWQSTQELSCDLTSETSDIQEPYGR
VRAASAGSYSEWSMTPRFTPWMTKIDPVMNITQVNGSLVITLHAPNLPYRQKEKN
VSIEDYXELLYRVFIINNSLEKQVYEGAHRVAIEALTPHSSYCVVAEIIYQMLDR
RSQRSERCVEIP"

BASE COUNT 685 a 381 c 421 g 662 t
ORIGIN

Query Match 63.1%; Score 831.6; DB 6; Length 2149;
Best Local Similarity 90.4%; Pred. No. 6.1e-169;
Matches 951; Conservative 0; Mismatches 4; Indels 97; Gaps 2;

QY 238 ATGATGCTTAACATTTGCTTTCTAGGCTTCCCTCATCAGTTTCTTCTTACTGCTAGCA 297
Db 1 ATGATGCTTAACATTTGCTTTCTAGGCTTCCCTCATCAGTTTCTTCTTACTGCTAGCA 60
QY 298 GGAACCTCAGTCAACGCATGAGTCTCTGAGCCTCAGAGGGTACAAATTTCAGTCCGAAAT 357
Db 61 GGAACCTCAGTCAACGCATGAGTCTCTGAGCCTCAGAGGGTACAAATTTCAGTCCGAAAT 120
QY 358 TTTCACAACATTTTGCATGCGAGCCTGGAGGGCCTTACTGGCAACAGCAGTCTCTAT 417
Db 121 TTTCACAACATTTTGCATGCGAGCCTGGAGGGCCTTACTGGCAACAGCAGTCTCTAT 180
QY 418 TTTCGAGTACAAATCATGTTCTCATGCATGAAAGCTCTCACAGAACCAAGT 477
Db 181 TTTCGAGTACAAATCATGTTCTCATGCATGAAAGCTCTCACAGAACCAAGT 197
QY 478 GGATGCTGGCAGCACATTTCTTGTAACTTCCAGGCTGCAGAACATTTGGCTAAATATGA 537
Db 198 -----ATATGA 204
QY 538 CAGAGACAATGAAAAATAAGAACTGTTGGGTACTCAAGAACTCTTGTGACCTT 597
Db 205 CAGAGACAATGAAAAATAAGAACTGTTGGGTACTCAAGAACTCTTGTGACCTT 264
QY 598 ACCAGTGAACCTCAGACATACAGAACCTTATTACGGAGGGTGAAGGCGGCTCGGCT 657
Db 265 ACCAGTGAACCTCAGACATACAGAACCTTATTACGGAGGGTGAAGGCGGCTCGGCT 324
QY 658 GGGAGCTACTCAGATGAGCATGACGCCGGGTCTCACTCCCTGGTGGAAAAACAATA 717
Db 325 GGGAGCTACTCAGATGAGCATGACGCCGGGTCTCACTCCCTGGTGGAAAAACAATA 384
QY 718 GATCCTCCAGTCAATATTAACCAAGTCAATGGCTTTGTTGTAATTCTCCATGCT 777
Db 385 GATCCTCCAGTCAATATTAACCAAGTCAATGGCTTTGTTGTAATTCTCCATGCT 444
QY 778 CCAAAATTACCATATAGATACCAAAAGAAAAAATGTATCTATAGAGATTACTATGAA 837
Db 445 CCAAAATTACCATATAGATACCAAAAGAAAAAATGTATCTATAGAGATTACTATGAA 504
QY 838 CTACTATACCGAGTTTATTAATTAACAATTCTACTAGAAAAAGAGCAAAAGTTATGAA 897
Db 505 CTACTATACCGAGTTTATTAATTAACAATTCTACTAGAAAAAGAGCAAAAGTTATGAA 564
QY 898 GGGGCTCAGAGAGCGTTGAAATTGAAGCTCTAACACACACTCCAGCTACTGTAGTG 957
Db 565 GGGGCTCAGAGAGCGTTGAAATTGAAGCTCTAACACACACTCCAGCTACTGTAGTG 624
QY 958 GCTGAAATATATCAGCCCATGTTAGACAGAGAAGTCAAGAGAGATGATGTG 1017
Db 625 GCTGAAATATATCAGCCCATGTTAGACAGAGAAGTCAAGAGAGATGATGTG 684
QY 1018 GAAATTTCCATGACTGTGGAATTGGCATTCAGCAATGTGGAATTCTAAAGCTCCCTGA 1077
Db 685 GAAATTTCCATGACTGTGGAATTGGCATTCAGCAATGTGGAATTCTAAAGCTCCCTGA 744
QY 1078 GAACAGATGACTGTGTTGAAGGATCTTATTTAAATTTGTTTGTATTTCTTAAG 1137
Db 745 GAACAGATGACTGTGTTGAAGGATCTTATTTAAATTTGTTTGTATTTCTTAAG 804

QY 1138 CAATATTCACCTGTACACCTTGGGAGCTTCTTGTATATCCATTTCTTATCCCTTATAT 1197
Db 805 CAATATTCACCTGTACACCTTGGGAGCTTCTTGTATATCCATTTCTTATCCCTTATAT 864
QY 1198 TTTCATTTGTAACATAATTTGAACGACATTCGCCCGGAAAAAATGAAATGTAAGATGAG 1257
Db 865 TTTCATTT-TAACTATATTTGAACGACATTCGCCCGGAAAAAATGAAATGTAAGATGAG 923
QY 1258 GCAGAGATAAAGTGTCTATGAAAAAAA 1289
Db 924 GCAGAGATAAAGTGTCTATGAAATTCAGAA 955

RESULT 12
AX399656 810 bp DNA linear PAT 06-JUN-2002
LOCUS
DEFINITION Sequence 5 from Patent EP1191035.
ACCESSION AX399656
VERSION AX399656.1 GI:21335432
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1
AUTHORS Weiss, B., Sabat, R., Assadullah, K. and Toshi, L.
TITLE Three members of the cytokin-receptor class II family
JOURNAL Patent: EP 1191035-A 5 27-MAR-2002;
FEATURES
location/Qualifiers
source 1. 810
/organism="Homo sapiens"
/db_xref="taxon:9606"

BASE COUNT 253 a 172 c 184 g 201 t
ORIGIN
Query Match 61.1%; Score 805.2; DB 6; Length 810;
Best Local Similarity 99.6%; Pred. No. 3e-163;
Matches 807; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 227 CACTTGCAACCATGATGCTTAACATTTGCTTCTAGGCTTCCCTCATCAGTTTCTTCTTA 286
Db 1 CACTTGCAACCATGATGCTTAACATTTGCTTCTAGGCTTCCCTCATCAGTTTCTTCTTA 60
QY 287 CTGGTGTAGCAGGAACCTCAGTCAACGCATGAGTCTCTGAAGCCTCAGAGGGTACAATTTC 346
Db 61 CTGGTGTAGCAGGAACCTCAGTCAACGCATGAGTCTCTGAAGCCTCAGAGGGTACAATTTC 120
QY 347 AGTCCCGAAATTTTCACAACATTTTGCATATGGCAGCCTGGGAGGGCACTTACTGGCAACA 406
Db 121 AGTCCCGAAATTTTCACAACATTTTGCATATGGCAGCCTGGGAGGGCACTTACTGGCAACA 180
QY 407 GCAGTGTCTATTTTGTGACATCAAAATCATGTCTCATGCGACATGAAAAAGCTCTCACC 466
Db 181 GCAGTGTCTATTTTGTGACATCAAAATCATGTCTCATGCGACATGAAAAAGCTCTCACC 240
QY 467 AGAAGCCAAGTGGATGCTGGCAGCACATTTCTTGTAACTTCCAGGCTGCAGAACATTTGG 526
Db 241 AGAAGCCAAGTGGATGCTGGCAGCACATTTCTTGTAACTTCCAGGCTGCAGAACATTTGG 300
QY 527 CTAATATGACAGACACAATGGAATAAAGAAAGACTGTGGGGTACTCAAGAACTCT 586
Db 301 CTAATATGACAGACACAATGGAATAAAGAAAGACTGTGGGGTACTCAAGAACTCT 360
QY 587 CTGTGACCTTACCAAGTGAACCTCAGACATACAGAACTTATTACGGAGAGGTGAGGG 646
Db 361 CTGTGACCTTACCAAGTGAACCTCAGACATACAGAACTTATTACGGAGAGGTGAGGG 420
QY 647 CGGCTCGGCTGGAGCTACTCAGAAATGAGCATGAGCGCGGCTCACCTCCCTGTGGG 706
Db 421 CGGCTCGGCTGGAGCTACTCAGAAATGAGCATGAGCGCGGCTCACCTCCCTGTGGG 480
QY 707 AAACAAAAATAGATCTCCAGTCATGATATTAACCAAGTCAATGGCTCTTGTGTGTA 766

|||||
Db 481 AAACAAATAGATCCTCCAGTCATGAATTAACCAAGTCAATGCTTTGTGTAA 540
QY 767 TTCTCCATGCTCCAAATTTACCATATAGATACCAAAAGAAAAATGTATCTATAGAAG 826
Db 541 TTCTCCATGCTCCAAATTTACCATATAGATACCAAAAGAAAAATGTATCTATAGAAG 600
QY 827 ATTACTATGACTACTATACCGAGTTTTATTAATTAACAATTCAGTAAAGAGCAAA 886
Db 601 ATTACTATGACTACTATACCGAGTTTTATTAATTAACAATTCAGTAAAGAGCAAA 660
QY 887 AGGTTATGAGGGGCTCACAGAGCGGTGAATGAAGCTCTAACACCACTCCAGCT 946
Db 661 AGGTTATGAGGGGCTCACAGAGCGGTGAATGAAGCTCTAACACCACTCCAGCT 720
QY 947 ACTGTGTAGTGGCTGAATATATATCAGCCCATGTAGACAGAAGAGTCAGAGAAGTGAAG 1006
Db 721 ACTGTGTAGTGGCTGAATATATATCAGCCCATGTAGACAGAAGAGTCGAGAAGTGAAG 780
1007 AGAGATGTGTGAAATTCATGACTGTGG 1036
781 AGAGATGTGTGAAATTCATGACTGTGG 810

RESULT 13
LOCUS AY040568 2593 bp mRNA linear PRI 19-AUG-2001
DEFINITION Homo sapiens interleukin 22-binding protein CRF2-10S (IL22BP) mRNA,
complete cds, alternatively spliced.
ACCESSION AY040568
VERSION AY040568.1 GI:15212829
KEYWORDS
SOURCE Homo sapiens.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
1 (bases 1 to 2593)
Kotenko, S.V., Izotova, L.S., Mirochnitchenko, O.V., Esterova, E.,
Dickensheets, H., Donnelly, R.P. and Pestka, S.
IDENTIFICATION, cloning, and characterization of a novel soluble
receptor that binds IL-22 and neutralizes its activity
J. Immunol. 166 (12), 7096-7103 (2001)
21286453
MEDLINE 11390454
PUBMED 2 (bases 1 to 2593)
Kotenko, S.V. and Pestka, S.
REFERENCE
AUTHORS Direct Submission
TITLE Submitted (15-JUN-2001) Molecular Genetics and Microbiology,
UMDNJ-Robert Wood Johnson Medical School, 675 Hoes Lane,
Piscataway, NJ 08854-5635, USA

FEATURES
source
1..2593
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="6"
/map="6q25.1"
1..2593
/gene="IL22BP"
275..667
/gene="IL22BP"
/note="secreted protein; short splice variant of
CRF2-10/IL-22BP; alternatively spliced"
/codon_start=1
/product="interleukin 22-binding protein CRF2-10S"
/protein_id="AAK85716.1"
/db_xref="GI:15212830"
/translation="MMPKHCFLGFLISFLTGAGTOSTHESLKPORVOFOSRNFHNI
LQWPGRALTGNSYFVQYKIYQORQWKNKEDCWGTQELSCDLTSETSDIOEPIYGR
VRAASAGSYSEMSMTPFRFTPWVERAKGL"
BASE COUNT 798 a 448 c 507 g 840 t

ORIGIN
Query Match 55.4%; Score 730.6; DB 9; Length 2593;

Best Local Similarity 79.1%; Pred. No. 3.5e-147;
Matches 1019; Conservative 0; Mismatches 4; Indels 266; Gaps 2;
QY 1 CAGTTTCTTCATCTGTACATCAATGAATTAATATACCAATCTCCTAGACTTCATAAGA 60
Db 38 CAGTTTCTTCATCTGTACATCAATGAATTAATATACCAATCTCCTAGACTTCATAAGA 97
QY 61 GGATTTAACAAAGACAAATATGGGAAAAACATAACATGGCGTCCCATTAATTAAGATCT 120
Db 98 GGATTTAACAAAGACAAATATGGGAAAAACATAACATGGCGTCCCATTAATTAAGATCT 157
QY 121 TATTATTGACACTAAATGGCATTTAAATTAACCAAAAGGAAGACAGCATCTGTTCTCT 180
Db 158 TATTATTGACACTAAATGGCATTTAAATTAACCAAAAGGAAGACAGCATCTGTTCTCT 217
QY 181 TTGTCCTGAGCTGGTTAAAGGAACACTGGTGGCTGAACAGTCAACACTTGAACCATG 240
Db 218 TTGTCCTGAGCTGGTTAAAGGAACACTGGTGGCTGAACAGTCAACACTTGAACCATG 277
QY 241 ATGCCATAACATTCCTTTCTAGGCTTCCCTCATCAGTTTCTTCTTACTGTTGACAGGA 300
Db 278 ATGCCATAACATTCCTTTCTAGGCTTCCCTCATCAGTTTCTTCTTACTGTTGACAGGA 337
QY 301 ACTCAGTCAACGCGATGAGTCTCTGAAAGCCTCAGAGGGTACAAATTTTCCGGAATTTT 360
Db 338 ACTCAGTCAACGCGATGAGTCTCTGAAAGCCTCAGAGGGTACAAATTTTCCGGAATTTT 397
QY 361 CACAACATTTTGCATATGGCAGCCTGGAGGGCAGCTTACTGGCAACAGCAGTGTCTATTTT 420
Db 398 CACAACATTTTGCATATGGCAGCCTGGAGGGCAGCTTACTGGCAACAGCAGTGTCTATTTT 457
QY 421 GTGCAGTACAAATCATGTCTCATGACATGAAAAAGCTCTCACCAAGAACCAAGTGA 480
Db 458 GTGCAGTACAAATCATGTCTCATGACATGAAAAAGCTCTCACCAAGAACCAAGTGA 471
QY 481 TGCTGGCAGCAGATTTCTGTAACTTCCAGGCTGAGAACATTTGGCTAAATATGACAG 540
Db 472 TGCTGGCAGCAGATTTCTGTAACTTCCAGGCTGAGAACATTTGGCTAAATATGACAG 481

QY 541 AGACAATGAAAAAATAAGAGAGCTGTTGGGTACTCAAGAACTCTTGTGACCTTACC 600
Db 482 AGACAATGAAAAAATAAGAGAGCTGTTGGGTACTCAAGAACTCTTGTGACCTTACC 541
QY 601 AGTGAACCTCAGACATACAGGAACCTTATTACGGAGGCTGAGGGCGCTCGGCTGGG 660
Db 542 AGTGAACCTCAGACATACAGGAACCTTATTACGGAGGCTGAGGGCGCTCGGCTGGG 601
QY 661 AGCTACTCAGATGAGCATGACGCGCGGCTTACTCCCTGGTGGGAAACAAATATAGAT 720
Db 602 AGCTACTCAGATGAGCATGACGCGCGGCTTACTCCCTGGTGGGAAACAAATATAGAT 650
QY 721 CCTCCAGTCATGAATATTAACCAAGTCAATGGCTTGTGTTGTAATTTCTCATGCTCCA 780
Db 651 CCTCCAGTCATGAATATTAACCAAGTCAATGGCTTGTGTTGTAATTTCTCATGCTCCA 650
QY 781 AATTTCACATATAGATACCAAAAGGAATAATGTATCTATAGAAGATTACTATGAACCTA 840
Db 651 AATTTCACATATAGATACCAAAAGGAATAATGTATCTATAGAAGATTACTATGAACCTA 650
QY 841 CTATACCGAGTTTATTAATTAACAATTCAGTAAAGAGCAAAAGGTTTATGAAGGG 900
Db 651 CTATACCGAGTTTATTAATTAACAATTCAGTAAAGAGCAAAAGGTTTATGAAGGG 671
QY 901 GCTCACAGAGCGGTGAAATTAAGCTCTTAACACACACACTCCAGCTACTGTAGTGCGT 960
Db 672 GCTCACAGAGCGGTGAAATTAAGCTCTTAACACACACACTCCAGCTACTGTAGTGCGT 731
QY 961 GAAATATATCAGCCCATGTAGACAGAAGAAGTCAAGAGAAGTGAAGAGATGTGTGAA 1020
Db 732 GAAATATATCAGCCCATGTAGACAGAAGAAGTCAAGAGAAGTGAAGAGATGTGTGAA 791
QY 1021 ATTCCATGACTTGTGAATTTGGCAATTCAGCAATGTGGAATTTCTAAAGCTCCCTGAGAA 1080
Db 1021 ATTCCATGACTTGTGAATTTGGCAATTCAGCAATGTGGAATTTCTAAAGCTCCCTGAGAA 1080

Db 792 ATTCATGACTGTGGAATTGGCAATTCAGCAATGTGAAATCTAAGCTCCCTGAGAA 851
QY 1081 CAGGATGACTGCTGTTGAAGGATCTTATTTAAATGTTTTGATTTCTTAAGCAA 1140
Db 852 CAGGATGACTGCTGTTGAAGGATCTTATTTAAATGTTTTGATTTCTTAAGCAA 911
QY 1141 TATTCACCTGTACACCTTGGGACCTTCTTTGTTATCCATCTTTATCTTATATTC 1200
Db 912 TATTCACCTGTACACCTTGGGACCTTCTTTGTTATCCATCTTTATCTTATATTC 971
QY 1201 ATTTGTAACCTATATTGGAACGACATTCCTCCCGAATAATGGAATGTAAGATGAGCA 1260
Db 972 ATTTGTAACCTATATTGGAACGACATTCCTCCCGAATAATGGAATGTAAGATGAGCA 1031
QY 1261 GAGAATAAAGTGTCTATGAAAAA 1289
Db 1032 GAGAATAAAGTGTCTATGAAATTCAGAA 1060

RESULT 14
97262

DEFINITION HSA297262 775 bp mRNA linear PRI 19-DEC-2001
Homo sapiens mRNA for interleukin-22 binding protein (IL-22BP gene).
ACCESSION AJ297262
VERSION AJ297262.1 GI:17974196
KEYWORDS IL-22BP gene; interleukin-22 binding protein.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE 1
Dumontier, L., Lejeune, D. and Renaud, J.C.
Cloning and characterization of interleukin-22 Binding Protein (IL-22BP), a natural antagonist of IL-17F/IL-22
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 775)
Renaud, J.C.
TITLE Direct Submission
JOURNAL Submitted (19-DEC-2000) Renaud J.C., UCL 74.59, Ludwig Institute for Cancer Research, Avenue Hippocrate, 74, B-1200 Brussels, BELGIUM

FEATURES
source location/Qualifiers
1. 775

gene
CDS
/organism="Homo sapiens"
/db_xref="taxon:9606"
/tissue_type="breast"
22. 717
/gene="IL-22BP"
22. 717
/gene="IL-22BP"
/codon_start=1
/product="interleukin-22 binding protein"
/protein_id="CAC83097.1"
/db_xref="GI:17974197"
/translation="MMPKHCFLGLISFLTGVAQTSTHESLKPQVQFOSRNFHNI
LQWPGRALTGNSSVYFVQKIYQROWKNKEDCWGTOELSDLTSETSDIQEPIYGR
VRAASAGSYSEMSMTPEFTPMWETKIDPPVMNITOVNGSLVILHAPNLPYRYQKEKN
VSIEDYELLYRVFIINNSLEKQKVEGAHRAVEITLPHSSYCVVAETIYQPMIDR
RSORSEERCEIIP"

BASE COUNT 248 a 157 c 175 g 195 t

Query Match 50.8%; Score 669; DB 9; Length 775;
Best Local Similarity 89.0%; Pred. No. 6.7e-134;
Matches 775; Conservative 0; Mismatches 0; Indels 96; Gaps 1;

QY 217 TGAACAGTCACACCTGCAACCATGATGCGCTTAACATTCCTTTCTAGGCTTCTCATCAGT 276
Db 1 TGAACAGTCACACCTGCAACCATGATGCGCTTAACATTCCTTTCTAGGCTTCTCATCAGT 60
QY 277 TTCTTCCTTACTGCTGTAGCAGAACTCAGTCAACGCATGAGTCTCTGAAGCCTCAGAG 336
|||||

Db 61 TTCTTCCTTACTGCTGTAGCAGAACTCAGTCAACGCATGAGTCTCTGAAGCCTCAGAG 120
QY 337 GTACAATTTCAGTCCCGAAATTTTCACACATTTTGCATATGCGAGCCTGGAGGCACTT 396
Db 121 GTACAATTTCAGTCCCGAAATTTTCACACATTTTGCATATGCGAGCCTGGAGGCACTT 180
QY 397 ACTGGACACAGCAGTGTCTATTTTGTGAGTACAAATTCATGTCTCATGACGATGAA 456
Db 181 ACTGGACACAGCAGTGTCTATTTTGTGAGTACAAAT
QY 457 AGCTCTCACCAGAACCAAGTGATGCTGGCAGCAATTTCTTGAATCTCCAGGCTGC 516
Db 219
QY 517 AGACATTGGCTAATATGACAGAGACAATGGAATAATAAGAGACTGTGGGCTACT 576
Db 219 -----ATATGACAGAGACAATGGAATAATAAGAGACTGTGGGCTACT 264
QY 577 CAAGACTCTCTTGTGACCTTACAGTGAACCTCAGACATACAGGAACCTTATTACGGG 636
Db 265 CAAGACTCTCTTGTGACCTTACAGTGAACCTCAGACATACAGGAACCTTATTACGGG 324
QY 637 AGGCTGAGGGCGGCGCTCGGCTGGAGCTACTCAGAATGAGCATGACCGCGGCTCACT 696
Db 325 AGGCTGAGGGCGGCGCTCGGCTGGAGCTACTCAGAATGAGCATGACCGCGGCTCACT 384
QY 697 CCTGTGTGGGAAACAAAATAGATCCCTCCAGTCATGATATTAACCAAGTCAATGGCTCT 756
Db 385 CCTGTGTGGGAAACAAAATAGATCCCTCCAGTCATGATATTAACCAAGTCAATGGCTCT 444
QY 757 TTGTTGTTAATTTCTCCATGCTCCCAATTTTACCATATAGATACCAAAAGAAAATGTA 816
Db 445 TTGTTGTTAATTTCTCCATGCTCCCAATTTTACCATATAGATACCAAAAGAAAATGTA 504
QY 817 TCTATAGAGATTACTATGAACTACTATACCGAGTTTATTAATTAACAATTCACGTAGAA 876
Db 505 TCTATAGAGATTACTATGAACTACTATACCGAGTTTATTAATTAACAATTCACGTAGAA 564
QY 877 AAGGAGCAAAAGGTTTATGAAGGGGCTCAGAGAGCGGTTGAAATGGAAGCTTAACACCA 936
Db 565 AAGGAGCAAAAGGTTTATGAAGGGGCTCAGAGAGCGGTTGAAATGGAAGCTTAACACCA 624
QY 937 CACTCCAGCTACTGTAGTGGCTGAATATATACGCCCATGTGAGACAGAAAGTCAAG 996
Db 625 CACTCCAGCTACTGTAGTGGCTGAATATATACGCCCATGTGAGACAGAAAGTCAAG 684
QY 997 AGAAGTGAAGAGATGTGTGGAATTTCCATGACTTGTGAATTTGGCATTGCAATGT 1056
Db 685 AGAAGTGAAGAGATGTGTGGAATTTCCATGACTTGTGAATTTGGCATTGCAATGT 744
QY 1057 GGAATTTCTAAAGCTCCCTGAGACAGCATG 1087
Db 745 GGAATTTCTAAAGCTCCCTGAGACAGCATG 775
|||||

RESULT 15
AX193705

LOCUS AX193705 696 bp DNA linear PAT 15-AUG-2001
DEFINITION Sequence 27 from Patent WO0136467.
ACCESSION AX193705
VERSION AX193705.1 GI:15211554
KEYWORDS human.
SOURCE Homo sapiens
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE 1 (bases 1 to 696)
Gorman, D.M.
Mammalian receptor proteins; related reagents and methods
Patent: WO 0136467-A 27 25-MAY-2001;
JOURNAL SCHERING CORPORATION (US)
TITLE Location/Qualifiers

FEATURES
source 1. 696

GenCore version 5.1.3
Copyright (c) 1993 - 2002 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 22, 2002, 06:48:36 ; Search time 252 Seconds
(without alignments)
11778.309 Million cell updates/sec

```
Title: US-09-964-994-1
Perfect score: 1318
Sequence: 1 cagttctcatctgtaca.....aaaaaaaaaaaaaaaa 1318
```

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 1125999159 residues
 1 number of hits satisfying chosen parameters: 4370478

```
Minimum DB seq length: 0
Maximum DB seq length: 2000000000
```

Post-processing:	Minimum Match	0%
	Maximum Match	100%
	Listing first	45 summaries

N_Geneseq_101002: *

- 1: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT: *
- 2: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT: *
- 3: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT: *
- 4: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT: *
- 5: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT: *
- 6: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT: *
- 7: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT: *
- 8: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT: *
- 9: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT: *
- 10: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT: *
- 11: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT: *
- 12: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT: *
- 13: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT: *
- 14: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT: *
- 15: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT: *
- 16: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT: *
- 17: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT: *
- 18: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT: *
- 19: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT: *
- 20: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT: *
- 21: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT: *
- 22: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT: *
- 23: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT: *
- 24: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	1318	100.0	1318	22	AAS15368	cDNA encoding huma
2	1094.4	83.0	2367	24	ABK50080	DNA encoding human
3	1079	81.9	1389	24	ABK70017	cDNA encoding huma
4	1078.4	81.8	1255	24	AAL46000	Human cytokine rec
5	910	69.0	2271	24	ABK50076	DNA encoding human
6	831.6	63.1	2149	22	AAD09745	Human ZCYTO18 solu
7	831.6	63.1	2149	22	AAF83735	Human cytokine rec
8	805.2	61.1	810	24	AAL46001	Human cytokine rec
9	792	60.1	792	24	AAD27816	Human cytokine rec

10	590	44.8	696	24	AAD27815	Human cytokine rec
11	588.4	44.6	696	22	AAD06414	Human DNAX cytokin
12	533	40.4	645	24	AAD27814	Human cytokine rec
13	449.2	34.1	750	22	AAD06410	Human DNAX cytokin
14	449.2	34.1	750	24	AAL45999	Human cytokine rec
15	398.2	30.2	693	22	AAD06415	Human DNAX cytokin
16	398.2	30.2	693	22	AAF83736	Human cytokine rec
17	319.6	24.2	747	22	AAD06411	Human DNAX cytokin
18	269.8	20.5	526	22	AAD06416	Human DNAX cytokin
19	197.8	15.0	298	24	AAL46018	Rat cytokine recep
20	171.4	13.0	478	22	ABA55915	Human foetal liver
21	171.4	13.0	478	24	ABS04167	Human genome-deriv
22	171.4	13.0	528	22	ABA59679	Human foetal liver
23	171.4	13.0	528	22	ABA28221	Probe #6687 for ge
24	171.4	13.0	528	22	AAK07949	Human brain expres
25	171.4	13.0	528	22	AAK33818	Human bone marrow
26	171.4	13.0	528	22	AAI16545	Probe #6478 for ge
27	171.4	13.0	528	22	AAI39544	Probe #8230 used t
28	171.4	13.0	528	24	ABS08670	Human genome-deriv
29	170	12.9	170	22	ABA72221	Human foetal liver
30	170	12.9	170	22	ABA38101	Probe #16567 for g
31	170	12.9	170	22	AAK20644	Human brain expres
32	170	12.9	170	22	AAK46787	Human bone marrow
33	170	12.9	170	22	AAI25742	Probe #15675 for g
34	170	12.9	170	22	AAI52626	Probe #21312 used
35	170	12.9	170	24	ABS21105	Human genome-deriv
36	166.2	12.6	390	22	AAD06417	Human DNAX cytokin
37	128	9.7	128	22	ABA68503	Human foetal liver
38	128	9.7	128	24	ABS16694	Human genome-deriv
39	75.4	5.7	1806	22	AAS07662	Mouse cDNA encodin
40	75.4	5.7	1806	22	AAH22834	Mouse IL-20 recep
41	75.4	5.7	1806	24	ABK96195	DNA encoding mouse
42	71	5.4	550	23	ABV57072	Human prostate exp
43	70	5.3	348	22	AAL10133	Human breast cancer
44	67.2	5.1	309	23	ABV44994	Human prostate exp
45	67	5.1	1720	22	AAS07675	Human IL-20RA/immu

ALIGNMENTS

RESULT 1	
AAS15368	
ID	AAS15368 standard; CDNA; 1318 BP.

AC AAS15368;

DT 16-JAN-2002 (first entry)

CDNA encoding human PRO19598 polypeptide.

KW Human; PRO19598; clone DNA145887; immune-related disorder;
KW inflammatory disorder; infectious disorder; immunodeficiency disorder;
KW autoimmune disorder; renal disease; demyelinating disease; skin disease
KW neoplasia; transplantation associated disease; gene therapy;
KW immunosuppressive; anti-inflammatory; antidiabetic; ss.

OS Homo sapiens.

FT	key	Location/Qualifiers
FT	CDS	241..1029
FT		/*tag= a
FT		/product= "PRO19598 polypeptide"
FT	sig_peptide	241..300
FT		/*tag= b
FT	mat_peptide	301..1026
FT		/*tag= c

XX 03-MAR-2000; 2000US-187202P.
PR 21-MAR-2000; 2000US-191015P.
PR 30-MAY-2000; 2000WO-US14941.
PR 05-JUN-2000; 2000US-209832P.
PR 24-AUG-2000; 2000WO-US23328.
PR 01-DEC-2000; 2000WO-US32678.

XX (GETH) GENENTECH INC.

XX PA Eaton DL, Fong S, Goddard A, Godowski PJ, Grimaldi CJ, Gurney AL;
PI Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2001-625876/72.
DR P-PSDB; AAU09186.

XX Nucleic acids encoding PRO polypeptides, useful for detecting and
PT treating immune related diseases and disorders in mammals including
PT autoimmune diseases, inflammatory diseases and asthma -

Claim 2; Fig 17; 122pp; English.

CC The present invention relates to the isolation of 9 novel human PRO
CC polypeptides (AAU09178-AAU09186) and the cDNA sequences encoding them.
CC The novel PRO polypeptides include PRO1356, PRO1268, PRO1884, PRO3444,
CC PRO3151, PRO4322, PRO9964, PRO10008 and PRO19598. The cDNA sequences
CC encoding these PRO polypeptides have been designated as clones
CC DNA6486-1601, DNA64903-1553, DNA84318-2520, DNA87997, DNA89273,
CC DNA92223-2567, DNA96973, DNA101921 and DNA145887 respectively.
CC Compositions (e.g. vaccines) containing PRO polypeptides and methods of
CC using these compositions are useful in the treatment and diagnosis of
CC immune-related disorders. Such disorders include immune-mediated
CC inflammatory disorders (e.g. osteoarthritis), non-immune-mediated
CC inflammatory disorders (e.g. diabetes mellitus), infectious disorders
CC (e.g. granulomatous hepatitis), immunodeficiency disorders (e.g. AIDS),
CC autoimmune disorders (e.g. rheumatoid arthritis), immune-related renal
CC diseases (e.g. cirrhosis), demyelinating diseases of the peripheral or
CC central nervous system (e.g. Guillain-Barre syndrome), immune-mediated
CC skin diseases (e.g. contact dermatitis), neoplasias and transplantation
CC associated diseases. The polynucleotide sequences of the invention may
CC be used in gene therapy. AAS15360-AAS15368 represent cDNA sequences
CC encoding for the novel human PRO polypeptides of the invention.

XX Sequence 1318 BP; 451 A; 251 C; 259 G; 357 T; 0 other;

Query Match 100.0%; Score 1318; DB 22; Length 1318;
Best Local Similarity 100.0%; Pred. No. 5.3e-263;

Matches 1318; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DB 1 CAGTTCTCTCATCTGTACATCAATGAATTAATATACCAATCTCTAGACTTCATAGA 60
1 CAGTTCTCTCATCTGTACATCAATGAATTAATATACCAATCTCTAGACTTCATAGA 60
QY 61 GGATTAACAAGACAATAATATGGGAAACATTAACATGGCTCCCATTAATTAGATCT 120
DB 61 GGATTAACAAGACAATAATATGGGAAACATTAACATGGCTCCCATTAATTAGATCT 120
QY 121 TATTAATGACACTAAATGGCATTAATTAACCAAAAGAGAGACAGCATCTGTTCTCT 180
DB 121 TATTAATGACACTAAATGGCATTAATTAACCAAAAGAGAGACAGCATCTGTTCTCT 180
QY 181 TTGCTCCTGAGCTGTTAAAGAGACACTGTTGCCCTGAACAGTCACTTGCAACCATG 240
DB 181 TTGCTCCTGAGCTGTTAAAGAGACACTGTTGCCCTGAACAGTCACTTGCAACCATG 240
QY 241 ATGCCTAAACATGCTTCTAGGCTTCTCATCATGTTTCTTCTTACTGTTAGCAGGA 300
DB 241 ATGCCTAAACATGCTTCTAGGCTTCTCATCATGTTTCTTCTTACTGTTAGCAGGA 300
QY 301 ACTCAGTCAACGACATGAGTCTGAGCCTCAGAGGGTACAAATTTCACTCCGAAATTTT 360
DB 301 ACTCAGTCAACGACATGAGTCTGAGCCTCAGAGGGTACAAATTTCACTCCGAAATTTT 360

QY 361 CACAACATTTTGGCAATGGCAGCCTGGAGGGCATTACTGGCAACAGCAGTGTCTATT 420
DB 361 CACAACATTTTGGCAATGGCAGCCTGGAGGGCATTACTGGCAACAGCAGTGTCTATT 420
QY 421 GTGAGTACAAAATCATGTCTTCATGACGATGAAAAGCTCTCACGAGAAGCCAAAGTGA 480
DB 421 GTGAGTACAAAATCATGTCTTCATGACGATGAAAAGCTCTCACGAGAAGCCAAAGTGA 480
QY 481 TGCTGGCAGCAGCATTTCTTGTAACTTCCAGGCTGACAGAACATTGGCTAATATGACAG 540
DB 481 TGCTGGCAGCAGCATTTCTTGTAACTTCCAGGCTGACAGAACATTGGCTAATATGACAG 540
QY 541 AGACAATGGAATAAAGAGAGACTGTTGGGGTACTCAAGAACTCTCTGTGACCTTACC 600
DB 541 AGACAATGGAATAAAGAGAGACTGTTGGGGTACTCAAGAACTCTCTGTGACCTTACC 600
QY 601 AGTGAACCTCAGACATTAACAGAAACCTTATTACGGGAGGGTGAGGGCGGCTGGG 660
DB 601 AGTGAACCTCAGACATTAACAGAAACCTTATTACGGGAGGGTGAGGGCGGCTGGG 660
QY 661 AGCTACTCAGAAATGAGCAATGACGCGCGGTTCACTCCCTGGTGGGAAACAAATATAGAT 720
DB 661 AGCTACTCAGAAATGAGCAATGACGCGCGGTTCACTCCCTGGTGGGAAACAAATATAGAT 720
QY 721 CCTCCAGTCAATATTAACCCCAAGTCAATGCTCTTGTGTTGTAATTTCTCCATGCTCCA 780
DB 721 CCTCCAGTCAATATTAACCCCAAGTCAATGCTCTTGTGTTGTAATTTCTCCATGCTCCA 780
QY 781 AATTACCATATAGATACCAAAAGGAAATGTATCTATAGAAGATTACTATGAACCTA 840
DB 781 AATTACCATATAGATACCAAAAGGAAATGTATCTATAGAAGATTACTATGAACCTA 840
QY 841 CTATACCGAGTTTATTAATTAACAATTCCTACTAGAAAAGAGCAAAAGGTTATGAAGG 900
DB 841 CTATACCGAGTTTATTAATTAACAATTCCTACTAGAAAAGAGCAAAAGGTTATGAAGG 900
QY 901 GCTCAGAGAGCGGTTGAATGAAGCTCTAACACCCACACTCAGCTACTGTAGTGGCT 960
DB 901 GCTCAGAGAGCGGTTGAATGAAGCTCTAACACCCACACTCAGCTACTGTAGTGGCT 960
QY 961 GAAATATATCAGCCCATGTTAGACAGAAAGAGTCAAGAGTGAAGATGTGTGAA 1020
DB 961 GAAATATATCAGCCCATGTTAGACAGAAAGAGTCAAGAGTGAAGATGTGTGAA 1020
QY 1021 ATTCCATGACTTGTGAATTTGGCATTCAGCAATGTGAATTTCTAAAGCTCCCTGAGAA 1080
DB 1021 ATTCCATGACTTGTGAATTTGGCATTCAGCAATGTGAATTTCTAAAGCTCCCTGAGAA 1080
QY 1081 CAGGATGACTCGTGTGGAAGATCTTATTAATTTGTTTGTATTTCTTAAGCAA 1140
DB 1081 CAGGATGACTCGTGTGGAAGATCTTATTAATTTGTTTGTATTTCTTAAGCAA 1140
QY 1141 TATTCACCTGTTACACCTTGGGACTTCTTGTATTCATCTTTATCCTTATATTTTC 1200
DB 1141 TATTCACCTGTTACACCTTGGGACTTCTTGTATTCATCTTTATCCTTATATTTTC 1200
QY 1201 ATTTGTAACTATATTGAACGACATTCCTCCCGGAAATTTGAATGTAAGATGAGCA 1260
DB 1201 ATTTGTAACTATATTGAACGACATTCCTCCCGGAAATTTGAATGTAAGATGAGCA 1260
QY 1261 GAGAAATAAAGTGTCTATGAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAAAG 1318
DB 1261 GAGAAATAAAGTGTCTATGAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAAAG 1318

RESULT 2
ABK50080
ID ABK50080 standard; DNA; 2367 BP.
XX ABK50080;
AC ABK50080;
XX 15-JUL-2002 (first entry)
DT
XX

XX 15-JUL-2002 (first entry)
XX CDNA encoding human Pro peptide #57.
DE Human; ss; gene; PRO; secreted protein; transmembrane protein;
KW genetic disorder; tumour; cancer.
XX Homo sapiens.
XX WO200224888-A2.
XX 28-MAR-2002.
XX 29-AUG-2001; 2001WO-US27099.
XX 01-SEP-2000; 2000US-229896P.
XX 05-SEP-2000; 2000US-230621P.
XX 22-SEP-2000; 2000US-235147P.
XX 10-NOV-2000; 2000WO-US30873.
XX 12-JAN-2001; 2001US-261878P.
XX 16-JAN-2001; 2001US-261910P.
XX 16-JAN-2001; 2001US-261939P.
XX 16-JAN-2001; 2001US-262150P.
XX 25-JAN-2001; 2001US-264395P.
XX 02-FEB-2001; 2001US-266421P.
XX 09-FEB-2001; 2001US-267623P.
XX 28-FEB-2001; 2001WO-US06520.
XX 09-MAR-2001; 2001US-274399P.
XX 03-APR-2001; 2001US-280982P.
XX 04-APR-2001; 2001US-282129P.
XX 04-APR-2001; 2001US-282199P.
XX 09-MAY-2001; 2001US-290589P.
XX 25-MAY-2001; 2001WO-US17092.
XX 01-JUN-2001; 2001WO-US17800.
XX 20-JUN-2001; 2001WO-US19692.
XX 29-JUN-2001; 2001WO-US21066.
XX 09-JUL-2001; 2001WO-US21735.
XX (GETH) GENENTECH INC.
XX Baker KP, Eaton DL, Filvaroff E, Goddard A, Grimaldi JC;
XX Gurney AL, Smith V, Stephan J, Watanabe CK, Wood WI, Zhang Z;
XX Fong S;
XX WPI; 2002-362426/39.
XX P-PSDB; ABG34086.

CC a human PRO protein of the invention.
XX Sequence 1389 BP; 460 A; 269 C; 260 G; 400 T; 0 other;
SQ
Query Match
Best Local Similarity 81.9%; Score 1079; DB 24; Length 1389;
Matches 1188; Conservative 0; Mismatches 5; Indels 96; Gaps 1;
QY 1 CAGTTTCTCATCTGTACATCAATGAATAATAATACCAATCTCTAGACTTCATAAGA 60
DB 63 CAGTTTCTCATCTGTACATCAATGAATAATAATACCAATCTCTAGACTTCATAAGA 122
QY 61 GGATTACAAAGACAAATATGGGAAAAACATACATGGCGTCCCATATATATAGATCT 120
DB 123 GGATTACAAAGACAAATATGGGAAAAACATACATGGCGTCCCATATATATAGATCT 182
QY 121 TATTTAGACACTAAATGGCATTAATAATTACCAAAAGAGACAGCATCTGTTCTCT 180
DB 183 TATTTAGACACTAAATGGCATTAATAATTACCAAAAGAGACAGCATCTGTTCTCT 242
QY 181 TTGTCCTGAGCTGTTAAAGGAACACACTGTTGCTGACAGTCACTTGAACCATG 240
DB 243 TTGTCCTGAGCTGTTAAAGGAACACACTGTTGCTGACAGTCACTTGAACCATG 302
QY 241 ATGCTTAACATTTGCTTTAGGCTTCTCTCATCATGTTCTTCTTACTGTTAGCAGA 300
DB 303 ATGCTTAACATTTGCTTTAGGCTTCTCTCATCATGTTCTTCTTACTGTTAGCAGA 362
QY 301 ACTCAGTCAACGATGAGTCTCTGAAGCCTCAGAGGATACAAATTTCCAGTCCGAAATTT 360
DB 363 ACTCAGTCAACGATGAGTCTCTGAAGCCTCAGAGGATACAAATTTCCAGTCCGAAATTT 422
QY 361 CACAACATTTTGCAATGGCAGCCGAGGAGGACACTTACTGGCAACAGCATGTCTATT 420
DB 423 CACAACATTTTGCAATGGCAGCCGAGGAGGACACTTACTGGCAACAGCATGTCTATT 482
QY 421 GTTCAGTACAAATCATGTCTTCATGACGATGAAAAGCTCTCACAGAACCAAGTGA 480
DB 483 GTTCAGTACAAATCATGTCTTCATGACGATGAAAAGCTCTCACAGAACCAAGTGA 496
QY 481 TGCTGGCAGCAGCATTTCTTGAATCTCCAGGCTGACAGACATTTGCTAATATGACAG 540
DB 497 -----ATATGACAG 506
QY 541 AGACAATGAAAAAATAAAGAGACTGTGGGTACTCAAGAACTCTGTGACCTTACC 600
DB 507 AGACAATGAAAAAATAAAGAGACTGTGGGTACTCAAGAACTCTGTGACCTTACC 566
QY 601 AGTGAACCTCAGACATACAGAACCTTATTACGGGAGGTGAGGCGGCTCGGCTGGG 660
DB 567 AGTGAACCTCAGACATACAGAACCTTATTACGGGAGGTGAGGCGGCTCGGCTGGG 626
QY 661 AGCTACTCAGAAATGAGCATGACGCGCGGTTCACCTCCCTGTTGGGAAACAAATAGAT 720
DB 627 AGCTACTCAGAAATGAGCATGACGCGCGGTTCACCTCCCTGTTGGGAAACAAATAGAT 686
QY 721 CCTCAGTCAATGATATTAACCAAGTCAATGGCTCTTGTGGTAAATCTCCATGCTCCA 780
DB 687 CCTCAGTCAATGATATTAACCAAGTCAATGGCTCTTGTGGTAAATCTCCATGCTCCA 746
QY 781 AATTACCATATAGATACCAAAAGAAAAAATGTATCTATAGAGATTTACTATGAAC 840
DB 747 AATTACCATATAGATACCAAAAGAAAAAATGTATCTATAGAGATTTACTATGAAC 806
QY 841 CTATACGAGTTTATATTAATTAACAAATCACTAGAAAAAGAGCAAAAGTTTATGAAGG 900
DB 807 CTATACGAGTTTATATTAATTAACAAATCACTAGAAAAAGAGCAAAAGTTTATGAAGG 866
QY 901 GCTCAGAGCGGTTGAATTTGAAGCTCTAACACACACACTCCAGCTACTGTAGTGCT 960
DB 867 GCTCAGAGCGGTTGAATTTGAAGCTCTAACACACACACTCCAGCTACTGTAGTGCT 926
QY 961 GAAATATATCAGCCCATGTTAGACAGAAAGAACTCAGAGAAAGTGAAGAGAGATGTGTGAA 1020

|||||
Db 927 GAAATATATCAGCCCATGTTAGACAGAGAAGTCAAGAGATGATGTGTGAA 986
QY 1021 ATTCCATGACTTGTGGAATTTGGCATTCAGCAATGTGAAATTTCTAAAGCTCCCTGAGAA 1080
Db 987 ATTCATGACTGTGGAATTTGGCATTCAGCAATGTGAAATTTCTAAAGCTCCCTGAGAA 1046
QY 1081 CAGGATGACTGTGTTGAAGCATCTTATTTAAATTTGTTTGTATTTCTTAAAGCAA 1140
Db 1047 CAGGATGACTGTGTTGAAGCATCTTATTTAAATTTGTTTGTATTTCTTAAAGCAA 1106
QY 1141 TATTCACGTGTACACCTTGGGACTCTTGTGTTTATCCATCTTTATCCCTTATATTTTC 1200
Db 1107 TATTCACGTGTACACCTTGGGACTCTTGTGTTTATCCATCTTTATCCCTTATATTTTC 1166
QY 1201 ATTTGTAACATATATTTGAACGACATTTCCCCGAAAAATTTGAAATGTAAAGATGAGCA 1260
Db 1167 ATTTGTAACATATATTTGAACGACATTTCCCCGAAAAATTTGAAATGTAAAGATGAGCA 1226
1261 GAGAAATAAGTGTCTATGAAAAA 1289
1227 GAGAAATAAGTGTCTATGAAATTCAGAA 1255

RESULT 4

AAAL46000
ID AAL46000 standard; cDNA; 1255 BP.

XX AC AAL46000;

XX 08-AUG-2002 (first entry)

DE Human cytokine receptor variant 2 coding sequence.

XX Human; cytokine receptor; immune disease; psoriasis; cancer; infection;
KW rheumatoid arthritis; multiple sclerosis; Crohn's disease;
KW ulcerative colitis; transplant rejection; abortion; antipsoriatic;
KW immunosuppressive; antirheumatic; antiarthritic; neuromodulatory;
KW antinflammatory; antitumor; cytostatic; dermatological;
KW Chromosome 6q24.1-25.2; receptor; gene; ss.

OS Homo sapiens.

EH Key Location/Qualifiers
FT CDS 304..999
FT /tag= a
FT /product= "cytokine receptor variant 2"

EP1191035-A2.

PD 27-MAR-2002.

PF 24-AUG-2001; 2001EP-0250307.

PR 25-SEP-2000; 2000DE-1048626.

PR 17-NOV-2000; 2000DE-1058907.

PR 19-DEC-2000; 2000DE-1064906.

XX (SCHD) SCHERING AG.

PI Weiss B, Sabat R, Assadullah K, Toshi L;

DR WPI: 2002-332210/37.

DR P-PSDB; AAO17381.

PT New nucleic acid encoding soluble cytokine receptor, useful for
PT diagnosis and treatment of e.g. immune disease, also related protein
PT and antibodies

PS Claim 1; Page 13; 21pp; German.

CC The present invention provides the protein and coding sequences of 3
CC variants of a human cytokine receptor. The sequences can be used in the

CC diagnosis, prevention and treatment of immune diseases, including
CC psoriasis, cancer, chronic/life-threatening infections, rheumatoid
CC arthritis, multiple sclerosis, Crohn's disease, ulcerative colitis and
CC transplant rejection and in reproductive medicine, e.g. for diagnosing
CC abnormal immune reactions which cause abortions. The present sequence is
CC the coding sequence of variant 2 of the invention.

XX Sequence 1255 BP; 402 A; 251 C; 246 G; 356 T; 0 other;

Query Match 81.8%; Score 1078.4; DB 24; Length 1255;

Best Local Similarity 92.4%; Pred. No. 1.6e-213;

Matches 1185; Conservative 0; Mismatches 1; Indels 96; Gaps 1;

QY 1 CAGTTTCTCATCTGTATACATCAATGAATTAATACCAATCTCCTAGACTTCATAGA 60

Db 67 CAGTTTCTCATCTGTATACATCAATGAATTAATACCAATCTCCTAGACTTCATAGA 126

QY 61 GGATTAACAAGACAAAATATGGGAAAAACATAACATGGCGTCCCATATATATAGATCT 120

Db 127 GGATTAACAAGACAAAATATGGGAAAAACATAACATGGCGTCCCATATATATAGATCT 186

QY 121 TATTTATGACACTTAAATGGCATTTAAATTTACCAAAAGAGACAGCATCTGTTCCTCT 180

Db 187 TATTTATGACACTTAAATGGCATTTAAATTTACCAAAAGAGACAGCATCTGTTCCTCT 246

QY 181 TTGTCCTGAGCTGTGTTAAAGAACACACTGTTGCCGTAACAGATCAGACTTGCACCATG 240

Db 247 TTGTCCTGAGCTGTGTTAAAGAACACACTGTTGCCGTAACAGATCAGACTTGCACCATG 306

QY 241 ATGCCATAACATGCTTTCTAGGCTTCCCTCATCTCTTCTTCTTCTTCTTCTTCTTCTTCT 300

Db 307 ATGCCATAACATGCTTTCTAGGCTTCCCTCATCTCTTCTTCTTCTTCTTCTTCTTCTTCT 366

QY 301 ACTCAGTCAACGATGAGTCTCTGAAGCCTCAGAGGGGTACAATTTCACTCCGAAATTTT 360

Db 367 ACTCAGTCAACGATGAGTCTCTGAAGCCTCAGAGGGGTACAATTTCACTCCGAAATTTT 426

QY 361 CACAACATTTTGCATATGGCAGCCTGGAGGGCACTTACTGGCAACAGCAGTGTCTATTTT 420

Db 427 CACAACATTTTGCATATGGCAGCCTGGAGGGCACTTACTGGCAACAGCAGTGTCTATTTT 486

QY 421 GTGACGTACAAATCATGTCTCTATGACAGATGAAAAAGCTCTCACCAGAACCAAGTGA 480

Db 487 GTGACGTACAAATCATGTCTCTATGACAGATGAAAAAGCTCTCACCAGAACCAAGTGA 500

QY 481 TGCTGGCAGCATTTCTTGTAACTTCCAGGCTGCAGAACATTTGGCTAATATGACAG 540

Db 501 -----ATATGACAG 510

QY 541 AGACAATGGAATAAAGAGACTGTGGGGTACTCAAGAACTCTTGTGACCTTACC 600

Db 511 AGACAATGGAATAAAGAGACTGTGGGGTACTCAAGAACTCTTGTGACCTTACC 570

QY 601 AGTGAACCTCAGACATACAGAACCTTATTACGGGAGGGTGAGGGCGGCTGGCTGGG 660

Db 571 AGTGAACCTCAGACATACAGAACCTTATTACGGGAGGGTGAGGGCGGCTGGCTGGG 630

QY 661 AGCTACTCAGAATGAGCATGACCGCGGCTTCACTCCCTGGTGGGAAACAAAATAGAT 720

Db 631 AGCTACTCAGAATGAGCATGACCGCGGCTTCACTCCCTGGTGGGAAACAAAATAGAT 690

QY 721 CCTCCAGTCATGAATATAACCCCAAGTCATGCTTTGTTGGTAAATCTCCATGCTCCA 780

Db 691 CCTCCAGTCATGAATATAACCCCAAGTCATGCTTTGTTGGTAAATCTCCATGCTCCA 750

QY 781 AATTTACATATAGATACCAAGGAAAAAATGTATCTATAGAGATTACTATGACTA 840

Db 751 AATTTACATATAGATACCAAGGAAAAAATGTATCTATAGAGATTACTATGACTA 810

QY 841 CTATACCGAGTTTATTAATTAACAATTCAGTAAAGAGACAAAGTTTATGAGGG 900

Db 811 CTATACCGAGTTTATTAATTAACAATTCAGTAAAGAGACAAAGTTTATGAGGG 870

QY 901 GCTCAGAGCGGTTGAATTTGAGCTCTAACACACACCTCCAGCTACTGTAGTGCT 960
DB 871 GCTCAGAGCGGTTGAATTTGAGCTCTAACACACACCTCCAGCTACTGTAGTGCT 930
QY 961 GAAATATATCAGCCCATGTTAGACAGAGAAGTCAAGAGTGAAGAGATGTGTGAA 1020
DB 931 GAAATATATCAGCCCATGTTAGACAGAGAAGTCAAGAGTGAAGAGATGTGTGAA 990
QY 1021 ATTCCATGACTTGTGGAATTTGGCATTCAGCAATGTGGAATTTCTAAAGCTCCCTGAGAA 1080
DB 991 ATTCCATGACTTGTGGAATTTGGCATTCAGCAATGTGGAATTTCTAAAGCTCCCTGAGAA 1050
QY 1081 CAGATGACTCGTGTGTTGAAGGATCTTAATAAATTGTTTGTATTTCTTAAAGCAA 1140
DB 1051 CAGATGACTCGTGTGTTGAAGGATCTTAATAAATTGTTTGTATTTCTTAAAGCAA 1110
QY 1141 TATTCATGTTACACCTTGGGACCTTTGTTTATCCATTTCTTTATCCCTTATATTTTC 1200
DB 1111 TATTCATGTTACACCTTGGGACCTTTGTTTATCCATTTCTTTATCCCTTATATTTTC 1170
QY 1201 ATTGTAACCTATATTTGAACGACATTTCCCCGAAATAATTGAAATGTAAAGATGAGGCA 1260
DB 1171 ATTGTAACCTATATTTGAACGACATTTCCCCGAAATAATTGAAATGTAAAGATGAGGCA 1230
QY 1261 GAGATTAAGTGTCTATGAAA 1282
DB 1231 GAGATTAAGTGTCTATGAAA 1252

RESULT 5
ID ABK50076 standard; DNA; 2271 BP.
AC ABK50076;
XX 15-JUL-2002 (first entry)
DT DNA encoding human IL-TIF/IL-22 binding protein #1.
DB Human; soluble protein; interleukin-TIF/IL-22; IL-TIF/IL-22; IL-22BP;
KW IL-TIF/IL-22 antagonist; gene; ds.
XX Homo sapiens.
OS
XX
FH Key Location/Qualifiers
FT CDS 110..805
FT /tag= a
FT /product= "Human IL-TIF/IL-22 binding protein #1"
FT /note= "This sequence can optionally start at position 113"

XX
PN WO200224912-A2.
XX 28-MAR-2002.
PD
XX 21-SEP-2001; 2001WO-US29576.
PF
XX 22-SEP-2000; 2000US-234583P.
PR 03-NOV-2000; 2000US-245495P.
PR 31-JUL-2001; 2001US-0919162.
XX
PA (LUDW-) LUDWIG INST CANCER RES.
XX
PI Renauld J, Dumoutier L;
XX
DR WPI: 2002-383190/41.
DR P-PSDB; AAU80000.
XX
PT Polynucleotide and polypeptide of soluble protein which binds to
PT interleukin-TIF/IL-22 useful for inhibiting effect of IL-TIF/IL-22 on a
PT cell
XX
PS Claim 1; Page 38-39; 42pp; English.

XX
CC The present invention relates to a new polynucleotide that encodes a
CC soluble protein which binds to interleukin (IL)-TIF/IL-22 (also referred
CC to as IL-22BP), where the complementary sequence of the invention
CC hybridises under stringent conditions to a nucleotide sequence of 2271
CC or 2366 base pairs, as given in the specification. The molecules of the
CC invention are useful for inhibiting (antagonising) effect of IL-TIF/IL-22
CC on a cell, for determining whether IL-TIF/IL-22 is present in a sample,
CC for inhibiting binding of IL-TIF/IL-22 to a binding partner, preferably
CC in vitro, and for obtaining an antibody molecule specific for the soluble
CC binding protein of the invention, from a population or panel of antibody
CC molecules of diverse binding specificity. The soluble protein is further
CC useful in manufacture of a medicament for treating an IL-22 mediated
CC disease and for assaying an agent, preferably an antibody or a peptide
CC fragment of IL-TIF/IL-22 or the soluble protein, that modulates binding
CC of the soluble protein to IL-TIF/IL-22, where the agent identified is
CC used in the manufacture of medicament for treating IL-TIF/IL-22 mediated
CC disorder. The antibody is useful for determining presence of the soluble
CC protein, where the antibody is detectably labelled. The present nucleic
CC acid sequence encodes the human IL-TIF/IL-22 binding protein #1 of the
CC invention.
CC
XX
SQ Sequence 2271 BP; 709 A; 400 C; 444 G; 718 T; 0 other;

Query Match 69.0%; Score 910; DB 24; Length 2271;
Best Local Similarity 91.0%; Pred. No. 1.1e-178;
Matches 1019; Conservative 0; Mismatches 5; Indels 96; Gaps 1;

QY 170 CTGTTTCTCTTTGCTCTGAGCTGTTTAAAGAAACACTGTTGCTGACAGTCAAC 229
DB 42 CAGTTTCTCTTTGCTCTGAGCTGTTTAAAGAAACACTGTTGCTGACAGTCAAC 101
QY 230 TTGCAACCAATGATGCTTAAACATTTGCTTAAAGCTTCTCATCAGTTTCTCTTACTG 289
DB 102 TTGCAACCAATGATGCTTAAACATTTGCTTAAAGCTTCTCATCAGTTTCTCTTACTG 161
QY 290 GTGTAGCAGGAACTCAGTCAACGATGAGTCTGAAAGCCTCAGAGGGTACAAATTTCACT 349
DB 162 GTGTAGCAGGAACTCAGTCAACGATGAGTCTGAAAGCCTCAGAGGGTACAAATTTCACT 221
QY 350 CCCGAAATTTTCAACAATTTTGCATATGGCAGCTGGAGGGGCACTTACTGGCAACAGCA 409
DB 222 CCCGAAATTTTCAACAATTTTGCATATGGCAGCTGGAGGGGCACTTACTGGCAACAGCA 281
QY 410 GTGTCTATTTTGTGAGTACAAATTCATGTTCTCATGACATGAAAGCTCTCACACAGA 469
DB 282 GTGTCTATTTTGTGAGTACAAATTCATGTTCTCATGACATGAAAGCTCTCACACAGA 306
QY 470 AGCCAAGTGAATGCTGGCAGCACAATTTCTGTAATTTCCAGGCTGCAGAACATTTGGCTA 529
DB 307 ----- 306
QY 530 AATATGACAGAGACAATGGAATAAAGAAAGCTGTGGGCTACTCAAGAACTCTCTT 589
DB 307 -ATATGACAGAGACAATGGAATAAAGAAAGCTGTGGGCTACTCAAGAACTCTCTT 365
QY 590 GTGACCTTACCAGTGAACCTCAGACATACAGAACTTATACGGGAGGTGAGGCGG 649
DB 366 GTGACCTTACCAGTGAACCTCAGACATACAGAACTTATACGGGAGGTGAGGCGG 425
QY 650 CCTCGGCTGGAGCTACTCAGAAATGAGCATGACGCGCGGTTCACTCCCTGTTGGGAAA 709
DB 426 CCTCGGCTGGAGCTACTCAGAAATGAGCATGACGCGCGGTTCACTCCCTGTTGGGAAA 485
QY 710 CAAAATAGATCTCCAGTCAATGATATTAACCAAGTCAATGCTCTTGTGTTAATTC 769
DB 486 CAAAATAGATCTCCAGTCAATGATATTAACCAAGTCAATGCTCTTGTGTTAATTC 545
QY 770 TCCATGCTCCAAATTTACATATAGATACCAAAAGGAAAAATGTATCTATAGAGATT 829
DB 546 TCCATGCTCCAAATTTACATATAGATACCAAAAGGAAAAATGTATCTATAGAGATT 605
QY 830 ACTATGAAGTACTATACGAGTTTATATTAATTAACAATTCAGTGAAGGAGCAAAAGG 889

Db 606 ACTATGACTACTATACCAGCTTTTATTAATTAACAAATTCACCTAGAAAAGCAGCAAAAGG 665
QY 890 TTTATGAAGGGGCTCACAGAGCGGTGAAATTTGAAGCTCTAACACCACTCCAGCTACT 949
Db 666 TTTATGAAGGGGCTCACAGAGCGGTGAAATTTGAAGCTCTAACACCACTCCAGCTACT 725
QY 950 GTGTAGTGGCTGAATATATATACAGCCCATGTTAGACAGAGAAGTCAGAGAAGTGAAGAGA 1009
Db 726 GTGTAGTGGCTGAATATATATACAGCCCATGTTAGACAGAGAAGTCAGAGAAGTGAAGAGA 785
QY 1010 GATGTGTGGAATTCATGACTTGTGGAATTTGGCATTCAGCAATGTGGAATTTCTAAAG 1069
Db 786 GATGTGTGGAATTCATGACTTGTGGAATTTGGCATTCAGCAATGTGGAATTTCTAAAG 845
QY 1070 CTCCCTGAGACAGAGTACTCGTGTGGAAGGATCTTATTTAAATTTGTTTGTATTT 1129
Db 846 CTCCCTGAGACAGAGTACTCGTGTGGAAGGATCTTATTTAAATTTGTTTGTATTT 905
Db 1130 TCTTAAAGCAATATCTACTGTTCACACCTTGGGACTCTTGTATCCATCTTTATTC 1189
QY 906 TCTTAAAGCAATATCTACTGTTCACACCTTGGGACTCTTGTATCCATCTTTATTC 965
QY 1190 CTTTATATTTCAATTTGTAACTATATTTGAACGACATTCGCCCGAAAAATTTGAATGTA 1249
Db 966 CTTTATATTTCAATTTGTAACTATATTTGAACGACATTCGCCCGAAAAATTTGAATGTA 1025
QY 1250 AAGATGAGCGCAGAGATTAAGTGTCTATGAAAAAAA 1289
Db 1026 AAGATGAGCGCAGAGATTAAGTGTCTATGAATTCAGAA 1065

RESULT 6

AAD09745
ID AAD09745 standard; cDNA; 2149 BP.
XX AAD09745;

DT 10-SEP-2001 (first entry)

DE Human zcytor18 soluble receptor antagonist cDNA, zcytor16.

KW Human; cytosolic; cytokine; zcytor18 protein; genetic abnormality;
KW cancer; inflammation; gene therapy; zcytor16; ss.

OS Homo sapiens.

Key Location/Qualifiers
CDS 1..696
/*tag= a
/product= "Human zcytor16 protein"

FN WO200146422-A1.

PD 28-JUN-2001.

PF 22-DEC-2000; 2000WO-US35308.

PR 23-DEC-1999; 99US-04711767.
PR 01-DEC-2000; 2000US-0250841.

PA (ZYMO) ZYMOGENETICS INC.

PI Presnell SR, Kindsvogel W;

DR WPI; 2001-408648/43.
DR P-PSDB; AAE05048.

PT Novel human cytokine polypeptide, zcytor18, useful for treating cancer -
XX Example 13A; Page 156-158; 167pp; English.
PS The patent discloses novel human cytokine, zcytor18 protein and its

CC corresponding DNA. zcytor18 protein induces proliferation of cells
CC expressing zcytor1, a receptor for zcytor18 or induces cytotoxicity
CC in K5626 cells. zcytor18 DNA is useful for detecting a genetic
CC abnormality in a patient. zcytor18 DNA and its antibodies are useful
CC for detecting cancer and inflammation. zcytor18 protein is useful for
CC killing cancer cells. It is useful for increasing platelets in a
CC patient or injured tissue. It is also used in gene therapy.
CC The present sequence is a cDNA encoding human zcytor16, which is a
CC naturally expressed soluble receptor antagonist of zcytor18 protein.
SQ Sequence 2149 BP; 685 A; 381 C; 421 G; 662 T; 0 other;

Query Match 63.1%; Score 831.6; DB 22; Length 2149;
Best Local Similarity 90.4%; Pred. No. 1.8e-162;
Matches 951; Conservative 0; Mismatches 4; Indels 97; Gaps 2;

QY 238 ATGATGCCCTAAACATTTGCTTTCTAGGCTTCCCTCATCAGTTTCTCTTACTGTTAGCA 297
Db 1 ATGATGCCCTAAACATTTGCTTTCTAGGCTTCCCTCATCAGTTTCTCTTACTGTTAGCA 60
QY 298 GGAAGCTCAGTCAACGCAATGAGTCTCTGAAAGCCTCAGAGGGTACAATTTCAAGTCCGAAAT 357
Db 61 GGAAGCTCAGTCAACGCAATGAGTCTCTGAAAGCCTCAGAGGGTACAATTTCAAGTCCGAAAT 120
QY 358 TTTCACACATTTTGGCAATGGCAGCCTGGGAGGGCAGTTACTGGCAACAGCAGTGTCTAT 417
Db 121 TTTCACACATTTTGGCAATGGCAGCCTGGGAGGGCAGTTACTGGCAACAGCAGTGTCTAT 180
QY 418 TTGTGCGAGTACAAAATCATGTTCTCTCATGACGATGAAAAGCTCTCACCAGAAAGCCAAGT 477
Db 181 TTGTGCGAGTACAAAAT-----ATATGGA 197
QY 478 GGATGTGGCAGACATTTCTTGTAACTTCCAGGCTGCAGAACATTTGGCTAAATATGGA 537
Db 198 -----ATATGGA 204
QY 538 CAGAGACAATGSAAAAATAAAGAGACTGTTGGGTAATCAAGAACTCTCTTGTGACCTT 597
Db 205 CAGAGACAATGSAAAAATAAAGAGACTGTTGGGTAATCAAGAACTCTCTTGTGACCTT 264
QY 598 ACCAGTGAACCTCAGACATACAGGAACCTTATTAACGGGAGGTTGAGGGCGGCTCGGCT 657
Db 265 ACCAGTGAACCTCAGACATACAGGAACCTTATTAACGGGAGGTTGAGGGCGGCTCGGCT 324
QY 658 GGGAGCTACTCAGATGAGCATGACGCGCGGCTCACTCCCTGGTGGAAACAATAATA 717
Db 325 GGGAGCTACTCAGATGAGCATGACGCGCGGCTCACTCCCTGGTGGAAACAATAATA 384
QY 718 GATCCTCAGTCAATGATATTAACCAAGTCAATGGCTCTTGTGTAATCTCCATGCT 777
Db 385 GATCCTCAGTCAATGATATTAACCAAGTCAATGGCTCTTGTGTAATCTCCATGCT 444
QY 778 CCAAAATTACCATATAGATACCAAAAGGAAAAAATGTATCTATAGACATTAATGAA 837
Db 445 CCAAAATTACCATATAGATACCAAAAGGAAAAAATGTATCTATAGACATTAATGAA 504
QY 838 CTAATAACCGAGTTTATATATTAACAATTCACCTAGAAAAGGAGCAAAAGGTTATGAA 897
Db 505 CTAATAACCGAGTTTATATATTAACAATTCACCTAGAAAAGGAGCAAAAGGTTATGAA 564
QY 898 GGGGCTCAGAGCGGTTGAAATTTGAAGCTCTAACACACACACACCTCAGCTACTGTAGTG 957
Db 565 GGGGCTCAGAGCGGTTGAAATTTGAAGCTCTAACACACACACACCTCAGCTACTGTAGTG 624
QY 958 GCTGAATATATCAGCCCATGTTAGACAGAAAGTCAAGAGTGAAGAGAGATGTGTG 1017
Db 625 GCTGAATATATCAGCCCATGTTAGACAGAAAGTCAAGAGTGAAGAGAGATGTGTG 684
QY 1018 GAAATTCATGACTGTGGAATTTGGCATTCAGCAATGTGAAATTTCTAAAGTCCCTGA 1077
Db 685 GAAATTCATGACTGTGGAATTTGGCATTCAGCAATGTGAAATTTCTAAAGTCCCTGA 744
QY 1078 GAACAGGATGACTCGTGTGGAAGGATCTTATTTAAATTTGTTTGTATTTCTTAAAG 1137

|||||
Db 745 GAACAGATGACTCGTGTGAGGATCTTATTAATAATGTTTGTATTTCTTAAG 804
QY 1138 CAATATTCACCTGTACACCTGGGAGCTTCTTTGTTATCCATTCCTTATAT 1197
Db 805 CAATATTCACCTGTACACCTGGGAGCTTCTTTGTTATCCATTCCTTATAT 864
QY 1198 TTCATTTGTAACATATTTGAACGACATTCCTCCCGAAATTTGAATGTAAGATGAG 1257
Db 865 TTCATTT-TAACTATATTTGAACGACATTCCTCCCGAAATTTGAATGTAAGATGAG 923
QY 1258 GCAGAGATTAAGTGTCTTATGAAAAAAA 1289
Db 924 GCAGAGATTAAGTGTCTTATGAAATTCAGAA 955
RESULT 7
AAF83735
ID AAF83735 standard; cDNA; 2149 BP.
AAF83735;
23-JUL-2001 (first entry)
Human cytokine receptor, zcytor16 encoding cDNA.
Cytokine receptor; zcytor16; IL-TIF; antiinflammatory; cytostatic;
antirheumatic; antiarthritic; antiasthmatic; antiatherosclerotic;
immunosuppressive; chromosome 6q24.1-25.2; human; ss.
Homo sapiens.
Key Location/Qualifiers
CDS 1..696
/*tag= a
/product= "zcytor16"
WO200140467-A1.
07-JUN-2001.
01-DEC-2000; 2000MO-US32703.
03-DEC-1999; 99US-0169049.
13-SEP-2000; 2000US-0232219.
31-OCT-2000; 2000US-0244610.
P (ZYMO) ZYMOGENETICS INC.
Presnell SR, Xu W, Kindsvogel W, Chen Z;
WPI: 2001-356158/37.
P-PSDB; AAB62657.
New soluble cytokine receptor polypeptides and polynucleotides, useful
for diagnosing and treating cancer and inflammatory conditions
Claim 10; Page 186-188; 210pp; English.
The invention relates to a human cytokine receptor polypeptide,
designated zcytor16. The zcytor16 polypeptide can be expressed by
standard recombinant methodology and can bind to IL-TIF (undefined). The
zcytor16 protein is useful for: inhibiting IL-TIF induced proliferation
or differentiation of hematopoietic cell(s) (progenitors); reducing
IL-TIF induced or IL-9 induced inflammation; and suppressing an
inflammatory response in a mammal with inflammation. Heteromeric/
multimeric receptor polypeptides such as soluble zcytor 16/CRF2-4 can be
used to reduce progression and symptoms of cancer. Zcytor16 polypeptides
can also be used to detect IL-TIF levels which is indicative of
pathological conditions including inflammatory states (e.g. rheumatoid
arthritis) and cancer. Antibodies that bind zcytor16 polypeptides and the
polypeptides themselves are useful for the treatment of inflammation,
inflammatory diseases (e.g. infection, asthma, inflammatory bowel

CC disease, rheumatoid arthritis and atherosclerosis) and autoimmune
CC diseases. The antibodies and zcytor16 polynucleotides are also useful
CC for detecting cancer. The present sequence represents a cDNA encoding
CC the human zcytor16 protein.
SQ Sequence 2149 BP; 685 A; 381 C; 421 G; 662 T; 0 other;
Query Match 63.1%; Score 831.6; DB 22; Length 2149;
Best Local Similarity 90.4%; Pred. No. 1.8e-162;
Matches 951; Conservative 0; Mismatches 4; Indels 97; Gaps 2;
QY 238 ATGATGCCCTAAACATTTGCTTCTAGGCTTCTCATCAGTTTCTTCTTACTGTAGCA 297
Db 1 ATGATGCCCTAAACATTTGCTTCTAGGCTTCTCATCAGTTTCTTCTTACTGTAGCA 60
QY 298 GGAAGCTCAGTCAACGCAAGAGTCTCTGAAGCCTCAGAGGGGTACAAATTCAGTCCGAAAT 357
Db 61 GGAAGCTCAGTCAACGCAAGAGTCTCTGAAGCCTCAGAGGGGTACAAATTCAGTCCGAAAT 120
QY 358 TTTCACACATTTTTCATGTCAGGCTGGGAGGCACTTACTGGCAACAGCAGTGTCTAT 417
Db 121 TTTCACACATTTTTCATGTCAGGCTGGGAGGCACTTACTGGCAACAGCAGTGTCTAT 180
QY 418 TTGTGTGAGTACAAATCATGTCTTCATGACATGAAAGCTCTCACCAAGCAAGT 477
Db 181 TTGTGTGAGTACAAAT----- 197
QY 478 GGATGCTGGCAGCAGCATTTCTTGTACTTCCAGGCTGCAGAACATTTGGCTAAATATGA 537
Db 198 -----ATATGA 204
QY 538 CAGAGCAATGGAATAATAAGAGACTGTGGGGTACTCAAGAACTCTCTGTGACCTT 597
Db 205 CAGAGCAATGGAATAATAAGAGACTGTGGGGTACTCAAGAACTCTCTGTGACCTT 264
QY 598 ACCAGTGAACCTCAGACATACAGGAACCTTATACGGGAGGGTGAGGGCGCTCGGCT 657
Db 265 ACCAGTGAACCTCAGACATACAGGAACCTTATACGGGAGGGTGAGGGCGCTCGGCT 324
QY 658 GGGAGCTACTCAGAAATGAGCATGACCGCGGCTCACTCCCTGTTGGGAACAAATA 717
Db 325 GGGAGCTACTCAGAAATGAGCATGACCGCGGCTCACTCCCTGTTGGGAACAAATA 384
QY 718 GATCCTCCAGTCAATGATATTAACCAAGTCAATGCTTGTGTAATTCATGCT 777
Db 385 GATCCTCCAGTCAATGATATTAACCAAGTCAATGCTTGTGTAATTCATGCT 444
QY 778 CCAATTTACCATATAGATACCAAAAGGAAAAATGTATCTATAGAAGATTACTATGA 837
Db 445 CCAATTTACCATATAGATACCAAAAGGAAAAATGTATCTATAGAAGATTACTATGA 504
QY 838 CTACTATACCGAGTTTATTAATTAACAATTCACCTAGAAAAGGCAAAAGGTTATGA 897
Db 505 CTACTATACCGAGTTTATTAATTAACAATTCACCTAGAAAAGGCAAAAGGTTATGA 564
QY 898 GGGGCTCAGAGAGCGGTTGAAATTTGAAGCTCTAACACACACTCCAGCTACTGTAGTG 957
Db 565 GGGGCTCAGAGAGCGGTTGAAATTTGAAGCTCTAACACACACTCCAGCTACTGTAGTG 624
QY 958 GCTGAATATATACGCCCATGTTAGACAGAAAGAGTCAAGAGAGAGATGTGTG 1017
Db 625 GCTGAATATATACGCCCATGTTAGACAGAAAGAGTCAAGAGAGAGATGTGTG 684
QY 1018 GAAATTCATGACTGTGGAATTTGGCATTCAGCAATGTGGAATTTCTAAAGCTCCCTGA 1077
Db 685 GAAATTCATGACTGTGGAATTTGGCATTCAGCAATGTGGAATTTCTAAAGCTCCCTGA 744
QY 1078 GAACAGATGACTCGTGTGGAAGATCTTATTAATAATGTTTGTATTTCTTAAG 1137
Db 745 GAACAGATGACTCGTGTGGAAGATCTTATTAATAATGTTTGTATTTCTTAAG 804
QY 1138 CAATATTCACCTGTACACCTGGGAGCTTCTTGTATTCATCTTTATCTTATAT 1197

Db 805 CAATATTCACGTGTACACCTGGGGACTTCTTTGTTATTCATCTTTATCCTTTATAT 864
QY 1198 TTCAATTTGTAACATATATTTGAACGACATTCCTCCCGAAATTTGAATGTAAAGATGAG 1257
Db 865 TTCAATTT-TAAACTATATTTGAACGACATTCCTCCCGAAATTTGAATGTAAAGATGAG 923
QY 1258 GCAGAGATTAAGTGTCTATGAAAAAAA 1289
Db 924 GCAGAGATTAAGTGTCTATGAAATTCAGAA 955

RESULT 8
AAL46001

ID AAL46001 standard; cDNA; 810 BP.

XX AAL46001;

DT 08-AUG-2002 (first entry)

XX Human cytokine receptor variant 3 coding sequence.

Human; cytokine receptor; immune disease; psoriasis; cancer; infection;
rheumatoid arthritis; multiple sclerosis; Crohn's disease;
ulcerative colitis; transplant rejection; abortion; antipsoriatic;
immunosuppressive; antirheumatic; antiarthritic; neuroprotective;
antiinflammatory; antilucer; cytostatic; dermatological;
chromosome 6q24.1-25.2; receptor; gene; ss.

OS Homo sapiens.

EH Key Location/Qualifiers
FT CDS 12..803

FT /*tag= a
/product= "cytokine receptor variant 3"

PN EP1191035-A2.

PD 27-MAR-2002.

PF 24-AUG-2001; 2001EP-0250307.

XX 25-SEP-2000; 2000DE-1048626.

PR 17-NOV-2000; 2000DE-1058907.

PR 19-DEC-2000; 2000DE-1064906.

XX (SCHD) SCHERING AG.

XX Weiss B, Sabat R, Assadullah K, Toshi L;

DR WPI; 2002-332210/37.

XX P-PSDB; AAO17382.

PT New nucleic acid encoding soluble cytokine receptor, useful for

PT diagnosis and treatment of e.g. immune disease, also related protein

PT and antibodies -

XX Claim 1; Page 14-15; 21pp; German.

XX The present invention provides the protein and coding sequences of 3

CC variants of a human cytokine receptor. The sequences can be used in the

CC diagnosis, prevention and treatment of immune diseases, including

CC psoriasis, cancer, chronic/life-threatening infections, rheumatoid

CC arthritis, multiple sclerosis, Crohn's disease, ulcerative colitis and

CC transplant rejection and in reproductive medicine, e.g. for diagnosing

CC abnormal immune reactions which cause abortions. The present sequence is

CC the coding sequence of variant 3 of the invention.

SO Sequence 810 BP; 253 A; 172 C; 184 G; 201 T; 0 other;

Query Match 61.1%; Score 805.2; DB 24; Length 810;
Best Local Similarity 99.6%; Pred. No. 4.1e-157;
Matches 807; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 227 CACTTGCAACCATGATGCCCTAAACATTTGCTTTAGGCTTCCTCATGATTTCTCTTA 286
Db 1 CACTTGCAACCATGATGCCCTAAACATTTGCTTTAGGCTTCCTCATGATTTCTCTTA 60
QY 287 CTGGTGTAGCAGGAAGTCAAGCAGTGAAGTCTCTGAAAGCCTCAGAGGCTACAATTTTC 346
Db 61 CTGGTGTAGCAGGAAGTCAAGCAGTGAAGTCTCTGAAAGCCTCAGAGGCTACAATTTTC 120
QY 347 AGTCCGGAATTTTCAACAACATTTTCAATGCGAGCCCTGGAGGGGCACTTACTGGCAACA 406
Db 121 AGTCCGGAATTTTCAACAACATTTTCAATGCGAGCCCGGGAGGGGCACTTACTGGCAACA 180
QY 407 GCAGTGTCTATTTTGTGACAGTACAAATCATGTCTCATGACGATGAAGAAAGCTCTCACC 466
Db 181 GCAGTGTCTATTTTGTGACAGTACAAATCATGTCTCATGACGATGAAGAAAGCTCTCACC 240
QY 467 AGAAGCCAAAGTGATGCTGGCAGCACATTTCTTGTAACTTCCAGGCTGACAGAAATTGG 526
Db 241 AGAAGCCAAAGTGATGCTGGCAGCACATTTCTTGTAACTTCCAGGCTGACAGAAATTGG 300
QY 527 CTAATATGACAGAGACAAATGGAATAAAGAAAGACTGTTGGGTACTCAAGAACTCT 586
Db 301 CTAATATGACAGAGACAAATGGAATAAAGAAAGACTGTTGGGTACTCAAGAACTCT 360
QY 587 CTGTGTACCTTACCAAGTGAACCTCAGACATACAGGAACCTTAATTACGGAGGGTGAGGG 646
Db 361 CTGTGTACCTTACCAAGTGAACCTCAGACATACAGGAACCTTAATTACGGAGGGTGAGGG 420
QY 647 CGGCTCGGCTGGAGCTACTCAGATGAGATGAGCATGACCGCGGTTCACCTCCCTGTGGG 706
Db 421 CGGCTCGGCTGGAGCTACTCAGATGAGATGAGCATGACCGCGGTTCACCTCCCTGTGGG 480
QY 707 AAACAAAATAGATCCTCAGTCAATATTAACCCAAAGTCAATGGCTTTTGTGTAA 766
Db 481 AAACAAAATAGATCCTCAGTCAATATTAACCCAAAGTCAATGGCTTTTGTGTAA 540
QY 767 TTCTCCATGCTCCAAATTTACCATATAGATACCAAAAGAAATAATGTATCTATAGAAG 826
Db 541 TTCTCCATGCTCCCAATTTACCATATAGATACCAAAAGAAATAATGTATCTATAGAAG 600
QY 827 ATTACTATGAACCTACTATACCGAGTTTATATTAATTAACAATTCAGTGAAGAGAGCAA 886
Db 601 ATTACTATGAACCTACTATACCGAGTTTATATTAATTAACAATTCAGTGAAGAGAGCAA 660
QY 887 AGTTTATGAAGGGCTCACAGAGCGGTTGAATTTGAAGCTCTAACACCCACACTCCAGCT 946
Db 661 AGTTTATGAAGGGCTCACAGAGCGGTTGAATTTGAAGCTCTAACACCCACACTCCAGCT 720
QY 947 ACTGTAGTGGCTGAATATATCAGCCCATGTTAGCAGAAAGTCAAGAGAGTGAAG 1006
Db 721 ACTGTAGTGGCTGAATATATCAGCCCATGTTAGCAGAAAGTCAAGAGAGTGAAG 780
QY 1007 AGAGATGTGTGGAATTCATGACTTGTGG 1036
Db 781 AGAGATGTGTGGAATTCATGACTTGTGG 810

RESULT 9

AAD27816
AAD27816 standard; DNA; 792 BP.

XX AAD27816;

AC 18-APR-2002 (first entry)

DE Human cytokine receptor gene, sbg456548Cytora #3.

Human; therapy; wound healing disorder; vaccine; cancer; infection;
autoimmune disorder; haematopoietic disorder; inflammation; arthritis;
Parkinson's disease; Huntington's chorea; schizophrenia; antiarrhythmic;
multiple sclerosis; Alzheimer's disease; analgesic; cardiac; asthma;
ischaemia; stroke; AIDS; bone disease; atherosclerosis; brain disorder;
depression; cardiovascular disease; myocardial infarction; renal failure;

KW respiratory disease; liver disorder; Fanconi's syndrome; spleen disorder;
type II diabetes mellitus; skeletal muscle disorder; immunosuppressive;
KW hypersplenism; renal disease; hypoglycaemia; gastrointestinal disease;
KW neutropenic; cirrhosis; Hodgkin's disease; neuroleptic; antiinflammatory;
KW haemostatic; vulvar; anticonvulsant; antirheumatic; neuroprotective;
KW nephrotropic; hypotensive; vasotropic; cytostatic; cerebroprotective;
KW allergy; cytokine receptor; gene; ds.
XX Homo sapiens.
OS
FH Key Location/Qualifiers
FT 1..792
FT CDS /*tag= a
FT /product= "Human cytokine receptor"
PN W0200198342-A1.
PD 27-DEC-2001.
XX 22-JUN-2001; 2001WO-US19929.
XX 22-JUN-2000; 2000US-213156P.
PR 22-JUN-2000; 2000US-213161P.
PA (SMIK) SMITHKLINE BEECHAM CORP.
PA (SMIK) SMITHKLINE BEECHAM PLC.
PA (GLAX) GLAXO GROUP LTD.
PI Agarwal P, Cogswell JP, Kabnic KS, Lai Y, Martensen SA;
PI Murdock PR, Smith RF, Strum JC, Xiang Z, Xie Q, Rizni SK;
XX WPI: 2002-139783/18.
DR P-PSDB; AAE17321.
XX
PT Novel secreted and membrane-associated polypeptides and polynucleotides
PT useful for preventing, ameliorating or correcting dysfunction or
PT disease including diabetes, cancer, hypertension and growth
PT abnormalities
PS Claim 2; Page 98; 138pp; English.
XX
CC The invention relates to secreted and membrane-associated polypeptides
CC and polynucleotides. The sequences of the invention are useful in
CC diagnostic assays for detecting diseases associated with inappropriate
CC activity or levels of these polynucleotides, and in identifying their
CC agonists and antagonists that are potentially useful in therapy. The
CC sequences of the invention are useful as vaccines for inducing
CC immunological response. The sequences of the invention are useful for
CC treating cancers, infections, autoimmune disorders, haematopoietic
CC disorders, wound healing disorders, cholesterol ester storage disease,
CC inflammation, congenital muscular dystrophy, junctional epidermolysis
CC bullosa, Parkinson's disease, Huntington's chorea, multiple sclerosis,
CC viral and bacterial infections, Alzheimer's disease, asthma, arthritis,
CC allergies, schizophrenia, sbg44245PROA-associated disorders, transplant rejection,
CC septicemia, psoriasis, inflammatory bowel disease, acute respiratory disease
CC graft versus host disease, ischaemia, stroke, acute respiratory disease
CC syndrome, restenosis, brain injury, AIDS, bone diseases, atherosclerosis,
CC brain disorders including parasupranuclear palsy, myotonic dystrophy,
CC depression, anxiety disorders and sleep disorders, cardiovascular
CC diseases including congestive heart failure and myocardial infarction,
CC respiratory diseases including chronic obstructive pulmonary disease,
CC acute bronchitis and adult respiratory distress syndrome, liver disorders
CC including hypercholesterolaemia, hypertiglyceridaemia, cirrhosis, viral
CC and non-viral hepatitis, type II diabetes mellitus, renal disease
CC including acute and chronic renal failure, glomerulonephritis, Fanconi's
CC syndrome, cystinuria, skeletal muscle disorders including hypoglycaemia
CC and tendinitis, gastrointestinal diseases including intestinal
CC obstruction and tropical sprue, spleen disorders including hypersplenism,
CC Hodgkin's disease and malignant lymphoma, testicular cancer, male
CC reproductive diseases including low testosterone and male infertility.
CC The present sequence is human cytokine receptor gene.
XX
SQ Sequence 792 BP; 251 A; 165 C; 178 G; 198 T; 0 other;

Query Match 60.1%; Score 792; DB 24; Length 792;
Best Local Similarity 100.0%; Pred. No. 2.2e-154;
Matches 792; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 238 ATGATGCTTAACATTTGCTTTCTAGGCTTCTCATCATGTTTCTTCTTACTGCTAGCA 297
DB 1 ATGATGCTTAACATTTGCTTTCTAGGCTTCTCATCATGTTTCTTCTTACTGCTAGCA 60
QY 298 GGAAGCTGATCAACGATGAGTCTGTAAGCTCAGAGGCTACAAATTCAGTCCGAAAT 357
DB 61 GGAAGCTGATCAACGATGAGTCTGTAAGCTCAGAGGCTACAAATTCAGTCCGAAAT 120
QY 358 TTTCACACATTTTTCATATGCGAGCGCTGGAGGCACTTACTGGCAACAGCAGTGTCTAT 417
DB 121 TTTCACACATTTTTCATATGCGAGCGCTGGAGGCACTTACTGGCAACAGCAGTGTCTAT 180
QY 418 TTGTGCGAGTACAAATCATGTCTCATGCGAGCAAGAAAGCTCTCACCAGAACCAAGT 477
DB 181 TTGTGCGAGTACAAATCATGTCTCATGCGAGCAAGAAAGCTCTCACCAGAACCAAGT 240
QY 478 GGATGCTGGCAGCATTTTCTTGTACTTCCAGGCTGCAAGACATTTGGCTAAATATGA 537
DB 241 GGATGCTGGCAGCATTTTCTTGTACTTCCAGGCTGCAAGACATTTGGCTAAATATGA 300
QY 538 CAGAGCAATGGAATAAATAAGAGACTGTTGGGTTACTCAAGAACTCTTGTGACCTT 597
DB 301 CAGAGCAATGGAATAAATAAGAGACTGTTGGGTTACTCAAGAACTCTTGTGACCTT 360
QY 598 ACCAGTGAACCTCAGACATACAGAACTTATACGGGAGGCTGAGGGCGGCTGGCT 657
DB 361 ACCAGTGAACCTCAGACATACAGAACTTATACGGGAGGCTGAGGGCGGCTGGCT 420
QY 658 GGGAGTACTCAGAAATGAGCATGAGCGCGGCTTCTCTCTGCTGGGAAACAAATA 717
DB 421 GGGAGTACTCAGAAATGAGCATGAGCGCGGCTTCTCTCTGCTGGGAAACAAATA 480
QY 718 GATCCTCCAGTCAATGAATAAACCAGTCAATGGCTTGTGTAATTCCTCATGCT 777
DB 481 GATCCTCCAGTCAATGAATAAACCAGTCAATGGCTTGTGTAATTCCTCATGCT 540
QY 778 CCAATTTACCATATATACCAAAAGGAAAAAATGTATCTATAGAAGATTACTATGAA 837
DB 541 CCAATTTACCATATATACCAAAAGGAAAAAATGTATCTATAGAAGATTACTATGAA 600
QY 838 CTACTATACCGAGTTTATATATTAACAATTCACCTAGAAAAGGCAAAAGTTATGAA 897
DB 601 CTACTATACCGAGTTTATATATTAACAATTCACCTAGAAAAGGCAAAAGTTATGAA 660
QY 898 GGGGCTCAGAGCGGTTGAAATGAAAGCTTAACACCCACACTCCAGCTACTGTAGTG 957
DB 661 GGGGCTCAGAGCGGTTGAAATGAAAGCTTAACACCCACACTCCAGCTACTGTAGTG 720
QY 958 GCTGAATATATCAGCCCATGTTAGACAGAAAGTCAAGAGTGAAGAGATGTGTG 1017
DB 721 GCTGAATATATCAGCCCATGTTAGACAGAAAGTCAAGAGTGAAGAGATGTGTG 780
QY 1018 GAAATTCATGA 1029
DB 781 GAAATTCATGA 792
RESULT 10
AAD27815
ID AAD27815 standard; DNA; 696 BP.
XX
AC AAD27815;
XX
DT 18-APR-2002 (first entry)
XX
DE Human cytokine receptor gene, sbg456548Cytora #2.
KW Human; therapy; wound healing disorder; vaccine; cancer; infection;

KW autoimmune disorder; haematopoietic disorder; inflammation; arthritis;
KW parkinson's disease; Huntington's chorea; schizophrenia; antiarrhythmic;
KW multiple sclerosis; Alzheimer's disease; analgesic; cardiant; asthma;
KW ischaemia; stroke; AIDS; bone disease; atherosclerosis; brain disorder;
KW depression; cardiovascular disease; myocardial infarction; renal failure;
KW respiratory disease; liver disorder; Fanconi's syndrome; spleen disorder;
KW type II diabetes mellitus; skeletal muscle disorder; immunosuppressive;
KW hyperplenism; renal disease; hypoglycaemia; gastrointestinal disease;
KW neurotic; cirrhosis; Hodgkin's disease; neuroleptic; antinflammatory;
KW haemostatic; vulnery; anticonvulsant; antirheumatic; neuroprotective;
KW nephrotropic; hypotensive; vasotropic; cytosatic; cerebroprotective;
KW allergy; cytokine receptor; gene; ds.
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 1..696 /tag= a
FT /product= "Human cytokine receptor"
FT
PD WO200198342-A1.
XX 27-DEC-2001.
PF 22-JUN-2001; 2001WO-US19929.
XX
PR 22-JUN-2000; 2000US-213156P.
PR 22-JUN-2000; 2000US-213161P.
XX
PA (SMIK) SMITHKLINE BEECHAM CORP.
PA (SMIK) SMITHKLINE BEECHAM PLC.
PA (GLAX) GLAXO GROUP LTD.
XX
PI Agarwal P, Cogswell JP, Kabnic KS, Lai Y, Martensen SA;
PI Murdock PR, Smith RF, Strum JC, Xiang Z, Xie Q, Rizni SK;
DR WPI; 2002-139783/18.
DR P-PSDB; AAEL17320.
XX
PT Novel secreted and membrane-associated polypeptides and polynucleotides
PT useful for preventing, ameliorating or correcting dysfunction or
PT disease including diabetes, cancer, hypertension and growth
PT abnormalities -
XX
PS Claim 2; Page 98; 138pp; English.
XX
CC The invention relates to secreted and membrane-associated polypeptides
CC and polynucleotides. The sequences of the invention are useful in
CC diagnostic assays for detecting diseases associated with inappropriate
CC activity or levels of these polynucleotides, and in identifying their
CC agonists and antagonists that are potentially useful in therapy. The
CC sequences of the invention are useful as vaccines for inducing
CC immunological response. The sequences of the invention are useful for
CC treating cancers, infections, autoimmune disorders, haematopoietic
CC disorders, wound healing disorders, cholesterol ester storage disease,
CC inflammation, congenital muscular dystrophy, junctional epidermolysis
CC bullosa, Parkinson's disease, Huntington's chorea, multiple sclerosis,
CC viral and bacterial infections, Alzheimer's disease, asthma, arthritis,
CC allergies, schizophrenia, sbg442445Proa-associated disorders,
CC septicaemia, psoriasis, inflammatory bowel disease, transplant rejection,
CC graft verse host disease, ischaemia, stroke, acute respiratory disease
CC syndrome, restenosis, brain injury, AIDS, bone diseases, atherosclerosis,
CC brain disorders including parasupranuclear palsy, myotonic dystrophy,
CC depression, anxiety disorders and sleep disorders, cardiovascular
CC diseases including congestive heart failure and myocardial infarction,
CC respiratory diseases including chronic obstructive pulmonary disease,
CC acute bronchitis and adult respiratory distress syndrome, liver disorders
CC including hypercholesterolaemia, hypertirglyceridaemia, cirrhosis, viral
CC and non-viral hepatitis, type II diabetes mellitus, renal disease
CC including acute and chronic renal failure, glomerulonephritis, Fanconi's
CC syndrome, cystinuria, skeletal muscle disorders including hypoglycaemia
CC and tendinitis, gastrointestinal diseases including intestinal
CC obstruction and tropical sprue, spleen disorders including hypersplenism,

CC Hodgkin's disease and malignant lymphoma, testicular cancer, male
CC reproductive diseases including low testosterone and male infertility.
CC The present sequence is human cytokine receptor gene.
XX
SQ Sequence 696 BP; 224 A; 140 C; 157 G; 175 T; 0 other;
Query Match 44.8%; Score 590; DB 24; Length 696;
Best Local Similarity 87.9%; Pred. No. 1.2e-112;
Matches 696; Conservative 0; Mismatches 0; Indels 96; Gaps 1;
QY 238 ATGATGCCCTAAACATTGCTTTCTTAGGCTTCCTCATCAGTTTCTTCTACTGCTAGCA 297
Db 1 ATGATGCCCTAAACATTGCTTTCTTAGGCTTCCTCATCAGTTTCTTCTACTGCTAGCA 60
QY 298 GGAAGCTCAGTCAAGCATGAGTCTCTGAAGCCTCAGAGGGTACAAATTTCAGTCCCGAAT 357
Db 61 GGAAGCTCAGTCAAGCATGAGTCTCTGAAGCCTCAGAGGGTACAAATTTCAGTCCCGAAT 120
QY 358 TTTCACACATTTTGGCAATGGCAGCCTGGAGGGGCACTTACTGGCAACAGCAGTGTCTAT 417
Db 121 TTTCACACATTTTGGCAATGGCAGCCTGGAGGGGCACTTACTGGCAACAGCAGTGTCTAT 180
QY 418 TTTGTGACATTAACAAATCATGTTCTCATGACATGAAGAAAGCTCTCACAGAGCCAACT 477
Db 181 TTTGTGACATTAACAAATCATGTTCTCATGACATGAAGAAAGCTCTCACAGAGCCAACT 197
QY 478 GGATGCTGGCAGCACAATTTCTTGAATCTCCAGGCTGAGAACATTTGGCTAATATATGA 537
Db 198 -----ATATGA 204
QY 538 CAGAGACATGGAATAATAAGAGACTGTGGGGTACTCAAGAACTCTTGTGACCTT 597
Db 205 CAGAGACATGGAATAATAAGAGACTGTGGGGTACTCAAGAACTCTTGTGACCTT 264
QY 598 ACCAGTGAACCTCAGACATACAGGAACCTTATTAAGGAGGGGTAGGGCGGCTGGCT 657
Db 265 ACCAGTGAACCTCAGACATACAGGAACCTTATTAAGGAGGGGTAGGGCGGCTGGCT 324
QY 658 GGGAGCTACTCAGATGAGCATGAGCAGCGCGGTCACTCCCTGGTGGAAACAAATA 717
Db 325 GGGAGCTACTCAGATGAGCATGAGCAGCGCGGTCACTCCCTGGTGGAAACAAATA 384
QY 718 GATCCTCAGTCAATGATATTAACCCAAAGTCAATGGCTTTGTGTGTAATTTCCATGCT 777
Db 385 GATCCTCAGTCAATGATATTAACCCAAAGTCAATGGCTTTGTGTGTAATTTCCATGCT 444
QY 778 CCAATTTACCATATAGATATACCAAAAGGAAAAAATGTATCTATAGAAAGATTACTATGA 837
Db 445 CCAATTTACCATATAGATATACCAAAAGGAAAAAATGTATCTATAGAAAGATTACTATGA 504
QY 838 CTACTATACCGAGTTTATTAATTAACAATTCAAGAAAGAGCAAAAGCTTATGA 897
Db 505 CTACTATACCGAGTTTATTAATTAACAATTCAAGAAAGAGCAAAAGCTTATGA 564
QY 898 GGGGCTACAGACGGGTTGAAATTGAAGCTCTAACACCACTCCAGCTACTGTGATG 957
Db 565 GGGGCTACAGACGGGTTGAAATTGAAGCTCTAACACCACTCCAGCTACTGTGATG 624
QY 958 GCTGAATATATCAGCCCATGTGTAGACAGAAAGATCAGAGAAGTGAAGAGAGATGTGTG 1017
Db 625 GCTGAATATATCAGCCCATGTGTAGACAGAAAGATCAGAGAAGTGAAGAGAGATGTGTG 684
QY 1018 GAAATTTCCATGA 1029
Db 685 GAAATTTCCATGA 696
RESULT 11
AAD06414
ID AAD06414 standard; cDNA; 696 BP.
XX
AC AAD06414;
XX

KW haemostatic; vulnery; anticonvulsant; antirheumatic; neuroprotective;
KW nephrotropic; hypotensive; vasotropic; cytostatic; cerebroprotective;
KW allergy; cytokine receptor; gene; ds.
OS Homo sapiens.
FH Key Location/Qualifiers
FT CDS 1..645
FT /tag= a
FT /product= "Human cytokine receptor"
XX WO200198342-A1.
XX PD 27-DEC-2001.
XX PF 22-JUN-2001; 2001WO-US19929.
XX PR 22-JUN-2000; 2000US-213156P.
XX PR 22-JUN-2000; 2000US-213161P.
XX (SMIK) SMITHKLINE BEECHAM CORP.
XX (SMIK) SMITHKLINE BEECHAM PLC.
XX (GLAX) GLAXO GROUP LTD.
XX Agarwal P, Cogswell JP, Kabnic KS, Lai Y, Martensen SA;
XX Murdock PR, Smith RF, Strum JC, Xiang Z, Xie Q, Rizni SK;
XX WPI; 2002-139783/18.
XX P-PSDB; AAE17319.
XX Novel secreted and membrane-associated polypeptides and polynucleotides
XX useful for preventing, ameliorating or correcting dysfunction or
XX disease including diabetes, cancer, hypertension and growth
XX abnormalities
XX
XX Claim 2; Page 97; 138pp; English.
XX
XX The invention relates to secreted and membrane-associated polypeptides
XX and polynucleotides. The sequences of the invention are useful in
XX diagnostic assays for detecting diseases associated with inappropriate
XX activity or levels of these polynucleotides, and in identifying their
XX agonists and antagonists that are potentially useful in therapy. The
XX sequences of the invention are useful as vaccines for inducing the
XX immunological response. The sequences of the invention are useful for
XX treating cancers, infections, autoimmune disorders, haematopoietic
XX disorders, wound healing disorders, cholesterol ester storage disease,
XX inflammation, congenital muscular dystrophy, junctional epidermolysis
XX bullosa, Parkinson's disease, Huntington's chorea, multiple sclerosis,
XX viral and bacterial infections, Alzheimer's disease, asthma, arthritis,
XX allergies, schizophrenia, sbg442445PROA-associated disorders,
XX septicemia, psoriasis, inflammatory bowel disease, transplant rejection,
XX graft verse host disease, ischaemia, stroke, acute respiratory disease
XX syndrome, restenosis, brain injury, AIDS, bone diseases, atherosclerosis,
XX brain disorders including paraspranuclear palsy, myotonic dystrophy,
XX depression, anxiety disorders and sleep disorders, cardiovascular
XX diseases including congestive heart failure and myocardial infarction,
XX respiratory diseases including chronic obstructive pulmonary disease,
XX acute bronchitis and adult respiratory distress syndrome, liver disorders
XX including hypercholesterolaemia, hypertriglyceridaemia, cirrhosis, viral
XX and non-viral hepatitis, type II diabetes mellitus, renal disease
XX including acute and chronic renal failure, glomerulonephritis, Fanconi's
XX syndrome, cystinuria, skeletal muscle disorders including hypoglycaemia
XX and tendinitis, gastrointestinal diseases including intestinal
XX obstruction and tropical sprue, spleen disorders including hypersplenism,
XX Hodgkin's disease and malignant lymphoma, testicular cancer, male
XX reproductive diseases including low testosterone and male infertility.
XX The present sequence is human cytokine receptor gene.
XX
XX Sequence 645 BP; 215 A; 127 C; 150 G; 153 T; 0 other;

Query Match 40.4%; Score 533; DB 24; Length 645;
Best Local Similarity 86.9%; Pred. NO. 6.8e-101;
Matches 639; Conservative 0; Mismatches 0; Indels 96; Gaps 1;

QY 295 GCAGAACTCAGTCAACGATGAGTCTCTGAAGCCCTCAGAGGGTACATTTCTAGTCCCGA 354
Db 7 GCAGAACTCAGTCAACGATGAGTCTCTGAAGCCCTCAGAGGGTACATTTCTAGTCCCGA 66
QY 355 AATTTTCACAACTTTTGCAATGGCAGCCCTGGAGGGCACTTACTGGCAACAGCAGTGTG 414
Db 67 AATTTTCACAACTTTTGCAATGGCAGCCCTGGAGGGCACTTACTGGCAACAGCAGTGTG 126
QY 415 TATTTTGTGACATCAAAATCATGTCTCTCATGACATGAAAAGCTCTCACCAGAACCA 474
Db 127 TATTTTGTGACATCAAAATCATGTCTCTCATGACATGAAAAGCTCTCACCAGAACCA 146
QY 475 AGTGATGCTGGCAGCACATTTCTTGTACTTCCAGGCTGCAGAACATTTGGCTAAATAT 534
Db 147 -----ATAT 150
QY 535 GGACAGAGACATGGAAAAATTAAGAAGACTGTGGGTACTCAAGAACTCTCTGTGAC 594
Db 151 GGACAGAGACATGGAAAAATTAAGAAGACTGTGGGTACTCAAGAACTCTCTGTGAC 210
QY 595 CTTACCACTGAAACCTCAGACATACAGAACTTATTACGGAGGGTGAGGGCGGCTCG 654
Db 211 CTTACCACTGAAACCTCAGACATACAGAACTTATTACGGAGGGTGAGGGCGGCTCG 270
QY 655 GCTGGAGCTACTCAGAAATGAGCATGAGCGCGGCTTCACTCCCTGGTGGAAACAATA 714
Db 271 GCTGGAGCTACTCAGAAATGAGCATGAGCGCGGCTTCACTCCCTGGTGGAAACAATA 330
QY 715 ATAGATCCTCCAGTCAATGATATATACCAAGTCAATGGCTTTGTTGGTAATTTCTCAT 774
Db 331 ATAGATCCTCCAGTCAATGATATATACCAAGTCAATGGCTTTGTTGGTAATTTCTCAT 390
QY 775 GCTCCAAATTTACCATATAGATACCAAAAGAAAAATGTATCTATAGAAATTACTAT 834
Db 391 GCTCCAAATTTACCATATAGATACCAAAAGAAAAATGTATCTATAGAAATTACTAT 450
QY 835 GAACACTATATACCGAGTTTATATATTAACAATTCACAGAAAGGCAAAAGTTTAT 894
Db 451 GAACACTATATACCGAGTTTATATATTAACAATTCACAGAAAGGCAAAAGTTTAT 510
QY 895 GAAGGGGCTCAGAGCGGTTGAATTTGAAGCTTAAACACACACACTCCAGCTACTGTGTA 954
Db 511 GAAGGGGCTCAGAGCGGTTGAATTTGAAGCTTAAACACACACACTCCAGCTACTGTGTA 570
QY 955 GTGGCTGAATATATACAGCCCATGTTAGACAGAAAGTCAAGAGTGAAGAGATGT 1014
Db 571 GTGGCTGAATATATATACAGCCCATGTTAGACAGAAAGTCAAGAGTGAAGAGATGT 630
QY 1015 GTGGAATTCATGA 1029
Db 631 GTGGAATTCATGA 645
RESULT 13
AAD06410
ID AAD06410 standard; cDNA; 750 BP.
XX
AC AAD06410;
XX
DT 10-AUG-2001 (first entry)
XX
DE Human DNAX cytokine receptor subunit 4.1 (DCRS4.1) cDNA.
XX
KW Human; immunomodulator; DNAX cytokine receptor subunit 4.1; DCRS4.1;
KW therapy; immunological disorder; drug screening; cell development;
KW chromosome 6q24.1-25.2; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 1..750
FT /tag= a

FT /product= "Human DNAX cytokine receptor subunit 4.1
FT (DCRS4.1)"
FT sig_peptide 1..63
FT /*tag= b
FT mat_peptide 64..747
FT /*tag= c
FT /product= "Human mature DNAX cytokine receptor
FT subunit 4.1 (DCRS4.1)"
XX WO200136467-A2.
XX PD 25-MAY-2001.
XX PF 16-NOV-2000; 2000WO-US31363.
XX PR 18-NOV-1999; 99US-0443060.
XX PR 13-DEC-1999; 99US-0170320.
XX PA (SCHE) SCHERING CORP.
XX Gorman DM;
XX WPI; 2001-343800/36.
XX P-PSDB; AAE02458.
XX New mammalian receptor proteins related to cytokine receptors, useful
XX for regulating cell development and for diagnosis and treatment of
XX immunological disorders
XX
XX Claim 16; Page 21-22; 124pp; English.

XX The present sequence is human DNAX cytokine receptor subunit 4.1
XX (DCRS4.1) cDNA. DCRS4 gene is located on chromosome 6q24.1-25.2.
XX Cytokine receptors, fragments and antibodies are useful for treating
XX immunological disorders. DCRS3 (50R), DCRS4 (cytor) or fragments are
XX useful in drug screening to identify compounds having binding affinity
XX to the receptor subunit. Modulators of DCRS are useful for modulating
XX the physiology or development of a cell or tissue culture cells. A
XX purified DCRS is useful as a reagent to detect antibodies generated in
XX response to the presence of elevated levels of expression, or
XX immunological disorders which lead to production of antibody to the
XX endogenous receptor. Cytokine receptor sequences are useful as probes
XX for detecting levels of the cytokine receptor in patients suspected of
XX having an immunological disorder. Antibodies have therapeutic value, are
XX useful as potent antagonist, in detecting or quantifying ligands, for
XX isolating DCRS proteins and peptides, to screen expression libraries for
XX particular expression products, to raise anti-idiotypic antibodies and
XX for detecting or diagnosing various immunological conditions related to
XX expression of the protein or cells which express the protein.

SQ Sequence 750 BP; 259 A; 147 C; 164 G; 180 T; 0 other;

Query Match 34.1%; Score 449.2; DB 22; Length 750;
Best Local Similarity 76.6%; Pred. No. 1.4e-83;
Matches 607; Conservative 0; Mismatches 143; Indels 42; Gaps 3;
QY 238 ATGATGCTTAACATTTGCTTAGGCTTCTCATCAGTTTCTTCTTACTGTAGCA 297
DB 1 ATGATGCTTAACATTTGCTTAGGCTTCTCATCAGTTTCTTCTTACTGTAGCA 60
QY 298 GGAAGTCAAGCATGAGTCTGAGGCTTCAGAGGTTACATTTTCCCGAAAT 357
DB 61 GGAAGTCAAGCATGAGTCTGAGGCTTCAGAGGTTACATTTTCCCGAAAT 120
QY 358 TTTCACACATTTTGCATGGCAGCCTGGAGGGCACTTACTGGCAACAGAGTGTCTAT 417
DB 121 TTTCACACATTTTGCATGGCAGCCTGGAGGGCACTTACTGGCAACAGAGTGTCTAT 180
QY 418 TTTGTGACATCAAAATCATGTCTTCATGCACATGAAAAGCTCTCACCAGAACCAAGT 477
DB 181 TTTGTGACATCAAAAT-ATATGGACAGAGACATGAAAAAATAAGAGACTGTGGGG 239
QY 478 GGATGCTGGCAGACATTTCTTGTAACTTCCAGGCTGCAGACATTTGGCTAAATATGA 537

DB 240 TACTCAAGAACTCTCTTGTGACCTTTACAGTGAACCTCAGACATACAGAACCTTATTA 299
QY 538 CAGAGACAAATGAAAAATAAAGAGACTGTGGGTACTCAAGAACTCTTGTGACCTT 597
DB 300 CGGAGAGAGGGCAAAATTAATAAG-----GGAATCCTTGGGGGCCAAA 347
QY 598 ACCAGTGAACCTCAGACATACAGGAACCTTATTACGGGAGGGTGAGGGCGCTCGGCT 657
DB 348 ACAAGTAACGGAATCAAGGGGAACCA----- 379
QY 658 GGGAGCTACTCAGATGAGCATGACCGCGGTTCACTCCCTGGTGGAAACAAATA 717
DB 380 -AGACCAACACAGTACTGCCCGCAGCTGCCCTGAAGCATTTGCTGATGTGCAAAATA 438
QY 718 GATCCTCCAGTCAATATATAACCAAGCTCAATGGCTTTGTTGTAATTCCTCATGCT 777
DB 439 GATCCTCCAGTCAATATATAACCAAGCTCAATGGCTTTGTTGTAATTCCTCATGCT 498
QY 778 CCAATTTACCATATAGATACCAAAAGGAAAAATGTATCTATAGAGATTACTATGAA 837
DB 499 CCAATTTACCATATAGATACCAAAAGGAAAAATGTATCTATAGAGATTACTATGAA 558
QY 838 CTACTATACCGAGTTTATTAATTAACTTACCAATTCACCTAGAGAAAGGCAAAAGTTATGAA 897
DB 559 CTACTATACCGAGTTTATTAATTAACTTACCAATTCACCTAGAGAAAGGCAAAAGTTATGAA 618
QY 898 GGGCTCACAGAGCGGTGAATTTGAAGCTTAACACACACTCCAGCTACTGTGTAGTG 957
DB 619 GGGCTCACAGAGCGGTGAATTTGAAGCTTAACACACACTCCAGCTACTGTGTAGTG 678
QY 958 GCTGAATATATACAGCCCATGTAGACAGAGAGTCAAGAGTGAAGAGATGTGTG 1017
DB 679 GCTGAATATATACAGCCCATGTAGACAGAGAGTCAAGAGTGAAGAGATGTGTG 738
QY 1018 GAAATTCATGA 1029
DB 739 GAAATTCATGA 750

RESULT 14

AL45999
ID AL45999 standard; cDNA: 750 BP.
AC AAL45999;
XX 08-AUG-2002 (first entry)

Human cytokine receptor variant 1 coding sequence.

Human; cytokine receptor; immune disease; psoriasis; cancer; infection;
rheumatoid arthritis; multiple sclerosis; Crohn's disease;
ulcerative colitis; transplant rejection; abortion; antipsoriatic;
immunosuppressive; antirheumatic; antiarthritic; neuroprotective;
antiinflammatory; antiulcer; cytostatic; dermatological;
chromosome 6q24.1-25.2; receptor; gene; ss.

Homo sapiens.
Key Location/Qualifiers
FT CDS 1..750
FT /*tag= a
FT /product= "cytokine receptor variant 1"

EP1191035-A2.
XX PD 27-MAR-2002.
XX PF 24-AUG-2001; 2001EP-0250307.
XX PR 25-SEP-2000; 2000DE-1048626.
XX PR 17-NOV-2000; 2000DE-1058907.
XX PR 19-DEC-2000; 2000DE-1064906.

XX (SCHD) SCHERING AG.
PA Weiss B, Sabat R, Assadullah K, Toshi L;
PI WPI: 2002-332210/37.
XX P-PSDB; AAO17380.
DR
XX
PT New nucleic acid encoding soluble cytokine receptor, useful for
PT diagnosis and treatment of e.g. immune disease, also related protein
XX and antibodies
XX
PS Claim 1; Page 12; 21pp; German.
XX
CC The present invention provides the protein and coding sequences of 3
CC variants of a human cytokine receptor. The sequences can be used in the
CC diagnosis, prevention and treatment of immune diseases, including
CC psoriasis, cancer, chronic/life-threatening infections, rheumatoid
CC arthritis, multiple sclerosis, Crohn's disease, ulcerative colitis and
CC transplant rejection and in reproductive medicine, e.g. for diagnosing
XX abnormal immune reactions which cause abortions. The present sequence is
XX the coding sequence of variant 1 of the invention.
SQ Sequence 750 BP; 259 A; 147 C; 164 G; 180 T; 0 other;
Query Match 34.1%; Score 449.2; DB 24; Length 750;
Best Local Similarity 76.6%; Pred. No. 1.4e-83;
Matches 607; Conservative 0; Mismatches 143; Indels 42; Gaps 3;
QY 238 ATGATGCGCTAAACATTCCTTTCTAGGCTTCCTCATCAGTTTCTTCTTACTGTGTAGCA 297
Db 1 ATGATGCGCTAAACATTCCTTTCTAGGCTTCCTCATCAGTTTCTTCTTACTGTGTAGCA 60
QY 298 GGAAGCTCAGTCAACGCGATGAGTCTCTGAAGCCTCAGAGGGTACAAATTTTCCCGGAAT 357
Db 61 GGAAGCTCAGTCAACGCGATGAGTCTCTGAAGCCTCAGAGGGTACAAATTTTCCCGGAAT 120
-QY 358 TTTCACACATTTTTCGATGCGAGCGCTGGAGGGGCACTTACTGGCAACAGCAGTGTCTAT 417
Db 121 TTTCACACATTTTTCGATGCGAGCGCTGGAGGGGCACTTACTGGCAACAGCAGTGTCTAT 180
QY 418 TTGTGTCAGTCAAAATCATGTTCTCATGTCAGCATGAAAGCTCTCACCAGAAAGCCAACT 477
Db 181 TTGTGTCAGTCAAAATCATGTTCTCATGTCAGCATGAAAGCTCTCACCAGAAAGCCAACT 239
QY 478 GGATGCTGGCAGCACATTTCTTGTAACTTCCAGGCTGCAGAACATTGGCTAAATATGGA 537
Db 240 TACTCAAGAACTCTCTTGTGACCTTACCAGTGAACCTCAGACATACAGGAACCTTATTA 299
QY 538 CAGAGACAATGAAAAATAAGAAGACTGTGGGCTTCAAGAACTCTTGTGACCTT 597
Db 300 CCGGAGAGGGGCAAAATAAATAAG-----GGAATCCTTGGGGGCCAAA 347
QY 598 ACCAGTGAACCTCAGACATACAGAACCTTATTAAGGGAGGGTGGGGCGGCTCGGCT 657
Db 348 ACAAGTAAACGAAATCAAGGGGAAACCAG----- 379
QY 658 GGGAGCTACTCAGAAATGAGCATGACCGCCGCTTCACTCCCTGGTGGAAACAAATA 717
Db 380 -AGACCAACACAGTGAAGTGGCCAGCTGGAAGGCATTTGCTGATGCAAAATA 438
QY 718 GATCCTCAGTCAATGATATTAACCAAGTCAATGGCTTTGTTGTAATTCCTCATGCT 777
Db 439 GATCCTCAGTCAATGATATTAACCAAGTCAATGGCTTTGTTGTAATTCCTCATGCT 498
QY 778 CCAAAATTACCATATAGATACCAAAAGGAAAAATGTATCTATAGAGATTACTATGAA 837
Db 499 CCAAAATTACCATATAGATACCAAAAGGAAAAATGTATCTATAGAGATTACTATGAA 558
QY 838 CTACTATACCGAGTTTATATATTAACAATTCCTAGAAAAGGCAAAAGTTTATGAA 897
Db 559 CTACTATACCGAGTTTATATATTAACAATTCCTAGAAAAGGCAAAAGTTTATGAA 618

QY 898 GGGGCTCACAGAGCGGTGAAATTGAAGCTCTTAACACACACACTCCAGCTACTGTAGTG 957
Db 619 GGGGCTCACAGAGCGGTGAAATTGAAGCTCTTAACACACACACTCCAGCTACTGTAGTG 678
QY 958 GCTGAATATATCAGCCCATGTGTAGACAGAGAAGTCAAGAGTGAAGAGATGTGTG 1017
Db 679 GCTGAATATATCAGCCCATGTGTAGACAGAGAAGTCAAGAGTGAAGAGATGTGTG 738
QY 1018 GAAATTCATGA 1029
Db 739 GAAATTCATGA 750

RESULT 15
AAD06415
ID AAD06415 standard; DNA; 693 BP.
XX
AC AAD06415;
XX
DT 10-AUG-2001 (first entry)
XX
DE Human DNAX cytokine receptor subunit 4.2 reverse translational DNA.
XX
KW Human: immunomodulator; DNAX cytokine receptor subunit 4.2; DCRS4.2;
KW therapy; immunological disorder; drug screening; cell development;
XX chromosome 6q24.1-25.2; ds.
OS Homo sapiens.
XX
PN WO200136467-A2.
XX
PD 25-MAY-2001.
XX
PF 16-NOV-2000; 2000WO-US31363.
XX
PR 18-NOV-1999; 99US-0443060.
PR 13-DEC-1999; 99US-0170320.
XX
PA (SCHE) SCHERING CORP.
PI Gorman DM;
XX
DR WPI: 2001-343800/36.
XX
XX
PT New mammalian receptor proteins related to cytokine receptors, useful
PT for regulating cell development and for diagnosis and treatment of
PT immunological disorders
XX
PS Disclosure; Page 25; 124pp; English.
XX
XX The present sequence is human DNAX cytokine receptor subunit 4.2
CC (DCRS4.2) reverse translational DNA. DCRS4 gene is located on
CC chromosome 6q24.1-25.2. Cytokine receptors, fragments and antibodies are
CC useful for treating immunological disorders. DCRS3 (50R), DCRS4 (cytor)
CC or fragments are useful in drug screening to identify compounds having
CC binding affinity to the receptor subunit. Modulators of DCRs are useful
CC for modulating the physiology or development of a cell or tissue culture
CC cells. A purified DCRs is useful as a reagent to detect antibodies
CC generated in response to the presence of elevated levels of expression,
CC or immunological disorders which lead to production of antibody to the
CC endogenous receptor. Cytokine receptor sequences are useful as probes
CC for detecting levels of the cytokine receptor in patients suspected of
CC having an immunological disorder. Antibodies have therapeutic value, are
CC useful as potent antagonist, in detecting or quantifying ligands, for
CC isolating DCRs proteins and peptides, to screen expression libraries for
CC particular expression products, to raise anti-idiotypic antibodies and
CC for detecting or diagnosing various immunological conditions related to
CC expression of the protein or cells which express the protein.
XX
SQ Sequence 693 BP; 131 A; 70 C; 108 G; 93 T; 291 other;
Query Match 30.2%; Score 398.2; DB 22; Length 693;
Best Local Similarity 51.0%; Pred. No. 4.9e-73;

Matches 402; Conservative 179; Mismatches 111; Indels 96; Gaps 1;

QY	238	ATGATGCCCTTAACATTTGCTTCTAGCCTTCTCATCATGTTTCTTCTTACTGTGTAGCA	297
Db	1	ATGATGCCNAARCAATGTTTGTGNGTFTYTNATHWSNTTFTTFTTNACNGNGTNGCN	60
QY	298	GGAACTCAGTCAACGATGAGTCTCTGAAGCCTCAGAGGGTACAAATTTTCCCGCAAT	357
Db	61	GGNACNCARMSNACNCAYGARMSNTYTNARCNCAARMGNTNCARTTYCARMSNGNAAY	120
QY	358	TTTCACACATTTTGCATGCGAGCCTGGGAGGCACTTACTGGCAACAGCAGTGTCTAT	417
Db	121	TTTCAYAAATHTYTNCAATGGCARCCNGNMGNGCNYTNACNGNAAYWSNWSNGTNTAY	180
QY	418	TTTGTGACAGTCAAAATCATGTCTCATGACGATGAAAGCTCTCACAGAGCCCAAGT	477
Db	181	TTTGTNCARTAYAAAT-----	197
QY	478	GGATGCTGGCAGCACATTTCTTGACTTCCAGGCTGCAGAACATTTGGCTAAATATGGA	537
Db	198	-----HTAYGNN	204
QY	538	CAGAGACAATGGAATAAAGAAGACTGTGGGGTACTCAAGAACTCTTGTGACCTT	597
Db	205	CARMGNCARTGGAARAAYAAARGARAYTGTGGGACNACARARNTWSNTGYAYTN	264
QY	598	ACCAGTGAACCTCAGACATACAGAGAACCTTATTACGGGAGGCTGAGGGCGCTCGGCT	657
Db	265	ACNWSNGARACNWSNGAYATHCARARCCNTAYTAYGNGMNGTNGMNGCNGCNGWSNGCN	324
QY	658	GGAGCTACTCAGAAATGAGCATGAGCATGCCCGCGGCTTCACTCCCTGTTGGGAAACAAATA	717
Db	325	GGNWSNTAYWSNGARTGWSNATGACNCCNMGNTTYACNCCNTGTTGGGARACNAARATH	384
QY	718	GATCCTCCAGTCATGAATATAACCCAGTCAATGGCTCTTGTGTAATCTCCATGCT	777
Db	385	GAYCCNCCNGTNAATGAAYATHACNCARGTNAAYGNGWSNTYTNGTNATHYTNCAAYGN	444
QY	778	CCAAATTTACCATATAGATACCAAAAGGAAAAATGTATCTATAGAAGATTAATGAA	837
Db	445	CCNAAYTNCNTAYMGNATYCARAARGARAARAYGTNWSNATHGARAYTAYGAR	504
QY	838	CTACTATACCGAGTTTATTAATTAACTTCACTAGAAAAGGAGCAAAAGGTTTATGAA	897
Db	505	YTNNTNTAYMGNNTTATTAATHAAYAAYSNTYNGARAARARARAGTNTAYGAR	564
QY	898	GGGCTCAGAGCGGCTGAATTTGAAGCTCTAACACCACTCCAGCTACTGTGTAGT	957
Db	565	GGNGCNCAYMNGCNGTNGARATHGARGCNTYNACNCCNCAIWSNWSNTAYTGYGTNGTN	624
QY	958	GCTGAATATATCAGCCCATGTTAGACAGAGAAGTCAAGAGAAGTGAAGAGATGTGTG	1017
Db	625	GCNGARATHATYCARCCNATGYTNAYMGNMGNWSNCAARMGWSNGARARMGNTGYGTN	684
QY	1018	GAATTTCC	1025
Db	685	GARATHCC	692

Search completed: December 22, 2002, 07:51:30
Job time : 265 secs

GenCore version 5.1.3
Copyright (c) 1993 - 2002 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 22, 2002, 07:43:01 ; Search time 1969 seconds
(without alignments)
10840.859 Million cell updates/sec

Title: US-09-964-994-1
Perfect score: 1318
Sequence: 1 cagttcttcacatctgttaaca.....aaaaaaaaaaaaaaaaaaaaa 1318

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 16154066 seqs, 8097743376 residues
1 number of hits satisfying chosen parameters: 32308132

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : EST:*

1:	em_estba:*
2:	em_esthum:*
3:	em_estin:*
4:	em_estmu:*
5:	em_estov:*
6:	em_estpl:*
7:	em_estro:*
8:	em_htc:*
9:	gb_est1:*
10:	gb_est2:*
11:	gb_htc:*
12:	gb_est3:*
13:	gb_est4:*
14:	gb_est5:*
15:	em_estfun:*
16:	em_estom:*
17:	gb_gss:*
18:	em_gss_hum:*
19:	em_gss_inv:*
20:	em_gss_pln:*
21:	em_gss_vrt:*
22:	em_gss_fun:*
23:	em_gss_mam:*
24:	em_gss_mus:*
25:	em_gss_other:*
26:	em_gss_pro:*
27:	em_gss_rod:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	686	52.0	698	10	AV714177
2	284.4	21.6	632	10	BB636466
3	222.4	16.9	663	10	BB222214
4	160	12.1	572	10	BB637530
5	124.2	9.4	494	12	BE809214
6	106.2	8.1	548	17	BH117626

C	7	84.6	6.4	645	17	AZ722045	AZ722045	RPCI-24-1
C	8	81	6.1	583	10	AW833620	AW833620	QV4-TT000
C	9	77.4	5.9	311	9	AL513907	AL513907	AL513907
C	10	77	5.8	311	9	AL513907	AL513907	AL513907
C	11	76.2	5.8	454	9	AL513951	AL513951	AL513951
C	12	75.8	5.8	304	9	AL514919	AL514919	AL514919
C	13	75.4	5.7	319	9	AL513977	AL513977	AL513977
C	14	75.2	5.7	365	9	AL515373	AL515373	AL515373
C	15	74.4	5.6	503	9	AL513809	AL513809	AL513809
C	16	74.2	5.6	366	9	AL514543	AL514543	AL514543
C	17	74.2	5.6	794	17	AZ530415	AZ530415	ENTBX01TR
C	18	74	5.6	240	9	AU074171	AU074171	AU074171
C	19	73.8	5.6	353	9	AL515235	AL515235	AL515235
C	20	73.8	5.6	621	10	BB666101	BB666101	BB666101
C	21	73.6	5.6	458	9	AL514085	AL514085	AL514085
C	22	73.4	5.6	329	9	AL513719	AL513719	AL513719
C	23	73.4	5.6	329	9	AL514627	AL514627	AL514627
C	24	73	5.5	401	9	AL515191	AL515191	AL515191
C	25	73	5.5	404	9	AL514087	AL514087	AL514087
C	26	73	5.5	638	9	AL513901	AL513901	AL513901
C	27	72.6	5.5	965	17	AZ529824	AZ529824	ENTCX56TF
C	28	72.4	5.5	449	9	AL513999	AL513999	AL513999
C	29	72	5.5	404	9	AL514087	AL514087	AL514087
C	30	71.8	5.4	335	9	AL513597	AL513597	AL513597
C	31	71.8	5.4	601	9	AL513631	AL513631	AL513631
C	32	71.6	5.4	316	13	BM651303	BM651303	170006873
C	33	71.6	5.4	379	9	AL514359	AL514359	AL514359
C	34	71.6	5.4	535	14	BQ400871	BQ400871	NISC_mpl1
C	35	71.4	5.4	329	9	AL514627	AL514627	AL514627
C	36	71.4	5.4	523	9	AL514015	AL514015	AL514015
C	37	71.2	5.4	425	9	AL514791	AL514791	AL514791
C	38	71	5.4	276	14	BQ527333	BQ527333	NISC_no21
C	39	71	5.4	276	14	BQ527333	BQ527333	NISC_no21
C	40	71	5.4	309	9	AL514691	AL514691	AL514691
C	41	71	5.4	313	14	BQ391420	BQ391420	NISC_mq18
C	42	71	5.4	313	14	BQ391420	BQ391420	NISC_mq18
C	43	71	5.4	367	14	BQ525045	BQ525045	NISC_no08
C	44	71	5.4	477	14	BQ390789	BQ390789	NISC_mq15
C	45	71	5.4	501	14	BQ525537	BQ525537	NISC_no11

ALIGNMENTS

RESULT 1
AV714177
LOCUS
DEFINITION AV714177 DCB Homo sapiens cDNA clone DCBAWF09 5', mRNA sequence.
ACCESSION AV714177
VERSION AV714177.1 GI:10795694
KEYWORDS
SOURCE
ORGANISM Homo sapiens
REFERENCE
AUTHORS Xu,X., Gu,J., Liu,F., Qu,J., Zhao,M., Li,Y., Huang,Q., Zhou,J., Song,H., Gu,Y., Yang,Y., Gao,G., Xiao,H., Li,N., Qian,B., Gao,X., Cheng,Z., Xu,S., Gu,W., Tu,Y., Jia,J., Fu,G., Ren,S., Zhong,M., Lu, G., Cheng,Z. and Han,Z.
Homo sapiens cDNA DCB clones
Unpublished (2000)
Contact: Zeguang Han
Chinese National Human Genome Center at Shanghai
351 Guo Shoujing Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai
201203, P. R. China
Tel: 86-21-50801919(ex.45)
Fax: 86-21-50801922
Email: hanzg@chgc.sh.cn
This clone is available at CHGC in Shanghai.
Location/Qualifiers
1..698
/organism="Homo sapiens"

TITLE
JOURNAL
COMMENT

FEATURES
source

[illegible]

RESULT	5
LOCUS	BE809214
DEFINITION	BE809214 494 bp mRNA linear EST 25-APR-2001
ACCESSION	BE809214 MARC 2BOV Bos taurus cDNA 5', mRNA sequence.
VERSION	BE809214.1 GI:10240317
KEYWORDS	EST.
SOURCE	COW.

REFERENCE AUTHORS

TITLE	JOURNAL
Sequence evaluation of four pooled-tissue normalized bovine cDNA libraries and construction of a gene index for cattle	Genome Res. 11 (4), 626-630 (2001)

JOURNAL
MEDLINE
MENT

FEATURES

Email: smith@email.marc.usda.gov
Single pass sequencing. Bases called and alt_trimmed with phred
v0.980904.e. Vector identified by cross_match with the -minscore 18
and -mismatch 12 options.
PCR Primers
FORWARD: AGGAACAGCTATGACCAT
BACKWARD: GTTTCGCCAGTCACGACG
Plate: 71 row: 0 column: 5
Seq primer: ATTTCAGCTGACACTATAG.
Location/Qualifiers
1. .494
/organism="Bos taurus"
/db_xref="taxon:9913"
/clone_lib="MARC 2B0V"
/tissue_type="pooled"
/lab_host="DH10B"
/note="Vector: PCMV SPORT6; Site_1: NotI; Site_2: SalI;
Library made from pooled tissue from testis, thymus,
semitendinosus muscle, longissimus muscle, pancreas,
adrenal, and endometrium."

BASE COUNT	176 a	89 c	112 g	117 t
ORIGIN				

Query Match	9.48;	Score 124.2;	DB 12;	Length 494;
Best Local Similarity	79.58;	Pred. No. 1.8e-09;		
Matches 147; Conservative	0;	Mismatches 38;	Indels 0;	Gaps 0;

QY	527	CTAATATGGACAGACACATGGAAAAATTAAGAAGACTGTGGGGTACTCAAGAACTCT	586
Db	294	CTAGGTATGGAGAGAGACAGTGGAAAAATTAAGAGACCTGTGGGGATTGAGAGTTCT	353
QY	587	CTGTGACCTTACCAGTGAACCTCAGACATACAGAACTTATACGGGAGGTGAGGG	646
Db	354	TCTGTGACCTTACCAGTGAACATCAGATATATGGGAACCTTATATGGGAGAGTGAAGA	413
QY	647	CGGCTCGGCTGGAGCTACTCAGATGAGCATGACGCCGGGTTCACCTCGTGGTGG	706
Db	414	CAGCTCTGGCTGGGATCCACTCAGGCTGGACCATGACACAGCGGTTCATTCATGTTGGG	473
QY	707	AAACA 711	
Db	474	AAAGA 478	

RESULT 6	
BH117626/c	
LOCUS	BH117626 548 bp DNA
DEFINITION	RPCI-24-253I22.TV RPCI-24 Mus musculus genomic clone RPCI-24-253I22
ACCESSION	BH117626
VERSION	BH117626
KEYWORDS	GI:14959077
SOURCE	GSS.
ORGANISM	house mouse.
	Mus musculus

REFERENCE
AUTHORS

TITLE	JOURNAL	COMMENT
Mouse BAC End Sequences from Library RPCI-24	Unpublished (1999)	Other_GSSS: RPCI-24-253I22.TJ

Contact: Shaying Zhao
Department of Eukaryotic Genomics
The Institute for Genomic Research
9712 Medical Center Dr., Rockville, MD 20850, USA
Tel: 301 838 0200
Fax: 301 838 0208
Email: szhao@tigr.org

Clones are derived from the mouse BAC library RPCT-24. For BAC library availability, please contact Pieter de Jong (pdejong@email.cho.org). Clones may be purchased from BACPAC Resources (<http://www.choi.ig.org/bacpac/orderingframe.htm>). BAC end page: http://www.tigr.org/tldb/bac_ends/mouse/bac_end_intro.html
plate: 253 row: I column: 22
Seq primer: T7
class: BAC ends.

FEATURES	Location/Qualifiers
source	1. .548

```

source
1. .548
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="RPCI-24-253I22"
/clone_lib="RPCI-24"
/sex="Male"
/cell_type="Spleen/Brain"
/note="Vector: pTRABAC1; Site_1: BamHI;
RPCI-24 Mouse BAC Library produced by Pieter de Jong. The
library was cloned in the pTRABAC1 cloning vector at the
BamHI sites using MboI partially digested male C57BL/6J
DNA."
BASE COUNT      182 a      85 c      100 g      181 t

```


QY	348	GTCCCGAAATTTTCACACATTTTGCATGGCAGCCT	384
Db	40	GTCCCGAAATTTTCACACATTTTGCACCTGCACCTCT	4

RESULT 9

LOCUS	311 bp	mRNA	linear	EST 13-FEB-2001
AL513907				
AL513907	LT1_NFL006_P12	Homo sapiens CDNA clone	CL0BA006ZC11	3
DEFINITION	prime, mRNA sequence.			

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

FEATURES	Location/Qualifiers
source	1..311

	BASE COUNT	121 a	5 c	4 g	162 t	19 others
		http://tallentgen.invtalogen.com				

Query Match	5.9%;	Score 77.4;	DB 9;	Length 311;
Best Local Similarity	55.8%;	Pred. No. 0.023;		
Matches 120;	Conservative 12;	Mismatches 83;	Indels 0;	Gaps 0;

1104 TCTATTAAAAATTGTTTTTTTGATTTTCTTAAAGCAATATTCACGTGTACACCTGGGGGA 1163
 | | | | | | | | | | : | : : : : : : : |
 283 TT 224

OY		1164	CTTCCTTGGTTATCCATTCTTTATCCTTTATAATTCAATTTGTAACACTATATTGGAACGA	1223
			:	: :
Dd	223	TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTAAATAAAAATTWWWWAAA	164	

[illegible]

QY	1284	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	1318
Db	103	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	69

RESULT 10	LOCUS	DEFINITION	ACCESSION	VERSION
AL513907	311 bp	mRNA	linear	EST 13-FEB-2001
AL513907	LTI_NFL006_PL2	Homo sapiens CDNA clone	CL08A006ZC11	3
AL513907	prime, mRNA	sequence.		
AL513907				
AL513907.1	GI:12777401			

KEYWORDS	EST.
SOURCE	human.
ORGANISM	Homo sapiens

REFERENCE	1 (bases 1 to 311)
AUTHORS	Li, W.B., Gruber, C., Jessee, J. and Polayes, D.
TITLE	Full-length cDNA libraries and normalization
JOURNAL	Unpublished (2001)
COMMENT	Contact: Genoscope

FEATURES	Location/Qualifiers
source	1. .311

BASE COUNT	121 a	5 c	4 g	162 t	19 others
ORIGIN					

Query Match	5.8%;	Score 77;	DB 9;	Length 311;
Best Local Similarity	55.38%;	Pred. No. 0.026;		
Matches 119;	Conservative. 13;	Mismatches 83;	Indels 0;	Gaps 0;

[illegible][illegible]

Oy	1224	CATTC	CCCCG	AAAAA	TGTGA	AATGT	AAAGAT	GAGGC	ACAGAA	TAAAGT	GTCTAT	GAAA	1283
		:					↓				: :	:	::
Db	187	AAAAA	AAAAA	WAAAAAAAA	AAAAAAAA	AAAAAAAA	AAAAAAAA	AAAAAAAA	ARARRR	RAGR	RAGARAA		246

Qy	1284	AAAAAAAAAAAAAAAAAAAAAAAAAAAAA	1318
		:	
Db	247	AAAAAAAAAAAAAAAAAAAAAAAAAAAAA	281

RESULT	11						
AL513951/c							
LOCUS	AL513951	454 bp	mRNA	linear	EST 13-FEB-2001		
DEFINITION	AL513951 LTI_NFL006_PL2	Homo sapiens	CDNA	clone CLOBA0102D12	3		
	prime, mRNA sequence.						
ACCESSION	AL513951						
VERSION	AL513951.1	GI:12777445					
KEYWORDS	EST.						
SOURCE	human.						
ORGANISM	Homo sapiens						

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 454)
Li, W.B., Gruber, C., Jesse, J. and Polayes, D.
Full-length cDNA libraries and normalization
Unpublished (2001)
Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France

Search completed: December 22, 2002, 09:11:13
Job time : 1977 secs

GenCore version 5.1.3
Copyright (c) 1993 - 2002 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 22, 2002, 07:44:21 ; Search time 55 Seconds
(without alignments)
7349.090 Million cell updates/sec

Title: US-09-964-994-1

Perfect score: 1318
Sequence: 1 cagttcttcctcgtcgtacaa.....aaaaaaaaaaaaaaaaaa 1318

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 441362 segs, 153338381 residues

1 number of hits satisfying chosen parameters: 882724

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued_Patents_NA:*
1: /cgn2_6/ptodata/1/ina/5A_COMB.seq:*
2: /cgn2_6/ptodata/1/ina/5B_COMB.seq:*
3: /cgn2_6/ptodata/1/ina/6A_COMB.seq:*
4: /cgn2_6/ptodata/1/ina/6B_COMB.seq:*
5: /cgn2_6/ptodata/1/ina/PCTUS_COMB.seq:*
6: /cgn2_6/ptodata/1/ina/backfiles1.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	69.2	5.3	1659	2	US-08-943-087-45 Sequence 45, Appl
2	68.6	5.2	1659	2	US-08-943-087-13 Sequence 13, Appl
3	68.6	5.2	1659	2	US-08-943-087-31 Sequence 31, Appl
4	68	5.2	1659	2	US-08-943-087-19 Sequence 19, Appl
5	67.8	5.1	663	2	US-08-943-087-53 Sequence 53, Appl
6	67	5.1	663	2	US-08-943-087-49 Sequence 49, Appl
7	67	5.1	663	2	US-08-943-087-51 Sequence 51, Appl
8	67	5.1	1659	2	US-08-943-087-15 Sequence 15, Appl
9	67	5.1	1659	2	US-08-943-087-17 Sequence 17, Appl
10	67	5.1	1659	2	US-08-943-087-23 Sequence 23, Appl
11	67	5.1	3516	2	US-08-943-087-1 Sequence 1, Appl
12	66.8	5.1	1659	2	US-08-943-087-25 Sequence 25, Appl
13	66.4	5.0	1659	2	US-08-943-087-21 Sequence 21, Appl
14	65.4	5.0	663	2	US-08-943-087-57 Sequence 57, Appl
15	65.4	5.0	1659	2	US-08-943-087-29 Sequence 29, Appl
16	65.4	5.0	1659	2	US-08-943-087-39 Sequence 39, Appl
17	64.2	4.9	663	2	US-08-943-087-59 Sequence 59, Appl
18	64.2	4.9	1659	2	US-08-943-087-37 Sequence 37, Appl
19	63.8	4.8	663	2	US-08-943-087-55 Sequence 55, Appl
20	63.8	4.8	1659	2	US-08-943-087-41 Sequence 41, Appl
21	63.8	4.8	1659	2	US-08-943-087-43 Sequence 43, Appl
22	63.6	4.7	1659	2	US-08-943-087-27 Sequence 27, Appl
23	62.2	4.7	1659	2	US-08-943-087-33 Sequence 33, Appl
24	61.4	4.7	6671	1	US-08-280-443-1 Sequence 1, Appl
25	61.4	4.7	6671	1	US-08-457-459-1 Sequence 1, Appl
26	61.4	4.7	6671	1	US-08-555-678-1 Sequence 1, Appl
27	61.4	4.7	6671	5	PCT-US95-02275-1 Sequence 1, Appl

28	61	4.6	1659	2	US-08-943-087-35	Sequence 35, Appl
29	60.8	4.6	3602	4	US-09-402-929-1	Sequence 1, Appl
30	58.6	4.4	5852	1	US-07-867-106-2	Sequence 2, Appl
31	56.4	4.3	1129	4	US-09-227-357-40	Sequence 40, Appl
32	55.8	4.2	1659	2	US-08-943-087-47	Sequence 47, Appl
33	55	4.2	578	4	US-09-602-877A-95	Sequence 95, Appl
34	54.8	4.2	1411	4	US-08-964-127-5	Sequence 5, Appl
35	54.8	4.2	1411	4	US-09-496-692-5	Sequence 5, Appl
36	54.6	4.1	882	2	US-08-909-965C-9	Sequence 9, Appl
37	54.6	4.1	6476	4	US-09-127-670-5	Sequence 5, Appl
38	54.4	4.1	1474	4	US-08-821-994-64	Sequence 64, Appl
39	54.2	4.1	1582	3	US-08-545-196B-10	Sequence 10, Appl
40	54.2	4.1	1582	3	US-08-545-196B-12	Sequence 12, Appl
41	54.2	4.1	2246	4	US-09-363-708-3	Sequence 3, Appl
42	54.2	4.1	2447	2	US-09-014-969-14	Sequence 14, Appl
43	54	4.1	1507	4	US-09-453-323-1	Sequence 1, Appl
44	53.6	4.1	2852	3	US-09-027-137-2	Sequence 2, Appl
45	53.6	4.1	2852	4	US-09-344-441-2	Sequence 2, Appl

ALIGNMENTS

RESULT 1
US-08-943-087-45
Sequence 45, Application US/08943087
Patent No. 5945511
GENERAL INFORMATION:
APPLICANT: Lok, Si
APPLICANT: Kho, Choon J.
APPLICANT: Jelmsberg, Anna C.
APPLICANT: Adams, Robyn L.
APPLICANT: Whitmore, Theodore E.
APPLICANT: Parrish, Theresa M.
TITLE OF INVENTION: CYTOKINE RECEPTOR
NUMBER OF SEQUENCES: 60
CORRESPONDENCE ADDRESS:
ADDRESSEE: ZymoGenetics, Inc.
STREET: 1201 Eastlake Avenue East
CITY: Seattle
STATE: WA
COUNTRY: USA
ZIP: 98102
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/943,087
FILING DATE:
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/803,305
FILING DATE: 20-FEB-1997
ATTORNEY/AGENT INFORMATION:
NAME: Lunn, Paul G
REGISTRATION NUMBER: 32,743
REFERENCE/DOCKET NUMBER: 96-24C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-442-6627
TELEFAX: 206-442-6678
TELEX:
INFORMATION FOR SEQ ID NO: 45:
SEQUENCE CHARACTERISTICS:
LENGTH: 1659 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
FEATURE:
NAME/KEY: Coding Sequence
LOCATION: 1...1659

NUMBER OF SEQUENCES: 60
CORRESPONDENCE ADDRESS:
ADDRESSEE: ZymoGenetics, Inc.
STREET: 1201 Eastlake Avenue East
CITY: Seattle
STATE: WA
COUNTRY: USA
ZIP: 98102
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FASTSEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/943,087
FILING DATE:
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/803,305
FILING DATE: 20-FEB-1997
ATTORNEY/AGENT INFORMATION:
NAME: Lunn, Paul G
REGISTRATION NUMBER: 32,743
REFERENCE/DOCKET NUMBER: 96-24C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-442-6627
TELEFAX: 206-442-6678
TELEX:
INFORMATION FOR SEQ ID NO: 51:
SEQUENCE CHARACTERISTICS:
LENGTH: 663 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
FEATURE:
NAME/KEY: Coding Sequence
LOCATION: 1..663
OTHER INFORMATION:
US-08-943-087-51

Query Match 5.1%; Score 67; DB 2; Length 663;
Best Local Similarity 51.5%; Pred. No. 7.9e-07;
Matches 154; Conservative 0; Mismatches 145; Indels 0; Gaps 0;
QY 529 AATATGACAGACAGACATGAAAAATAAGAGAGCTGTGGGGTACTCAAGACTCTCT 588
136 ATATATGGGCAAAAGAAATGGCTGAATTAATCAGAAATGCAAAATATCAATAGAACCTAC 195
589 TGTGACCTTACCAAGTGAACCTCAGACATACAGGAACCTTATACGGAGGAGGAGCGC 648
196 TGTGATCTTTCTGCTGAACCTTCTGACTACGAAACACAGATATATGCCAAAGTTAAGGCC 255
QY 649 GCCTCGGCTGGAGCTACTCAGAATGAGCATGACGCCGCGTTCACCTCCCTGGTGGAA 708
256 ATTTGGGAACAAGTGTCCAATGCGCTGAAGTGAACGGTTCTATCTTTTGTAGAA 315
QY 709 ACAAAAATAGATCCTCCAGTCATGATATTAACCAAGTCAATGGCTCTTGTGTGAAT 768
316 ACACAAATTTGGCCACACAGAGGTGGGACTGACTACAGATGAGAAATCCATTTCTGTGTC 375
QY 769 CTCCATGCTCCAAATTATCATATAGATACCAAAAGGAAAAAATGTATCTATAGAAGA 827
376 CTGACAGCTCCAGAGAAGTGAAGAGAAATCCAGAACCTCTCTGTTTCATGCAACA 434
Db

RESULT 8
US-08-943-087-15
Sequence 15, Application us/08943087
Patent No. 5945511
GENERAL INFORMATION:
APPLICANT: Lok, Si
APPLICANT: Kho, Choon J.

APPLICANT: Jelmsberg, Anna C.
APPLICANT: Adams, Robyn L.
APPLICANT: Whitmore, Theodore E.
APPLICANT: Farrah, Theresa M.
TITLE OF INVENTION: CYTOKINE RECEPTOR
NUMBER OF SEQUENCES: 60
CORRESPONDENCE ADDRESS:
ADDRESSEE: ZymoGenetics, Inc.
STREET: 1201 Eastlake Avenue East
CITY: Seattle
STATE: WA
COUNTRY: USA
ZIP: 98102
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FASTSEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/943,087
FILING DATE:
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/803,305
FILING DATE: 20-FEB-1997
ATTORNEY/AGENT INFORMATION:
NAME: Lunn, Paul G
REGISTRATION NUMBER: 32,743
REFERENCE/DOCKET NUMBER: 96-24C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-442-6627
TELEFAX: 206-442-6678
TELEX:
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 1659 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
FEATURE:
NAME/KEY: Coding Sequence
LOCATION: 1..1659
OTHER INFORMATION:
US-08-943-087-15

Query Match 5.1%; Score 67; DB 2; Length 1659;
Best Local Similarity 51.5%; Pred. No. 1e-06;
Matches 154; Conservative 0; Mismatches 145; Indels 0; Gaps 0;
QY 529 AATATGACAGACAGACATGAAAAATAAGAGAGCTGTGGGGTACTCAAGACTCTCT 588
223 ATATATGGGCAAAAGAAATGGCTGAATTAATCAGAAATGCAAAATATCAATAGAACCTAC 282
QY 589 TGTGACCTTACCAAGTGAACCTCAGACATACAGGAACCTTATACGGAGGAGGAGCGC 648
283 TGTGATCTTTCTGCTGAACCTTCTGATTACGAAACACAGATATATGCCAAAGTTAAGGCC 342
QY 649 GCCTCGGCTGGAGCTACTCAGAATGAGCATGACGCCGCGTTCACCTCCCTGGTGGAA 708
343 ATTTGGGAACAAGTGTCCAATGCGCTGAAGTGAACGGTTCTATCTTTTGTAGAA 402
QY 709 ACAAAAATAGATCCTCCAGTCATGATATTAACCAAGTCAATGGCTCTTGTGTGAAT 768
403 ACACAAATTTGGCCACACAGAGGTGGGACTGACTACAGATGAGAAATCCATTTCTGTGTC 462
QY 769 CTCCATGCTCCAAATTATCATATAGATACCAAAAGGAAAAAATGTATCTATAGAAGA 827
463 CTGACAGCTCCAGAGAAGTGAAGAGAAATCCAGAACCTCTCTGTTTCATGCAACA 521
Db

RESULT 9
US-08-943-087-17

Db 403 ACACAAATTTGGCCACACAGAGTGGCACTGACTACATGAGAAGTCCATTCTGTTGTC 462
QY 769 CTCATGCTCCAAATTTACCATATAGATACCAAAAGGAAAAATGTATCTATAGAGA 827
Db 463 CTGACAGCTCCAGAGAGTGAAGAGAAATCCAGAGACCCTTCTGTTCCATGCAACA 521

RESULT 11

US-08-943-087-1
; Sequence 1, Application US/08943087
; Patent No. 5945511

GENERAL INFORMATION:

APPLICANT: Lok, Si
APPLICANT: Kho, Choon J.
APPLICANT: Jelmeberg, Anna C.
APPLICANT: Adams, Robyn L.
APPLICANT: Whitmore, Theodore E.
APPLICANT: Farrah, Theresa M.
TITLE OF INVENTION: CYTOKINE RECEPTOR
NUMBER OF SEQUENCES: 60
CORRESPONDENCE ADDRESS:

ADDRESSEE: Zymogenetics, Inc.
STREET: 1201 Eastlake Avenue East
CITY: Seattle
STATE: WA
COUNTRY: USA
ZIP: 98102

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/943,087

FILING DATE:

CLASSIFICATION: 536

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/803,305

FILING DATE: 20-FEB-1997

ATTORNEY/AGENT INFORMATION:

NAME: Lunn, Paul G

REGISTRATION NUMBER: 32,743

REFERENCE/DOCKET NUMBER: 96-24C1

TELECOMMUNICATION INFORMATION:

TELEPHONE: 206-442-6627

TELEFAX: 206-442-6678

TELEX:

INFORMATION FOR SEQ ID NO: 1:

SEQUENCE CHARACTERISTICS:

LENGTH: 3516 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: cDNA

FEATURE:

NAME/KEY: Coding Sequence

LOCATION: 237...1895

OTHER INFORMATION:

US-08-943-087-1

Query Match 5.1%; Score 67; DB 2; Length 3516;
Best Local Similarity 51.5%; Pred. No. 1.3e-06;
Matches 154; Conservative 0; Mismatches 145; Indels 0; Gaps 0;

QY 529 AAATATGACAGACAGACATGAAATAAAGACACTGTGGGCTACTCAAGAACTCTCT 588
Db 459 ATATATGGGCAAGAAATGCTGAATTAATCAGAAATGCAAGAAATATCAATAGAACTTAC 518

QY 589 TGTGACCTTACCAAGTGAACCTCAGACATACAGAACCTTATTACGGGAGGCTGAGGCG 648
Db 519 TGTGATCTTCTGCTGAACCTTCTGACTACGAGAACCAAGTATTATGCCAAAGTTAAGGCC 578

QY 649 GCCTGGCTGGAGCTACTCAGATGAGCAGACGCCGGGTTCACTCCCTGGTGGGA 708
Db 579 ATTTGGGAACAAGTGTCCAAATGGCTGAAGTGACGGTTCTATCTTTTACAA 638
QY 709 ACACAAATATGATCTCCAGCTCATGATATAACCCAGTCAATGGCTCTTTGTTGTAAT 768
Db 639 ACACAAATTTGGCCACACAGAGTGGCACTGACTACATGAGAAGTCCATTCTGTTGTC 698
QY 769 CTCATGCTCCAAATTTACCATATAGATACCAAAAGGAAAAATGTATCTATAGAGA 827
Db 699 CTGACAGCTCCAGAGAGTGAAGAGAAATCCAGAGACCCTTCTGTTCCATGCAACA 757

RESULT 12

US-08-943-087-25
; Sequence 25, Application US/08943087
; Patent No. 5945511

GENERAL INFORMATION:

APPLICANT: Lok, Si
APPLICANT: Kho, Choon J.
APPLICANT: Jelmeberg, Anna C.
APPLICANT: Adams, Robyn L.
APPLICANT: Whitmore, Theodore E.
APPLICANT: Farrah, Theresa M.
TITLE OF INVENTION: CYTOKINE RECEPTOR
NUMBER OF SEQUENCES: 60
CORRESPONDENCE ADDRESS:

ADDRESSEE: Zymogenetics, Inc.
STREET: 1201 Eastlake Avenue East
CITY: Seattle
STATE: WA
COUNTRY: USA
ZIP: 98102

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/943,087

FILING DATE:

CLASSIFICATION: 536

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/803,305

FILING DATE: 20-FEB-1997

ATTORNEY/AGENT INFORMATION:

NAME: Lunn, Paul G

REGISTRATION NUMBER: 32,743

REFERENCE/DOCKET NUMBER: 96-24C1

TELECOMMUNICATION INFORMATION:

TELEPHONE: 206-442-6627

TELEFAX: 206-442-6678

TELEX:

INFORMATION FOR SEQ ID NO: 25:

SEQUENCE CHARACTERISTICS:

LENGTH: 1659 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: cDNA

FEATURE:

NAME/KEY: Coding Sequence

LOCATION: 1...1659

OTHER INFORMATION:

US-08-943-087-25

Query Match 5.1%; Score 66.8; DB 2; Length 1659;
Best Local Similarity 51.3%; Pred. No. 1.2e-06;
Matches 155; Conservative 0; Mismatches 147; Indels 0; Gaps 0;

QY 532 TATGACAGAGACATGAAATAAAGAGACTGTGGGCTACTCAAGAACTCTCTGT 591
Db 226 TATGGCAAGAAATGCTGAATTAATCAGAAATGCAAGAAATATCAATAGAACTACTGT 285

CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/803,305
FILING DATE: 20-FEB-1997
ATTORNEY/AGENT INFORMATION:
NAME: Lunn, Paul G
REGISTRATION NUMBER: 32,743
REFERENCE/DOCKET NUMBER: 96-24CL
TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-442-6627
TELEFAX: 206-442-6678
TELEX:
INFORMATION FOR SEQ ID NO: 57:
SEQUENCE CHARACTERISTICS:
LENGTH: 663 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

TELEPHONE: 206-442-6627
TELEFAX: 206-442-6678
TELEX:
INFORMATION FOR SEQ ID NO: 29;

QY 529 AAATATGGACAGACACAAATGGAAAAATAAGAGACTGTGGGTACTCAAGAACTCTCT 588
 Db 223 ATATATGGGCCAAAAGAAAGTGGCTGAATAGTCAAGATGCAGAAATATCAATAGAACCTAC 282
 QY 589 TGTGACCTTACCACTGAAACCTCAGACATACAGCAACTTATTACGGGAGGTGAGGCG 648
 Db 283 TGTGATCTTTCTGCTGAAACTTCTGACTACGACACCAAGTATTATGCCAAGGTTAAGGCC 342
 QY 649 GCCTCGGCTGGGAGCTACTCAGAAATGAGACATGACGCCGGGTTCACTCCCTGGTGGA 708
 Db 343 ATTTGGGGAAACAAGTGTTCCAAGTGGGCTGAAAGTGAGCGGTTCTATCCTTTTGGAA 402
 QY 709 ACAAAAATAGATCCTCCAGTCATGAATATTAACCCAAGTCAATGGCTTTTGGTAAAT 768
 Db 403 ACACAAATTTGGCCACACAGAGTGGCACTGACTACAGATGAGAAGTCCATTTCTGTTGTC 462
 QY 769 CTCCTATGCTCCAATTTTACCATATAGATACCAAAAAGAAAAAATGTATCTATAGAAGA 827
 Db 463 CTGACAGCTCCAGAGAAGTGAAGAGAAAATCCAGAAGACCTTCTGTTTCCATGCAACA 521

Search completed: December 22, 2002, 09:12:33
Job time : 65 secs

GenCore version 5.1.3
Copyright (c) 1993 - 2002 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 22, 2002, 08:38:11 ; Search time 63 Seconds
(without alignments)
8302.512 Million cell updates/sec

Title: US-09-964-994-1
Perfect score: 1318
Sequence: 1 cagttcttcctcctgttaaca.....aaaaaaaaaaaaaaaaaa 1318

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 356696 seqs, 198428768 residues

1 number of hits satisfying chosen parameters: 713392

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications_NA:*

1: /cgn2_6/ptodata/1/pubpna/US07_PUBCOMB.seq:*
2: /cgn2_6/ptodata/1/pubpna/PCT_NEW_PUB.seq:*
3: /cgn2_6/ptodata/1/pubpna/US06_NEW_PUB.seq:*
4: /cgn2_6/ptodata/1/pubpna/US06_PUBCOMB.seq:*
5: /cgn2_6/ptodata/1/pubpna/US07_NEW_PUB.seq:*
6: /cgn2_6/ptodata/1/pubpna/PCTUS_PUBCOMB.seq:*
7: /cgn2_6/ptodata/1/pubpna/US08_NEW_PUB.seq:*
8: /cgn2_6/ptodata/1/pubpna/US08_PUBCOMB.seq:*
9: /cgn2_6/ptodata/1/pubpna/US09_NEW_PUB.seq:*
10: /cgn2_6/ptodata/1/pubpna/US09_PUBCOMB.seq:*
11: /cgn2_6/ptodata/1/pubpna/US10_NEW_PUB.seq:*
12: /cgn2_6/ptodata/1/pubpna/US10_PUBCOMB.seq:*
13: /cgn2_6/ptodata/1/pubpna/US60_NEW_PUB.seq:*
14: /cgn2_6/ptodata/1/pubpna/US60_PUBCOMB.seq:*

Pred. NO. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1318	100.0	1318	US-09-964-994-1	Sequence 1, Appli
2	831.6	63.1	2149	US-09-728-911-1	Sequence 1, Appli
3	398.2	30.2	693	US-09-728-911-3	Sequence 3, Appli
4	171.4	13.0	478	US-09-864-761-15058	Sequence 15058, A
5	171.4	13.0	528	US-09-864-761-6687	Sequence 6687, Ap
6	170	12.9	170	US-09-864-761-23421	Sequence 23421, A
7	128	9.7	128	US-09-864-761-31588	Sequence 31588, A
8	75.4	5.7	1806	US-09-746-359A-36	Sequence 36, Appli
9	69.2	5.3	424	US-09-960-352-11218	Sequence 11218, A
10	67	5.1	1720	US-09-746-359A-52	Sequence 52, Appli
11	67	5.1	1750	US-10-052-586-397	Sequence 397, App
12	67	5.1	1801	US-09-746-359A-22	Sequence 22, Appli
13	67	5.1	3516	US-09-746-359A-10	Sequence 10, Appli
14	66.2	5.0	277	US-09-960-352-12673	Sequence 12673, A
15	64.2	4.9	375	US-09-960-352-15014	Sequence 15014, A
16	63	4.8	447	US-09-960-352-8533	Sequence 8533, Ap
17	62.2	4.7	308	US-09-960-352-7670	Sequence 7670, Ap
18	61.4	4.7	277	US-09-960-352-12673	Sequence 12673, A
19	61.4	4.7	1492	US-09-925-299-112	Sequence 112, App

C	20	60.8	4.6	300	10	US-09-960-352-6251	Sequence 6251, Ap
	21	60.4	4.6	3772	9	US-09-992-598-61	Sequence 61, Appl
	22	60.4	4.6	3772	9	US-09-989-293A-61	Sequence 61, Appl
	23	60.4	4.6	3772	10	US-09-989-722-61	Sequence 61, Appl
	24	60.4	4.6	3772	10	US-09-989-723-61	Sequence 61, Appl
	25	60.4	4.6	3772	10	US-09-989-279-61	Sequence 61, Appl
	26	60.4	4.6	3772	10	US-09-989-727-61	Sequence 61, Appl
	27	60.4	4.6	3772	10	US-09-989-731-61	Sequence 61, Appl
	28	60.4	4.6	3772	10	US-09-989-732-61	Sequence 61, Appl
	29	60.4	4.6	3772	10	US-09-990-442-61	Sequence 61, Appl
	30	60.4	4.6	3772	10	US-09-990-456-61	Sequence 61, Appl
	31	60.4	4.6	3772	10	US-09-991-163-61	Sequence 61, Appl
	32	60.4	4.6	3772	10	US-09-993-604-61	Sequence 61, Appl
	33	60.4	4.6	3772	10	US-09-990-456-61	Sequence 61, Appl
	34	60.4	4.6	3772	10	US-09-989-721-61	Sequence 61, Appl
	35	60.2	4.6	397	10	US-09-960-352-13784	Sequence 13784, A
	36	60.2	4.6	415	10	US-09-960-352-6869	Sequence 6869, Ap
	37	59.6	4.5	239	10	US-09-960-352-11438	Sequence 11438, A
	38	59.6	4.5	312	10	US-09-960-352-8414	Sequence 8414, Ap
	39	59	4.5	347	10	US-09-960-352-3371	Sequence 3371, Ap
	40	58.8	4.5	302	10	US-09-925-299-710	Sequence 710, App
	41	58.6	4.4	419	10	US-09-960-352-11234	Sequence 11234, A
	42	58.4	4.4	236	10	US-09-960-352-12183	Sequence 12183, A
	43	58.4	4.4	298	10	US-09-960-352-1004	Sequence 1004, Ap
	44	58.2	4.4	325	10	US-09-764-846-30	Sequence 30, Appl
	45	58.2	4.4	621	10	US-09-764-846-105	Sequence 105, App

ALIGNMENTS

RESULT 1
US-09-964-994-1
Sequence 1, Application US/09964994
Patent No. US20020137909A1
GENERAL INFORMATION:
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Watanabe, Colin K.
APPLICANT: Wood, William I.
TITLE OF INVENTION: NOVEL POLYPEPTIDES HAVING SEQUENCE SIMILARITY TO
TITLE OF INVENTION: CYTOKINE RECEPTORS AND NUCLEIC ACIDS ENCODING THE SAME
FILE REFERENCE: P3121R1
CURRENT APPLICATION NUMBER: US/09/964, 994
CURRENT FILING DATE: 2001-09-26
PRIOR APPLICATION NUMBER: PCT/US00/08439
PRIOR FILING DATE: 2000-03-30
PRIOR APPLICATION NUMBER: PCT/US01/06520
PRIOR FILING DATE: 2001-02-28
PRIOR APPLICATION NUMBER: US 60/191, 015
PRIOR FILING DATE: 2000-03-21
PRIOR APPLICATION NUMBER: US 09/941, 992
PRIOR FILING DATE: 2001-08-28
NUMBER OF SEQ ID NOS: 7
SEQ ID NO 1
LENGTH: 1318
TYPE: DNA
ORGANISM: Homo Sapien
US-09-964-994-1

Query Match 100.0%; Score 1318; DB 10; Length 1318;
Best Local Similarity 100.0%; Pred. No. 6.5e-254;
Matches 1318; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	CAGTTCTTCATCTGTACATCAATGATATATATACCAATCTCTAGACTTCATAAGA	60
Db	1	CAGTTCTTCATCTGTACATCAATGATATATATACCAATCTCTAGACTTCATAAGA	60
QY	61	GGATTACCAAGACCAAAATATGGGAAAAACATTAACATGGCGTCCATTAATTAGATCT	120
Db	61	GGATTACCAAGACCAAAATATGGGAAAAACATTAACATGGCGTCCATTAATTAGATCT	120

OY		121	TATTATTGACACTAAAAATGGCACTTAAATTAACCAAAAGGAAGACAGCATCTGTTCCTCT	180
Dd		121	TATTATTGACACTAAAAATGGCACTTAAATTAACCAAAAGGAAGACAGCATCTGTTCCTCT	180
OY		181	TTGGTCCCTGAGCTGGTTAAAGGAACACTGGTTGCCCTGAACAGTCCACTTGCAACCATG	240
Dd		181	TTGGTCCCTGAGCTGGTTAAAGGAACACTGGTTGCCCTGAACAGTCCACTTGCAACCATG	240
OY		241	ATGCCTTAACATTTGCTTCTAGGCTTCCTCATTACAGTTTCTCCTTACTGGGTAGCAGGA	300
Dd		241	ATGCCTTAACATTTGCTTCTAGGCTTCCTCATTACAGTTTCTCCTTACTGGGTAGCAGGA	300
OY		301	ACTCAGTCAACCGCATGAGTCTCTGAAGCCTCAGAAGGTACAATTTTCAGTCCCAGAAATTTT	360
Dd		301	ACTCAGTCAACCGCATGAGTCTCTGAAGCCTCAGAAGGTACAATTTTCAGTCCCAGAAATTTT	360
OY		361	CACACATTTTGGCAATGGCAGCCCTGGGAGGCACTTACTGGCAACAGCAGTGTCTAATTTT	420
Dd		361	CACACATTTTGGCAATGGCAGCCCTGGGAGGCACTTACTGGCAACAGCAGTGTCTAATTTT	420
OY		421	GTCGAGTACAAAATCATGTGTTCTCATGACAGATGA AAAAGCTCTCACAGGAAGCCAGTGA	480
Dd		421	GTCGAGTACAAAATCATGTGTTCTCATGACAGATGA AAAAGCTCTCACAGGAAGCCAGTGA	480
OY		481	TGCTGGCAGCACATTTCTTGTAACTTCCAGGCTGCAGAACATTTGGCTAAATATGACAG	540
Dd		481	TGCTGGCAGCACATTTCTTGTAACTTCCAGGCTGCAGAACATTTGGCTAAATATGACAG	540
OY		541	AGACAATGGA AAAATTAAGAAGACTGTTGGGGTACTCAACAACCTCTTGTGACCTTACC	600
Dd		541	AGACAATGGA AAAATTAAGAAGACTGTTGGGGTACTCAACAACCTCTTGTGACCTTACC	600
OY		601	AGTGAACCTTCAGACATACAGGAACCTTATTACGGGAGGGTGAGGGCGGCTCGGCTGGG	660
Dd		601	AGTGAACCTTCAGACATACAGGAACCTTATTACGGGAGGGTGAGGGCGGCTCGGCTGGG	660
OY		661	AGTACTCAGATGAGACCATGACGCCCGGGTTCACCTCCCTGGTGGGAAAACAAAATAGAT	720
Dd		661	AGTACTCAGATGAGACCATGACGCCCGGGTTCACCTCCCTGGTGGGAAAACAAAATAGAT	720
OY		721	CCTCCAGTCATGATATAATAACCCCAAGTCAATGGCTCTTGTGTGTAATTTCTCCATGCTCCA	780
Dd		721	CCTCCAGTCATGATATAATAACCCCAAGTCAATGGCTCTTGTGTGTAATTTCTCCATGCTCCA	780
OY		781	AATTTACCATATAGATACC AAAAGGAAAAAATGTATCTATAGAAAGATTACTATGAACCTA	840
Dd		781	AATTTACCATATAGATACC AAAAGGAAAAAATGTATCTATAGAAAGATTACTATGAACCTA	840
OY		841	CTATACCGAGTTTTTATATAATTAA CAATTCACCTAGAAAAAGAGCAAAGGTTATGAAGG	900
Dd		841	CTATACCGAGTTTTTATATAATTAA CAATTCACCTAGAAAAAGAGCAAAGGTTATGAAGG	900
OY		901	GCTCACAGAGCGGTTGAAATTTGAAGCTCTTAACACACACTCCAGCTACTGTGTAGTGGCT	960
Dd		901	GCTCACAGAGCGGTTGAAATTTGAAGCTCTTAACACACACTCCAGCTACTGTGTAGTGGCT	960
OY		961	GAAATATATCAGCCCATGTTAGACAGAGAAGTCA GAGAAGTGAAGAGAGATGTGTGAA	1020
Dd		961	GAAATATATCAGCCCATGTTAGACAGAGAAGTCA GAGAAGTGAAGAGAGATGTGTGAA	1020
OY		1021	ATTCATGACTTGTGGAATTTGGCA TTCAGCAATGTGAAATTTCTAAAGCTCCCTGAGAA	1080
Dd		1021	ATTCATGACTTGTGGAATTTGGCA TTCAGCAATGTGAAATTTCTAAAGCTCCCTGAGAA	1080
OY		1081	CAGGATGACTCGTGTGTTGAAGGATCTAATTTAA AATTTGTTTGTATTTCTTAAAGCAA	1140
Dd		1081	CAGGATGACTCGTGTGTTGAAGGATCTAATTTAA AATTTGTTTGTATTTCTTAAAGCAA	1140
OY		1141	TATTCACGTGTACACCTTGGGACCTTCTTGTAT TCATCCATTTATCCCTTATATATTTTC	1200
Dd		1141	TATTCACGTGTACACCTTGGGACCTTCTTGTAT TCATCCATTTATCCCTTATATATTTTC	1200
OY		1201	ATTGTAAACTATATTTGAACGACATTTCCCCCGA AAATTTGAAATGTAAAGATGAGGCA	1260

[illegible]


```
QY 718 GATCCTCCAGTCATGATATATAACCCCAAGTCATGCTCTTTGTTGTAATTCCTCATGCT 777
Db 385 GATCCTCCAGTCATGATATATAACCCCAAGTCATGCTCTTTGTTGTAATTCCTCATGCT 444
QY 778 CCAAAATTTACCATATAGATACCAAAAGAAAAAATGTATCTATAGAGATTACTATGAA 837
Db 445 CCAAAATTTACCATATAGATACCAAAAGAAAAAATGTATCTATAGAGATTACTATGAA 504
QY 838 CTACTATACCGAGTTTATATATTAACAATTCCTAGAAAAGAGCAAAAGGTTTATGAA 897
Db 505 CTACTATACCGAGTTTATATATTAACAATTCCTAGAAAAGAGCAAAAGGTTTATGAA 564
QY 898 GGGGCTCACAGAGCGGTTGAATTTGAAGCTCTAACACACACTCCAGCTACTGTAGTG 957
Db 565 GGGGCTCACAGAGCGGTTGAATTTGAAGCTCTAACACACACTCCAGCTACTGTAGTG 624
QY 958 GCTGAATATATACAGCCCATGTTAGACAGAAAGTCAAGAGTGAAGAGAGATGTGTG 1017
Db 625 GCTGAATATATACAGCCCATGTTAGACAGAAAGTCAAGAGTGAAGAGAGATGTGTG 684
QY 1018 GAAATTCATGACTGTGTGAATTTGGCAATTCAGCAATGTGAATTTCTAAAGCTCCCTGA 1077
Db 685 GAAATTCATGACTGTGTGAATTTGGCAATTCAGCAATGTGAATTTCTAAAGCTCCCTGA 744
QY 1078 GAACAGGATGACTCGTGTGTTGAAGGATCTTATTTAAATTTGTTTGTATTTCTTAAG 1137
Db 745 GAACAGGATGACTCGTGTGTTGAAGGATCTTATTTAAATTTGTTTGTATTTCTTAAG 804
QY 1138 CAATATTCACGTGTACACCTTGGGACTCTTGTGTTATCCATTTCTTATCCTTATAT 1197
Db 805 CAATATTCACGTGTACACCTTGGGACTCTTGTGTTATCCATTTCTTATCCTTATAT 864
QY 1198 TTCATTTGTAACATATTTGAACGACATTCCTCCCGAATAATTTGAATGTAAGATGAG 1257
Db 865 TTCATTTT-TAAACATATTTGAACGACATTCCTCCCGAATAATTTGAATGTAAGATGAG 923
QY 1258 GCAGAGAATAAGTGTCTATGAAAAAATA 1289
Db 924 GCAGAGAATAAGTGTCTATGAATTCAGAA 955
```

RESULT 3

```
US-09-728-911-3
; Sequence 3, Application US/09728911
; Patent No. US20020012669A1
; GENERAL INFORMATION:
; APPLICANT: Presnell, Scott R.
; APPLICANT: Xu, Wenfeng
; APPLICANT: Kindsvogel, Wayne
; APPLICANT: Chen, Zhi
; TITLE OF INVENTION: Human Cytokine Receptor
; FILE REFERENCE: 99-93
; CURRENT APPLICATION NUMBER: US/09/728, 911
; CURRENT FILING DATE: 2000-12-01
; PRIOR APPLICATION NUMBER: US 60/169, 049
; PRIOR FILING DATE: 1999-12-03
; PRIOR APPLICATION NUMBER: US 60/232, 219
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: US 60/244, 610
; PRIOR FILING DATE: 2000-10-31
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 3
; LENGTH: 693
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: This degenerate nucleotide sequence encodes the
; OTHER INFORMATION: amino acid sequence of SEQ ID NO:2.
; NAME/KEY: misc_feature
; LOCATION: (1)...(693)
; OTHER INFORMATION: n = A,T,C or G
```

US-09-728-911-3

Query Match 30.2%; Score 398.2; DB 10; Length 693;
Best Local Similarity 51.0%; Pred. No. 9e-71;
Matches 402; Conservative 179; Mismatches 111; Indels 96; Gaps 1;

```
QY 238 ATGATGCTTAACATTTGCTTTAGGCTTCTCATCAGTTTCTTCTTACTGTGTAGCA 297
Db 1 ATGATGCTTAACATTTGCTTTAGGCTTCTCATCAGTTTCTTCTTACTGTGTAGCA 60
QY 298 GGAAGTCAAGTCAACGAGTGTCTGAGGCTCAGAGGCTACAAATTTCCCGAAAT 357
Db 61 GGNACNCARMSNACNAYGARMSNYTNAARCCNARMNGTNCARTTYCARMSNGNAY 120
QY 358 TTTCACAAACATTTTGCATGCGAGCTGGAGGCGCACTTACTGGCAACAGAGTGTCTAT 417
Db 121 TTYCAAYAATHTYTNCARTGGCARGCNGMNGNNGNYTNACNGNAYMSNGTNTAY 180
QY 418 TTTGTGCAAGTACAAATCATGTCTTCATGACGATGAAAAGCTTCACCAAGCCAAAGT 477
Db 181 TTYGTNCARTAYARAT-----
QY 478 GGAATGCTGGCAGACATTTCTTGTAACTTCCAGGCTGAGAACATTTGGCTAAATATGA 537
Db 198 -----HTAYGN 204
QY 538 CAGAGACAATGAAAAATAAAGAGACTGTTGGGTACTCAAGACTCTCTGTGACCTT 597
Db 205 CARMGNCARTGGAARAAYAARBARGAYTGTGGGNACNCARCARAYTNWSNTGYAYTN 264
QY 598 ACCAGTGAACCTCAGACATACAGGAACCTTATTACGGAGGAGGCGGCGCTCGGCT 657
Db 265 ACNWSNGARACNWSNGAYATHCARGARCCNTAYTAGNMGNGTNGNNGCNGNWSNGCN 324
QY 658 GGGAGCTACTCAGATGAGATGACGCGCGGCTTCACTCCCTGCTGGGAACAATAATA 717
Db 325 GGNWSNTAYWSNGARTGWSNATGACNCCNMGNTTACNCCNTGCTGGARACNAARATH 384
QY 718 GATCCTCCAGTCATGATATATAACCCCAAGTCAATGCGCTTTGTTGTAATTCCTCATGCT 777
Db 385 GAYCCNCCNGTINATGAAYATHACNCARGTNAAYGNGNSNTYNTNGTNAHTYTNCAAYGCN 444
QY 778 CCAAAATTTACCATATAGATACCAAAAGAAAAAATGTATCTATAGAGATTACTATGAA 837
Db 445 CCNAAAYTNCNTAYMGNTAYCARAARGAARAARAYGTNWSNATHGARGAYTAYTAGAR 504
QY 838 CTACTATACCGAGTTTATATATTAACAATTCCTAGAAAAGAGCAAAAGGTTTATGAA 897
Db 505 YTNNTAYMNGNTTYATHTATHAAYAAYWSNYTNGARAARGAARAARGTNTAYGAR 564
QY 898 GGGGCTCACAGAGCGGTTGAATTTGAAGCTCTTAAACACCACTCCAGCTACTGTAGTG 957
Db 565 GNGCNCAYMNGCNGTNGARATHGARGCNTYNAACNCAYWSNWSNTAYTYGCTNGTN 624
QY 958 GCTGAATATATACAGCCCATGTTAGACAGAAAGTCAAGAGTGAAGAGAGATGTGTG 1017
Db 625 GCGARATHAYCARCCNATGYTNGAYMNGNWSNCARMGNSNGARGARMGNTGYGTN 684
QY 1018 GAAATTC 1025
Db 685 GARATHCC 692
```

RESULT 4

```
US-09-864-761-15058/c
; Sequence 15058, Application US/09864761
; Patent No. US20020048763A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; APPLICANT: Chen, Wensheng
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FO
```

```

TITLE OF INVENTION: GENE EXPRESSION ANALYSIS BY MICROARRAY
FILE REFERENCE: Aeomica-X-1
CURRENT APPLICATION NUMBER: US/09/864,761
CURRENT FILING DATE: 2001-05-23
PRIOR APPLICATION NUMBER: US 60/180,312
PRIOR FILING DATE: 2000-02-04
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: US 09/632,366
PRIOR FILING DATE: 2000-08-03
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 09/608,408
PRIOR FILING DATE: 2000-06-30
PRIOR APPLICATION NUMBER: US 09/774,203
PRIOR FILING DATE: 2001-01-29
NUMBER OF SEQ ID NOS: 49117
SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
SEQ ID NO 15058
LENGTH: 478
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
OTHER INFORMATION: MAP TO AL050337.6
OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 0.67
OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.77
US-09-864-761-15058

```

Query Match	13.0%;	Score 171.4;	DB 10;	Length 478;	
Best Local Similarity	99.4%;	Pred. No. 1.2e-25;			
Matches 172;	Conservative	0;	Mismatches 1;	Indels	0;
QY	708	AACAAAAATAGATCCCTCCAGTCATGAATATAACCCAAAGTCATGGCTCTTGTGGTAAT	767		
Db	475	AGCAAAATAGATCCCTCCAGTCATGAATATAACCCAAAGTCATGGCTCTTGTGGTAAT	416		
QY	768	TCTCCATGCTCCAAATTTACCATATAGATACCAAAGGAAAAAATGTATCTATAGAAGA	827		
Db	415	TCTCCATGCTCCAAATTTACCATATAGATACCAAAGGAAAAAATGTATCTATAGAAGA	356		
QY	828	TTACTATGAATCTATATACCGAGTTTATTAATTAAACAATTCACCTAGAAAAAGG	880		
Db	355	TTACTATGAATCTATATACCGAGTTTATTAATTAAACAATTCACCTAGAAAAAGG	303		
RESULT 5					
US-09-864-761-6687					
; Sequence 6687, Application US/09864761					
; Patent No. US20020048763A1					

```

: GENERAL INFORMATION:
: APPLICANT: Penn, Sharon G.
: APPLICANT: Rank, David R.
: APPLICANT: Hanzel, David K.
: APPLICANT: Chen, Wensheng
: TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
: TITLE OF INVENTION: GENE EXPRESSION ANALYSIS BY MICROARRAY
: FILE REFERENCE: Aecmica-X-1
: CURRENT APPLICATION NUMBER: US/09/864,761
: CURRENT FILING DATE: 2001-05-23
: PRIOR APPLICATION NUMBER: US 60/180,312
: PRIOR FILING DATE: 2000-02-04
: PRIOR APPLICATION NUMBER: US 60/207,456
: PRIOR FILING DATE: 2000-05-26
: PRIOR APPLICATION NUMBER: US 09/632,366
: PRIOR FILING DATE: 2000-08-03
: PRIOR APPLICATION NUMBER: GB 24263.6
: PRIOR FILING DATE: 2000-10-04
: PRIOR APPLICATION NUMBER: US 60/236,359
: PRIOR FILING DATE: 2000-09-27
: PRIOR APPLICATION NUMBER: PCT/US01/00666
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00667
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00664
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00669
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00665
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00668
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00663
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00662
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00661
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00670
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: US 60/234,687
: PRIOR FILING DATE: 2000-09-21
: PRIOR APPLICATION NUMBER: US 09/608,408
: PRIOR FILING DATE: 2000-06-30
: PRIOR APPLICATION NUMBER: US 09/774,203
: PRIOR FILING DATE: 2001-01-29
: NUMBER OF SEQ ID NOS: 49117
: SOFTWARE: Annonmax Sequence Listing Engine vers. 1.1
: SEQ ID NO 6687
: LENGTH: 528
: TYPE: DNA
: ORGANISM: Homo sapiens
: FEATURE:
: OTHER INFORMATION: MAP TO AL158138.1
: OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 2.5
: OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 2.8
: OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 1.7
: OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 2.5
: OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 3.3
: OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 2.9
: OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 2.7
: OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 2.3
US-09-864-761-6687

```

Query Match	13.0%;	Score 171.4;	DB 10;	Length 528;
Best Local Similarity	99.4%;	Pred. No. 1.3e-25;		
Matches 172; Conservative	0;	Mismatches 1;	Indels 0;	Gaps 0;
QY 708 AACAAATAGATCCCTCCAGTCATGCAATATAACCCAGTCATGGCTCTTTGTTGTAAT				767
1				
Db 176 AGCAAAATAGATTCCTCCAGTCATGAATATAACCCAGTCATGGCTCTTTGTTGTAAT				235
QY 768 TCTCCATGCTCCAAATTTACCATATAGATACCAAAAGGAAAAAATGTATCTATAGAAGA				827

Db 236 TCTCCATGCTCCAAATTACCATATAGATACCAAGAAAGAAATGTATCTATAGAGA 295
 QY 828 TTACTATGAAGTACTATACCGAGTTTAAATTAACAATTCTACTAGAAAG 880
 Db 296 TTACTATGAAGTACTATACCGAGTTTAAATTAACAATTCTACTAGAAAG 348

RESULT 6
 US-09-864-761-23421

; Sequence 23421, Application US/09864761
 ; Patent No. US20020048763A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Penn, Sharron G.
 ; APPLICANT: Rank, David R.
 ; APPLICANT: Hanzel, David K.
 ; APPLICANT: Chen, Wensheng
 ; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
 ; FILE REFERENCE: Aomic-X-1
 ; CURRENT FILING DATE: 2001-05-23
 ; PRIOR APPLICATION NUMBER: US/09/864,761
 ; PRIOR FILING DATE: 2000-02-04
 ; PRIOR APPLICATION NUMBER: US 60/180,312
 ; PRIOR FILING DATE: 2000-02-04
 ; PRIOR APPLICATION NUMBER: US 60/207,456
 ; PRIOR FILING DATE: 2000-05-26
 ; PRIOR APPLICATION NUMBER: US 09/632,366
 ; PRIOR FILING DATE: 2000-08-03
 ; PRIOR APPLICATION NUMBER: GB 24263.6
 ; PRIOR FILING DATE: 2000-10-04
 ; PRIOR APPLICATION NUMBER: US 60/236,359
 ; PRIOR FILING DATE: 2000-09-27
 ; PRIOR APPLICATION NUMBER: PCT/US01/00666
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00667
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00663
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00662
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00661
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00670
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: US 60/234,687
 ; PRIOR FILING DATE: 2000-09-21
 ; PRIOR APPLICATION NUMBER: US 09/608,408
 ; PRIOR FILING DATE: 2000-06-30
 ; PRIOR APPLICATION NUMBER: US 09/774,203
 ; PRIOR FILING DATE: 2001-01-29
 ; NUMBER OF SEQ ID NOS: 49117
 ; SOFTWARE: Anomax Sequence Listing Engine vers. 1.1
 ; SEQ ID NO 23421
 ; LENGTH: 170
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 ; FEATURE:
 ; OTHER INFORMATION: MAP TO AL158138.1
 ; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 2.5
 ; OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 2.8
 ; OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 1.7
 ; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 2.5
 ; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 3.3
 ; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 2.9
 ; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 2.7

; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 2.3
 ; OTHER INFORMATION: EST_HUMAN HIT: AV714177.1, EVALU 2.00e-78
 ; OTHER INFORMATION: SWISSPROT HIT: O28438, EVALU 1.30e+00
 ; US-09-864-761-23421

Query Match 12.9%; Score 170; DB 10; Length 170;
 Best Local Similarity 100.0%; Pred. No. 1.7e-25;
 Matches 170; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 710 CAAAATAGATCTCCAGTCATGATATACCAAGCAATGCTCTTGTGGTAATTC 769
 Db 1 CAAAATAGATCTCCAGTCATGATATACCAAGCAATGCTCTTGTGGTAATTC 60
 QY 770 TCCATGCTCCAAATTACCATATAGATACCAAGAAAGAAATGTATCTATAGAGATT 829
 Db 61 TCCATGCTCCAAATTACCATATAGATACCAAGAAAGAAAGAAATGTATCTATAGAGATT 120
 QY 830 ACTATGAAGTACTATACCGAGTTTAAATTAACAATTCTACTAGAAAG 879
 Db 121 ACTATGAAGTACTATACCGAGTTTAAATTAACAATTCTACTAGAAAG 170

RESULT 7

US-09-864-761-31588/c
 ; Sequence 31588, Application US/09864761
 ; Patent No. US20020048763A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Penn, Sharron G.
 ; APPLICANT: Rank, David R.
 ; APPLICANT: Hanzel, David K.
 ; APPLICANT: Chen, Wensheng
 ; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FO
 ; FILE REFERENCE: Aomic-X-1
 ; CURRENT FILING DATE: 2001-05-23
 ; PRIOR APPLICATION NUMBER: US/09/864,761
 ; PRIOR FILING DATE: 2000-02-04
 ; PRIOR APPLICATION NUMBER: US 60/180,312
 ; PRIOR FILING DATE: 2000-02-04
 ; PRIOR APPLICATION NUMBER: US 60/207,456
 ; PRIOR FILING DATE: 2000-05-26
 ; PRIOR APPLICATION NUMBER: US 09/632,366
 ; PRIOR FILING DATE: 2000-08-03
 ; PRIOR APPLICATION NUMBER: GB 24263.6
 ; PRIOR FILING DATE: 2000-10-04
 ; PRIOR APPLICATION NUMBER: US 60/236,359
 ; PRIOR FILING DATE: 2000-09-27
 ; PRIOR APPLICATION NUMBER: PCT/US01/00666
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00667
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00663
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00662
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00661
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: US 60/234,687
 ; PRIOR FILING DATE: 2000-09-21
 ; PRIOR APPLICATION NUMBER: US 09/608,408
 ; PRIOR FILING DATE: 2000-06-30
 ; PRIOR APPLICATION NUMBER: US 09/774,203
 ; PRIOR FILING DATE: 2001-01-29
 ; NUMBER OF SEQ ID NOS: 49117

SOFTWARE: Anomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 31588
; LENGTH: 128
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO AL050337.6
; OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 0.67
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.77
; OTHER INFORMATION: EST_HUMAN HIT: AV714177.1, EVALUE 1.00e-53
; OTHER INFORMATION: SWISSPROT HIT: O28438, EVALUE 1.80e+00
US-09-864-761-31588

Query Match 9.7%; Score 128; DB 10; Length 128;
Best Local Similarity 100.0%; Pred. No. 3.7e-17;
Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 710 CAAAATAGATCTCCAGTCATGATATTAACCAAGTCAATGCTCTTTGTTGTAATTC 769
128 CAAAATAGATCTCCAGTCATGATATTAACCAAGTCAATGCTCTTTGTTGTAATTC 69
770 TCCATGCTCCAAATTTACCATATAGATACCAAGAAAGAAATGTATCTATAGAGATT 829
68 TCCATGCTCCAAATTTACCATATAGATACCAAGAAAGAAATGTATCTATAGAGATT 9

QY 830 ACTATGAA 837
Db 8 ACTATGAA 1

RESULT 8
US-09-746-359A-36
; Sequence 36, Application US/09746359A
; Patent No. US20020042366A1
; GENERAL INFORMATION:
; APPLICANT: Thompson, Penny
; APPLICANT: Foster, Donald C.
; APPLICANT: Xu, Wenfeng
; APPLICANT: Madden, Karen L.
; APPLICANT: Kelly, James D.
; APPLICANT: Sprecher, Cindy A.
; APPLICANT: Blumberg, Hal
; APPLICANT: Eagan, Maribeth A.
; APPLICANT: Jaspers, Stephen R.
; APPLICANT: Chandrasekhar, Yasmin A.
; APPLICANT: No. US20020042366A1ak, Julia E.
; TITLE OF INVENTION: Method for Treating Inflammation
; FILE REFERENCE: 99-108
; CURRENT APPLICATION NUMBER: US/09/746,359A
; PRIORITY FILING DATE: 2001-05-21
; PRIOR FILING DATE: 1999-12-23
; PRIOR APPLICATION NUMBER: 60/213,341
; PRIOR FILING DATE: 2000-06-22
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 36
; LENGTH: 1806
; TYPE: DNA
; ORGANISM: Mus musculus
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (38)...(1675)
US-09-746-359A-36

Query Match 5.7%; Score 75.4; DB 10; Length 1806;
Best Local Similarity 48.1%; Pred. No. 2.4e-06;
Matches 214; Conservative 0; Mismatches 231; Indels 0; Gaps 0;

QY 383 CTGGAGGCGACTTACTGCAACAGCAGTGTCTATTTGTGACAGTACAAATCATGTTCT 442
123 CGGGACGCGAGTCTCTGTGTCTTCTGTGTCTTGTGCTTAACCTACAAATATACCTTCT 182

QY 443 CATGCAGCATGAAGAGCTCTCACCAGAACCCAGTGATGCTGCGACACATTTCTGTGA 502
183 TATCCATCAACATGAAGATGTCTGATTTGAATCCACCAGAGAGTCTACACGAGTTG 242
QY 503 ACTTCCAGGCTGCAGACATTTGGCTAAATATGACAGACAGACAAATGAAGAAAG 562
243 AAGTCACATACACTGTGCAATATTTCAATATATGCGCAGAGAAAGAAATGGCTGAATGCTCTA 302
QY 563 ACTTTGGGGTACTCAAGAACTCTTTGACCTTACCAGTGAACCTCAGACATACAGG 622
303 AATGCGGAGTATCAACAGACCTTACTGTGACCTTTCTGTTGAGACCTCAGACTATGAAC 362
QY 623 AACCTTATACGGGAGGCTGAGGCGCGGCTCGGCTGGAGCTACTCAGAAATGAGCATGA 682
363 ACCAGTTCTATGCCAAAGTGAAGGCCATTTGGGAAAGCCAGGTGCTCCGAAATGGCCGAGA 422
QY 683 CGCGCGGTTCACTCCCTGCTGGGAAACAAATAGATCCTCCAGTCAATATTAACCC 742
423 CGGAACGCTCTATCTCTTTCTTGGAAACTCAAGTCAAGCCACACAGAGATTGCCCTGACAA 482
QY 743 AAGTCAATGCTCTTTGTTGTAATTCCTCATGCTCCAAATTTACCATATAGATACCAA 802
483 CTGGCAGAGATTCATCTCTATTGCTGACAGCACACAGAGAGTGAAGAAATCCAC 542
QY 803 AGGAAAAAATGTATCTATAGAGA 827
543 AAGACCACACTGTTCTATGCAACA 567

RESULT 9
US-09-960-352-11218/c
; Sequence 11218, Application US/09960352
; Patent No. US20020137139A1
; GENERAL INFORMATION:
; APPLICANT: Warren, Wesley C.
; APPLICANT: Tao, Nengbing
; APPLICANT: Byatt, John C.
; APPLICANT: Mathialagan, Nagappan
; TITLE OF INVENTION: NUCLEIC ACID AND OTHER MOLECULES ASSOCIATED WITH LACTATION AND
; FILE REFERENCE: 16511.006/37-21(10298)C
; CURRENT APPLICATION NUMBER: US/09/960,352
; NUMBER OF SEQ ID NOS: 15112
; SEQ ID NO 11218
; LENGTH: 424
; TYPE: DNA
; ORGANISM: Bos taurus
; OTHER INFORMATION: Clone ID: 48-LIB3058-026-Q1-K1-D12
US-09-960-352-11218

Query Match 5.3%; Score 69.2; DB 10; Length 424;
Best Local Similarity 56.6%; Pred. No. 2.7e-05;
Matches 128; Conservative 0; Mismatches 98; Indels 0; Gaps 0;

QY 1093 TGTTTGAAGATCTTATTTAAATTTGTTTGTATTTCTTTAAAGCAATATTCACCTGTTA 1152
247 TTTTAAATTTCTTAAATTTTATTTTATTTTAAATTTTAAATTTTAAATTTTAAATTTT 188
QY 1153 CACCTTGGGACTCTTTGTTTAAATTTCTTTTAAATTTTAAATTTTAAATTTTAAATTTT 1212
187 TAAATTTATTTTAAATTTTAAATTTTAAATTTTAAATTTTAAATTTTAAATTTTAAATTTT 128
QY 1213 TATTTGAACGACATTTCCCGGAAATTTGAATTTGAATTTGAATTTGAATTTGAATTTGA 1272
127 TTTTATTTTATTTTATTTTATTTTAAATTTTAAATTTTAAATTTTAAATTTTAAATTTT 68
QY 1273 TTCTATGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 1318
67 AAAAAACCAAAAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 22

RESULT 10


```

US-09-746-359A-52
; Sequence 52, Application US/09746359A
; Patent No. US20020042366A1
; GENERAL INFORMATION:
; APPLICANT: Thompson, Penny
; APPLICANT: Foster, Donald C.
; APPLICANT: Xu, Wenfeng
; APPLICANT: Madden, Karen L.
; APPLICANT: Kelly, James D.
; APPLICANT: Sprecher, Cindy A.
; APPLICANT: Blumberg, Hal
; APPLICANT: Eagan, Maribeth A.
; APPLICANT: Jaspers, Stephen R.
; APPLICANT: Chandrasekhar, Yasmin A.
; APPLICANT: No. US20020042366A1ak, Julia E.
; TITLE OF INVENTION: Method for Treating Inflammation
; FILE REFERENCE: 99-108
; CURRENT APPLICATION NUMBER: US/09/746,359A
; CURRENT FILING DATE: 2001-05-21
; PRIOR APPLICATION NUMBER: 60/171,969
; PRIOR FILING DATE: 1999-12-23
; PRIOR APPLICATION NUMBER: 60/213,341
; PRIOR FILING DATE: 2000-06-22
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 52
; LENGTH: 1720
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (1)...(1713)
US-09-746-359A-52

Query Match          5.1%; Score 67; DB 10; Length 1720;
Best Local Similarity 51.5%; Pred. No. 0.00011;
Matches 154; Conservative 0; Mismatches 145; Indels 0; Gaps 0;

QY 529 AAATATGGACAGACATGGAATAAAGAGACTGTTGGGTACTCAAGACTCTCT 588
    ||||| ||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 208 ATATATGGGCAAAAGAAATGCTGTAATTAATCAAGAAATATCAATAGAACCTTAC 267
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 589 TGTGACCTTACCAAGTGAACCTCAGACATACAGAACCTTATTACGGAGGGTGAAGGCG 648
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 268 TGTGATCTTTCTGCTGAAACTTCTGACTACGACACAGTATATGCCAAGTTAGGCC 327
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 649 GCCTGGCTGGAGCTTACTCAGAATGAGCATGAGCCGCGTTCACCTCCCTGGTGGA 708
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 328 ATTTGGGGAACAAAGTGTTCCTCAATGGGCTGAAGTGAAGCGTTCTATCTCTTTTGA 387
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 709 ACAAAATAGATCTCTCCAGTCATGATTAACCCAGTCAATGGCTCTTTGTTGTAAT 768
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 388 ACACAAATGGCCACCCAGAGGTGGCAGTACATGATGAGAAAGTCCATTTCTGTTGTC 447
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 769 CTCATGCTCCAAATTACCATATAGATACCAAAAGGAAAAATGTATCTATAGAGA 827
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 448 CTGACAGCTCCAGAGAGTGAAGAGAAATCCAGAGACCTTCTGTTCCATGCAACA 506
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 11
US-10-052-586-397
; Sequence 397, Application US/10052586
; Patent No. US20020127584A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Chen, Jian
; APPLICANT: Desnoyers, Luc
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Pan, James
; APPLICANT: Smith, Victoria
; APPLICANT: Watanabe, Colin K.

```

```

; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3430R1C1
; CURRENT APPLICATION NUMBER: US/10/052,586
; CURRENT FILING DATE: 2002-01-15
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059266
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063120
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063121
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063486
; PRIOR FILING DATE: 1997-10-21
; PRIOR APPLICATION NUMBER: 60/063540
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/063541
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/063544
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/063734
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063870
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066120
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/066466
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/066772
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/069335
; PRIOR FILING DATE: 1997-12-11
; PRIOR APPLICATION NUMBER: 60/069425
; PRIOR FILING DATE: 1997-12-12
; PRIOR APPLICATION NUMBER: 60/069870
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/068017
; PRIOR FILING DATE: 1997-12-18
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/078886
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/078939
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079664
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079786
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/080107
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/080194
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/080327
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/080333
; PRIOR FILING DATE: 1998-04-01
; PRIOR APPLICATION NUMBER: 60/081049
; PRIOR FILING DATE: 1998-04-08

```

PRIOR APPLICATION NUMBER: 60/081070
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081195
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081838
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/082568
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082569
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082704
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082797
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/083495
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083496
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083499
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083559
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/084366
PRIOR FILING DATE: 1998-05-05
PRIOR APPLICATION NUMBER: 60/084414
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084639
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084640
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084643
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/085573
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085579
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085580
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085582
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085700
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/086023
PRIOR FILING DATE: 1998-05-18
PRIOR APPLICATION NUMBER: 60/086392
PRIOR FILING DATE: 1998-05-22
PRIOR APPLICATION NUMBER: 60/086486
PRIOR FILING DATE: 1998-05-22
PRIOR APPLICATION NUMBER: 60/087098
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087208
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212

PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088722
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088740
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088811
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088825
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088863
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089090
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089908

Query Match 5.1%; Score 67; DB 12; Length 1750;
Best Local Similarity 51.5%; Pred. No. 0.00011;
Matches 154; Conservative 0; Mismatches 145; Indels 0; Gaps 0;

QY 529 AATATGACAGACATGGAATAAGAACTGTTGGGTACTCAAGACTCTCT 588
DB 191 ATATATGGCAAGAAATGGCTGAATTAATCAGATGCAAGAAATATCAATAGAACCTAC 250
QY 589 TGTGACCTTACAGTGAACCTCAGACATACAGCACTTATTACGGAGGTGAGGCG 648
DB 251 TGTGATCTTCTGCTGAACCTTCTGACTACGACACAGTATTATGCCAAGTTAAGGCC 310
QY 649 GCCTGGCTGGAGCTACTCAGAATGAGCATGACGCCGCTTCACTCCCTGGTGGAA 708
DB 311 ATTTGGGAACAAGTGTTCAAATGGCTGAAGTGAAGCGTTCTATCTTTTAGAA 370
QY 709 ACAAAATAGATCTCCAGTCATGATATAACCCAGTCAATGGCTCTTTGTTGTAAT 768
DB 371 ACACAAATGGCCACAGAGGTGGCAGTACTGACTACAGATGAGAAGTCCATTCTGTTGTC 430
QY 769 CTCCATGCTCAAAATTTACATATAGATACCAAAAGCAAAAATGTATCTATAGAGA 827
DB 431 CTGACAGCTCCAGAGAGTGAAGAAATCCAGAAAGACTTCTGTTCCATGCAACA 489

RESULT 12
US-09-746-359A-22
Sequence 22, Application US/09746359A
Patent No. US20020042366A1
GENERAL INFORMATION:

```

; APPLICANT: Thompson, Penny
; APPLICANT: Foster, Donald C.
; APPLICANT: Xu, Wenfeng
; APPLICANT: Madden, Karen L.
; APPLICANT: Kelly, James D.
; APPLICANT: Sprechter, Cindy A.
; APPLICANT: Blumberg, Hal
; APPLICANT: Eagan, Maribeth A.
; APPLICANT: Jaspers, Stephen R.
; APPLICANT: Chandrasekher, Yasmin A.
; APPLICANT: No. US20020042366A1ak, Julia E.
; TITLE OF INVENTION: Method for Treating Inflammation
; FILE REFERENCE: 99-108
; CURRENT APPLICATION NUMBER: US/09/746,359A
; PRIOR FILING DATE: 2001-05-21
; PRIOR APPLICATION NUMBER: 60/171,969
; PRIOR FILING DATE: 1999-12-23
; PRIOR APPLICATION NUMBER: 60/213,341
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 22
; LENGTH: 1801
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (8)...(1789)
; US-09-746-359A-22

```

```

Query Match
Best Local Similarity 51.8%; Score 67; DB 10; Length 1801;
Matches 154; Conservative 0; Mismatches 145; Indels 0; Gaps 0;

```

```

QY 529 AAATATGACAGACATGGAATAAAGAGAGCTGGGCTACTCAAGAACTCTCT 588
Db 248 ATATATGGGCAAGAAATGGCTGAATAATCAGAAATATCAATAGAACCTAC 307
QY 589 TGTGACCTTACCACTGAAACCTCAGACATACAGAACTTATTACGGAGGAGGCG 648
Db 308 TGTGATCTTCTGCTGAAGCTTCTGACTACGACACCAAGTATTATGCCAAAGTTAAGCC 367
QY 649 GCCTGGGCTGGAGCTACTCAGATGAGCATGACGCCGGTTCACCTCCCTGGTGGAA 708
Db 368 ATTTGGGGAACAAGTGTTCCTCAATGGGCTGAAGTGAACGGTCTATCCTTTTAAAG 427
QY 709 ACAAAATAGATCTCTCAGTCATGAATATACCAAGTCAATGCTCTTTGTTGTAAT 768
Db 428 ACACAAATTTGGCCACACAGAGGTGGCTGACTACAGATGAGAAGTCCATTTCTGTTGC 487
QY 769 CTCCATGCTCCCAATTTACCATATAGATACCAAAAGGAAAAAATGTATATAGAAGA 827
Db 488 CTGACAGCTCCAGAGAGTGAAGAGAAATCCAGAAAGCCTTCTGTTCCATGCAACA 546

```

RESULT 13

```

; Sequence 10, Application US/09746359A
; Patent No. US20020042366A1
; GENERAL INFORMATION:

```

```

; APPLICANT: Thompson, Penny
; APPLICANT: Foster, Donald C.
; APPLICANT: Xu, Wenfeng
; APPLICANT: Madden, Karen L.
; APPLICANT: Kelly, James D.
; APPLICANT: Sprechter, Cindy A.
; APPLICANT: Blumberg, Hal
; APPLICANT: Eagan, Maribeth A.
; APPLICANT: Jaspers, Stephen R.
; APPLICANT: Chandrasekher, Yasmin A.
; APPLICANT: No. US20020042366A1ak, Julia E.
; TITLE OF INVENTION: Method for Treating Inflammation
; FILE REFERENCE: 99-108

```

```

; CURRENT APPLICATION NUMBER: US/09/746,359A
; PRIOR FILING DATE: 2001-05-21
; PRIOR APPLICATION NUMBER: 60/171,969
; PRIOR FILING DATE: 1999-12-23
; PRIOR APPLICATION NUMBER: 60/213,341
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 10
; LENGTH: 3516
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (237)...(1895)
; US-09-746-359A-10

```

```

Query Match
Best Local Similarity 51.8%; Score 67; DB 10; Length 3516;
Matches 154; Conservative 0; Mismatches 145; Indels 0; Gaps 0;

```

```

QY 529 AAATATGACAGACATGGAATAAAGAGAGCTGGGCTACTCAAGAACTCTCT 588
Db 459 ATATATGGGCAAGAAATGGCTGAATAATCAGAAATGAGAAATATCAATAGAACCTAC 518
QY 589 TGTGACCTTACCACTGAAACCTCAGACATACAGAACTTATTACGGAGGAGGCG 648
Db 519 TGTGATCTTCTGCTGAAGCTTCTGACTACGACACCAAGTATTATGCCAAAGTTAAGCC 578
QY 649 GCCTGGGCTGGAGCTACTCAGATGAGCATGACGCCGGTTCACCTCCCTGGTGGAA 708
Db 579 ATTTGGGGAACAAGTGTTCCTCAATGGGCTGAAGTGAACGGTCTATCCTTTTAAAG 638
QY 709 ACAAAATAGATCTCTCAGTCATGAATATACCAAGTCAATGCTCTTTGTTGTAAT 768
Db 639 ACACAAATTTGGCCACACAGAGGTGGCAGTACAGATGAGAAGTCCATTTCTGTTGC 698
QY 769 CTCCATGCTCCCAATTTACCATATAGATACCAAAAGGAAAAAATGTATATAGAAGA 827
Db 699 CTGACAGCTCCAGAGAGTGAAGAGAAATCCAGAAAGCCTTCTGTTCCATGCAACA 757

```

RESULT 14

```

; Sequence 12673, Application US/09960352
; Patent No. US20020137139A1
; GENERAL INFORMATION:

```

```

; APPLICANT: Warren, Wesley C.
; APPLICANT: Tao, Nengbing
; APPLICANT: Byatt, John C.
; APPLICANT: Mathialagan, Nagappan
; TITLE OF INVENTION: NUCLEIC ACID AND OTHER MOLECULES ASSOCIATED WITH LACTATION AND
; FILE REFERENCE: 16511.006/37-21(10298)C
; CURRENT APPLICATION NUMBER: US/09/960,352
; NUMBER OF SEQ ID NOS: 15112
; SEQ ID NO 12673
; LENGTH: 277
; TYPE: DNA
; ORGANISM: Bos taurus
; OTHER INFORMATION: Clone ID: 54-LIB3058-039-Q1-K1-F10
; US-09-960-352-12673

```

```

Query Match
Best Local Similarity 54.8%; Score 66.2; DB 10; Length 277;
Matches 131; Conservative 0; Mismatches 108; Indels 0; Gaps 0;

```

```

QY 1080 ACAGATGACTCGTTTGAAGAGATCTTATTAATAATCTTTTGTATTTCTTAAGCA 1139
Db 275 AAATATTAATAATTTATTTTATTTTATTTTATTTTATTTTATTTTATTTTCA 216
QY 1140 ATATTCACCTGTACACCTTGGGAGCTCTTTGTTTATCCATCTTTATCTTATATTT 1199

```


GenCore version 5.1.3
Copyright (c) 1993 - 2002 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: December 22, 2002, 09:11:22 ; Search time 67 Seconds

(without alignments)
521.070 Million cell updates/sec

Title: US-09-964-994-2
Perfect score: 1427
Sequence: 1 MPKHCFGLGFLISFLLGVAG.....YQPMIDRRSQRSERECVEIP 262

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

1 number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_101002:*
1: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA2001.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqp-emb1/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	1427	100.0	262	22	AAU09186	Human PRO19598 pol
2	1427	100.0	263	23	AAE17321	Human cytokine rec
3	1423	99.7	263	23	AAO17382	Human cytokine rec
4	1392	97.5	263	23	AAU80324	Human IL-TIF/IL-22
5	1213	85.0	231	22	AAE05048	Human ZCYT018 solu
6	1213	85.0	231	22	AAE02460	Human DNAX cytokin
7	1213	85.0	231	22	AAE02460	Human DNAX cytokin
8	1213	85.0	231	23	AAO17381	Human cytokine rec
9	1213	85.0	231	23	AAU80000	Human IL-TIF/IL-22
10	1213	85.0	231	23	ABG34086	Human Pro peptide

11	1213	85.0	231	23	AAE17320	Human cytokine rec
12	1114	78.1	214	23	AAE17319	Human cytokine rec
13	1104	77.4	210	22	AAB62663	Human zcytor16 ext
14	1045	73.2	249	22	AAE02458	Human DNAX cytokin
15	1045	73.2	249	22	AAO17380	Human cytokine rec
16	656	46.0	130	22	AAE02461	Human DNAX cytokin
17	310	21.7	207	22	AAB85289	Human IL-20 recept
18	310	21.7	207	23	ABG67220	Interleukin-20 sub
19	310	21.7	214	22	AAB85287	Interleukin-20 sub
20	310	21.7	214	23	ABG67218	Interleukin-20 sub
21	310	21.7	217	22	AAB85280	Interleukin-20 sub
22	310	21.7	221	22	AAB85269	Human IL-20 recept
23	310	21.7	221	23	ABG67200	Human IL-20 recept
24	310	21.7	221	23	AAE23354	Human IL-20RA matu
25	310	21.7	221	23	AAU29222	Human PRO polypept
26	310	21.7	542	22	AAU12265	Human PRO4978 poly
27	310	21.7	542	22	AAB85279	Human IL-20RA-Ig g
28	310	21.7	547	22	ABG67210	Interleukin-20RA/I
29	310	21.7	547	23	ABG67210	Human IL-20RA EC d
30	310	21.7	547	23	AAE23362	zcytor7 cytokine r
31	310	21.7	553	19	AAW79159	Human class II cyt
32	310	21.7	553	22	ABBI1582	Human IL-20 recept
33	310	21.7	553	22	AAU04058	Human IL-20 recept
34	310	21.7	553	22	AAB85268	Human Interleukin-
35	310	21.7	553	23	ABG67199	Human Interleukin-
36	310	21.7	553	23	AAE23353	Human IL-20RA/Immu
37	310	21.7	555	22	AAU04072	IL-20RA-Ig gamma1
38	310	21.7	559	22	AAB85286	IL-20RA extracellu
39	310	21.7	559	23	ABG67217	Human IL-20RA EC d
40	310	21.7	559	23	AAE23361	Human IL-20RA/Immu
41	310	21.7	571	22	AAU04065	Human IL-20RA-Ig g
42	310	21.7	571	22	AAB85278	Human IL-20RA-Ig g
43	310	21.7	571	23	ABG67209	Interleukin-20RB/I
44	310	21.7	571	23	AAE23359	Human IL-20RA extr
45	310	21.7	594	22	AAU04062	Human IL-20RA/Immu

ALIGNMENTS

RESULT 1	
AAU09186	AAU09186 standard; Protein; 262 AA.
XX	AAU09186;
AC	16-JAN-2002 (first entry)
XX	
DT	Human PRO19598 polypeptide.
XX	
DE	
XX	Human; PRO19598; clone DNA145887; immune-related disorder;
KW	inflammatory disorder; infectious disorder; immunodeficiency disorder;
KW	autoimmune disorder; renal disease; demyelinating disease; skin disease;
KW	neoplasia; transplantation associated disease; immunosuppressive;
KW	anti-inflammatory; antiasthmatic; antidiabetic.
XX	
OS	Homo sapiens.
XX	
FH	
FT	Key
FT	Peptide
FT	Location/Qualifiers
FT	1..20
FT	/label= Signal_peptide
FT	17..22
FT	/note= "N-myristoylation site"
FT	20..25
FT	/note= "N-myristoylation site"
FT	21..262
FT	/label= Mature_PRO19598_polypeptide
FT	55..58
FT	/note= "N-glycosylation site"
FT	165..168
FT	/note= "N-glycosylation site"
FT	170..173
FT	/note= "N-glycosylation site"

FT Modified-site 191..194
FT /note="N-glycosylation site"
FT Modified-site 208..211
FT /note="N-glycosylation site"
FT Modified-site 220..225
FT /note="N-myristoylation site"
XX
XX WO200166740-A2.
XX
XX 13-SEP-2001.
XX
XX 01-MAR-2001; 2001WO-US06666.
XX
XX 03-MAR-2000; 2000US-187202P.
XX 21-MAR-2000; 2000US-191015P.
XX 30-MAY-2000; 2000WO-US14941.
XX 05-JUN-2000; 2000US-209832P.
XX 24-AUG-2000; 2000WO-US23328.
XX 01-DEC-2000; 2000WO-US32678.
XX
XX (GETH) GENENTECH INC.
XX Eaton DL, Fong S, Goddard A, Godowski PJ, Grimaldi CJ, Gurney AL;
XX Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI: 2001-625876/72.
XX N-PSDB; AAS15368.
XX
XX Nucleic acids encoding PRO polypeptides, useful for detecting and
XX treating immune related diseases and disorders in mammals including
XX autoimmune diseases, inflammatory diseases and asthma -
XX
XX Claim 10; Fig 18; 122pp; English.
XX
XX The present invention relates to the isolation of 9 novel human PRO
XX polypeptides and the cDNA sequences (AAS15360-AAS15368) encoding them.
XX The novel PRO polypeptides include PRO1356, PRO1268, PRO1884, PRO3444,
XX PRO3151, PRO4322, PRO9964, PRO10008 and PRO19598. The cDNA sequences
XX encoding these PRO polypeptides have been designated as clones
XX DNA64886-1601, DNA64903-1553, DNA84318-2520, DNA87997, DNA89273,
XX DNA92223-2567, DNA96973, DNA101921 and DNA145887 respectively.
XX Compositions (e.g. vaccines) containing PRO polypeptides and methods of
XX using these compositions are useful in the treatment and diagnosis of
XX immune-related disorders. Such disorders include immune-mediated
XX inflammatory disorders (e.g. osteoarthritis), non-immune-mediated
XX inflammatory disorders (e.g. diabetes mellitus), infectious disorders
XX (e.g. granulomatous hepatitis), immunodeficiency disorders (e.g. AIDS),
XX autoimmune disorders (e.g. rheumatoid arthritis), immune-related renal
XX diseases (e.g. cirrhosis), demyelinating diseases of the peripheral or
XX central nervous system (e.g. Guillain-Barre syndrome), immune-mediated
XX skin diseases (e.g. contact dermatitis), neoplasias and transplantation
XX associated diseases. The polynucleotide sequences of the invention may
XX be used in gene therapy. AAU09178-AAU09186 represent the novel human
XX PRO polypeptides of the invention.
XX
XX Sequence 262 AA;
XX
XX Query Match 100.0%; Score 1427; DB 22; Length 262;
XX Best Local Similarity 100.0%; Pred. No. 2.4e-134;
XX Matches 262; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 181 NLPYRYQKEKNVSIEDYELLRYRVFIINNSLEKEQKVEGAHRAVEIETLPHSSYCVVA 240
DB 181 NLPYRYQKEKNVSIEDYELLRYRVFIINNSLEKEQKVEGAHRAVEIETLPHSSYCVVA 240
QY 241 EITYQPMIDRRSQSRSEERCVEIP 262
DB 241 EITYQPMIDRRSQSRSEERCVEIP 262
RESULT 2
AAE17321
ID AAE17321 standard; Protein; 263 AA.
XX
XX AAE17321;
XX
XX 18-APR-2002 (first entry)
XX
XX Human cytokine receptor protein, sbg456548Cytora #3.
XX
XX Human; therapy; wound healing disorder; vaccine; cancer; infection;
XX autoimmune disorder; haematopoietic disorder; inflammation; arthritis;
XX Parkinson's disease; Huntington's chorea; schizophrenia; antiarrhythmic;
XX multiple sclerosis; Alzheimer's disease; analgesic; cardiac; asthma;
XX ischaemia; stroke; AIDS; bone disease; atherosclerosis; brain disorder;
XX depression; cardiovascular disease; myocardial infarction; renal failure;
XX respiratory disease; liver disorder; Fanconi's syndrome; spleen disorder;
XX type II diabetes mellitus; skeletal muscle disorder; immunosuppressive;
XX hypersplenism; renal disease; hypoglycaemia; gastrointestinal disease;
XX nootropic; cirrhosis; Hodgkin's disease; neuroleptic; antiinflammatory;
XX haemostatic; vulnery; anticonvulsant; antirheumatic; neuroprotective;
XX nephrotropic; hypotensive; vasotropic; cytostatic; cerebroprotective;
XX allergy; cytokine receptor.
XX
XX Homo sapiens
XX OS
XX WO200198342-A1.
XX
XX 27-DEC-2001
XX
XX 22-JUN-2001; 2001WO-US19929.
XX
XX 22-JUN-2000; 2000US-213156P.
XX 22-JUN-2000; 2000US-213161P.
XX
XX (SMIK) SMITHKLINE BEECHAM CORP.
XX (SMIK) SMITHKLINE BEECHAM PLC.
XX (GLAX) GLAXO GROUP LTD.
XX
XX Agarwal P, Cogswell JP, Kabnic KS, Lai Y, Martensen SA;
XX Murdock PR, Smith RF, Strum JC, Xiang Z, Xie Q, Rizni SK;
XX WPI: 2002-139783/18.
XX N-PSDB; AAD27816.
XX
XX Novel secreted and membrane-associated polypeptides and polynucleotides
XX useful for preventing, ameliorating or correcting dysfunction or
XX disease including diabetes, cancer, hypertension and growth
XX abnormalities -
XX
XX Claim 1; Page 133-134; 138pp; English.
XX
XX The invention relates to secreted and membrane-associated polypeptides
XX and polynucleotides. The sequences of the invention are useful in
XX diagnostic assays for detecting diseases associated with inappropriate
XX activity or levels of these polynucleotides, and in identifying their
XX agonists and antagonists that are potentially useful in therapy. The
XX sequences of the invention are useful as vaccines for inducing
XX immunological response. The sequences of the invention are useful for
XX treating cancers, infections, autoimmune disorders, haematopoietic
XX disorders, wound healing disorders, cholesterol ester storage disease,
XX inflammation, congenital muscular dystrophy, junctional epidermolysis
XX bullosa, Parkinson's disease, Huntington's chorea, multiple sclerosis,
XX viral and bacterial infections, Alzheimer's disease, asthma, arthritis,

CC allergies, schizophrenia, sbp44245PROa-associated disorders,
CC septicemia, psoriasis, inflammatory bowel disease, transplant rejection,
CC graft verse host disease, ischemia, stroke, acute respiratory disease
CC syndrome, restenosis, brain injury, AIDS, bone diseases, atherosclerosis,
CC brain disorders including parasupranuclear palsy, myotonic dystrophy,
CC depression, anxiety disorders and sleep disorders, cardiovascular
CC diseases including congestive heart failure and myocardial infarction,
CC respiratory diseases including chronic obstructive pulmonary disease,
CC acute bronchitis and adult respiratory distress syndrome, liver disorders
CC including hypercholesterolaemia, hypertriglyceridaemia, cirrhosis, viral
CC and non-viral hepatitis, type II diabetes mellitus, renal disease
CC including acute and chronic renal failure, glomerulonephritis, Fanconi's
CC syndrome, cystinuria, skeletal muscle disorders including hypoglycaemia
CC and tendinitis, gastrointestinal diseases including intestinal
CC obstruction and tropical sprue, spleen disorders including hypersplenism,
CC Hodgkin's disease and malignant lymphoma, testicular cancer, male
CC reproductive diseases including low testosterone and male infertility.
CC The present sequence is human cytokine receptor.
XX

Sequence 263 AA;

Query Match

Best Local Similarity 100.0%; Score 1427; DB 23; Length 263;
Matches 262; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 MPKHCFGLFLISFLLTGAGTQSTHESLKPQVQFQSRNFHNLQWQPGRALTGNSVYF 60
Db 2 MPKHCFGLFLISFLLTGAGTQSTHESLKPQVQFQSRNFHNLQWQPGRALTGNSVYF 61
OY 61 VQKIMFSCSMKSSHQKPSGCWQHISCNFPGCRTLAKYGQROWKNKEDCWGTQELSCDLT 120
Db 62 VQKIMFSCSMKSSHQKPSGCWQHISCNFPGCRTLAKYGQROWKNKEDCWGTQELSCDLT 121
OY 121 SETSDIQEPYGRVRAASAGSYSEMSMTPRFTPWETKIDPVMNITQVNGSLVILHAP 180
Db 122 SETSDIQEPYGRVRAASAGSYSEMSMTPRFTPWETKIDPVMNITQVNGSLVILHAP 181
OY 181 NLPYRYQKEKNVSIEDYELLYRVFIINNSLEKEQKYEGAHRAVEIEALTPHSSYCYVA 240
Db 182 NLPYRYQKEKNVSIEDYELLYRVFIINNSLEKEQKYEGAHRAVEIEALTPHSSYCYVA 241
OY 241 EITYQMLDRRSQRSEERCVEIP 262
Db 242 EITYQMLDRRSQRSEERCVEIP 263

RESULT 3
AA017382

AA017382 standard; Protein; 263 AA.

AA017382;

08-AUG-2002 (first entry)

Human cytokine receptor variant 3.

Human; cytokine receptor; immune disease; psoriasis; cancer; infection;
rheumatoid arthritis; multiple sclerosis; Crohn's disease;
ulcerative colitis; transplant rejection; abortion; antipsoriatic;
immunosuppressive; antirheumatic; antiarthritic; neuroprotective;
antiinflammatory; antiulcer; cytostatic; dermatological;
chromosome 6q24.1-25.2; receptor.

Homo sapiens.

EP1191035-A2.

27-MAR-2002.

24-AUG-2001; 2001EP-0250307.

25-SEP-2000; 2000DE-1048626.

17-NOV-2000; 2000DE-1058907.

PR 19-DEC-2000; 2000DE-1064906.
XX
PA (SCHD) SCHERING AG.
XX
PI Weiss B, Sabat R, Assadullah K, Toshi L;
XX
DR WPI: 2002-332210/37.
DR N-PSDB; AAL46001.

PT New nucleic acid encoding soluble cytokine receptor, useful for
PT diagnosis and treatment of e.g. immune disease, also related protein
PT and antibodies

PS Claim 6; Page 15; 21pp; German.

CC The present invention provides the protein and coding sequences of 3
CC variants of a human cytokine receptor. The sequences can be used in the
CC diagnosis, prevention and treatment of immune diseases, including
CC psoriasis, cancer, chronic/life-threatening infections, rheumatoid
CC arthritis, multiple sclerosis, Crohn's disease, ulcerative colitis and
CC transplant rejection and in reproductive medicine, e.g. for diagnosing
CC abnormal immune reactions which cause abortions. The present sequence is
CC variant 3 of the invention.
XX

Sequence 263 AA;

Query Match

Best Local Similarity 99.7%; Score 1423; DB 23; Length 263;
Matches 261; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1 MPKHCFGLFLISFLLTGAGTQSTHESLKPQVQFQSRNFHNLQWQPGRALTGNSVYF 60
Db 2 MPKHCFGLFLISFLLTGAGTQSTHESLKPQVQFQSRNFHNLQWQPGRALTGNSVYF 61
OY 61 VQKIMFSCSMKSSHQKPSGCWQHISCNFPGCRTLAKYGQROWKNKEDCWGTQELSCDLT 120
Db 62 VQKIMFSCSMKSSHQKPSGCWQHISCNFPGCRTLAKYGQROWKNKEDCWGTQELSCDLT 121
OY 121 SETSDIQEPYGRVRAASAGSYSEMSMTPRFTPWETKIDPVMNITQVNGSLVILHAP 180
Db 122 SETSDIQEPYGRVRAASAGSYSEMSMTPRFTPWETKIDPVMNITQVNGSLVILHAP 181
OY 181 NLPYRYQKEKNVSIEDYELLYRVFIINNSLEKEQKYEGAHRAVEIEALTPHSSYCYVA 240
Db 182 NLPYRYQKEKNVSIEDYELLYRVFIINNSLEKEQKYEGAHRAVEIEALTPHSSYCYVA 241
OY 241 EITYQMLDRRSQRSEERCVEIP 262
Db 242 EITYQMLDRRSQRSEERCVEIP 263

RESULT 4
AAU80324

AAU80324 standard; Protein; 263 AA.

AAU80324;

15-JUL-2002 (first entry)

Human IL-TIF/IL-22 binding protein #2.

Human; soluble protein; interleukin-TIF/IL-22; IL-TIF/IL-22; IL-22BP;
IL-TIF/IL-22 antagonist.

Homo sapiens.

WO200224912-A2.

28-MAR-2002.

21-SEP-2001; 2001WO-US29576.

22-SEP-2000; 2000US-234583P.

PR 03-NOV-2000; 2000US-245495P.
PR 31-JUL-2001; 2001US-0919162.
XX
XX (LUDW-) LUDWIG INST CANCER RES.
XX
XX Renauld J, Dumoutier L;
XX
XX WPI; 2002-383190/41.
DR N-PSDB; ABR50080.
XX

PT polynucleotide and polypeptide of soluble protein which binds to
PT interleukin-TIF/IL-22 useful for inhibiting effect of IL-TIF/IL-22 on a
PT cell
XX
XX Claim 14; Page 41-42; 42pp; English.

CC The present invention relates to a new polynucleotide that encodes a
CC soluble protein which binds to interleukin (IL)-TIF/IL-22 (also referred
CC to as IL-22BP), where the complementary sequence of the invention
CC hybridises under stringent conditions to a nucleotide sequence of 2271
CC or 2366 base pairs, as given in the specification. The molecules of the
CC invention are useful for inhibiting (antagonising) effect of IL-TIF/IL-22
CC on a cell, for determining whether IL-TIF/IL-22 is present in a sample,
CC for inhibiting binding of IL-TIF/IL-22 to a binding partner, preferably
CC in vitro, and for obtaining an antibody molecule specific for the soluble
CC binding protein of the invention, from a population or panel of antibody
CC molecules of diverse binding specificity. The soluble protein is further
CC useful in manufacture of a medicament for treating an IL-22 mediated
CC disease and for assaying an agent, preferably an antibody or a peptide
CC fragment of IL-TIF/IL-22 or the soluble protein, that modulates binding
CC of the soluble protein to IL-TIF/IL-22, where the agent identified is
CC used in the manufacture of medicament for treating IL-TIF/IL-22 mediated
CC disorder. The antibody is useful for determining presence of the soluble
CC protein, where the antibody is detectably labelled. The present amino
CC acid sequence represents the human IL-TIF/IL-22 binding protein #2 of
CC the invention.
XX
XX SQ Sequence 263 AA;

Query Match 97.5%; Score 1392; DB 23; Length 263;
Best Local Similarity 98.1%; Pred. No. 7.6e-131;
Matches 257; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1 MPKHCFGLFLISFLTGVAGTQSTHESLKPQRVQFQSRNFHNLQWQGRALTGNSVYF 60
DB 2 MPKHCFGLFLISFLTGVAGTQSTHESLKPQRVQFQSRNFHNLQWQGRALTGNSVYF 61
61 VOYKIMFSCSMKSSHQKPSGCWQHISCNFPGCRTLAKYGQRQWKNKEDCWGTQELSCDLT 120
62 VOYKIMFSCSMKSSHQKPSGCWQHISCNFPGCRTLAKYGQRQWKNKEDCWGTQELSCDLT 121
OY 121 SETSDIOEPYGGVRAASAGSYSEWSMTPTFTPWETKIDPPVNMITQVNGSLVILHAP 180
DB 122 SETSDIOEPYGGVRAASAGSYSEWSMTPTFTPWETKIDPPVNMITQVNGSLVILHAP 181
OY 181 NLPYRYQKEKNVSIEDYYELLYRVFIINNSLEKEQKVYEGAHRAVEIEALTPHSSYCVVA 240
DB 182 NLPYRYQKEKNVSIEDYYELLYRVFIINNSLEKEQKVYEGAHRAVEIEALTPHSSYCVVA 241
OY 241 EIVQPMIDRRSQRSEERCVEIP 262
DB 242 EIVQPMIDRRSQRSEERCVEIP 263

RESULT 5
AAE05048
ID AAE05048 standard; Protein; 231 AA.
XX
XX AAE05048;
AC
XX
XX 10-SEP-2001 (first entry)
DT
XX
DE Human ZCYTO18 soluble receptor antagonist, zcytor16 protein.

XX
KW Human; cytostatic; cytokine; ZCYTO18 protein; genetic abnormality;
KW cancer; inflammation; gene therapy; zcytor16.
XX
XX Homo sapiens.
XX
XX WO200146422-A1.
XX
XX 28-JUN-2001.
XX
XX 22-DEC-2000; 2000WO-US35308.
XX
XX 23-DEC-1999; 99US-0471767.
PR 01-DEC-2000; 2000US-0250841.
XX
XX (ZYMO) ZYMOGENETICS INC.
XX
XX Presnell SR, Kindsvogel W;
XX
XX WPI; 2001-408648/43.
DR N-PSDB; AAD09745.
XX

PT Novel human cytokine polypeptide, ZCYTO18, useful for treating cancer -
XX
XX Example 13A; Page 158-159; 167pp; English.

CC The patent discloses novel human cytokine, ZCYTO18 protein and its
CC corresponding DNA. ZCYTO18 protein induces proliferation of cells
CC expressing zcytor1, a receptor for ZCYTO18 or induces cytotoxicity
CC in K562 cells. ZCYTO18 DNA is useful for detecting a genetic
CC abnormality in a patient. ZCYTO18 DNA and its antibodies are useful
CC for detecting cancer and inflammation. ZCYTO18 protein is useful for
CC killing cancer cells. It is useful for increasing platelets in a
CC patient or injured tissue. It is also used in gene therapy.
CC The present sequence is human zcytor16, which is a naturally expressed
CC soluble receptor antagonist of ZCYTO18 protein.
XX
XX SQ Sequence 231 AA;

Query Match 85.0%; Score 1213; DB 22; Length 231;
Best Local Similarity 87.8%; Pred. No. 5.2e-113;
Matches 230; Conservative 0; Mismatches 0; Indels 32; Gaps 1;

QY 1 MPKHCFGLFLISFLTGVAGTQSTHESLKPQRVQFQSRNFHNLQWQGRALTGNSVYF 60
DB 2 MPKHCFGLFLISFLTGVAGTQSTHESLKPQRVQFQSRNFHNLQWQGRALTGNSVYF 61
OY 61 VOYKIMFSCSMKSSHQKPSGCWQHISCNFPGCRTLAKYGQRQWKNKEDCWGTQELSCDLT 120
DB 62 VOYKI-----YQQRQWKNKEDCWGTQELSCDLT 89
OY 121 SETSDIOEPYGGVRAASAGSYSEWSMTPTFTPWETKIDPPVNMITQVNGSLVILHAP 180
DB 90 SETSDIOEPYGGVRAASAGSYSEWSMTPTFTPWETKIDPPVNMITQVNGSLVILHAP 149
OY 181 NLPYRYQKEKNVSIEDYYELLYRVFIINNSLEKEQKVYEGAHRAVEIEALTPHSSYCVVA 240
DB 150 NLPYRYQKEKNVSIEDYYELLYRVFIINNSLEKEQKVYEGAHRAVEIEALTPHSSYCVVA 209
OY 241 EIVQPMIDRRSQRSEERCVEIP 262
DB 210 EIVQPMIDRRSQRSEERCVEIP 231

RESULT 6
AAE02460
ID AAE02460 standard; Protein; 231 AA.
XX
XX AAE02460;
AC
XX
XX 10-AUG-2001 (first entry)
DT
XX
DE Human DNAX cytokine receptor subunit 4.2 (DCRS4.2).

XX Human; immunomodulator; DNAX cytokine receptor subunit 4.2; DCRS4.2;
KW therapy; immunological disorder; drug screening; cell development;
KW chromosome 6q24.1-25.2.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Peptide 1..21
FT /label= Signal-peptide
FT Protein 22..231
FT /label= DCRS4.2
FT /note= "Human mature DNAX cytokine receptor
FT subunit 4.2"
XX
PN WO200136467-A2.
XX
PD 25-MAY-2001.
XX
PD 16-NOV-2000; 2000WO-US31363.
XX
PI 18-NOV-1999; 99US-0443060.
XX 13-DEC-1999; 99US-0170320.
XX (SCHE) SCHERING CORP.
XX
PI Gorman DM;
XX
DR WPI; 2001-343800/36.
DR N-PSDB; AAD06414.
XX
XX
PT New mammalian receptor proteins related to cytokine receptors, useful
PT for regulating cell development and for diagnosis and treatment of
PT immunological disorders
XX
PS Claim 3; Page 23; 124pp; English.
XX
XX The present sequence is human DNAX cytokine receptor subunit 4.2
CC (DCRS4.2). DCRS4 gene is located on chromosome 6q24.1-25.2.
CC Cytokine receptors, fragments and antibodies are useful for treating
CC immunological disorders. DCRS3 (50R), DCRS4 (cytor) or fragments are
CC useful in drug screening to identify compounds having binding affinity
CC to the receptor subunit. Modulators of DCRS are useful for modulating
CC the physiology or development of a cell or tissue culture cells. A
CC purified DCRS is useful as a reagent to detect antibodies generated in
CC response to the presence of elevated levels of expression, or
CC immunological disorders which lead to production of antibody to the
CC endogenous receptor. Cytokine receptor sequences are useful as probes
CC for detecting levels of the cytokine receptor in patients suspected of
CC having an immunological disorder. Antibodies have therapeutic value, are
CC useful as potent antagonist, in detecting or quantifying ligands, for
CC isolating DCRS proteins and peptides, to screen expression libraries for
CC particular expression products, to raise anti-idiotypic antibodies and
CC for detecting or diagnosing various immunological conditions related to
CC expression of the protein or cells which express the protein.
XX
SQ Sequence 231 AA;
Query Match 85.0%; Score 1213; DB 22; Length 231;
Best Local Similarity 87.8%; Pred. No. 5.2e-113;
Matches 230; Conservative 0; Mismatches 0; Indels 32; Gaps 1;

OY 181 NLPYRQKEKNVSIEDYELLRYRVFIINNSLEKEQKVYEGAHRAVEIALTPHSSYCYVA 240
Db 150 NLPYRQKEKNVSIEDYELLRYRVFIINNSLEKEQKVYEGAHRAVEIALTPHSSYCYVA 209
OY 241 EITYQPMIDRRSQSRSEERCVEIP 262
Db 210 EITYQPMIDRRSQSRSEERCVEIP 231
RESULT 7
AAB62657
ID AAB62657 standard; Protein; 231 AA.
XX
AC AAB62657;
XX
DT 23-JUL-2001 (first entry)
XX
DE Human cytokine receptor, zcytor16.
XX
KW Cytokine receptor; zcytor16; IL-TIF; antiinflammatory; cytostatic;
KW antirheumatic; antiarthritic; antiasthmatic; antiatherosclerotic;
KW immunosuppressive; chromosome 6q24.1-25.2; human.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Domain 22..108
FT /note= "Ig domain 1"
FT Domain 22..231
FT /note= "Ig domain 2"
FT Domain 112..210
FT /note= "Ig domain 2"
XX
PN WO200140467-A1.
XX
PD 07-JUN-2001.
XX
PD 01-DEC-2000; 2000WO-US32703.
XX
PF 03-DEC-1999; 99US-0169049.
XX 13-SEP-2000; 2000US-0232219.
XX 31-OCT-2000; 2000US-0244610.
XX (ZYMO) ZYMOGENETICS INC.
XX
PI Presnell SR, Xu W, Kindsvogel W, Chen Z;
XX WPI; 2001-356158/37.
XX N-PSDB; AAF83735.
XX
PT New soluble cytokine receptor polypeptides and polynucleotides, useful
PT for diagnosing and treating cancer and inflammatory conditions -
XX
PS Claim 1; Page 186-188; 210pp; English.
XX
XX The invention relates to a human cytokine receptor polypeptide,
CC designated zcytor16. The zcytor16 polypeptide can be expressed by
CC standard recombinant methodology and can bind to IL-TIF (undefined). The
CC zcytor16 protein is useful for: inhibiting IL-TIF induced proliferation
CC or differentiation of hematopoietic cell(s) (progenitors); reducing
CC IL-TIF induced or IL-9 induced inflammation; and suppressing an
CC inflammatory response in a mammal with inflammation. Heteromeric/
CC multimeric receptor polypeptides such as soluble zcytor 16/CRF2-4 can be
CC used to reduce progression and symptoms of cancer. Zcytor16 polypeptides
CC can also be used to detect IL-TIF levels which is indicative of
CC pathological conditions including inflammatory states (e.g. rheumatoid
CC arthritis) and cancer. Antibodies that bind zcytor16 polypeptides and the
CC polypeptides themselves are useful for the treatment of inflammation,
CC inflammatory diseases (e.g. infection, asthma, inflammatory bowel
CC disease, rheumatoid arthritis and atherosclerosis) and autoimmune
CC diseases. The antibodies and zcytor16 polynucleotides are also useful
CC for detecting cancer. The present sequence represents the human

CC zcytor16 protein.
XX
SQ Sequence 231 AA;

Query Match 85.0%; Score 1213; DB 22; Length 231;
Best Local Similarity 87.8%; Pred. No. 5.2e-113;
Matches 230; Conservative 0; Mismatches 0; Indels 32; Gaps 1;

QY 1 MPKHCFGLGFLISFLLGVAGTQSTHESLKPQRYVQFSRNFHNLQWQGRALTGNSVYF 60
DB 2 MPKHCFGLGFLISFLLGVAGTQSTHESLKPQRYVQFSRNFHNLQWQGRALTGNSVYF 61
QY 61 VQKIMFSCSMKSSHQKPSGCWQHISCNFPGCRTLAKYGRQWKNKEDCWGTQELSCDLT 120
DB 62 VQYKI-----YGRQWKNKEDCWGTQELSCDLT 89
QY 121 SETSDIQEPYGRVRAASAGSYSEWSMTPRFTPWETKIDPVMNITQVNGSLVILHAP 180
DB 90 SETSDIQEPYGRVRAASAGSYSEWSMTPRFTPWETKIDPVMNITQVNGSLVILHAP 149
DB 181 NLPYRYQKEKNVSIEDYELLRYVFIINNSLEKEQKYEGAHRAVEIEALTPHSSYCVVA 240
150 NLPYRYQKEKNVSIEDYELLRYVFIINNSLEKEQKYEGAHRAVEIEALTPHSSYCVVA 209
QY 241 EIQPMLDRRSQSRSEERCVEIP 262
DB 210 EIQPMLDRRSQSRSEERCVEIP 231

RESULT 8
AAOI7381
ID AAOI7381 standard; Protein; 231 AA.

AC AAOI7381;
DT 08-AUG-2002 (first entry)
DE Human cytokine receptor variant 2.
DE Human cytokine receptor; immune disease; psoriasis; cancer; infection;
KW Human; cytokine receptor; immune disease; psoriasis; cancer; infection;
KW rheumatoid arthritis; multiple sclerosis; Crohn's disease;
KW ulcerative colitis; transplant rejection; abortion; antipsoriatic;
KW immunosuppressive; antirheumatic; antiarthritic; neuroprotective;
KW antiinflammatory; antidiabetic; cytostatic; dermatological;
KW chromosome 6q24.1-25.2; receptor.
XX
OS Homo sapiens.

EP1191035-A2.

27-MAR-2002.

24-AUG-2001; 2001EP-0250307.

25-SEP-2000; 2000DE-1048626.

17-NOV-2000; 2000DE-1058907.

19-DEC-2000; 2000DE-1064906.

(SCHD) SCHERING AG.

Weiss B, Sabat R, Assadullah K, Toshi L;

WPI; 2002-332210/37.

N-PSDB; AAL46000.

New nucleic acid encoding soluble cytokine receptor, useful for
diagnosis and treatment of e.g. immune disease, also related protein
and antibodies

Claim 6; Page 14; 21pp; German.

The present invention provides the protein and coding sequences of 3
variants of a human cytokine receptor. The sequences can be used in the

CC diagnosis, prevention and treatment of immune diseases, including
CC psoriasis, cancer, chronic/life-threatening infections, rheumatoid
CC arthritis, multiple sclerosis, Crohn's disease, ulcerative colitis and
CC transplant rejection and in reproductive medicine, e.g. for diagnosing
CC abnormal immune reactions which cause abortions. The present sequence is
CC variant 2 of the invention.

XX
SQ Sequence 231 AA;

Query Match 85.0%; Score 1213; DB 23; Length 231;
Best Local Similarity 87.8%; Pred. No. 5.2e-113;
Matches 230; Conservative 0; Mismatches 0; Indels 32; Gaps 1;

QY 1 MPKHCFGLGFLISFLLGVAGTQSTHESLKPQRYVQFSRNFHNLQWQGRALTGNSVYF 60
DB 2 MPKHCFGLGFLISFLLGVAGTQSTHESLKPQRYVQFSRNFHNLQWQGRALTGNSVYF 61
QY 61 VQKIMFSCSMKSSHQKPSGCWQHISCNFPGCRTLAKYGRQWKNKEDCWGTQELSCDLT 120
DB 62 VQYKI-----YGRQWKNKEDCWGTQELSCDLT 89
QY 121 SETSDIQEPYGRVRAASAGSYSEWSMTPRFTPWETKIDPVMNITQVNGSLVILHAP 180
DB 90 SETSDIQEPYGRVRAASAGSYSEWSMTPRFTPWETKIDPVMNITQVNGSLVILHAP 149
QY 181 NLPYRYQKEKNVSIEDYELLRYVFIINNSLEKEQKYEGAHRAVEIEALTPHSSYCVVA 240
DB 150 NLPYRYQKEKNVSIEDYELLRYVFIINNSLEKEQKYEGAHRAVEIEALTPHSSYCVVA 209
QY 241 EIQPMLDRRSQSRSEERCVEIP 262
DB 210 EIQPMLDRRSQSRSEERCVEIP 231

RESULT 9
AAU80000
ID AAU80000 standard; Protein; 231 AA.

AC AAU80000;
DT 15-JUL-2002 (first entry)
DE Human IL-TIF/IL-22 binding protein #1.
DE Human IL-TIF/IL-22 binding protein #1.
KW Human; soluble protein; interleukin-TIF/IL-22; IL-TIF/IL-22; IL-22BP;
KW IL-TIF/IL-22 antagonist.
XX
OS Homo sapiens.

WO200224912-A2.

28-MAR-2002.

21-SEP-2001; 2001WO-US29576.

22-SEP-2000; 2000US-234583P.

03-NOV-2000; 2000US-245495P.

31-JUL-2001; 2001US-0919162.

(LUDW-) LUDWIG INST CANCER RES.

Renauld J, Dumoutier L;

WPI; 2002-383190/41.

N-PSDB; ABK50076.

Polynucleotide and polypeptide of soluble protein which binds to
interleukin-TIF/IL-22 useful for inhibiting effect of IL-TIF/IL-22 on a
cell

Claim 14; Page 39; 42pp; English.

The present invention relates to a new polynucleotide that encodes a

CC soluble protein which binds to interleukin (IL)-TIF/IL-22 (also referred
CC to as IL-22BP), where the complementary sequence of the invention
CC hybridises under stringent conditions to a nucleotide sequence of 2271
CC or 2366 base pairs, as given in the specification. The molecules of the
CC invention are useful for inhibiting (antagonising) effect of IL-TIF/IL-22
CC on a cell, for determining whether IL-TIF/IL-22 is present in a sample,
CC for inhibiting binding of IL-TIF/IL-22 to a binding partner, preferably
CC in vitro, and for obtaining an antibody molecule specific for the soluble
CC binding protein of the invention, from a population or panel of antibody
CC molecules of diverse binding specificity. The soluble protein is further
CC useful in manufacture of a medicament for treating an IL-22 mediated
CC disease and for assaying an agent, preferably an antibody or a peptide
CC fragment of IL-TIF/IL-22 or the soluble protein, that modulates binding
CC of the soluble protein to IL-TIF/IL-22, where the agent identified is
CC used in the manufacture of medicament for treating IL-TIF/IL-22 mediated
CC disorder. The antibody is useful for determining presence of the soluble
CC protein, where the antibody is detectably labelled. The present amino
CC acid sequence represents the human IL-TIF/IL-22 binding protein #1 of
CC the invention.

Sequence 231 AA;

Query Match 85.0%; Score 1213; DB 23; Length 231;
Best Local Similarity 87.8%; Pred. No. 5.2e-113;
Matches 230; Conservative 0; Mismatches 0; Indels 32; Gaps 1;

QY 1 MPKHCFGLISFELTGVAGTQSTHESLKPQRYQFSRNFHNLQWQPGRALTGNSSYF 60
Db 2 MPKHCFGLISFELTGVAGTQSTHESLKPQRYQFSRNFHNLQWQPGRALTGNSSYF 61
QY 61 VOYKIMFSCSMKSSHQKPSGCWQHISCNFPGCRTLAKYQQRQWKNKEDCWGTQELSCDLT 120
Db 62 VOYKI-----YQQRQWKNKEDCWGTQELSCDLT 89
QY 121 SETSDIQEPYGRVRAASAGSYSEWSMTPTPTWETKIDPVMNITQVNGSLVILHAP 180
Db 90 SETSDIQEPYGRVRAASAGSYSEWSMTPTPTWETKIDPVMNITQVNGSLVILHAP 149
QY 181 NLPYRYQKEKNVSIEDIYELLYRVFIINNSLEKEQKVEGAHRAVEIEALTTPHSSYCVVA 240
Db 150 NLPYRYQKEKNVSIEDIYELLYRVFIINNSLEKEQKVEGAHRAVEIEALTTPHSSYCVVA 209
QY 241 EIIQPMIDRRSQSRSEECVEIP 262
Db 210 EIIQPMIDRRSQSRSEECVEIP 231

RESULT 10

ABG34086 standard; Protein; 231 AA.

ABG34086;

15-JUL-2002 (first entry)

Human Pro peptide #57.

Human; PRO; secreted protein; transmembrane protein;
genetic disorder; tumour; cancer.

Homo sapiens.

WO200224888-A2.

28-MAR-2002.

29-AUG-2001; 2001WO-US27099.

01-SEP-2000; 2000US-229896P.
05-SEP-2000; 2000US-230621P.
22-SEP-2000; 2000US-235147P.
10-NOV-2000; 2000WO-US30873.
12-JAN-2001; 2001US-261878P.

PR 16-JAN-2001; 2001US-261910P.
PR 16-JAN-2001; 2001US-261939P.
PR 16-JAN-2001; 2001US-262150P.
PR 25-JAN-2001; 2001US-264395P.
PR 02-FEB-2001; 2001US-266421P.
PR 09-FEB-2001; 2001US-267623P.
PR 28-FEB-2001; 2001WO-US06520.
PR 09-MAR-2001; 2001US-274399P.
PR 03-APR-2001; 2001US-280982P.
PR 04-APR-2001; 2001US-282129P.
PR 04-APR-2001; 2001US-282199P.
PR 09-MAY-2001; 2001US-290589P.
PR 25-MAY-2001; 2001WO-US17092.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.

(GETH) GENENTECH INC.

Baker KP, Eaton DL, Filvaroff E, Goddard A, Grimaldi JC;
Curney AL, Smith V, Stephan J, Watanabe CK, Wood WI, Zhang Z;
Fong S;

WPI; 2002-362426/39.
N-PSDB; ABK70017.

New PRO polypeptides and polynucleotides encoding the polypeptides,
useful in gene therapy, chromosome identification, tissue typing, or
for genetic analysis of individuals with genetic disorders
Claim 11; Figure 114; 218pp; English.

This invention relates to the cDNA and protein sequences of novel
secreted and transmembrane polypeptides PRO polypeptides. The
invention also comprises a method for producing the proteins of the
invention by recombinant means and antibodies specific for the protein
of the invention. The antibody may be used for detecting the PRO
proteins of the invention and may be used to modify their activity.
CC polynucleotides may be used as hybridisation probes for a cDNA library
CC to isolate the full-length PRO cDNA or to isolate other cDNAs, to
CC construct hybridisation probes for mapping the gene which encodes that
CC PRO and for genetic analysis of individuals with genetic disorders, in
CC assays to identify other proteins or molecules involved in binding
CC reaction, to generate transgenic animals or knock-out animals which in
CC turn are useful in the development and screening of therapeutically
CC useful reagents, for chromosome identification, and as molecular weight
CC markers for protein electrophoresis purposes. The sequences may
CC also be used to detect overexpression on PRO polypeptides in cancerous
CC tumours and for screening for differentially expressed genes using
CC microarray technology. The present sequence represents a human PRO
CC protein of the invention.

Sequence 231 AA;

Query Match 85.0%; Score 1213; DB 23; Length 231;
Best Local Similarity 87.8%; Pred. No. 5.2e-113;
Matches 230; Conservative 0; Mismatches 0; Indels 32; Gaps 1;

QY 1 MPKHCFGLISFELTGVAGTQSTHESLKPQRYQFSRNFHNLQWQPGRALTGNSSYF 60
Db 2 MPKHCFGLISFELTGVAGTQSTHESLKPQRYQFSRNFHNLQWQPGRALTGNSSYF 61
QY 61 VOYKIMFSCSMKSSHQKPSGCWQHISCNFPGCRTLAKYQQRQWKNKEDCWGTQELSCDLT 120
Db 62 VOYKI-----YQQRQWKNKEDCWGTQELSCDLT 89
QY 121 SETSDIQEPYGRVRAASAGSYSEWSMTPTPTWETKIDPVMNITQVNGSLVILHAP 180
Db 90 SETSDIQEPYGRVRAASAGSYSEWSMTPTPTWETKIDPVMNITQVNGSLVILHAP 149
QY 181 NLPYRYQKEKNVSIEDIYELLYRVFIINNSLEKEQKVEGAHRAVEIEALTTPHSSYCVVA 240

Db 150 NLPYRYQKEKNVSIEDYELLVRFVFIINNSLEKEQKVEGAHRAVEIEALTPHSSYCVVA 209
QY 241 EIIYQPMIDRRSQRSEERCVEIP 262
Db 210 EIIYQPMIDRRSQRSEERCVEIP 231

RESULT 11
AAE17320
ID AAE17320 standard; Protein; 231 AA.
XX
AC AAE17320;
DT 18-APR-2002 (first entry)
XX
DE Human cytokine receptor protein, sbg456548Cytora #2.
XX
KW Human; therapy; wound healing disorder; vaccine; cancer; infection;
KW autoimmune disorder; haematopoietic disorder; inflammation; arthritis;
KW Parkinson's disease; Huntington's chorea; schizophrenia; antiarrhythmic;
KW ischaemia; stroke; AIDS; bone disease; atherosclerosis; brain disorder;
KW depression; cardiovascular disease; myocardial infarction; renal failure;
KW respiratory disease; liver disorder; Fanconi's syndrome; spleen disorder;
KW type II diabetes mellitus; skeletal muscle disorder; immunosuppressive;
KW hypersplenism; renal disease; hypoglycaemia; gastrointestinal disease;
KW neurotropic; cirrhosis; Hodgkin's disease; neuroleptic; antiinflammatory;
KW haemostatic; vulnery; anticonvulsant; antirheumatic; neuroprotective;
KW nephrotropic; hypotensive; vasotropic; cytostatic; cerebroprotective;
KW allergy; cytokine receptor.
XX
OS Homo sapiens.
XX
PN WO200198342-A1.
XX
PD 27-DEC-2001.
XX
PF 22-JUN-2001; 2001WO-US19929.
XX
PR 22-JUN-2000; 2000US-213156P.
XX
PR 22-JUN-2000; 2000US-213161P.
XX
PA (SMIK) SMITHKLINE BEECHAM CORP.
PA (SMIK) SMITHKLINE BEECHAM PLC.
PA (GLAX) GLAXO GROUP LTD.
XX
Agarwal P, Cogswell JP, Kabnic KS, Lai Y, Martensen SA;
Murdoch PR, Smith RF, Strum JC, Xiang Z, Xie Q, Rizni SK;
WPI; 2002-139783/18.
DR N-PSDB; AAD27815.
XX
PT Novel secreted and membrane-associated polypeptides and polynucleotides
PT useful for preventing, ameliorating or correcting dysfunction or
PT disease including diabetes, cancer, hypertension and growth
PT abnormalities -
XX
PS Claim 1; Page 132-133; 138pp; English.
XX
CC The invention relates to secreted and membrane-associated polypeptides
CC and polynucleotides. The sequences of the invention are useful in
CC diagnostic assays for detecting diseases associated with inappropriate
CC activity or levels of these polynucleotides, and in identifying their
CC agonists and antagonists that are potentially useful in therapy. The
CC sequences of the invention are useful as vaccines for inducing
CC immunological response. The sequences of the invention are useful for
CC treating cancers, infections, autoimmune disorders, haematopoietic
CC disorders, wound healing disorders, cholesterol ester storage disease,
CC inflammation, congenital muscular dystrophy, junctional epidermolysis
CC bullosa, Parkinson's disease, Huntington's chorea, multiple sclerosis,
CC viral and bacterial infections, Alzheimer's disease, asthma, arthritis,
CC allergies, schizophrenia, sbg442445PROA-associated disorders,

CC septicaemia, psoriasis, inflammatory bowel disease, transplant rejection,
CC graft verse host disease, ischaemia, stroke, acute respiratory disease
CC syndrome, restenosis, brain injury, AIDS, bone diseases, atherosclerosis,
CC brain disorders including parasupranuclear palsy, myotonic dystrophy,
CC depression, anxiety disorders and sleep disorders, cardiovascular
CC diseases including congestive heart failure and myocardial infarction,
CC respiratory diseases including chronic obstructive pulmonary disease,
CC acute bronchitis and adult respiratory distress syndrome, liver disorders
CC including hypercholesterolaemia, hypertirglyceridaemia, cirrhosis, viral
CC and non-viral hepatitis, type II diabetes mellitus, renal disease
CC including acute and chronic renal failure, glomerulonephritis, Fanconi's
CC syndrome, cystinuria, skeletal muscle disorders including hypoglycaemia
CC and tendinitis, gastrointestinal diseases including intestinal
CC obstruction and tropical sprue, spleen disorders including hypersplenism,
CC Hodgkin's disease and malignant lymphoma, testicular cancer, male
CC reproductive diseases including low testosterone and male infertility.
CC The present sequence is human cytokine receptor.
XX
SQ Sequence 231 AA;
XX
Query Match 85.0%; Score 1213; DB 23; Length 231;
Best Local Similarity 87.8%; Pred. No. 5.2e-113;
Matches 230; Conservative 0; Mismatches 0; Indels 32; Gaps 1;
QY 1 MPKHCFGLISFELTGVAGTQSTHESLKPQVQFQSRNFHNILOWOPGRALTGSSVVF 60
Db 2 MPKHCFGLISFELTGVAGTQSTHESLKPQVQFQSRNFHNILOWOPGRALTGSSVVF 61
QY 61 VQKIMFSCSMKSSHQKPSGCWQHISCNPPGCRTLAKYGQROWKKNKDCWGTQELSCDLT 120
Db 62 VQYKI-----YQROWKKNKDCWGTQELSCDLT 89
QY 121 SETSDIQEPYGRVRAASAGSYSEMSMTPTPTWWTETKIDPPVMNITQVNGSLVTLHAP 180
Db 90 SETSDIQEPYGRVRAASAGSYSEMSMTPTPTWWTETKIDPPVMNITQVNGSLVTLHAP 149
QY 181 NLPYRYQKEKNVSIEDYELLVRFVFIINNSLEKEQKVEGAHRAVEIEALTPHSSYCVVA 240
Db 150 NLPYRYQKEKNVSIEDYELLVRFVFIINNSLEKEQKVEGAHRAVEIEALTPHSSYCVVA 209
QY 241 EIIYQPMIDRRSQRSEERCVEIP 262
Db 210 EIIYQPMIDRRSQRSEERCVEIP 231

RESULT 12
AAE17319
ID AAE17319 standard; Protein; 214 AA.
XX
AC AAE17319;
XX
DT 18-APR-2002 (first entry)
XX
DE Human cytokine receptor protein, sbg456548Cytora #1.
XX
KW Human; therapy; wound healing disorder; vaccine; cancer; infection;
KW autoimmune disorder; haematopoietic disorder; inflammation; arthritis;
KW Parkinson's disease; Huntington's chorea; schizophrenia; antiarrhythmic;
KW multiple sclerosis; Alzheimer's disease; analgesic; cardiant; asthma;
KW ischaemia; stroke; AIDS; bone disease; atherosclerosis; brain disorder;
KW depression; cardiovascular disease; myocardial infarction; renal failure;
KW respiratory disease; liver disorder; Fanconi's syndrome; spleen disorder;
KW type II diabetes mellitus; skeletal muscle disorder; immunosuppressive;
KW hypersplenism; renal disease; hypoglycaemia; gastrointestinal disease;
KW neurotropic; cirrhosis; Hodgkin's disease; neuroleptic; antiinflammatory;
KW haemostatic; vulnery; anticonvulsant; antirheumatic; neuroprotective;
KW nephrotropic; hypotensive; vasotropic; cytostatic; cerebroprotective;
KW allergy; cytokine receptor.
XX
OS Homo sapiens.
XX
PN WO200198342-A1.
XX

PD 27-DEC-2001.
XX
PF 22-JUN-2001; 2001WO-US19929.
XX
PR 22-JUN-2000; 2000US-213156P.
PR 22-JUN-2000; 2000US-213161P.
XX
PA (SMIK) SMITHKLINE BEECHAM CORP.
PA (SMIK) SMITHKLINE BEECHAM PLC.
PA (GLAX) GLAXO GROUP LTD.
XX
PI Agarwal P, Cogswell JP, Kabnic KS, Lai Y, Martensen SA;
PI Murdoch PR, Smith RF, Strum JC, Xiang Z, Xie Q, Rizni SK;
XX
WPI; 2002-139783/18.
DR N-PSDB; AAD27814.

Novel secreted and membrane-associated polypeptides and polynucleotides useful for preventing, ameliorating or correcting dysfunction or disease including diabetes, cancer, hypertension and growth abnormalities -

The invention relates to secreted and membrane-associated polypeptides and polynucleotides. The sequences of the invention are useful in diagnostic assays for detecting diseases associated with inappropriate activity or levels of these polynucleotides, and in identifying their agonists and antagonists that are potentially useful in therapy. The sequences of the invention are useful as vaccines for inducing immunological response. The sequences of the invention are useful for treating cancers, infections, autoimmune disorders, haematopoietic disorders, wound healing disorders, cholesterol ester storage disease, inflammation, congenital muscular dystrophy, junctional epidermolysis bullosa, Parkinson's disease, Huntington's chorea, multiple sclerosis, viral and bacterial infections, Alzheimer's disease, asthma, arthritis, allergies, schizophrenia, sbg442445PROA-associated disorders, septicemia, psoriasis, inflammatory bowel disease, transplant rejection, graft versus host disease, ischaemia, stroke, acute respiratory disease syndrome, restenosis, brain injury, AIDS, bone diseases, atherosclerosis, brain disorders including parasupranuclear palsy, myotonic dystrophy, depression, anxiety disorders and sleep disorders, cardiovascular diseases including congestive heart failure and myocardial infarction, respiratory diseases including chronic obstructive pulmonary disease, acute bronchitis and adult respiratory distress syndrome, liver disorders including hypercholesterolaemia, hypertriglyceridaemia, cirrhosis, viral and non-viral hepatitis, type II diabetes mellitus, renal disease including acute and chronic renal failure, glomerulonephritis, Fanconi's syndrome, cystinuria, skeletal muscle disorders including hypoglycaemia and tendinitis, gastrointestinal diseases including intestinal obstruction and tropical sprue, spleen disorders including hypersplenism, Hodgkin's disease and malignant lymphoma, testicular cancer, male reproductive diseases including low testosterone and male infertility. The present sequence is human cytokine receptor.

Sequence 214 AA;

Query Match	78.1%;	Score 1114;	DB 23;	Length 214;
Best Local Similarity	86.9%;	Pred. No. 3.8e-103;		
Matches 212; Conservative	0;	Mismatches 0;	Indels 32;	Gaps 1;

OY 19 AGTQSTHESLKPVRFVQFSRNFHNILQWQGRALTGSSVFVQYKIMFSCMSKSSHQP 78
|||||
Dd 3 AGTQSTHESLKPVRFVQFSRNFHNILQWQGRALTGSSVFVQYKI----- 49

79 SGCWQHISCNFPGCRTLAKYGQRQWKNKEDCWTQELSCDLTSETSDIQEPYGRVRAAS 138

Db 50 -----YGRQWKNEKDCWGTQELSCDLTSETSDIQEPYGRVRAAS 90

QY	139 AGSISEWMSMTPRFTPMWEETKIDBPVMNITQVNGSLVLILHAPNLPRYOKEKNVSIEDYY	198
Db	91 AGSISEWMSMTPRFTPMWEETKIDBPVMNITQVNGSLVLILHAPNLPRYOKEKNVSIEDYY	150

Qy	199	ELLYRVFIINNSLEKEÖKVYEGAHRAVEIT	ALTPHSSSYCVALETYQ	PMLDRRSÖRSEERC	258
Db	151	ELLYRVFIINNSLEKEÖKVYEGAHRAVEIT	ALTPHSSSYCVALETYQ	PMLDRRSÖRSEERC	210

QY	259	VEIP	262
Db	211	VEIP	214

RESULT 13
AAB62663

ID AAB62663 standard; Protein; 210 AA.

AC AAB62663;

DT 23-JUL-2001 (first entry)

DE Human zcytor16 extracellular domain fragment (residues 22-231).

KM Cytokine receptor; zcytor16; IL-T1F; antiinflammatory; cytostatic;
KM antirheumatic; antiarthritic; antiasthmatic; antiatherosclerotic;
KM immunosuppressive; chromosome 6q24.1-25.2; human.

05 Homo sapiens.

PN W0200140467-A1.

PD 07-JUN-2001.

PF 01-DEC-2000; 2000WO-US32703.

PR 03-DEC-1999; 99US-0169049.

PR 31-OCT-2000; 2000US-0244610.

PA (ZYMO) ZYMOGENETICS INC.

PI Presnell SR, Xu W, Kindsvogel W, Chen Z;

DR WPI; 2001-356158/37.

PT New soluble cytokine receptor polypeptides and polynucleotides, useful
PT for diagnosing and treating cancer and inflammatory conditions -

PS Claim 1; Page 193; 210pp; English.

The invention relates to a human cytokine receptor polypeptide, designated zcytor16. The zcytor16 polypeptide can be expressed by standard recombinant methodology and can bind to IL-TIF (undefined). The zcytor16 protein is useful for: inhibiting IL-TIF induced proliferation or differentiation of hematopoietic cell(s) (progenitors); reducing IL-TIF induced or IL-9 induced inflammation; and suppressing an inflammatory response in a mammal with inflammation. Heteromeric/ multimeric receptor polypeptides such as soluble zcytor 16/CRF2-4 can be used to reduce progression and symptoms of cancer. Zcytor16 polypeptides can also be used to detect IL-TIF levels which is indicative of pathological conditions including inflammatory states (e.g. rheumatoid arthritis) and cancer. Antibodies that bind zcytor16 polypeptides and the polypeptides themselves are useful for the treatment of inflammation, inflammatory diseases (e.g. infection, asthma, inflammatory bowel disease, rheumatoid arthritis and atherosclerosis) and autoimmune diseases. The antibodies and zcytor16 polynucleotides are also useful for detecting cancer. The present sequence represents the human zcytor16 extracellular domain fragment.

Sequence 210 AA;

Query Match	77.4%;	Score 1104;	DB 22;	length 210;
Best Local Similarity	86.8%;	Pred. No. 3.7e-102;		
Matches 210; Conservative	0;	Mismatches 0;	Indels 32;	Gaps 1;

QY	21	TOSTHESLKPORVOFOSRNEHNILOWQGRALTGNSSVYFVQYKIMFSCSMKSSHQKPSG	80

Db 1 TQSTHESLKPQRVQFSRNEHNLQWQGRALTGNSSVYFVQYKI----- 45
QY 81 CWQHISCNFGCRTLAKYGRQWKNKEDCWGTQELSCDLTSETSDIQEPYGRVRAASAG 140
Db 46 -----YGRQWKNKEDCWGTQELSCDLTSETSDIQEPYGRVRAASAG 88
QY 141 SESEWSMTPRFTPWETKIDPEVMNITQVNGSLVILHAPNLPYRYQKEKNVSIEDYEL 200
Db 89 SESEWSMTPRFTPWETKIDPEVMNITQVNGSLVILHAPNLPYRYQKEKNVSIEDYEL 148
QY 201 LYRVFIINNSLEKEQKYEGAHRAVEIEALTPHSSYCVVAETIYQPMIDRRSQRSEERCVE 260
Db 149 LYRVFIINNSLEKEQKYEGAHRAVEIEALTPHSSYCVVAETIYQPMIDRRSQRSEERCVE 208
QY 261 IP 262
Db 209 IP 210
ULT 14
2458
AAE02458 standard; Protein; 249 AA.
XX AAE02458;
XX 10-AUG-2001 (first entry)
XX Human DNAX cytokine receptor subunit 4.1 (DCRS4.1).
DE Human; immunomodulator; DNAX cytokine receptor subunit 4.1; DCRS4.1;
XX therapy; immunological disorder; drug screening; cell development;
KW chromosome 6q24.1-25.2.
XX Homo sapiens.
OS
XX Key location/Qualifiers
FH 1..21
FT Peptide /label= Signal-peptide
FT Protein 22..249
FT /label= DCRS4.1
FT /note= "Human mature DNAX cytokine receptor
subunit 4.1"
FT 24
FT Modified-site /note= "CK2 phosphorylation site"
FT 25
FT Modified-site /note= "Calcium phosphorylation site"
FT 28
FT Modified-site /note= "PKC phosphorylation site"
FT 31..70
FT /label= Cytokine_receptor_domain
FT 51
FT Modified-site /note= "cAMP PK site"
FT 56
FT Modified-site /note= "N-glycosylated"
FT 78..86
FT /label= Conserved_disulphide_linkage
FT 81
FT Modified-site /note= "Calcium phosphorylation site"
FT 85
FT Modified-site /note= "Calcium phosphorylation site"
FT 89
FT Modified-site /note= "Calcium phosphorylation site"
FT 92
FT Modified-site /note= "Calcium phosphorylation site"
FT 100
FT Modified-site /note= "Calcium phosphorylation site"
FT 110
FT Modified-site /note= "Amidation site"
FT 118
FT Modified-site /note= "Myristoyl site"
FT 119
FT Modified-site /note= "PKC phosphorylation site"
FT 119
FT Modified-site /note= "cAMP phosphorylation site"
FT 119
FT Modified-site

FT Modified-site /note= "cAMP PK site"
FT 124
FT Modified-site /note= "Myristoyl site"
FT 127
FT Modified-site /note= "cAMP PK site"
FT 152
FT Modified-site /note= "N-glycosylated"
FT 157
FT Modified-site /note= "N-glycosylated"
FT 177
FT Modified-site /note= "cAMP PK site"
FT 178
FT Modified-site /note= "N-glycosylated"
FT 180
FT Modified-site /note= "Calcium phosphorylation site"
FT 180
FT Modified-site /note= "CK2 phosphorylation site"
FT 195
FT Modified-site /note= "N-glycosylated"
FT 197
FT Modified-site /note= "Calcium phosphorylation site"
FT 207
FT Modified-site /note= "Myristoyl site"
FT 238
FT Modified-site /note= "PKC phosphorylation site"
FT 241
FT /note= "Calcium phosphorylation site"
XX WO200136467-A2.
XX 25-MAY-2001.
XX 16-NOV-2000; 2000WO-US31363.
XX 18-NOV-1999; 99US-0443060.
XX 13-DEC-1999; 99US-0170320.
XX (SCHE) SCHERING CORP.
XX Gorman DM;
XX WPI; 2001-343800/36.
XX N-PSDB; AAD06410.
XX
XX New mammalian receptor proteins related to cytokine receptors, useful
XX for regulating cell development and for diagnosis and treatment of
XX immunological disorders
XX
XX Claim 3; Page 22; 124pp; English.
XX
XX The present sequence is human DNAX cytokine receptor subunit 4.1
XX (DCRS4.1). DCRS4 gene is located on chromosome 6q24.1-25.2.
XX Cytokine receptors, fragments and antibodies are useful for treating
XX immunological disorders. DCRS3 (50R), DCRS4 (cytor) or fragments are
XX useful in drug screening to identify compounds having binding affinity
XX to the receptor subunit. Modulators of DCRS are useful for modulating
XX the physiology or development of a cell or tissue culture cells. A
XX purified DCRS is useful as a reagent to detect antibodies generated in
XX response to the presence of elevated levels of expression, or
XX immunological disorders which lead to production of antibody to the
XX endogenous receptor. Cytokine receptor sequences are useful as probes
XX for detecting levels of the cytokine receptor in patients suspected of
XX having an immunological disorder. Antibodies have therapeutic value, are
XX useful as potent antagonist, in detecting or quantifying ligands, for
XX isolating DCRS proteins and peptides, to screen expression libraries for
XX particular expression products, to raise anti-idiotypic antibodies and
XX for detecting or diagnosing various immunological conditions related to
XX expression of the protein or cells which express the protein.
XX
XX Sequence 249 AA;
XX
XX Query Match 73.2%; Score 1045; DB 22; Length 249;
XX Best Local Similarity 74.4%; Pred. No. 3.8e-96;

Matches 209; Conservative 3; Mismatches 17; Indels 52; Gaps 4;

QY 1 MPKHCFGLGFLISFFLTGVAQTOSTHESLKPQRYQFQSRNFHNILOWOPGRALTGNSVYF 60
DB 2 MPKHCFGLGFLISFFLTGVAQTOSTHESLKPQRYQFQSRNFHNILOWOPGRALTGNSVYF 61
QY 61 VQKIMFSCSMKSSHQKPSGCWQHISCNFPGCRTLAKYGQROWKNKEDCWGTQELSCDLT 120
DB 62 VQYKI-----YQORQWKNKEDCWGTQELSCDLT 89
QY 121 SETSDIQEPPYGRVRAASAGSYSEWS-----MTPRFTPWWE--TKIDP 161
DB 90 SETSDIQEPPYGR-RGKNKNKGNPWGPKQSKRKSNGKNTNTVTAPALKAFAAGCAKIDP 148
QY 162 PVMNITQVNGSLVILHAPNLPYRYQKEKNVSIEDYELLRYRVFIINNSLEKEQKYEGA 221
DB 149 PVMNITQVNGSLVILHAPNLPYRYQKEKNVSIEDYELLRYRVFIINNSLEKEQKYEGA 208
QY 222 HRAVEIEALTPHSSYCVVAEITYQPMIDRRSQRSEERCVEIP 262
DB 209 HRAVEIEALTPHSSYCVVAEITYQPMIDRRSQRSEERCVEIP 249

RESULT 15
AAO17380
ID AAO17380 standard; Protein; 249 AA.
XX
AC AAO17380;
XX
DT 08-AUG-2002 (first entry)
XX
DE Human cytokine receptor variant 1.
XX
DE Human; cytokine receptor; immune disease; psoriasis; cancer; infection;
KW rheumatoid arthritis; multiple sclerosis; Crohn's disease;
KW ulcerative colitis; transplant rejection; abortion; antipsoriatic;
KW immunosuppressive; antirheumatic; antiarthritic; neuroprotective;
KW antinflammatory; antidiabetic; cytostatic; dermatological;
KW chromosome 6q24.1-25.2; receptor.
XX
OS Homo sapiens.
XX
PN EP1191035-A2.
XX
PD 27-MAR-2002.
XX
PF 24-AUG-2001; 2001EP-0250307.
XX
PR 25-SEP-2000; 2000DE-1048626.
XX 17-NOV-2000; 2000DE-1058907.
XX 19-DEC-2000; 2000DE-1064906.
PA (SCHD) SCHERING AG.
XX
PI Weiss B, Sabat R, Assadullah K, Toshi L;
XX
DR WPI; 2002-332210/37.
DR N-PSDB; AAL45999.
XX
XX
PT New nucleic acid encoding soluble cytokine receptor, useful for
PT diagnosis and treatment of e.g. immune disease, also related protein
PT and antibodies
XX
PS Claim 6; Page 12-13; 21pp; German.
XX
XX The present invention provides the protein and coding sequences of 3
XX variants of a human cytokine receptor. The sequences can be used in the
XX diagnosis, prevention and treatment of immune diseases, including
XX psoriasis, cancer, chronic/life-threatening infections, rheumatoid
XX arthritis, multiple sclerosis, Crohn's disease, ulcerative colitis and
XX transplant rejection and in reproductive medicine, e.g. for diagnosing
XX abnormal immune reactions which cause abortions. The present sequence is
XX variant 1 of the invention.

XX
SQ Sequence 249 AA;
Query Match 73.2%; Score 1045; DB 23; Length 249;
Best Local Similarity 74.4%; Pred. No. 3.8e-96;
Matches 209; Conservative 3; Mismatches 17; Indels 52; Gaps 4;

QY 1 MPKHCFGLGFLISFFLTGVAQTOSTHESLKPQRYQFQSRNFHNILOWOPGRALTGNSVYF 60
DB 2 MPKHCFGLGFLISFFLTGVAQTOSTHESLKPQRYQFQSRNFHNILOWOPGRALTGNSVYF 61
QY 61 VQKIMFSCSMKSSHQKPSGCWQHISCNFPGCRTLAKYGQROWKNKEDCWGTQELSCDLT 120
DB 62 VQYKI-----YQORQWKNKEDCWGTQELSCDLT 89
QY 121 SETSDIQEPPYGRVRAASAGSYSEWS-----MTPRFTPWWE--TKIDP 161
DB 90 SETSDIQEPPYGR-RGKNKNKGNPWGPKQSKRKSNGKNTNTVTAPALKAFAAGCAKIDP 148
QY 162 PVMNITQVNGSLVILHAPNLPYRYQKEKNVSIEDYELLRYRVFIINNSLEKEQKYEGA 221
DB 149 PVMNITQVNGSLVILHAPNLPYRYQKEKNVSIEDYELLRYRVFIINNSLEKEQKYEGA 208
QY 222 HRAVEIEALTPHSSYCVVAEITYQPMIDRRSQRSEERCVEIP 262
DB 209 HRAVEIEALTPHSSYCVVAEITYQPMIDRRSQRSEERCVEIP 249

Search completed: December 22, 2002, 10:10:49
Job time : 68 secs

C;Accession: JC6311
R;Gibbs, V.C.; Pennica, D.
Gene 186, 97-101, 1997
A;Title: CRE2-4:isolation of cDNA clones encoding the human and mouse proteins
A;Reference number: JC6311; MUID:97199375; PMID:9047351
A;Accession: JC6311
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-349 <GIB>
A;Cross-references: GB:U53696

Query Match	10.98;	Score 156;	DB 2;	Length 349;
Best Local Similarity	26.88;	Pred. No. 4.1e-06;		
Matches	72;	Conservative	30;	Mismatches 89;
			Indels	78;
			Gaps	13;

[illegible]

QY 117 CDLTSETSDIQEPYIGRVRAASAGSYSEWSMTPRFTPWETKIDPPVMNITQVNGSLVY 176
 Db 85 -----YTVRVARAELADEHSEW-VNVTFCPVEDTIIIGPPEMQITSLAESLELR 130

```
QY 177 LHA1NLP2RYQ3KE-----KN4VSIED5YELL6RYV-FI7INNSLEKEQ8KYVGAHRAVEIEA 229
      || : | ||: | ||| : | | | | : :
Db 131 FSA1QI2---ENE3PETW4LKNI---YD5SWAYR6VQYWKNGTNEKEQ7YV--SPYDSEVL8RN 180
```

```
QY      230 LTPHSSYCVVAEIIYQPMIDRRSQSRSEERC 258
          | | ::||: : : : | | | |
Db      181 LEPWTTTCIQVQGFLLDQNRRTGENSEPIC 209
```

RESULT 5
I56215

Interleukin-10 receptor - human
C/Species: Homo sapiens (man)
C/Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 28-Jul-2000
C/Accession: I56215
R/Liu, Y.; Wei, S.H.; Ho, A.S.; de Waal Malefyt, R.; Moore, K.W.
J. Immunol. 152, 1821-1829, 1994
A/Title: Expression cloning and characterization of a human IL-10 receptor.
A/Reference number: I56215; MUID:94165477; PMID:8120391
A/Accession: I56215

Status: preliminary; translated from GB/EMBL/DBJ
molecule type: mRNA
residues: 1-578 <RES>

A:Cross-references: EMBL:U00672; NID:g482802; PIDN:AAAL7896.1; PTD:g482803
C:Genetics:
A:Gene: GDB:IL10R; HIL-10R
A:Cross-references: GDB:330958; OMIM:146933
A:Map position: 11q23.3-11q23.3
C:Superfamily: interleukin-10 receptor IL10R
C:Keywords: cytokine receptor

Query Match	10.7%;	Score 152.5;	DB 2;	Length 578;
Best Local Similarity	24.5%;	Pred. No. 1.6e-05;		
Matches 67;	Conservative 39;	Mismatches 94;	Indels 73;	Gaps 14;

QY 7 LGFLISFEELTGYA-GTQSTHESLKPQRVQEQSRNHNILQWQGRALTGNSSVFVQYKI 655
| : | | | | | : | : | : | : | :
Db 9 LVALLSLRIGSDAGT----ELRSPPSVWFEEAEFFHHILLHTP----- 477

```
QY      66 MFSCSMKSSHOKPBGCMQHISCNBPGRCLAKYGQRQWKNEDCWGTQEILSCLDTSETSD 125  
         ::|::: |::: |::: |::: |::: |::: |::: |:::  
Db     48 -----IPNQSESTCYE-----VALLRYGIESWNISNC--SQTLSYDLTAAYLD 89
```

```
QY 126 I-QEPPYGRVRAASAGSYSEWSMT-PRFTPMWETKIDPPYMNITQV-----NGSLVIL 177
      : | ||| : |::| || : | : | : | :
Db 90 LYHSNGRRARVRAVDGSRHSNMTVNTFRS-----VDEVTLLVGSVNLFIHNGFIIGKI 143
```

```

QY 178 HAPNLPYRQKEKNVSIEDYELLRYRF-IINNSLEKEQKVYEGAHRAVEIATLTPHSS- 235
      |      |      |      |      |      |      |      |      |      |
Db 144 QLP-----RPKMAMPANDTYESIFSHREYELAIRKVPGNFTFTTHKKVYKHENFSLTSG 196
      |      |      |      |      |      |      |      |      |      |
QY 236 ----YCVVAELIYOPMLDRSQR--SEERCVEI 261
      ||      ||      ||      ||      ||
Db 197 EYGEFCVQV---KPSVASRSNKGMSKEECISL 226

```

RESULT 6
A47003

Cytokine receptor family class II protein CRF2-4 precursor - human
C:Species: Homo sapiens (man)
C:Date: 09-Sep-1994 #sequence__revision 09-Sep-1994 #text__change 01-Dec-2000
C:Accession: A47003; G01418
R:Luftalla, G.; Gardiner, K.; Uze, G.
Genomics 16, 366-373, 1993

A;Title: A new member of the cytokine receptor gene family maps on chromosome 21 at 1
A;Accession number: A47003; MUID:93300510; PMID:8314576
A;Reference number: A47003
A;Accession: A47003
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-325<LUT>

submitted to the EMBL Data Library, April 1994

A: Status: preliminary; translated from GB/EMBL/DBJ

A;Cross-references: EMBL:U08988; NID:g571295; PID:g571296

A:Gene GDB:CREB4; CRE2-4
A:Cross-references: GDB:138168; OMIM:123889
A:Map position: 21q; 21q22.1-21q22.2
A:Introns: 17/1; 58/2; 111/1; 166/3; 216/1
C;Keywords: transmembrane protein

Query Match	10.5%	Score 149.5;	DB 2;	Length 325;
Best Local Similarity	24.1%;	Pred. No. 1.4e-05;		
Matches 57; Conservative	32;	Mismatches 89;	Indels 59;	Gaps 8;

```
QY      30  PQRVQFSQRNFHNLLOWQPGRALTGN--SSVYFVQYKIMFSCSMKSSHQKPSGCMQHISC  87
      1: 1: 1 1 1 1 1 1: 1: 1: 1: 1:
Db      24  PENVRMNSVNEKNLLOWESPFAKGNLTFTAQYLSYRIF----- 62
```

```
QY      88 NPPGCRITLAKYQQRQWKNKEDCWGTQELSCDLLTSETSDIQEPYVG----RVRASAGSYS 1433
          :: | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db      63 -----QDKCMNTLTTECEDFSSLSK-----YGDHTLRVRAEFADEHS 98
```

```
QY 144 EWSMTPRETPWMEETKIDPPVMMNIQYNGSLVLHAPNLPYRYQ--KEKNVSIEDYYELL 201
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 99 DW-VNITECPVDDTIIGPPGMOVEVLADSLHMRFLAPKIENEFETWTMKNV---YNSWT 153
```

QY 202 YRVFIINNSLEKEQVYEGAHRAVEIEALTPHSSYCVAAEIIYQPMLDRSRQRSEERC 258
| | : : : | : | : |||| : : : ||
Db 154 YNVQYWKNGSTDEKFOITPQDYDFEV-LRNLEPWTTYCVQVRGFLPDRNKAGWSESPVC 209

RESULT 7
KEBO3

tissue factor precursor - bovine
N:Alternate names: coagulation factor III
C:Species: Bos primigenius taurus (cattle)
C:Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 22-Jun-1999
C:Accession: JQ1319
R:Takayenoki, Y.; Muta, T.; Miyata, T.; Iwanaga, S.
Biochem. Biophys. Res. Commun. 181, 1145-1150, 1991
A:Title: cDNA and amino acid sequences of bovine tissue factor.
A:Reference number: JQ1319; MUID:92109720; PMID:1764065
A:Accession: JQ1319

A;Molecule type: mRNA
A;Residues: 1-292 <TAK>
A;Cross-references: GB:S74147; NID:g241438; PIDN:AAB20755.1; PID:g241439
A;Experimental source: adrenal gland
A;Note: part of this sequence, including the amino end of the mature protein, was confirmed
C;Comment: Tissue factor is an integral membrane glycoprotein that serves as a receptor
C;Comment: Expression of tissue factor can be induced in a variety of tissues by certain
C;Superfamily: tissue factor
C;Keywords: blood coagulation; glycoprotein; lipoprotein; thiolester bond; transmembrane
F;1-35/Domain: signal sequence #status predicted <SIG>
F;36-292/Product: tissue factor #status experimental <MAT>
F;36-248/Domain: extracellular #status predicted <EXT>
F;249-271/Domain: transmembrane #status predicted <TM>
F;272-292/Domain: intracellular #status predicted <INT>
F;43,153,181/Binding site: carbohydrate (Asn) (covalent) #status predicted
F;81-89,215-238/Disulfide bonds: #status predicted
F;118,124/Binding site: carbohydrate (Thr) (covalent) #status predicted
F;274/Binding site: palmitate (Cys) (covalent) #status experimental

Query Match	9.7%;	Score 138.5;	DB 1;	Length 292;
Best Local Similarity	22.68;	Pred. No. 0.00011;		
Matches 59; Conservative	43;	Mismatches 104;	Indels 55;	Gaps 12

QY 10 LISFELTGAGTQSTHESLKPRVQFQSRNFHNLQWQPRALTGNSVYEVQYKIMESC 69
 | | | : : : : : | | | : : | |
 Db 21 LFGVLIIQAGAGTDDVVAAYNITWKSTNEKTILEWEKPI---NHVYTVQIS----- 71

```

QY 70 SMKSHQKPSGCWQHISCNFPGCRTLAKYGRQWKNKEDCWGTQELSCDLTSE-TSDIOE 128
      : | 1111 | : | 11:1 | ...: |
Db 72 -----PRLG--NMKNK--CFYTTNTECDVTDIYKNVRE 101

```

QY 129 PYGRVRAASAGSYSE----WSMTPRFTPMWEKTI-DPVMNITQVNGSLVLILHAPNL 182

QY 183 PYRYQEKENVSTEDYY--ELLYRVFIINNSLEKEQKYEGAH--AVEIEALTPHSSYC-- 237

```

QY      238 VVAEIYQPMIDRRSQRSEERC 258
        | | | : : : | | : |
DB      218 VQAVITLSPRVNOKSPESPIC 238

```

RESULT 8
A32694

Accession: A332694. S17112
 Date: 22-Jun-1990 #sequence_revision 22-Jun-1990 #text_change 22-Oct-1999
 C_Species: Homo sapiens (man)
 Interleukin alpha/beta receptor precursor - human

Ri:Uze, G.; Lutfialla, G.; Gresser, I.
Cell 60, 225-234, 1990
A:Title: Genetic transfer of a functional human interferon alpha receptor into mouse cells
A:Reference number: A32694: MIMD-90124632: PMID-2153461

A;Accession: A32694
A;Molecule type: mRNA
A;Residues: 1-557 <UZE>
A;Cross-references: CB:103171. NID:0184645. PIDD:0306914

R;Lutfalla, G.
submitted to the EMBL Data Library, July 1991
A:Description: The structure of the human interferon alpha/beta receptor gene
Accession number: U01113

A;Accession: S17112
A;Molecule type: DNA
A;Residues: 1-16, 'A', 18-329, 'V', 343-557 <LUT>

C;Genetics:
A;Gene: GDB:1FNAR1; IFNAR; IFRC
A;Cross-references: GDB:120078; OMIM:107450

A; Introns: 26/1; 67/2; 126/1; 177/3; 225/1; 263/2; 342/1; 381/3; 432/1; 480/3
C; Keywords: cytokine receptor; glycoprotein; transmembrane protein
F; 1-21/Domain: transmembrane #status predicted <TRNL>

F:437-455/Domain: transmembrane #status predicted <TRN2>
F:50,58,81,88,110,172,254,313,314,376,416,433,507,518,537/Binding site: carbohydrate

Query Match	9.6%;	Score 136.5;	DB 2;	Length 557;
Best Local Similarity	20.8%;	Pred. No. 0.00039;		
Matches 54;	Conservative 39;	Mismatches 115;	Indels 51;	Gaps 7,

```
QY      2 PKHCFGLGISFELTGVAQTQSTHESLKPQRVQFQSRNFHNLQWQPGRALTGNSSVYFV 61
      1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Db     217 PVHCT-----KITVENELPPPENIEVSQONQNYVLKWD---YTYANNTTFQV 259
```

```

QY      62 QYKIMFSCSMKSSHQKPSGCWQHISCNFPGCRTLAQYQOROWKNKEDCWGTQELSDLT 121
      1: 1: 1: 1: 1:
Db      260 QWTHAFLEKRNPGNH-----LYKKWKQIPDCENVKITTCQYFPQ 295

```

QY 122 ETSDIQEPYGRVARASAGSYSEWSMPTRETPMWEETKIDPVMNITQVNGSLVLHAEN 181
: | |||: : | | : : ||| | : : | : | |

Dh 296 NVFO-KGIYLLRVOASDGNNTSFWSSEIKFDETEIOAFILPPVFNIRSLSDSFHIYICAP- 353

[illegible]

```

QY      242  IX--QPMIDRRSQRSEERC  258
      :      |::| | |
DB      408  AHMTDEKLNKSSVESDVC  426

```

RESULT 9
ME303

interferon alpha/beta receptor - mouse
C;Species: Mus musculus (house mouse)
C;Date: 25-Mar-1993 #sequence_revision 18-Nov-1994 #text_change 05-Nov-1999
C;Accession: AF0293, U08473, U08474, U08475, U08476, U08477, U08478, U08479, U08480, U08481, U08482, U08483, U08484, U08485, U08486, U08487, U08488, U08489, U08490, U08491, U08492, U08493, U08494, U08495, U08496, U08497, U08498, U08499, U08500, U08501, U08502, U08503, U08504, U08505, U08506, U08507, U08508, U08509, U08510, U08511, U08512, U08513, U08514, U08515, U08516, U08517, U08518, U08519, U08520, U08521, U08522, U08523, U08524, U08525, U08526, U08527, U08528, U08529, U08530, U08531, U08532, U08533, U08534, U08535, U08536, U08537, U08538, U08539, U08540, U08541, U08542, U08543, U08544, U08545, U08546, U08547, U08548, U08549, U08550, U08551, U08552, U08553, U08554, U08555, U08556, U08557, U08558, U08559, U08560, U08561, U08562, U08563, U08564, U08565, U08566, U08567, U08568, U08569, U08570, U08571, U08572, U08573, U08574, U08575, U08576, U08577, U08578, U08579, U08580, U08581, U08582, U08583, U08584, U08585, U08586, U08587, U08588, U08589, U08590, U08591, U08592, U08593, U08594, U08595, U08596, U08597, U08598, U08599, U08600, U08601, U08602, U08603, U08604, U08605, U08606, U08607, U08608, U08609, U08610, U08611, U08612, U08613, U08614, U08615, U08616, U08617, U08618, U08619, U08620, U08621, U08622, U08623, U08624, U08625, U08626, U08627, U08628, U08629, U08630, U08631, U08632, U08633, U08634, U08635, U08636, U08637, U08638, U08639, U08640, U08641, U08642, U08643, U08644, U08645, U08646, U08647, U08648, U08649, U08650, U08651, U08652, U08653, U08654, U08655, U08656, U08657, U08658, U08659, U08660, U08661, U08662, U08663, U08664, U08665, U08666, U08667, U08668, U08669, U08670, U08671, U08672, U08673, U08674, U08675, U08676, U08677, U08678, U08679, U08680, U08681, U08682, U08683, U08684, U08685, U08686, U08687, U08688, U08689, U08690, U08691, U08692, U08693, U08694, U08695, U08696, U08697, U08698, U08699, U08700, U08701, U08702, U08703, U08704, U08705, U08706, U08707, U08708, U08709, U08710, U08711, U08712, U08713, U08714, U08715, U08716, U08717, U08718, U08719, U08720, U08721, U08722, U08723, U08724, U08725, U08726, U08727, U08728, U08729, U08730, U08731, U08732, U08733, U08734, U08735, U08736, U08737, U08738, U08739, U08740, U08741, U08742, U08743, U08744, U08745, U08746, U08747, U08748, U08749, U08750, U08751, U08752, U08753, U08754, U08755, U08756, U08757, U08758, U08759, U08760, U08761, U08762, U08763, U08764, U08765, U08766, U08767, U08768, U08769, U08770, U08771, U08772, U08773, U08774, U08775, U08776, U08777, U08778, U08779, U08780, U08781, U08782, U08783, U08784, U08785, U08786, U08787, U08788, U08789, U08790, U08791, U08792, U08793, U08794, U08795, U08796, U08797, U08798, U08799, U08800, U08801, U08802, U08803, U08804, U08805, U08806, U08807, U08808, U08809, U08810, U08811, U08812, U08813, U08814, U08815, U08816, U08817, U08818, U08819, U08820, U08821, U08822, U08823, U08824, U08825, U08826, U08827, U08828, U08829, U08830, U08831, U08832, U08833, U08834, U08835, U08836, U08837, U08838, U08839, U08840, U08841, U08842, U08843, U08844, U08845, U08846, U08847, U08848, U08849, U08850, U08851, U08852, U08853, U08854, U08855, U08856, U08857, U08858, U08859, U08860, U08861, U08862, U08863, U08864, U08865, U08866, U08867, U08868, U08869, U08870, U08871, U08872, U08873, U08874, U08875, U08876, U08877, U08878, U08879, U08880, U08881, U08882, U08883, U08884, U08885, U08886, U08887, U08888, U08889, U08890, U08891, U08892, U08893, U08894, U08895, U08896, U08897, U08898, U08899, U08900, U08901, U08902, U08903, U08904, U08905, U08906, U08907, U08908, U08909, U08910, U08911, U08912, U08913, U08914, U08915, U08916, U08917, U08918, U08919, U08920, U08921, U08922, U08923, U08924, U08925, U08926, U08927, U08928, U08929, U08930, U08931, U08932, U08933, U08934, U08935, U08936, U08937, U08938, U08939, U08940, U08941, U08942, U08943, U08944, U08945, U08946, U08947, U08948, U08949, U08950, U08951, U08952, U08953, U08954, U08955, U08956, U08957, U08958, U08959, U08960, U08961, U08962, U08963, U08964, U08965, U08966, U08967, U08968, U08969, U08970, U08971, U08972, U08973, U08974, U08975, U08976, U08977, U08978, U08979, U08980, U08981, U08982, U08983, U08984, U08985, U08986, U08987, U08988, U08989, U08990, U08991, U08992, U08993, U08994, U08995, U08996, U08997, U08998, U08999, U09000, U09001, U09002, U09003, U09004, U09005, U09006, U09007, U09008, U09009, U09010, U09011, U09012, U09013, U09014, U09015, U09016, U09017, U09018, U09019, U09020, U09021, U09022, U09023, U09024, U09025, U09026, U09027, U09028, U09029, U09030, U09031, U09032, U09033, U09034, U09035, U09036, U09037, U09038, U09039, U09040, U09041, U09042, U09043, U09044, U09045, U09046, U0

R; Uze, G.; Lutfalla, G.; Bandu, M.T.; Proudnon, D.; Mogensen, K.E. Proc. Natl. Acad. Sci. U.S.A. 89, 4774-4778, 1992

A; Title: Behavior of a cloned murine interferon alpha/beta receptor expressed in homo

A;Accession: A45283
A;Status: preliminary
A;Molecule type: mRNA

A;Cross-references: GB:M896641; NID:g194111; PID:g194112
A;Note: sequence extracted from NCBI backbone (NCBIN:102354, NCBI:P:102357)
R;Lutfalla, G.; Uze, G.
140 342346 1004

A;Title: Structure of the murine interferon alpha/beta
A;Reference number: I48423; MUID:95047447; PMID:7958966
A;Accession: I48423

A: Molecule type: DNA
A: Residues: 118-125 <RES>
A: Cross-references: EMBL:U06237; NID:g497103; PIDN:AAA65003.1; PID:g755810

A:Status: preliminary; translated from GB/EMBL/DBDj
A:Molecule type: DNA
A:Residues: 127-224 <RE3>

A:Accession: I48425
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA

A1:Cross-references: EMBL:U06239; NID:g497106; PIDN:AAA65004.1; PID:g510261
A1:Accession: I48426
A1:Status: preliminary; translated from GB/EMBL/DBJ

A:Residues: 265-375 <RE4>
A:Cross-references: EMBL:006240; NID:g497108; PIDN:AAA65005.1; PID:g510262z
A:Accession: I48427

A: Molecule type: DNA
A: Residues: 397-424 <RE5>
A: Cross-references: EMBL:U06241; NID:g497110; PIDN:AAA65006.1; PID:g755812

QY 217 VEGAHRAVEIEALTPHSSYCVVAETIQPMLDRSQ-RSEERCVEIP 262
Db 187 GNMSGNFTYIIDKLIPNTNYCV--SVYLEHSDQAVIKSPLKCTLIP 231

RESULT 15

A54295
interferon alpha/beta receptor precursor - human
C;Species: Homo sapiens (man)
C;Date: 09-Sep-1994 #sequence_revision 09-Sep-1994 #text_change 05-Nov-1999
C;Accession: A54295
R;Novick, D.; Cohen, B.; Rubinstein, M.
Cell 77, 391-400, 1994
A;Title: The human interferon alpha/beta receptor: characterization and molecular cloning
A;Reference number: A54295; MUID:94236684; PMID:8181059
A;Accession: A54295
A;Status: preliminary
A;Molecule type: mRNA
Residues: 1-331 <NOV>
Cross-references: GB:X77722; NID:g488363; PIDN:CA54785.1; PID:g488364
Keywords: cytokine receptor

Query Match 7.1%; Score 101.5; DB 2; Length 331;
Best Local Similarity 20.3%; Pred. No. 0.25;
Matches 46; Conservative 39; Mismatches 99; Indels 43; Gaps 7;
QY 38 RNFHNILOWOPGRALTGNSVYFVQYKIMFSCSMKSSHQKPSGCWQHISCNPGCRTLAK 97
Db 46 RNFRSILSWE-----LKNHSIVPTHYTLVLTIMSK----- 75
QY 98 YGORQWKNKEDCGTQELSCDLTSETSDIQEPIYGRVRAASAGSYSEWSMTPRFTPWWT 157
Db 76 --PEDLKVKVKNCAANTTRSFCDLTDEWRSTHEAYV-TVEGFSGNTTLFSCSHNEFWLAIDM 132
QY 158 KIDPVMNITQVNGSLVILHAPNL-PYRYQKEKNVSIEDYELLRYVFIIINNSLEKEQK 216
Db 133 SFEPPFEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVK-----KHKPEIK 186
QY 217 VEGAHRAVEIEALTPHSSYCVVAETIQPMLDRSQ-RSEERCVEIP 262
Db 187 GNMSGNFTYIIDKLIPNTNYCV--SVYLEHSDQAVIKSPLKCTLIP 231

Search completed: December 22, 2002, 10:14:23
Job time : 46 secs

GenCore version 5.1.3
Copyright (c) 1993 - 2002 Compugen Ltd.

OM protein - protein search, using sw model

Run on: December 22, 2002, 09:12:37 ; Search time 25 Seconds
(without alignments)
434.672 Million cell updates/sec

Title: US-09-964-994-2
Perfect score: 1427
Sequence: 1 MPKHCFGLISFLLTGVA.....YQPMIDRRSQRSERCEVEIP 262

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 112892 seqs, 41476328 residues
Number of hits satisfying chosen parameters: 112892

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : SwissProt_40:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	164.5	11.5	575	110R_MOUSE	Q61727 mus musculu
2	163	11.4	295	TF_HUMAN	P13726 homo sapien
3	158	11.1	560	INR1_BOVIN	Q04790 bos taurus
4	156	10.9	349	110S_MOUSE	Q61190 mus musculu
5	152.5	10.7	578	110R_HUMAN	Q13651 homo sapien
6	149.5	10.5	325	110S_HUMAN	Q08334 homo sapien
7	138.5	9.7	292	TF_BOVIN	P30931 bos taurus
8	136.5	9.6	289	TF_CAVPO	Q911u8 cavia porce
9	136.5	9.6	557	INR1_HUMAN	P17181 homo sapien
10	136.5	9.6	560	INR1_SHEEP	Q28589 ovis aries
11	134.5	9.4	590	INR1_MOUSE	P33896 mus musculu
12	132.5	9.3	292	TF_RABIT	P24055 oryctolagus
13	128.5	9.0	295	TF_RAT	P42533 rattus norv
14	124	8.7	294	TF_MOUSE	P20352 mus musculu
15	122.5	8.6	489	INGR_HUMAN	P15260 homo sapien
16	115	8.1	536	INR2_SHEEP	Q95207 ovis aries
17	104	7.3	530	INR2_BOVIN	Q95141 bos taurus
18	101.5	7.1	515	INR2_HUMAN	P48551 homo sapien
19	92	6.4	337	INGS_HUMAN	P38484 homo sapien
20	92	6.4	1254	POLS_RRV	P08491 ross river
21	90.5	6.3	424	KPSH_HUMAN	P11801 homo sapien
22	90	6.3	1253	POLS_SFV	P03315 semliki for
23	88.5	6.2	1170	TSP2_BOVIN	Q95116 bos taurus
24	87.5	6.1	676	KALM_CHICK	P33005 gallus gall
25	86	6.0	477	INGR_MOUSE	P15261 mus musculu
26	85	6.0	792	RIRI_HUMAN	P23921 homo sapien
27	84.5	5.9	274	VC06_SPKA	P32226 swinepox vi
28	82.5	5.8	478	HLV4_ECOLI	P09986 escherichia
29	81	5.7	564	YUES_CAEEL	P90859 caenorhabdi
30	81	5.7	810	CAN3_CHICK	Q92177 gallus gall
31	81	5.7	1247	POLS_ONNVG	P22056 c'nyong-nyo
32	80.5	5.6	478	HLVD_ECOLI	P06739 escherichia
33	80	5.6	582	KICH_YEAST	P20485 saccharomyc

34	79.5	5.6	1411	1	Y297_HUMAN	O15040 homo sapien
35	79	5.5	410	1	CPXI_BACME	P14762 bacillus me
36	79	5.5	606	1	Z214_HUMAN	Q9u159 homo sapien
37	78.5	5.5	576	1	GRK6_RAT	P97711 ratius norv
38	78.5	5.5	760	1	YBIL_ECOLI	P75780 escherichia
39	78.5	5.5	1003	1	POL_HYV1N5	P12497 human immun
40	78	5.5	626	1	HCYD_EURCA	P02241 eurypelma c
41	78	5.5	1254	1	POLS_RRYN	P13890 ross river
42	77.5	5.4	526	1	CATA_HUMAN	P04040 homo sapien
43	77.5	5.4	638	1	GHR_HUMAN	P10912 homo sapien
44	77.5	5.4	897	1	CYRB_HUMAN	P32927 homo sapien
45	77.5	5.4	1172	1	TSP2_HUMAN	P35442 homo sapien

ALIGNMENTS

RESULT 1	ID	110R_MOUSE	STANDARD;	PRT;	575 AA.
AC	Q61727;				
DT	15-JUL-1998 (Rel. 36, Created)				
DT	15-JUL-1998 (Rel. 36, Last sequence update)				
DT	16-OCT-2001 (Rel. 40, Last annotation update)				
DE	Interleukin-10 receptor alpha chain precursor (IL-10R-A) (IL-10R1).				
GN	IL10RA OR IL10R.				
OS	Mus musculus (Mouse).				
OC	Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;				
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.				
OX	NCBI_TaxID=10090;				
RN	[1]				
RP	SEQUENCE FROM N.A.				
RC	STRAIN=C57BL/6 X AJ F1; TISSUE=Hematopoietic;				
RX	MEDLINE=94068585; PubMed=8248239;				
RA	Ho A.S.-Y., Liu Y., Khan T.A., Hsu D.-H., Bazan J.F., Moore K.W.;				
RT	"A receptor for interleukin 10 is related to interferon receptors.";				
RL	Proc. Natl. Acad. Sci. U.S.A. 90:11267-11271(1993).				
CC	-1- FUNCTION: RECEPTOR FOR IL-10; BINDS IL-10 WITH A HIGH AFFINITY.				
CC	-1- SUBCELLULAR LOCATION: Type I membrane protein.				
CC	-1- SIMILARITY: BELONGS TO THE CLASS II CYTOKINE FAMILY OF RECEPTORS.				
CC	-----				
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration				
CC	between the Swiss Institute of Bioinformatics and the EMBL outstation -				
CC	the European Bioinformatics Institute. There are no restrictions on its				
CC	use by non-profit institutions as long as its content is in no way				
CC	modified and this statement is not removed. Usage by and for commercial				
CC	entities requires a license agreement (See http://www.isb-sib.ch/announce/				
CC	or send an email to license@isb-sib.ch).				
CC	-----				
DR	EMBL: L12120; AAA16156.1; -				
DR	MGD; MGI:96538; I110ra.				
DR	InterPro; IPR000282; Cytok_receptor_2.				
KW	Receptor; Transmembrane; Glycoprotein; Signal.				
FT	SIGNAL	1	16		POTENTIAL.
FT	CHAIN	17	575		INTERLEUKIN-10 RECEPTOR ALPHA CHAIN.
FT	DOMAIN	17	241		POTENTIAL.
FT	TRANSMEM	242	262		EXTRACELLULAR (POTENTIAL).
FT	DOMAIN	263	575		POTENTIAL.
FT	DISULFID	204	225		CYTOPLASMIC (POTENTIAL).
FT	CARBOHYD	50	50		POTENTIAL.
FT	CARBOHYD	66	66		N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	113	113		N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	182	182		N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	238	238		N-LINKED (GLCNAC. . .) (POTENTIAL).
SQ	SEQUENCE	575 AA;	64248 MW;	820B9CD576F686B7 CRC64;	
Query Match					
Best Local Similarity 11.5%; Score 164.5; DB 1; Length 575;					
Matches 74; Conservative 37; Mismatches 89; Indels 77; Gaps 16;					
QY	6 FLGLISFLLTGVA-GTOSTHESLKPQRVQFSRNFHILQWQGRALTGNSVYEVQYK 64				
DB	8 FLVTISLSLEFIAYGT----ELPSPSYVWFARFQHLHWKP--IPNSESSTY--YE 58				

```

OY 65 IMFSCSMKSSHQKPSGCMOHISCNFPGCRTLAKYGQROKKNKEDCWGTQELSCDLTSETS 124
DB 59 V-----ALQYGNSTWMDIHICRKAQALSCDLTFTTL 90
OY 125 DIOEPYTG--RVRAASAGSYSEWSMT-PRFTPWETKIDPPVMNITQV-----NGSLLV 175
DB 91 DLYHRSYGYRARRAVADNSQYSNMTTETRTFT-----VDEVILTVDSVTLKAMDGIITG 144
OY 176 ILHAPNLPYRYQEKVNSIEDYELLY--RVFIINNSLEKEQKVEGAHRAVEIEALT- 231
DB 145 TIHP-----RPTTPAGDEVEQFKDLRVYKI--SIRKSEL-KNATKRVKQETFTL 194
OY 232 ----PHSSYCVAAEITYQPMIDR--SORSEERCVEI 261
DB 195 TVPIGVKFECKV--LPRLESIRINKAEWSEEQCLLI 228

RESULT 2
HUMAN TF_HUMAN STANDARD; PRT; 295 AA.
P13726;
01-JAN-1990 (Rel. 13, Created)
01-JAN-1990 (Rel. 13, Last sequence update)
16-OCT-2001 (Rel. 40, Last annotation update)
Tissue factor precursor (TF) (Coagulation factor III)
(Thromboplastin) (CD142 antigen).
F3.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP MEDLINE=89247359; PubMed=2719931;
RA Mackman N., Morrissey J.H., Fowler B., Edgington T.S.;
RT "Complete sequence of the human tissue factor gene, a highly
RT regulated cellular receptor that initiates the coagulation protease
RT cascade.";
RL Biochemistry 28:1755-1762(1989).
RN [2]
RP MEDLINE=87260946; PubMed=3037536;
RA Spicer E.K., Horton R., Bloem L., Bach R., Williams K.R., Guha A.,
RA Kraus J., Lin T.C., Nemerson Y., Konigsberg W.H.;
RT "Isolation of cDNA clones coding for human tissue factor: primary
RT structure of the protein and cDNA.";
RT Proc. Natl. Acad. Sci. U.S.A. 84:5148-5152(1987).
RN [3]
RP MEDLINE=87244317; PubMed=3297348;
RA Morrissey J.H., Fakhrat H., Edgington T.S.;
RT "Molecular cloning of the cDNA for tissue factor, the cellular
RT receptor for the initiation of the coagulation protease cascade.";
RL Cell 50:129-135(1987).
RN [4]
RP MEDLINE=88050796; PubMed=2823875;
RA Scarpati E.M., Wen D., Broze G.J. Jr., Milelich J.P.,
RA Flendermeyer R.R., Siegel N.R., Sadler J.E.;
RT "Human tissue factor: cDNA sequence and chromosome localization of
RT the gene.";
RL Biochemistry 26:5234-5238(1987).
RN [5]
RP MEDLINE=88100453; PubMed=3424286;
RA Fisher K.L., Gorman C.M., Velhrt G.A., O'Brien D.P., Lawn R.M.;
RT "Cloning and expression of human tissue factor cDNA.";
RL Thromb. Res. 48:89-99(1987).
RN [6]
RP DISULFIDE BONDS, AND PALMITOYLATION.
RX MEDLINE=89000604; PubMed=3166978;
RA Bach R., Konigsberg W.H., Nemerson Y.;

```

```

RT "Human tissue factor contains thioester-linked palmitate and stearate
RT on the cytoplasmic half-cystine.";
RL Biochemistry 27:4227-4231(1988).
RN [7]
RP X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 33-243.
RX MEDLINE=94368785; PubMed=8086403;
RA Muller Y.A., Ultsch M.H., Kelley R.F., de Vos A.M.;
RT "Structure of the extracellular domain of human tissue factor:
RT location of the factor VIIa binding site.";
RL Biochemistry 33:10864-10870(1994).
RN [8]
RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 33-243.
RX MEDLINE=96190957; PubMed=8609606;
RA Muller Y.A., Ultsch M.H., de Vos A.M.;
RT "The crystal structure of the extracellular domain of human tissue
RT factor refined to 1.7-A resolution.";
RL J. Mol. Biol. 256:144-159(1996).
RN [9]
RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 33-251 IN COMPLEX WITH FVIIA.
RX MEDLINE=96175641; PubMed=8598903;
RA Banner D.W., D'Arcy A., Chene C., Winkler F.K., Guha A.,
RA Konigsberg W.H., Nemerson Y., Kirchhofer D.;
RT "The crystal structure of the complex of blood coagulation factor
RT VIIa with soluble tissue factor.";
RL Nature 380:41-46(1996).
RN [10]
RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 37-242 IN COMPLEX WITH FVIIA.
RX MEDLINE=99126538; PubMed=9925787;
RA Zhang E., St Charles R., Tulinsky A.;
RT "Structure of extracellular tissue factor complexed with factor VIIa
RT inhibited with a Bp1 mutant.";
RL J. Mol. Biol. 285:2089-2104(1999).
CC -I- FUNCTION: INITIATES BLOOD COAGULATION BY FORMING A COMPLEX WITH
CC CIRCULATING FACTOR VII OR VIIA. THE [TF:VIIA] COMPLEX ACTIVATES
CC FACTORS IX OR X BY SPECIFIC LIMITED PROTEOLYSIS. TF PLAYS A ROLE IN
CC NORMAL HEMOSTASIS BY INITIATING THE CELL-SURFACE ASSEMBLY AND
CC PROPAGATION OF THE COAGULATION PROTEASE CASCADE.
CC -I- SUBCELLULAR LOCATION: Type I membrane protein.
CC -I- INDUCTION: TF EXPRESSION IS HIGHLY DEPENDENT UPON CELL TYPE. TF
CC CAN ALSO BE INDUCED BY THE INFLAMMATORY MEDIATORS INTERLEUKIN 1
CC AND TNF, AS WELL AS BY ENDOTOXIN, TO APPEAR ON MONOCYTES AND
CC VASCULAR ENDOTHELIAL CELLS AS A COMPONENT OF CELLULAR IMMUNE
CC RESPONSE.
CC -I- SIMILARITY: BELONGS TO THE TISSUE FACTOR FAMILY.
CC -I- DATABASE: NAME=PROW; NOTE=CD guide CD142 entry;
CC WWW="http://www.ncbi.nlm.nih.gov/prow/cd/cd142.htm".
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL: J02931; AAA61150.1; -
DR EMBL: M16553; AAA61151.1; -
DR EMBL: J02846; AAA61152.1; -
DR EMBL: M27436; AAA36734.1; -
DR EMBL: A19048; CAA01438.1; -
DR PIR: A28320; KFHU3.
DR PIR: A43645; A43645.
DR PIR: A47574; A47574.
DR PDB: 1BOY; 10-JUN-96.
DR PDB: 2HFT; 29-JAN-96.
DR PDB: 1DAN; 04-SEP-97.
DR PDB: 1AHW; 19-AUG-98.
DR PDB: 1TFH; 19-AUG-98.
DR PDB: 1FAK; 03-DEC-99.
DR Genew; HGNC:3541; F3.
DR MIM: 134390; -
DR InterPro: IPR000282; Cytok_receptor_2.
DR InterPro: IPR001187; Tissue_factor.

```

```
DR pfam; PF01108; Tissue_fac; 1.
DR PRINTS; PR00346; TISSUEFACTOR.
DR PROSITE; PS00621; TISSUE_FACTOR; 1.
KW Glycoprotein; Blood coagulation; Transmembrane; Signal; Lipoprotein;
KW Palmitate; 3D-structure; Polymorphism.
FT SIGNAL 1 32
FT CHAIN 33 295
FT DOMAIN 33 251
FT TRANSMEM 252 274
FT DOMAIN 275 295
FT SITE 46 48
FT SITE 77 79
FT SITE 190 192
FT CARBOHYD 156 156
FT CARBOHYD 169 169
FT DISULFID 81 89
FT DISULFID 218 241
FT LIPID 277 277
FT VARIANT 163 163
CONFICT 260 260
SEQUENCE 295 AA; 33067 MW; D3486C713ED8EAD0 CRC64;

Query Match 11.4%; Score 163; DB 1; Length 295;
Best Local Similarity 23.4%; Pred. No. 1.1e-07;
Matches 62; Conservative 45; Mismatches 100; Indels 58; Gaps 13;

QY 10 LISFELTGAGTOSTHESLKPQRVQFOSRNFHNLQWQPGRALTGSSVYFVQYKIMESC 69
   | : | | | | : : | | | | : | | |
Db 21 LIGWVFAQVAGASGTTNTVAAYNLWMSKSTNFKTLEWEPKPV---NQVYTVQ-----I 70

QY 70 SMKSSHQKPSGCWOHISCNFGCRTLAKYQGRQWKNKEDCWGTQELSCDLTSE-TSDIQE 128
   | | | | | | | | | | | | | | | |
Db 71 STKSG-----DWKSK--CFYTTDTECDLDEIVKDVQK 101

QY 129 PYRGV-----RAASAGSYSE--WMTPTFTPWMTETKI-DPPVMNTQVNGSLVILHA 179
   | | | | | | | | | | | | | | | |
Db 102 TYLARVESYPAGNVESTGSAGEPLVENSPEFTPYLETNLGQPTIQSFQVGTKNVTVED 161

QY 180 PNLPRYQKEKNVSIEDYY--ELLYRVFIINNSLEKEQKYVEGAHR-AVEIEALTPHSSY 236
   | : | : | : | : | : | : | : | : |
Db 162 ERTLVR-RNNTFLSLRDVFGKDLITLLYWKSSSSGKKTAKTNTNEFLIDVD--KGENY 217

QY 237 C--VVAEIQPMDRRSRQSEERCY 259
   | | | | | | | | | | | | | |
Db 218 CFSVQAVIPSRVTNRKSTDSPEECM 242

QY 3
Db 1
ID INRI_BOVIN STANDARD; PRT; 560 AA.
AC 004790;
DT 01-OCT-1993 (Rel. 27, Created)
DT 01-FEB-1994 (Rel. 28, Last sequence update)
DT 01-NOV-1997 (Rel. 35, Last annotation update)
DE Interferon-alpha/beta receptor alpha chain precursor (IFN-alpha-REC).
GN IFNAR1 OR IFNAR.
OS Bos taurus (Bovine).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovidae; Bovinae; Bos.
OC NCBL_TaxID=9913;
OX [1]
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Lung;
RX MEDLINE=93076908; PubMed=1446745;
RA Mouchel-Vielh E., Lutfalla G., Mogensen K.E., Uze G.;
RT "Specific antiviral activities of the human alpha interferons are
   determined at the level of receptor (IFNAR) structure.";
RL FEBS Lett. 313:255-259(1992).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=93305725; PubMed=8318540;
```

```
RA Lim J.-K., Langer J.A.;
RT "Cloning and characterization of a bovine alpha interferon receptor.";
RL Biochim. Biophys. Acta 1173:314-319(1993).
CC -I- FUNCTION: RECEPTOR FOR INTERFERONS ALPHA AND BETA. BINDING TO TYPE
CC I IFNS TRIGGERS TYROSINE PHOSPHORYLATION OF A NUMBER OF PROTEINS
CC INCLUDING JAKS, TYK2, STAT PROTEINS AND IFN-R ALPHA-AND BETA-
CC SUBUNITS THEMSELVES.
CC -I- SUBCELLULAR LOCATION: Type I membrane protein.
CC -I- SIMILARITY: CONTAINS 2 FIBRONECTIN TYPE III-LIKE DOMAINS.
CC -I- SIMILARITY: BELONGS TO THE CLASS II CYTOKINE FAMILY OF RECEPTORS.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; X68443; CAA48484.1; -.
DR EMBL; L06320; AAA02571.1; -.
DR PIR; S33770; S33770.
DR PIR; S27387; S27387.
DR InterPro; IPR000282; Cytok_receptor_2.
DR InterPro; IPR001187; Tissue_factor.
DR pfam; PF01108; Tissue_fac; 1.
KW Receptor; Transmembrane; Glycoprotein; Signal.
FT SIGNAL 1 24
FT CHAIN 25 560
FT DOMAIN 25 437
FT TRANSMEM 438 458
FT DOMAIN 459 560
FT DISULFID 76 84
FT DISULFID 199 220
FT CARBOHYD 47 47
FT CARBOHYD 55 55
FT CARBOHYD 85 85
FT CARBOHYD 109 109
FT CARBOHYD 172 172
FT CARBOHYD 254 254
FT CARBOHYD 313 313
FT CARBOHYD 377 377
FT CARBOHYD 434 434
FT CONFLICT 422 422
SQ SEQUENCE 560 AA; 63818 MW; 66D76B72861E1D11 CRC64;

Query Match 11.1%; Score 158; DB 1; Length 560;
Best Local Similarity 24.1%; Pred. No. 6.7e-07;
Matches 57; Conservative 38; Mismatches 100; Indels 42; Gaps 8;

QY 21 TOSTHESLKPQRVQFOSRNFHNLQWQPGRALTGSSVYFVQYKIMESCMSKSSHQKPSG 80
   | : | : | : | : | : | : | : | : |
Db 223 TTERHKVPSPENIQINADNQIYVLKWD---YPENATFQAQWLRAFKKIPGNHSD--- 275

QY 81 CWOHISCNFGCRTLAKYQGRQWKNKEDCWGTQELSCDLTSETSDIQEPYGRVRAASAG 140
   | | | | | | | | | | | | | | | |
Db 276 -----KWQIIPNCENVSTSTHCVPREVS--RGITYVRVRAASNGN 313

QY 141 SYSEWSMTPTFTPWMTETKIDPPVMTQV-NGSLVILHAPNLPYRYQKEKNVSIEDYYE 199
   | | | | | | | | | | | | | | | |
Db 314 GTSFWSSEKEFNTKTIIFPPVISVKSVTDDSLHVSAGS-----EESENMSVNQLYP 367

QY 200 LLYRVFIINNSLEKEQKYVEGAHRAVEIEALTPHSSYCVVAEITYQPM--DRSQRS 254
   | : | : | : | : | : | : | : | : |
Db 368 LYEVIWMENTSNAERKYLEKRTNFI-FPDLKPLTYVCYKA---RALIENDRRNKG 420

RESULT 4
ID 110S_MOUSE STANDARD; PRT; 349 AA.
AC 061190;
DT 16-OCT-2001 (Rel. 40, Created)
```

```
DT 16-OCT-2001 (Rel. 40, last sequence update)
DT 15-JUN-2002 (Rel. 41, last annotation update)
DE Interleukin-10 receptor beta chain precursor (IL-10R-B) (IL-10R2)
DE (Cytokine receptor class-II CRF2-4).
GN IL10RB OR CRFB4.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=97199375; PubMed=9047351;
RA Gibbs V.C., Pennica D.;
RT "CRF2-4: isolation of cDNA clones encoding the human and mouse
RT proteins."
RL Gene 186:97-101(1997).
RN [2]
RP CHARACTERIZATION.
RX MEDLINE=98130620; PubMed=9463407;
RA Spencer S.D., Di Marco F., Hookey J., Pitts-Meek S., Bauer M.,
RA Ryan A.M., Sordat B., Gibbs V.C., Aguet M.;
RT "The orphan receptor CRF2-4 is an essential subunit of the interleukin
RT 10 receptor."
RL J. Exp. Med. 187:571-578(1998).
RN [1]
RP FUNCTION: RECEPTOR FOR IL-10 AND IL-22. SERVES AS AN ACCESSORY
RN CHAIN ESSENTIAL FOR THE ACTIVE IL-10 RECEPTOR COMPLEX AND TO
RN INITIATE IL-10-INDUCED SIGNAL TRANSDUCTION EVENTS.
CC -1- SUBCELLULAR LOCATION: Type I membrane protein.
CC -1- SIMILARITY: CONTAINS 2 FIBRONECTIN TYPE III-LIKE DOMAINS.
CC -1- SIMILARITY: BELONGS TO THE CLASS II CYTOKINE FAMILY OF RECEPTORS.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL: U53696; AAC53062.1; -.
DR MGD; MGI:109380; IL10rb.
DR InterPro: IPR000282; Cytok_receptor_2.
DR InterPro: IPR003961; FN_III.
DR SMART; SMO0060; FN3; 1.
KW Receptor; Transmembrane; Glycoprotein; Signal.
FT SIGNAL 1
FT CHAIN 19 POTENTIAL.
FT DOMAIN 20 349 INTERLEUKIN-10 RECEPTOR BETA CHAIN.
FT TRANSMEM 20 220 EXTRACELLULAR (POTENTIAL).
FT TRANSMEM 221 241 POTENTIAL.
FT DOMAIN 242 349 CYTOPLASMIC (POTENTIAL).
FT DOMAIN 113 205 FIBRONECTIN TYPE-III.
FT DOMAIN 66 74 BY SIMILARITY.
FT DISULFID 188 209 BY SIMILARITY.
FT CARBOHYD 49 49 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 102 102 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 161 161 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 199 199 N-LINKED (GLCNAC. . .) (POTENTIAL).
SQ SEQUENCE 349 AA; 39774 MW; 58BA4F6B86330A39 CRC64;
Query Match 10.9%; Score 156; DB 1; Length 349;
Best Local Similarity 26.8%; Pred. No. 5.8e-07;
Matches 72; Conservative 30; Mismatches 89; Indels 78; Gaps 13;
QY 5 CFTGLISFLLTGVAQTOSTHESLKPQVQFQSRNPFHNLQWQ---PGRALTGSSVYF 60
DB 4 CVAGWLGFLYVPAIGMIP-----PPEKVRMSVNFKNILQWEVPAFPKTNLT-----FT 53
QY 61 VOYKIMFS-----CSMKSSHQKPSGCWQHISCNFPGCRTLAKYGQROWKNKEDCWGTQELS 116
DB 54 AQYESYRSFQDHCKRTASTQ-----CDF-----SHLSKYGD----- 84
QY 117 CDLTSETSDIQEPYGRVRAASAGSYSWMSMFPRTPMWETKIDPVMNITQVNGSLVY 176
```

```
DB 85 -----YTVRVRAELADEHSEW-VNVTECPVEDTIIGPPEMQIESLAESLHLR 130
QY 177 LHAPNLPYRYQKE-----KNVSIEDYELLRYV-FIINNSLEKEQKYEGAHAIVEIA 229
DB 131 FSAPQI-----ENEPETWTLKNI-----YDSWAYRYQYWKNGTNEKFQVV--SPYDSEVLRN 180
QY 230 LTPHSSYCVAAEITYQDPMIDRRSQRSEERC 258
DB 181 LEPWTTYCIQVQGLLDQNRGTGEMSEPIC 209
RESULT 5
ID 110R HUMAN STANDARD; PRT; 578 AA.
AC Q13651;
DT 15-JUL-1998 (Rel. 36, Created)
DT 15-JUL-1998 (Rel. 36, last sequence update)
DT 16-OCT-2001 (Rel. 40, last annotation update)
DE Interleukin-10 receptor alpha chain precursor (IL-10R-A) (IL-10R1).
GN IL10RA OR IL10R.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX TISSUE=Lymphoma;
RX MEDLINE=94165477; PubMed=8120391;
RA Liu Y., Wei S.H.-Y., Ho A.S.-Y., de Waal Malefyt R., Moore K.W.;
RT "Expression cloning and characterization of a human IL-10 receptor."
RL J. Immunol. 152:1821-1829(1994).
CC -1- FUNCTION: RECEPTOR FOR IL-10; BINDS IL-10 WITH A HIGH AFFINITY.
CC -1- SUBCELLULAR LOCATION: Type I membrane protein.
CC -1- TISSUE SPECIFICITY: SPLEEN, THYMUS, AND PBMC. FAINT EXPRESSION
CC IN PANCREAS, SKELETAL MUSCLE, BRAIN, HEART, AND KIDNEY. PLACENTA,
CC LUNG, AND LIVER SHOWED INTERMEDIATE LEVELS. MONOCYTES, B CELLS,
CC LARGE GRANULAR LYMPHOCYTES, AND T CELLS EXPRESS HIGH LEVELS OF IL-
CC 10R.
CC -1- SIMILARITY: BELONGS TO THE CLASS II CYTOKINE FAMILY OF RECEPTORS.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL: U00672; AAA17896.1; -.
DR Genew; HGNC:5964; IL10RA.
DR MIM; 146933; -.
DR InterPro: IPR000282; Cytok_receptor_2.
KW Receptor; Transmembrane; Glycoprotein; Signal.
FT SIGNAL 1
FT CHAIN 21 POTENTIAL.
FT DOMAIN 22 578 INTERLEUKIN-10 RECEPTOR ALPHA CHAIN.
FT TRANSMEM 22 235 EXTRACELLULAR (POTENTIAL).
FT TRANSMEM 236 256 POTENTIAL.
FT DOMAIN 257 578 CYTOPLASMIC (POTENTIAL).
FT DISULFID 202 223 POTENTIAL.
FT CARBOHYD 50 50 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 74 74 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 110 110 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 154 154 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 177 177 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 189 189 N-LINKED (GLCNAC. . .) (POTENTIAL).
SQ SEQUENCE 578 AA; 62903 MW; EELB29064338157C CRC64;
Query Match 10.7%; Score 152.5; DB 1; Length 578;
Best Local Similarity 24.5%; Pred. No. 2.2e-06;
Matches 67; Conservative 39; Mismatches 94; Indels 73; Gaps 14;
QY 7 LGFLISFLLTGA-VGTOSTHESLKPQVQFQSRNPFHNLQWQPGRALTGSSVYFVQYKI 65
```



```
Db 9 LAALLSLRLGSDAHGT-----ELPSPSPVWEAEFFHILHWP-----47
QY 66 MFSCSMKSHQKPSGCWQHISCNFPGCCRTLAKYGQROWKNKEDCWGTQLSCDLTSETSD 125
Db 48 -----IPNQSESTCYE-----VALLRYGIESWNSISNC--SQTLSYDLTAVTLD 89
QY 126 I--QEPYGRVRAASAGSYSEWSMT-PRFTPWETKIDPPVYNITQV-----NGSLVITL 177
Db 90 LYHSNGYRARVRAVDGSRHSNMTVTNTRFS-----VDEVTLTVGSVNLEIHNGFILGKI 143
QY 178 HAPNLPYRYQKEKNVSTIEDYELLYRVF-IINNSLEKEQKYEGAHRAVEIEALTPHSS- 235
Db 144 QLP-----RPKMAPANDYTESIFSHFREYEIAIRKVPDGNFTFTHKVKHENSLLTSG 196
QY 236 ----YCVVAEIQPMLDRSQR---SEERCVEI 261
Db 197 EVGEFCVQV---KPSVASRSNKGMSKEECISL 226

MULT 6
HUMAN
110S_HUMAN STANDARD; PRT; 325 AA.
AC Q08334;
DT 01-FEB-1995 (Rel. 31, Created)
DT 01-FEB-1995 (Rel. 31, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Interleukin-10 receptor beta chain precursor (IL-10R-B) (IL-10R2)
DE (Cytokine receptor class-II CRF2-4).
GN IL10RB OR CRFB4.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OX NCBI_Taxid=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Fetal brain;
RX MEDLINE=93300510; PubMed=8314576;
RA Lutfalla G., Gardiner K., Uze G.;
RT "A new member of the cytokine receptor gene family maps on chromosome
RT 21 at less than 35 kb from IFNAR.";
RL Genomics 16:366-373(1993).
[2]
RP SEQUENCE FROM N.A.
RX MEDLINE=96054036; PubMed=7563119;
RA Lutfalla G., McInnis M.G., Antonarakis S.E., Uze G.;
RT "Structure of the human CRFB4 gene: comparison with its IFNAR
RT neighbor.";
RL J. Mol. Evol. 41:338-344(1995).
[3]
CHARACTERIZATION.
RX MEDLINE=97459974; PubMed=9312047;
RA Kottenko S.V., Krause C.D., Izotova L.S., Pollack B.P., Wu W.,
RA Pestka S.;
RT "Identification and functional characterization of a second chain of
RT the interleukin-10 receptor complex.";
RL EMBO J. 16:5894-5903(1997).
[4]
CHARACTERIZATION.
RX MEDLINE=20469498; PubMed=10875937;
RA Xie M.-H., Aggarwal S., Ho W.-H., Foster J., Zhang Z., Stinson J.,
RA Wood W.I., Goddard A.D., Gurney A.L.;
RT "Interleukin (IL)-22, a novel human cytokine that signals through the
RT interferon receptor-related proteins CRF2-4 and IL-22R.";
RL J. Biol. Chem. 275:31335-31339(2000).
[5]
RP FUNCTION: RECEPTOR FOR IL-10 AND IL-22. SERVES AS AN ACCESSORY
RP CHAIN ESSENTIAL FOR THE ACTIVE IL-10 RECEPTOR COMPLEX AND TO
RP INITIATE IL-10-INDUCED SIGNAL TRANSDUCTION EVENTS.
[6]
RP SUBCELLULAR LOCATION: Type I membrane protein.
[7]
RP SIMILARITY: CONTAINS 2 FIBRONECTIN TYPE III-LIKE DOMAINS.
[8]
RP SIMILARITY: BELONGS TO THE CLASS II CYTOKINE FAMILY OF RECEPTORS.
[9]
This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
```

```
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL, Z17227; CAA78933.1; -.
DR EMBL, U08988; AAA86872.1; -.
DR PIR, A47003; A47003.
DR HSSP, P13726; 1TFH.
DR Genew; HGNC:5965; IL10RB.
DR MIM; 123889; -.
DR InterPro; IPR00282; Cytok_receptor_2.
DR InterPro; IPR001187; Tissue_factor.
DR Pfam; PF01108; Tissue_fac; 1.
DR Receptor; Transmembrane; Glycoprotein; Signal.
FT SIGNAL 1 19
FT CHAIN 20 325
FT DOMAIN 20 220
FT TRANSMEM 221 242
FT DOMAIN 243 325
FT DOMAIN 113 205
FT DISULFID 66 74
FT DISULFID 188 209
FT CARBOHYD 49 49
FT CARBOHYD 68 68
FT CARBOHYD 102 102
FT CARBOHYD 161 161
FT CONFLICT 124 124
FT CONFLICT 269 273
FT CONFLICT 274 325
SQ SEQUENCE 325 AA; 37011 MW; 66706C79F8514B23 CRC64;

Query Match 10.5%; Score 149.5; DB 1; Length 325;
Best Local Similarity 24.1%; Pred. No. 2.1e-06;
Matches 57; Conservative 32; Mismatches 89; Indels 59; Gaps 8;

QY 30 PQRVQFQSRNFHNLQWQGRALTGN--SSVYFVQYKIMFSCSMKSSHQKPSGCWQHISC 87
Db 24 PENVRMNSVNEFKNLQWESPAFAKGNLTFTAQYLSYRIF-----62
QY 88 NFGCRTLAKYGRQWKNKEDCWGTQLSCDLTSETSDIQEPYRG---RVRAASAGSYS 143
Db 63 -----QDKCMNTLTTECDSSLSK-----YGDHTLRVRAFEDEHS 98
QY 144 EWSMTPRFTPWETKIDPPVYNITQVNSLLYLHAPNLPYRYQ--KEKNVSIEDYELL 201
Db 99 DW-VNITPCPYDDTTIGPPGMQVEVLADSLHMRFLAPKIENEYETWTMKNV---YNSWT 153
QY 202 YRVFIINNSLEKEQKYEGAHRAVEIEALTPHSSYCVVAEIQPMLDRRSQSRSEERC 258
Db 154 YNVQYWKNGTEDEKQITPQYDFEV-LRNLEPWTYYCVQVRGFLPDRNKAGEWSEPCV 209

RESULT 7
TF_BOVIN
ID TF_BOVIN STANDARD; PRT; 292 AA.
AC P30931;
DT 01-JUL-1993 (Rel. 26, Created)
DT 01-JUL-1993 (Rel. 26, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Tissue factor precursor (TF) (Coagulation factor III).
GN F3.
OS Bos taurus (Bovine).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidea;
OC Bovidae; Bovinae; Bos.
OX NCBI_Taxid=9913;
RN [1]
RP SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.
RC TISSUE=Adrenal gland;
RX MEDLINE=92109720; PubMed=1764065;
RA Takayenoki Y., Muta T., Miyata T., Iwanaga S.;
```

"cDNA and amino acid sequences of bovine tissue factor.";
Biochem. Biophys. Res. Commun. 181:1145-1150(1991).
-1- FUNCTION: INITIATES BLOOD COAGULATION BY FORMING A COMPLEX WITH
CIRCULATING FACTOR VII OR VIIA. THE [TF:VIIA] COMPLEX ACTIVATES
FACTORS IX OR X BY SPECIFIC LIMITED PROLYSIS. TF PLAYS A ROLE IN
NORMAL HEMOSTASIS BY INITIATING THE CELL-SURFACE ASSEMBLY AND
PROPAGATION OF THE COAGULATION PROTEASE CASCADE.
-1- SUBCELLULAR LOCATION: Type I membrane protein.
-1- SIMILARITY: BELONGS TO THE TISSUE FACTOR FAMILY.

This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
or send an email to license@isb-sib.ch).

EMBL; S74147; AAB20755.1; -.
PIR; JQ1319; KFB03.
HSSP; P24055; 1A21.
InterPro; IPR001187; Tissue_factor.
InterPro; IPR001187; Tissue_factor.
DR Pfam; PF01108; Tissue_fac; 1.
DR PRINTS; PR00346; TISSUEFACTOR.
DR PROSITE; PS00621; TISSUE_FACTOR; 1.
KW Glycoprotein; Blood coagulation; Transmembrane; Signal; Lipoprotein;
KW Palmitate.
FT SIGNAL 1 35
FT CHAIN 36 292 TISSUE FACTOR.
FT DOMAIN 36 248 EXTRACELLULAR (POTENTIAL).
FT TRANSMEM 249 271 POTENTIAL.
FT DOMAIN 272 292 CYTOPLASMIC (POTENTIAL).
FT SITE 46 48 WKS MOTIF.
FT CARBOHYD 43 43 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 153 153 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 181 181 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT DISULFID 81 89 BY SIMILARITY.
FT DISULFID 215 238 BY SIMILARITY.
FT LIPID 274 274 PALMITATE (BY SIMILARITY).
SQ SEQUENCE 292 AA; 32475 MW; 5E471D92BFCE163 CRC64;

Query Match 9.7%; Score 138.5; DB 1; Length 292;
Best Local Similarity 22.6%; Pred. No. 1.9e-05;
Matches 59; Conservative 43; Mismatches 104; Indels 55; Gaps 12;

QY 10 LISFELTGAGTQSTHESLKPQRVQFQSRNFHNLQWQGRALTGNSVYFVQYKIMFSC 69
1 LFGVLVIGAGVAGTIDVVAAYNITWKTSTNFKTILEWPKPI-----NHVYTVQIS----- 71
QY 70 SMKSSHQKPSGCWQHISCNFPGCRTLAKYGQROWKKNKEDCWGTQELSCDLTSE-TSDIOE 128
72 -----PRLG--NWKNK--CFYTTNTECDVTDEIVKNVRE 101
DB 129 PYYGRVRAASAGSYSE-----WSMTPRFTPWETKI-DPPYVNITQVNGSLVILHAPNL 182
DB 102 TYLARVLSTPADTSSSTVEPPFTNSPEFTPYLETNLGQPTIQSHEQVGTKLNVTVQDART 161
QY 183 PYYRQEKKNVSIEDYY--ELLYRVFIINNSLEKEQKYEGAHRAVEIEALTPHSSYC-- 237
DB 162 LVR-ANSAFLSLRDVFGKDLNVTLLYWKASSTGKKKATNTNGFLIDVD--KGENYCFH 217
QY 238 VVAEIIYQPMIDRRSQRSEREC 258
DB 218 VQAVILSRVNVQKSPSPKIC 238

RESULT 8
TF_CAVPO STANDARD; PRT; 289 AA.
ID TF_CAVPO
AC Q9JLU8;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)

DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Tissue factor precursor (TF) (Coagulation factor III).
GN F3.
OS Cavia porcellus (Guinea pig).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Hystriognathi; Caviidae; Cavia.
OX NCBI_Taxid-10141;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Lung;
RX MEDLINE=20206020; Pubmed=10744153;
RA Shi R.J., Li W.Z., Marder V.J., Sporn L.A.;
RT "Cloning of guinea pig tissue factor cDNA: comparison of primary
structure among six mammalian species.";
RL Thromb. Haemost. 83:455-461(2000).
CC -1- FUNCTION: INITIATES BLOOD COAGULATION BY FORMING A COMPLEX WITH
CIRCULATING FACTOR VII OR VIIA. THE [TF:VIIA] COMPLEX ACTIVATES
FACTORS IX OR X BY SPECIFIC LIMITED PROLYSIS. TF PLAYS A ROLE IN
NORMAL HEMOSTASIS BY INITIATING THE CELL-SURFACE ASSEMBLY AND
PROPAGATION OF THE COAGULATION PROTEASE CASCADE.
CC -1- SUBCELLULAR LOCATION: Type I membrane protein.
CC -1- SIMILARITY: BELONGS TO THE TISSUE FACTOR FAMILY.

This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
or send an email to license@isb-sib.ch).

EMBL; AF131949; AAF36523.1; -.
HSSP; P13726; 1TFH.
InterPro; IPR001187; Tissue_factor.
InterPro; IPR001187; Tissue_factor.
DR Pfam; PF01108; Tissue_fac; 1.
DR PRINTS; PR00346; TISSUEFACTOR.
DR PROSITE; PS00621; TISSUE_FACTOR; FALSE_NEG.
KW Glycoprotein; Blood coagulation; Transmembrane; Signal; Lipoprotein;
KW Palmitate.
FT SIGNAL 1 32 BY SIMILARITY.
FT CHAIN 33 289 TISSUE FACTOR.
FT DOMAIN 33 247 EXTRACELLULAR (POTENTIAL).
FT TRANSMEM 248 268 POTENTIAL.
FT DOMAIN 269 289 CYTOPLASMIC (POTENTIAL).
FT SITE 44 46 WKS MOTIF.
FT CARBOHYD 75 77 WKS MOTIF.
FT CARBOHYD 41 41 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 111 111 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 151 151 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 164 164 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT DISULFID 79 87 BY SIMILARITY.
FT DISULFID 213 236 BY SIMILARITY.
FT LIPID 271 271 PALMITATE (BY SIMILARITY).
SQ SEQUENCE 289 AA; 32456 MW; 7AB97F8F58199FB1 CRC64;

Query Match 9.6%; Score 136.5; DB 1; Length 289;
Best Local Similarity 24.9%; Pred. No. 2.9e-05;
Matches 50; Conservative 32; Mismatches 52; Indels 67; Gaps 11;

QY 10 LISFELTGAGTQSTHESLKPQRVQFQSRNFHNLQWQGRALTGNSVYFVQYKIMFSC 69
21 LLGWLVQVAGAGGI--PVKPYNLTWKSTNFKTILEWPKPI-----NNVYTVQ-----IST 70
DB 21 LLGWLVQVAGAGGI--PVKPYNLTWKSTNFKTILEWPKPI-----NNVYTVQ-----IST 70
QY 70 SMKSSHQKPSGCWQHISCNFPGCRTLAKYGQROWKKNKEDCWGTQELSCDLTSETS-DIOE 128
DB 71 ALSD-----WKS-----CFSITATECDLTSEMAPNVQ 99
QY 129 PYYGRVRAA--SAGSYSE--WSMTPRFTPWETKIDPP-----VMNIT----- 167
DB 100 TYLARVISLPLNSTGFLEDAVYSNSPEFTPYQETNLGQPKIESFKLVGTKLNVTRDTQT 159
QY 168 --QVNGSLVIT--LHAPNLPY 184

Db 160 LARNGTFLSLRDI FGKNLQY 180

RESULT 9

INRL_HUMAN

ID INRL_HUMAN STANDARD; PRT; 557 AA.

AC P17181;

DT 01-AUG-1990 (Rel. 15, Created)

DT 01-AUG-1990 (Rel. 15, Last sequence update)

DT 16-OCT-2001 (Rel. 40, Last annotation update)

DE Interferon-alpha/beta receptor alpha chain precursor (IFN-alpha-REC).

GN IFNAR1 OR IFNAR.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

OX NCBI_TaxID=9606;

FT [1]

RP SEQUENCE FROM N.A.

RA MEDLINE=90124632; PubMed=2153461;

RT "Genetic transfer of a functional human interferon alpha receptor into mouse cells: cloning and expression of its cDNA.";

RL Cell 60:225-234(1990).

RN [2]

RP SEQUENCE FROM N.A.

RA MEDLINE=92129376; PubMed=1370833;

RA Lutfalla G., Gardiner K., Proudhon D., Vielh E., Uze G.;

RT "The structure of the human interferon alpha/beta receptor gene.";

RL J. Biol. Chem. 267:2802-2809(1992).

RN [3]

RP PHOSPHORYLATION BY TYK2.

RX MEDLINE=95059042; PubMed=7526154;

RA Colamonici O., Yan H., Domanski P., Handa R., Smalley D.,

RA Mulersman J., Witte M., Krishnan K., Krolewski J.;

RT "Direct binding to and tyrosine phosphorylation of the alpha subunit of the type I interferon receptor by p135tyk2 tyrosine kinase.";

RL Mol. Cell. Biol. 14:8133-8142(1994).

CC -1- FUNCTION: RECEPTOR FOR INTERFERONS ALPHA AND BETA. BINDING TO TYPE I IFNS TRIGGERS TYROSINE PHOSPHORYLATION OF A NUMBER OF PROTEINS INCLUDING JAKS, TYK2, STAT PROTEINS AND IFN-R ALPHA- AND BETA-SUBUNITS THEMSELVES.

CC -1- SUBCELLULAR LOCATION: Type I membrane protein.

CC -1- TISSUE SPECIFICITY: IFN RECEPTORS ARE PRESENT IN ALL TISSUES AND EVEN ON THE SURFACE OF MOST IFN-RESISTANT CELLS.

CC -1- PTM: PHOSPHORYLATED ON TYROSINE RESIDUES BY TYK2 TYROSINE KINASE.

CC -1- SIMILARITY: CONTAINS 2 FIBRONECTIN TYPE III-LIKE DOMAINS.

CC -1- SIMILARITY: BELONGS TO THE CLASS II CYTOKINE FAMILY OF RECEPTORS.

CC -----

CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).

CC -----

CC EMBL; J03171; AAM52730.1; -

CC EMBL; X60459; CAA42992.1; -

CC PIR; A32694; A32694.

CC PIR; S17112; S17112.

CC Gene; HGNC:5432; IFNAR1.

CC MIM; 107450; -

CC InterPro; IPR000282; Cytok_receptor_2.

CC Receptor; Transmembrane; Glycoprotein; Signal; Polymorphism;

CC Phosphorylation.

CC SIGNAL 1 27 POTENTIAL.

CC CHAIN 28 557 INTERFERON-ALPHA/BETA RECEPTOR ALPHA CHAIN.

CC DOMAIN 28 436 EXTRACELLULAR (POTENTIAL).

CC TRANSMEM 437 457 POTENTIAL.

CC DOMAIN 458 557 CYTOPLASMIC (POTENTIAL).

CC DISULFID 79 87 BY SIMILARITY.

FT DISULFID 199 220 BY SIMILARITY.

FT MOD_RES 466 466 PHOSPHORYLATION (BY TYK2) (PROBABLE).

FT MOD_RES 481 481 PHOSPHORYLATION (BY TYK2) (PROBABLE).

FT CARBOHYD 50 50 N-LINKED (GLCNAC. . .) (POTENTIAL).

FT CARBOHYD 58 58 N-LINKED (GLCNAC. . .) (POTENTIAL).

FT CARBOHYD 81 81 N-LINKED (GLCNAC. . .) (POTENTIAL).

FT CARBOHYD 88 88 N-LINKED (GLCNAC. . .) (POTENTIAL).

FT CARBOHYD 110 110 N-LINKED (GLCNAC. . .) (POTENTIAL).

FT CARBOHYD 172 172 N-LINKED (GLCNAC. . .) (POTENTIAL).

FT CARBOHYD 254 254 N-LINKED (GLCNAC. . .) (POTENTIAL).

FT CARBOHYD 313 313 N-LINKED (GLCNAC. . .) (POTENTIAL).

FT CARBOHYD 314 314 N-LINKED (GLCNAC. . .) (POTENTIAL).

FT CARBOHYD 376 376 N-LINKED (GLCNAC. . .) (POTENTIAL).

FT CARBOHYD 416 416 N-LINKED (GLCNAC. . .) (POTENTIAL).

FT CARBOHYD 433 433 N-LINKED (GLCNAC. . .) (POTENTIAL).

FT VARIANT 168 168 L -> V.

FT CONFLICT 17 17 /FTID=VAR_002717.

FT SQ SEQUENCE 557 AA; 63525 MW; 0F6744C8A1ADBE73 CRC64;

Query Match 9.6%; Score 136.5; DB 1; Length 557;

Best Local Similarity 20.8%; Pred. No. 6.3e-05;

Matches 54; Conservative 39; Mismatches 115; Indels 51; Gaps 7;

QY 2 PKHCFGLGFLISFLLTGVAQTSTHESLKPQRVQFQSRNFHNLQMPGRALTGNSVYFV 61

Db 217 PVHCT-----KTTVENELPPPENIEVSVQNNVYLMKD---YTYANMTFQV 259

QY 62 QYKIMFSCSMKSSHQKPSGCWQHISCNFPGCRTLAKYGQRQWKNECDWGTELSDLTS 121

Db 260 QWLHAFILKRNPGNH-----LYKWKQIPDCENVKTTQCVFEPQ 295

QY 122 ETSDIQEPYGRVRAASAGSYSEWSMTPRFTPWETKIDPPVAMNITOVNGSLVILHAPN 181

Db 296 NVFO-KGIYLLRVQASDGNNTSFWSSEIKFDTEIQAFLLPPVFNIRSLSDSFHYIGAP- 353

QY 182 LPYRQKEKNVSIEDYVELLYRVFIINNSLEKEQKYEGAHRAVEIALTPHSSYCVAAE 241

Db 354 -----KQSGNTPVIQDPLIYEILFWENTSNAERKIE-KKQDVTPNLKPLTVYCVKAR 407

QY 242 IY--QPMIDRRSQRSEERC 258

Db 408 AHTMDEKLKSSVSFSDAVC 426

RESULT 10

INRL_SHEEP

ID INRL_SHEEP STANDARD; PRT; 560 AA.

AC Q28589; Q95206;

DT 01-NOV-1997 (Rel. 35, Created)

DT 01-NOV-1997 (Rel. 35, Last sequence update)

DT 30-MAY-2000 (Rel. 39, Last annotation update)

DE Interferon-alpha/beta receptor alpha chain precursor (IFN-alpha-REC)

GN IFNAR1 OR IFNAR.

OS Ovis aries (Sheep).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;

OC Bovidae; Caprinae; Ovis.

OX NCBI_TaxID=9940;

RN [1]

RP SEQUENCE FROM N.A.

RC TISSUE=Endometrium;

RX MEDLINE=97135690; PubMed=8981227;

RA Kaluz S., Fisher P.A., Kaluzova M., Sheldrick E.L., Flint A.P.F.;

RT "Structure of an ovine interferon receptor and its expression in endometrium.";

RL J. Mol. Endocrinol. 17:207-215(1996).

RN [2]

RP SEQUENCE FROM N.A.

RC TISSUE=Endometrium;

RX MEDLINE=98006426; PubMed=9348203;

RA Han C.-S., Mathialagan N., Klemann S.W., Roberts R.M.;

RT "Molecular cloning of ovine and bovine type I interferon receptor
RT subunits from uteri, and endometrial expression of messenger
RT ribonucleic acid for ovine receptors during the estrous cycle and
RT pregnancy.";

RL Endocrinology 138:4757-4767(1997).

CC -I- FUNCTION: RECEPTOR FOR INTERFERONS ALPHA AND BETA. BINDING TO TYPE
CC I IFNS TRIGGERS TYROSINE PHOSPHORYLATION OF A NUMBER OF PROTEINS
CC INCLUDING JAKS, TYK2, STAT PROTEINS AND IFN-R ALPHA-AND BETA-
CC SUBUNITS THEMSELVES.

CC -I- SUBCELLULAR LOCATION: Type I membrane protein.

CC -I- TISSUE SPECIFICITY: EXPRESSED IN ALL TISSUES EXAMINED EXCEPT
CC CONCEPTUS AT DAY 15 OF PREGNANCY.

CC -I- SIMILARITY: CONTAINS 2 FIBRONECTIN TYPE III-LIKE DOMAINS.

CC -I- SIMILARITY: BELONGS TO THE CLASS II CYTOKINE FAMILY OF RECEPTORS.

CC -----

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
or send an email to license@isb-sib.ch).

CC	- - - - -
DR	EMBL; X95939; CAA65183.1; -. .
DR	EMBL; U65978; AAB84231.1; -. .
DR	InterPro; IPR000282; CytoK_receptor_2.
KW	Receptor; Transmembrane; Glycoprotein; Signal.
FT	SIGNAL 1 24 BY SIMILARITY.
FT	CHAIN 25 560 INTERFERON-ALPHA/BETA RECEPTOR ALPHA CHAIN.
FT	DIRECTED TO EXTRACELLULAR (POTENTIAL).
FT	POTENTIAL.
FT	CYTOPLASMIC (POTENTIAL).
FT	BY SIMILARITY.
FT	DISULFID 76 84 BY SIMILARITY.
FT	DISULFID 199 220 BY SIMILARITY.
FT	CARBOHYD 47 47 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD 55 55 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD 85 85 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD 108 108 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD 109 109 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD 172 172 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD 222 222 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD 285 285 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD 313 313 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD 359 359 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD 377 377 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD 434 434 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD 434 434 S -> G (IN REF. 2).
FT	CONFLICT 352 352 A -> D (IN REF. 2).
FT	CONFLICT 522 522
SEQUENCE	560 AA; 63918 MW; E7198A1905D4805C CRC64;

	Query Match	9.6%;	Score 136.5;	DB 1,	Length 560;	
	Best Local Similarity	23.3%;	Pred No. 6.3e-05;			
	Matches 57;	Conservative 32;	Mismatches 109;	Indels 47;	Gaps 8;	
QY	21 TQSTHESLKPQRVQFQS RNFHNILMQPGRALTGNSSVFVQYKIMFGCSMKSSHOKPSG 80	: : :	: :	: :	:	
Db	223 TTERHKVPSPENVOINVDNQAAYVLKMD---YPYESTTFQAQWLRAFLKKIPGKH----- 273	: : :	: :	: :	:	
QY	81 CWOHTSCNFPGCRTLAKYGQRQWKNKEDCWGTQLISC---DLTSETSDIQEPYYGRVA 136	: :	:	:		
Db	274 -----SNKWQQLPCNCENVTTTHCVFPRDIFS----MGIYYVRVA 309					
QY	137 ASAGSYSSEMSMTPRFTPMWETKIDPPVMNTIQQV-NGSLLVILHAPNLPRYRQKEKNVSIE 195	: : :	: :::	: :	: : :	
Db	310 SNGNGTSFWSEEKEFNTEVKPIIFPVISMKSITDDSLHVSVAS-----ESENMSVN 363					
QY	196 DYVELLYRVFIINNSLEKEQKYVEGAHRAVEIALTPHSSYCVAE--ITYPMLDRRSQR 253	: :	: :	: :	:	
Db	364 QLYPLVYEVIWFMENTSNAERKVL E-KRFDETFPNLKPLTVYCVKARALIENDRWNKGSYS 422					
QY	254 SEERC 258	:				

Db 423 SDTV C 427

RESULT 11

INR1_MOUSE	STANDARD;	PRT;	590 AA.
ID			

DT	01-FEB-1994 (Rel. 28, Created)
AC	P33090;

DM	30-MAY-2000	38	Last annotation update)
DT	01-FEB-1994	(Rel. 28,	Last sequence update)

DE Interferon- α /beta receptor alpha chain precursor (IFN- α -REC).

OS Mus musculus (Mouse).

Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

OX	NCBI_TaxID=10090
PN	111

RP SEQUENCE FROM N.A.

RA Uze G., Lutfalla G., Bandu M.T., Proudhon D., Mogensen K.E.;

RT in homospecific or heterospecific background.";

RL P₁OC. Natl. Acad. Sci. U.S.A. 89:4774-4778 (1992).

CC I IENS TRIGGERS TYROSINE PHOSPHORYLATION OF A NUMBER OF PROTEINS
CC TWO INDUCTION OF TYROSINE PHOSPHORYLATION OF A NUMBER OF PROTEINS
CC TWO INDUCTION OF TYROSINE PHOSPHORYLATION OF A NUMBER OF PROTEINS

CC SUBUNITS THEMSELVES.

CC -I- SIMILARITY: CONTAINS 2 FIBRONECTIN TYPE III-LIKE DOMAINS.

CC -1- SIMILARITY: BELONGS TO THE CLASS OF CLOSING PHRASES OF INDEFINITE

This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL Outstation in Heidelberg.

CC the European Bioinformatics Institute. There are no restrictions on its

modified and this statement is not removed. Usage by and for commercial

or send an email to license@isb.ch;
 cc license@isb.ch (see <http://www.isb.ch/announcements>)

```
cc -----
db -----
EWBT : M89641 : AAA37890 1 : -
```

DR PIR; A45283; A45283.

DR InterPro; IPR000282; cytok_receptor_2.

FT	SIGNAL	1	26	POTENTIAL.
----	--------	---	----	------------

FT	CHAIN	2 /	390	CHAIN.	INIEKTRON ALFMA/BEIN AKCEKTRON ALFMA
FT	CHAIN	2 /	390	CHAIN.	INIEKTRON ALFMA/BEIN AKCEKTRON ALFMA

FT	DOMAIN	27	429	EXTRACELLULAR (POTENTIAL).
FT	DOMAIN	27	429	EXTRACELLULAR (POTENTIAL).

FT	DOMAIN	450	590	CYTOPLASMIC (POTENTIAL).

FT	DISULFID	199	220	BY SIMILARITY.
----	----------	-----	-----	----------------

FT	109	109	N-LINKED (GLCNAC. . .) (POTENTIAL).
FI	43	43	N-LINKED (GLCNAC. . .) (POTENTIAL):
CARBOHYD	109	109	N-LINKED (GLCNAC. . .) (POTENTIAL):

FT	FT	FT	FT
181	181	181	181
CARBOHYD	CARBOHYD	CARBOHYD	CARBOHYD
N-LINKED (GLCNAC. . .)	N-LINKED (GLCNAC. . .)	N-LINKED (GLCNAC. . .)	N-LINKED (GLCNAC. . .)
(POTENTIAL)	(POTENTIAL)	(POTENTIAL)	(POTENTIAL)

FT	CARBOHYD	314	314	N-LINKED (GLCNAC. . .) (POTENTIAL) .
FT	CARBOHYD	314	314	N-LINKED (GLCNAC. . .) (POTENTIAL) .

FT CARBOHYD	409	409	N-LINKED (GLCNAC. . .) (POTENTIAL).
-------------	-----	-----	--------------------------------------

SO	SEQUENCE	590	AA:	65776	MM:	7EC6DEFF370185D3A	CRC64:
F1	CARBOHID	413	413	N	LINKED (OCCUR: 1/1) (POLYMERIZED):		

Current Watch 0 48: score 134 5: DB 1: Length 590:

Best Local Similarity 21.4%; Pred. No. 0.0001;

QY 25 NSSVIF--QINIMFDCBMNDHQNFDCQWZHUJLQCNFLCCNLEHATDCQWZHUJLQCNFLCCNLEHAT

D6 34 NIDVYIIDDNYTLKW-----SSHGESMG-----SVLFS-----AEIRKIDEAANWLVFEC / 8

QY 110 WGTQELSCDLTSETSDIQEPYGRVRAASAGSYSEWSMTPRFTPWETKIDPPVINITQV 169

Db 79 QHTTTCESLDTNVIKTQFRVRAEENSTSSWNEVDPIPTTAHMSPEVRLEAE 138


```

OY 170 NCSLLVILHAPNLPYRYQKENVSIEDYYELLYRVFIINNSLEKEQKVEGAHRAVEIEA 229
      : : | | : | : : : : : : : : : : : : : : : : : : : : : : : :
Db 139 DKAILVHISPPG-----QDGNMALEKEKPSFSYTIIRIWQKS-SSDKKTINSTYYVEKIPE 191

OY 230 LTPHSSYCVVAETIYQPMLEDRSQRSERCV 259
      | | : : | : | : | : | : | : | : | : | : | : | : | : | : | :
Db 192 LLPETTYCLEVKAIHPSLKHSNYSTVQCI 221

RESULT 12
TF_RABIT
ID TF_RABIT STANDARD; PRT; 292 AA.
AC P24055;
DT 01-MAR-1992 (Rel. 21, Created)
DT 01-MAR-1992 (Rel. 21, Last sequence update)
DE 16-OCT-2001 (Rel. 40, Last annotation update)
DE Tissue factor precursor (TF) (Coagulation factor III).
GN F3.
OX Oryctolagus cuniculus (Rabbit).
RA Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
NCBI_ML TaxID=9986;
NCBI_TaxID=9986;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Heart;
RX MEDLINE=91200676; PubMed=1840552;
RA Andrews B.S., Rehmentulla A., Fowler B.J., Edgington T.S., Mackman N.;
RT "Conservation of tissue factor primary sequence among three mammalian
RT species.";
RL Gene 98:265-269(1991).
RN [2]
RP SEQUENCE OF 33-292 FROM N.A.
RC STRAIN=New Zealand white; TISSUE=Brain;
RX MEDLINE=92081032; PubMed=1746002;
RA Pawashe A., Ezekowitz M., Lin T.C., Horton R., Bach R., Konigsberg W.;
RT "Molecular cloning, characterization and expression of cDNA for
RT rabbit brain tissue factor.";
RL Thromb. Haemost. 66:315-320(1991).
RN [3]
RP X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 36-240.
RX MEDLINE=98266351; PubMed=9605315;
RA Muller Y.A., Kelley R.F., de Vos A.M.;
RT "Hinge bending within the cytokine receptor superfamily revealed by
RT the 2.4 A crystal structure of the extracellular domain of rabbit
RT tissue factor.";
RL Protein Sci. 7:1106-1115(1998).
CC -!- FUNCTION: INITIATES BLOOD COAGULATION BY FORMING A COMPLEX WITH
CC CIRCULATING FACTOR VII OR VIIA. THE [TF:VIIA] COMPLEX ACTIVATES
CC FACTORS IX OR X BY SPECIFIC LIMITED PROTOCOLS. TF PLAYS A ROLE IN
CC NORMAL HEMOSTASIS BY INITIATING THE CELL-SURFACE ASSEMBLY AND
CC PROPAGATION OF THE COAGULATION PROTEASE CASCADE.
CC -!- SUBCELLULAR LOCATION: Type I membrane protein.
CC -!- TISSUE SPECIFICITY: BRAIN, HEART.
CC -!- SIMILARITY: BELONGS TO THE TISSUE FACTOR FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; M55390; AAA63469.1; -.
CC EMBL; X53521; CAA37597.1; -.
CC PIR; JU0441; KERB3.
CC PIR; S23681; S23681.
CC PDB; 1A21; 27-MAY-98.
CC InterPro; IPR000282; Cytok_receptor_2.
CC InterPro; IPR001187; Tissue_factor.
CC Pfam; PF01108; Tissue_fac; 1.
CC PRINTS; PR00346; TISSUEFACTOR.

```

DR PROSITE; PS00621; TISSUE_FACTOR; 1.
KW Glycoprotein; Blood coagulation; Transmembrane; Signal; Lipoprotein;
KW Palmitate; 3D-structure.

FT	SIGNAL	1	32		TISSUE FACTOR.
FT	CHAIN	33	292		EXTRACELLULAR (POTENTIAL).
FT	DOMAIN	33	250		POTENTIAL.
FT	TRANSMEM	251	271		CYTOPLASMIC (POTENTIAL).
FT	DOMAIN	272	292		WKS MOTIF.
FT	SITE	44	46		WKS MOTIF.
FT	SITE	75	77		N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	41	41		N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	114	114		N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	154	154		N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	167	167		N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD	182	182		N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	DISULFID	79	87		
FT	DISULFID	216	239		
FT	LIPID	274	274		
SO	SEQUENCE	292 AA;	32738 MW;	4860A1CADBACEF71 CRC64;	

Query Match 9.3%; Score 132.5; DB 1; Length 292;
Best Local Similarity 22.2%; Pred. No. 6.7e-05;
Matches 62; Conservative 39; Mismatches 89; Indels 89; Gaps 13;

```

QY 10 LISFELTGAGTOSTHESLKPQRVQFQSRRNFHNILQWOPGRALTGNSSVFYVQKIMESC 69
   |: :| | | | : : : :| | | | | | | | | | | | | | | | | | | | | | | |
Db 21 LLGWLQAQVARADT--TGRAYNLTWKSTNFKTILEWEPE-----KSIDHV-YTVQIST 70

QY 70 SMKSSHOKPSGCWOHISCNPFCRTLAKYGQROWKNKEDCWGTQLSCDLTSE-TSDIQE 128
   ::| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 71 RLEN-----WKSK-CFLTAETCDLTDENVKDVQG 99

QY 129 PYYGRV----RAASAGSYSE--WSMTPRFTPWETKIDPV-----MNTQVN 170
   | || | | | | : : : : : : | | | | | | | | | | | | | | | | | | | |
Db 100 TYMARVLSPARRNGNTGPPEEPFRNSPEFTPYLDTNIGOPTIQSFQVGTKLVNTVQD 159

QY 171 GSLVLHLAPNLPLYR--YOKEKNVSIEDYEELY-----RVFIINNSLEKEQKYEGA 221
   || : | | | | | : : | | | | | | | | | | | | | | | | | | | | | |
Db 160 ARTLVRRNGTFLLRAVEGKDUN-----YLLYYWRASSGTGKKATATTNTNEFLIDVDKGE 213

QY 222 HRAVEIEALTPHSSYCVAETIYQM LDRRSQRSEERCVE 260
   : : : : | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 214 NYCFSVQAVIPSR-----KRKQRSPESLTE 238

RESULT 13.
TF_RAT
ID TF_RAT STANDARD; PRT; 295 AA.
AC P42533;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Tissue factor precursor (TF) (Coagulation factor III).
CF3.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
[1]
RP SEQUENCE FROM N.A.
RC STRAIN=Sprague-Dawley;
RX MEDLINE=97108126; PubMed=8950776;
RA Taby O., Rosenfield C.L., Bogdanov V., Nemerson Y., Taubman M.B.;
RT "Cloning of the rat tissue factor cDNA and promoter: identification
RT of a serum-response region.";
RL Thromb. Haemost. 76:697-702(1996).
CC -!- FUNCTION: INITIATES BLOOD COAGULATION BY FORMING A COMPLEX WITH
CC CIRCULATING FACTOR VII OR VIIA. THE [TF:VIIA] COMPLEX ACTIVATES
CC FACTORS IX OR X BY SPECIFIC LIMITED PROLYSIS. TF PLAYS A ROLE IN
CC NORMAL HEMOSTASIS BY INITIATING THE CELL-SURFACE CASCADE.
CC PROPAGATION OF THE COAGULATION PROTEASE CASCADE.
CC -!- SUBCELLULAR LOCATION: Type I membrane protein.
CC -!- SIMILARITY: BELONGS TO THE TISSUE FACTOR FAMILY.
```



```
Db 92 DWTWAYEAKVLSVPRRNSVHGDQDLVHGEHPFTNAPKFLPYRDTNLGQVYIQOFEQD 151
QY 164 ---MNTQVNGSLVILHAPNLPYRQKEKNVSIEDYELLYRVFIINNSLEKEQKVEG 220
Db 152 GRKLNYYKDSLTLVRKNGFTLRLQVFGKDLG---YIITYRK--GSSYGRKNTNT 204
QY 221 AHRVETALTPHSSYC--VVAETIYQPMIDRRSQSRSERCVE 260
Db 205 NEFSIDE---EGVSYCFVQAMIFSRKTNQNSPGSSVTCVE 243

RESULT 15
INGR_HUMAN
ID INGR_HUMAN STANDARD; PRT; 489 AA.
AC P15260;
DT 01-APR-1990 (Rel. 14, Created)
DT 01-APR-1990 (Rel. 14, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
PT Interferon-gamma receptor alpha chain precursor (CDw119).
PF IFNGR1.
OC Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=89003065; PubMed=2971451;
RA Aguet M., Dembic Z., Meriin G.;
RT "Molecular cloning and expression of the human interferon-gamma
RT receptor.";
RL Cell 55:273-280(1988).
RN [2]
RP SEQUENCE FROM N.A.
RA Phillipore B.;
RL Submitted (JUL-1999) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RC TISSUE=Prostate;
RA Strausberg R.;
RL Submitted (MAR-2001) to the EMBL/GenBank/DBJ databases.
RN [4]
RP DISULFIDE BONDS, PARTIAL SEQUENCE, AND MUTAGENESIS.
RX MEDLINE=93183911; PubMed=8443182;
RA Stueber D., Friedlein A., Fountoulakis M., Lahm H.-W., Garotta G.;
RT "Alignment of disulfide bonds of the extracellular domain of the
RT interferon gamma receptor and investigation of their role in
RT biological activity.";
RL Biochemistry 32:2423-2430(1993).
RN [5]
RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 26-248.
RX MEDLINE=95342235; PubMed=7617032;
RA Walter M.R., Windsor W.T., Nagabhushan T.L., Lundell D.J., Lunn C.A.,
RA Zauodny P.J., Narula S.K.;
RT "Crystal structure of a complex between interferon-gamma and its
RT soluble high-affinity receptor.";
RL Nature 376:230-235(1995).
RN [6]
RP X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 28-122 IN COMPLEX WITH
RP ANTIBODY.
RX MEDLINE=98035727; PubMed=9367779;
RA Sogabe S., Stuart F., Henke C., Bridges A., Williams G., Birch A.,
RA Winkler F.K., Robinson J.A.;
RT "Neutralizing epitopes on the extracellular interferon gamma receptor
RT (IFNGAMMAR) alpha-chain characterized by homolog scanning mutagenesis
RT and X-ray crystal structure of the A6 fab-IFNGAMMAR1-108 complex.";
RL J. Mol. Biol. 273:882-897(1997).
RN [7]
RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF COMPLEX WITH ING.
RX MEDLINE=20444407; PubMed=10986460;
RA Thiel D.J., Le Du M.-H., Walter R.L., D'Arcy A., Chene C.,
RA Fountoulakis M., Garotta G., Winkler F.K., Ealick S.E.;
RT "Observation of an unexpected third receptor molecule in the crystal
```

```
RT structure of human interferon-gamma receptor complex.";
RL Structure 8:927-936(2000).
CC -!- FUNCTION: RECEPTOR FOR INTERFERON GAMMA. TWO RECEPTORS BIND ONE
CC INTERFERON-GAMMA DIMER.
CC -!- SUBUNIT: MONOMER.
CC -!- SUBCELLULAR LOCATION: Type I membrane protein.
CC -!- PTM: PHOSPHORYLATED AT SER/THR RESIDUES.
CC -!- SIMILARITY: CONTAINS 2 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.
CC -!- SIMILARITY: CONTAINS 2 FIBRONECTIN TYPE III-LIKE DOMAINS.
CC -!- SIMILARITY: BELONGS TO THE CLASS II CYTOKINE FAMILY OF RECEPTORS.
CC -!- DATABASE: NAME=PROW; NOTE=CD guide CDw119 entry;
CC WWW="http://www.ncbi.nlm.nih.gov/prow/cd/cdw119.htm".
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL: J03143; AA52731.1; -
DR EMBL: AL050337; CAB53062.1; -
DR EMBL: BC005333; AAH05333.1; -
DR PIR: A31555; A31555.
DR PDB: 1JRH; 25-MAR-98.
DR PDB: 1FG9; 11-AUG-00.
DR GlycosuitedB; P15260; -.
DR Genew; HGNC:5439; IFNGR1.
DR MIM; 107470; -.
DR MIM; 209950; -.
DR InterPro; IPR000282; Cyto_k_receptor_2.
DR Receptor; Transmembrane; Glycoprotein; Signal; Phosphorylation;
KW Immunoglobulin domain; 3D-structure.
FT SIGNAL 1 17
FT CHAIN 18 489
FT DOMAIN 18 245
FT TRANSMEM 246 266
FT DOMAIN 267 489
FT DISULFID 77 85
FT DISULFID 122 167
FT DISULFID 195 200
FT DISULFID 214 235
FT CARBOHYD 34 34
FT CARBOHYD 79 79
FT CARBOHYD 86 86
FT CARBOHYD 179 179
FT CARBOHYD 240 240
SQ SEQUENCE 489 AA; 54404 MW; DCF9E574D8F47400 CRC64;

Query Match 8.6%; Score 122.5; DB 1; Length 489;
Best Local Similarity 20.1%; Pred. No. 0.001;
Matches 56; Conservative 49; Mismatches 103; Indels 71; Gaps 10;

QY 9 FLISFLTGVA---GTQSTHESL--KPQRYQFQSRNHNILQWQPGRALTGNSSVYFVQ 62
Db 5 FLPLPVMQGVSRRAEMGTADLGSSVPTPIVNTIESYMNPIVYV-----E 49
QY 63 YKIM-----FSCSMKSSHOKPSGCWQHISCNPPGCRTLAKYGQORQWKNKEDCGTQELSC 117
Db 50 YQIMPQVYVTFVEVKN-----YGVKNSEWIDACINISHHYC 85
QY 118 DLTSETSDIQEPYRGRVRAASAGSYSEWMTPTPTWMTKIDPVMNTQVNGSLVIL 177
Db 86 NISDHVGDPSNSLWVRKARVGQKESAVAKSEFAVCRDGIKIPKLDIRKEQIMIDI 145
QY 178 HAPNLPYRQKEKNVSIEDY-----YELLYRVFIINNSLEKEQKVE-----GAH 222
Db 146 FHPVSFVNGDEQEV---DYDPETTCYIRVYVYVVMNGSEIQYKILQKEDDCDEIQCQ 201
QY 223 RAVETALTPHSSYCVAETIYQPMIDRRSQSRSERCVEI 261
Db 202 LAIPVSSL--NSQYCSAEGVLHVMGVTTTEKSKEVCITI 238
```

Mon Dec 23 08:50:22 2002

us-09-964-994-2.rsp

Page 12

Search completed: December 22, 2002, 10:11:37
Job time : 28 secs

GenCore version 5.1.3
Copyright (c) 1993 - 2002 Compugen Ltd.

OM protein - protein search, using sw model

Run on: December 22, 2002, 10:09:37 ; Search time 26 Seconds

(without alignments)
296.493 Million cell updates/sec

Title: US-09-964-994-2

Perfect score: 1427

Sequence: 1 MPKHCFGLGFLISFELTGAVG.....YQPMIDRSQSRSERCVEIP 262

Scoring table: BLOSUM62

Searched: 262574 seqs, 29422922 residues

1 number of hits satisfying chosen parameters: 262574

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued_Patents_AA:*

- 1: /cgn2_6/ptodata/1/iaa/5A.COMB.pep:*
- 2: /cgn2_6/ptodata/1/iaa/5B.COMB.pep:*
- 3: /cgn2_6/ptodata/1/iaa/6A.COMB.pep:*
- 4: /cgn2_6/ptodata/1/iaa/6B.COMB.pep:*
- 5: /cgn2_6/ptodata/1/iaa/PCTUS.COMB.pep:*
- 6: /cgn2_6/ptodata/1/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	311	21.8	221	2	US-08-943-087-52
2	310	21.7	221	2	US-08-943-087-50
3	310	21.7	221	2	US-08-943-087-56
4	310	21.7	553	2	US-08-943-087-2
5	310	21.7	553	2	US-08-943-087-14
6	310	21.7	553	2	US-08-943-087-16
7	310	21.7	553	2	US-08-943-087-18
8	310	21.7	553	2	US-08-943-087-20
9	310	21.7	553	2	US-08-943-087-22
10	310	21.7	553	2	US-08-943-087-24
11	310	21.7	553	2	US-08-943-087-26
12	310	21.7	553	2	US-08-943-087-28
13	310	21.7	553	2	US-08-943-087-30
14	310	21.7	553	2	US-08-943-087-32
15	310	21.7	553	2	US-08-943-087-34
16	310	21.7	553	2	US-08-943-087-36
17	310	21.7	553	2	US-08-943-087-38
18	310	21.7	553	2	US-08-943-087-40
19	310	21.7	553	2	US-08-943-087-42
20	310	21.7	553	2	US-08-943-087-44
21	310	21.7	553	2	US-08-943-087-46
22	310	21.7	553	2	US-08-943-087-48
23	308	21.6	221	2	US-08-943-087-54
24	303	21.2	221	2	US-08-943-087-58
25	299	21.0	221	2	US-08-943-087-60
26	240	16.8	574	2	US-08-906-713-2
27	164.5	11.5	575	1	US-08-424-788-2

28	164.5	11.5	575	1	US-08-110-683-4	Sequence 4, Appli
29	164.5	11.5	575	2	US-08-477-166-4	Sequence 4, Appli
30	164.5	11.5	575	2	US-08-472-097-4	Sequence 4, Appli
31	164.5	11.5	575	4	US-09-439-672-4	Sequence 4, Appli
32	164.5	11.5	575	5	PCT-US93-11638-4	Sequence 4, Appli
33	163	11.4	251	1	US-07-882-202A-2	Sequence 2, Appli
34	163	11.4	251	1	US-07-683-682B-4	Sequence 4, Appli
35	163	11.4	251	1	US-08-021-615A-2	Sequence 2, Appli
36	163	11.4	251	1	US-08-321-777-2	Sequence 2, Appli
37	163	11.4	251	1	US-08-463-931-6	Sequence 6, Appli
38	163	11.4	251	1	US-08-464-237A-4	Sequence 4, Appli
39	163	11.4	251	5	PCT-US92-02898A-4	Sequence 4, Appli
40	163	11.4	251	5	PCT-US93-04493-2	Sequence 2, Appli
41	163	11.4	295	1	US-08-463-931-2	Sequence 2, Appli
42	163	11.4	295	2	US-08-372-887-20	Sequence 2, Appli
43	163	11.4	295	4	US-09-224-048A-4	Sequence 4, Appli
44	162	11.4	559	1	US-08-424-788-3	Sequence 3, Appli
45	155	10.9	227	4	US-08-871-572B-14	Sequence 14, Appli

ALIGNMENTS

RESULT 1
US-08-943-087-52
; Sequence 52, Application US/08943087
; Patent No. 5945511
; GENERAL INFORMATION:
; APPLICANT: Lok, Si
; APPLICANT: Kho, Choon J.
; APPLICANT: Jelmeberg, Anna C.
; APPLICANT: Adams, Robyn L.
; APPLICANT: Whitmore, Theodore E.
; APPLICANT: Farrah, Theresa M.
; TITLE OF INVENTION: CYTOKINE RECEPTOR
; NUMBER OF SEQUENCES: 60
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ZymoGenetics, Inc.
; STREET: 1201 Eastlake Avenue East
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98102
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/943,087
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/803,305
; FILING DATE: 20-FEB-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Lunn, Paul G
; REGISTRATION NUMBER: 32,743
; REFERENCE/DOCKET NUMBER: 96-24C1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-442-6627
; TELEFAX: 206-442-6678
; TELEX:
; INFORMATION FOR SEQ ID NO: 52:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 221 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FRAGMENT TYPE: internal
; US-08-943-087-52

Query Match 21.8%; Score 311; DB 2; Length 221;
Best Local Similarity 32.0%; Pred. No. 1.3e-27;
Matches 74; Conservative 33; Mismatches 90; Indels 34; Gaps 3;

29 KPRVQFOSRNFHNILOWOPGRALTGNSSVYFVQYKIMFSCSMKSSHQKPSGCWQHISCN 88
10 KPGNITFLSINMKNVLQWTPPEGLQGVKVTYVQYFI----- 46
89 FPGCRITLAKYGQROWKNKEDCWGTQELSCDLTSETSDIQEPYGRVRAASAGSYSEWSMT 148
47 -----YGQKKWLKSECRNINRTYCDLSAETSDEHYAKYAKAIWGTCKSKWAES 97
149 PRFTPWETKIDPVMNITQVNGSLVILHAPNLPYRYQKEKNVSIEDYY-ELLYRVFII 207
98 GRFYPLETQIGPPEVGLTDEKSISSVLTAPKWKRNPEDLPVSMQIYSNLKYNVSVL 157
208 NNSLEKEQKYEGAHRAVEIEALTPHSSYCVVAETIQPMLDRRSQRSEERC 258
158 NTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVHVESFVPGPPRAQPSSEKOC 207

RESULT 2

US-08-943-087-50
Sequence 50, Application US/08943087
Patent No. 5945511

GENERAL INFORMATION:

APPLICANT: Lok, Si
APPLICANT: Kho, Choon J.
APPLICANT: Jelmeberg, Anna C.
APPLICANT: Adams, Robyn L.
APPLICANT: Whitmore, Theodore E.
APPLICANT: Farrah, Theresa M.
TITLE OF INVENTION: CYTOKINE RECEPTOR
NUMBER OF SEQUENCES: 60
CORRESPONDENCE ADDRESS:
ADDRESSEE: Zymogenetics, Inc.
STREET: 1201 Eastlake Avenue East
CITY: Seattle
STATE: WA
COUNTRY: USA
ZIP: 98102

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/943,087

FILING DATE:

CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/803,305
FILING DATE: 20-FEB-1997
ATTORNEY/AGENT INFORMATION:
NAME: Luun, Paul G
REGISTRATION NUMBER: 32,743
REFERENCE/DOCKET NUMBER: 96-24C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-442-6627
TELEFAX: 206-442-6678
TELEX:

INFORMATION FOR SEQ ID NO: 50:

SEQUENCE CHARACTERISTICS:
LENGTH: 221 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
FRAGMENT TYPE: internal
US-08-943-087-50

Query Match 21.7%; Score 310; DB 2; Length 221;
Best Local Similarity 32.0%; Pred. No. 1.7e-27;

Matches 74; Conservative 33; Mismatches 90; Indels 34; Gaps 3;

29 KPRVQFOSRNFHNILOWOPGRALTGNSSVYFVQYKIMFSCSMKSSHQKPSGCWQHISCN 88
10 KPGNITFLSINMKNVLQWTPPEGLQGVKVTYVQYFI----- 46
89 FPGCRITLAKYGQROWKNKEDCWGTQELSCDLTSETSDIQEPYGRVRAASAGSYSEWSMT 148
47 -----YGQKKWLKSECRNINRTYCDLSAETSDEHYAKYAKAIWGTCKSKWAES 97
149 PRFTPWETKIDPVMNITQVNGSLVILHAPNLPYRYQKEKNVSIEDYY-ELLYRVFII 207
98 GRFYPLETQIGPPEVALTDEKSISSVLTAPKWKRNPEDLPVSMQIYSNLKYNVSVL 157
208 NNSLEKEQKYEGAHRAVEIEALTPHSSYCVVAETIQPMLDRRSQRSEERC 258
158 NTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVHVESFVPGPPRAQPSSEKOC 207

RESULT 3

US-08-943-087-56
Sequence 56, Application US/08943087
Patent No. 5945511

GENERAL INFORMATION:

APPLICANT: Lok, Si
APPLICANT: Kho, Choon J.
APPLICANT: Jelmeberg, Anna C.
APPLICANT: Adams, Robyn L.
APPLICANT: Whitmore, Theodore E.
APPLICANT: Farrah, Theresa M.
TITLE OF INVENTION: CYTOKINE RECEPTOR
NUMBER OF SEQUENCES: 60
CORRESPONDENCE ADDRESS:
ADDRESSEE: Zymogenetics, Inc.
STREET: 1201 Eastlake Avenue East
CITY: Seattle
STATE: WA
COUNTRY: USA
ZIP: 98102

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/943,087

FILING DATE:

CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/803,305
FILING DATE: 20-FEB-1997
ATTORNEY/AGENT INFORMATION:
NAME: Luun, Paul G
REGISTRATION NUMBER: 32,743
REFERENCE/DOCKET NUMBER: 96-24C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-442-6627
TELEFAX: 206-442-6678
TELEX:

INFORMATION FOR SEQ ID NO: 56:

SEQUENCE CHARACTERISTICS:
LENGTH: 221 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
FRAGMENT TYPE: internal
US-08-943-087-56

Query Match 21.7%; Score 310; DB 2; Length 221;
Best Local Similarity 31.6%; Pred. No. 1.7e-27;
Matches 73; Conservative 34; Mismatches 90; Indels 34; Gaps 3;

QY 89 FPGCRTLAKYGOROWKNKEDCWGTQELSCDLTSETSDIOEPYIGRVRAASAGSYSEWSMT 148
Db 76 -----YGOKKWLKSECRNINRTYCDLSAETSDYEHQYAKVKAIWGTCKSKWAES 126
QY 149 PRFTPWETKIDPVMNITQVNGSLVILHAPNLPYRYQKEKNVSIEDY-ELLYRVFI 207
Db 127 GREYPLETQIGPREVALTTDEKSI SVLTAPEKWKRNPEDLPSMOQIYSNLKYNSVL 186
QY 208 NNSLEKEQKVYEGAHRAVEIEALTPHSSYCVVAEIIYQPMIDRRSQSEERC 258
Db 187 NTKSNRTWSQCVTNHTLV-LTWLEPNLTLYCVHVESFVPGPPRAQPSERKC 236

RESULT 6

US-08-943-087-16
; Sequence 16, Application US/08943087
; Patent No. 5945511
; GENERAL INFORMATION:
; APPLICANT: Lok, Si
; APPLICANT: Kho, Choon J.
; APPLICANT: Jelmeberg, Anna C.
; APPLICANT: Adams, Robyn L.
; APPLICANT: Whitmore, Theodore E.
; APPLICANT: Farrah, Theresa M.
; TITLE OF INVENTION: CYTOKINE RECEPTOR
; NUMBER OF SEQUENCES: 60
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ZymoGenetics, Inc.
; STREET: 1201 Eastlake Avenue East
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98102
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/943,087
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/803,305
; FILING DATE: 20-FEB-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Lunn, Paul G
; REGISTRATION NUMBER: 32,743
; REFERENCE/DOCKET NUMBER: 96-24C1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-442-6627
; TELEFAX: 206-442-6678
; TELEX:
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 553 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FRAGMENT TYPE: internal
; US-08-943-087-16

Query Match 21.7%; Score 310; DB 2; Length 553;
Best Local Similarity 32.0%; Pred. No. 7.2e-27;
Matches 74; Conservative 33; Mismatches 90; Indels 34; Gaps 3;

QY 29 KPQRVQFQSRNFHNLQWOPGRALTONSSVYFVQYKIMFSCSMKSSHQKPSGCWQHISCN 88
Db 39 KPNITFLINMKNVLQWTPPEGLOGVKVTVYQYFI----- 75
QY 89 FPGCRTLAKYGOROWKNKEDCWGTQELSCDLTSETSDIOEPYIGRVRAASAGSYSEWSMT 148
Db 89 FPGCRTLAKYGOROWKNKEDCWGTQELSCDLTSETSDIOEPYIGRVRAASAGSYSEWSMT 148

Db 76 -----YGOKKWLKSECRNINRTYCDLSAETSDYEHQYAKVKAIWGTCKSKWAES 126
QY 149 PRFTPWETKIDPVMNITQVNGSLVILHAPNLPYRYQKEKNVSIEDY-ELLYRVFI 207
Db 127 GREYPLETQIGPREVALTTDEKSI SVLTAPEKWKRNPEDLPSMOQIYSNLKYNSVL 186
QY 208 NNSLEKEQKVYEGAHRAVEIEALTPHSSYCVVAEIIYQPMIDRRSQSEERC 258
Db 187 NTKSNRTWSQCVTNHTLV-LTWLEPNLTLYCVHVESFVPGPPRAQPSERKC 236

RESULT 7

US-08-943-087-18
; Sequence 18, Application US/08943087
; Patent No. 5945511
; GENERAL INFORMATION:
; APPLICANT: Lok, Si
; APPLICANT: Kho, Choon J.
; APPLICANT: Jelmeberg, Anna C.
; APPLICANT: Adams, Robyn L.
; APPLICANT: Whitmore, Theodore E.
; APPLICANT: Farrah, Theresa M.
; TITLE OF INVENTION: CYTOKINE RECEPTOR
; NUMBER OF SEQUENCES: 60
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ZymoGenetics, Inc.
; STREET: 1201 Eastlake Avenue East
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98102
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/943,087
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/803,305
; FILING DATE: 20-FEB-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Lunn, Paul G
; REGISTRATION NUMBER: 32,743
; REFERENCE/DOCKET NUMBER: 96-24C1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-442-6627
; TELEFAX: 206-442-6678
; TELEX:
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 553 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FRAGMENT TYPE: internal
; US-08-943-087-18

Query Match 21.7%; Score 310; DB 2; Length 553;
Best Local Similarity 32.0%; Pred. No. 7.2e-27;
Matches 74; Conservative 33; Mismatches 90; Indels 34; Gaps 3;

QY 29 KPQRVQFQSRNFHNLQWOPGRALTONSSVYFVQYKIMFSCSMKSSHQKPSGCWQHISCN 88
Db 39 KPNITFLINMKNVLQWTPPEGLOGVKVTVYQYFI----- 75
QY 89 FPGCRTLAKYGOROWKNKEDCWGTQELSCDLTSETSDIOEPYIGRVRAASAGSYSEWSMT 148
Db 76 -----YGOKKWLKSECRNINRTYCDLSAETSDYEHQYAKVKAIWGTCKSKWAES 126

OY 149 PRFTPWETKIDPPVMTITQVNGSLVILHAPNLPYRYQKEKNVSIEDYY-ELLYRVFII 207
DB 127 GRFPFLETQIGPREVALTTDEKSISVVLTAPEKWKRPEDLPVSMQOITYSNLKYNSVL 186
OY 208 NNSLEKEQKVEGAHRAVEIEALTPHSSYCVVAEIQPMLDRRSQSEERC 258
DB 187 NTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVHVESFVPGPPRAQPSEROC 236

RESULT 8

US-08-943-087-20

; Sequence 20, Application US/08943087
; Patent No. 5945511

; GENERAL INFORMATION:

; APPLICANT: Lok, Si
; APPLICANT: Kho, Choon J.
; APPLICANT: Jelmerberg, Anna C.
; APPLICANT: Adams, Robyn L.
; APPLICANT: Whitmore, Theodore E.
; APPLICANT: Farrah, Theresa M.
; TITLE OF INVENTION: CYTOKINE RECEPTOR
; NUMBER OF SEQUENCES: 60
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: ZymoGenetics, Inc.
; STREET: 1201 Eastlake Avenue East
; CITY: Seattle
; STATE: WA
; COUNTRY: USA

; ZIP: 98102
; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/943,087
; FILING DATE:
; CLASSIFICATION: 536

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/803,305
; FILING DATE: 20-FEB-1997

; ATTORNEY/AGENT INFORMATION:
; NAME: Lunn, Paul G
; REGISTRATION NUMBER: 32,743
; REFERENCE/DOCKET NUMBER: 96-24C1

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-442-6627
; TELEFAX: 206-442-6678

; TELEX:
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:

; LENGTH: 553 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FRAGMENT TYPE: internal
; US-08-943-087-20

Query Match 21.7%; Score 310; DB 2; Length 553;
Best Local Similarity 32.0%; Pred. No. 7.2e-27;
Matches 74; Conservative 33; Mismatches 90; Indels 34; Gaps 3;

OY 29 KPQRYQFQSRNFHNILOPGRALTGNSVYFVQYKIMFSCSMKSSHQKPSGCWQHISCN 88
DB 39 KPNITFLSINMKNVLOWTPPEGLQGVKVTYTVQYFI----- 75
OY 89 FPGCRTLAKYGQROWKKNKEDCWGTOELSCDLTSETSDIOEPYIGRYRAASAGSYSEWSMT 148
DB 76 -----YGQKWLKNSKCRNINRTYCDLSAETSDYEHQYAKYKAIWGTCKSKWAES 126
OY 149 PRFTPWETKIDPPVMTITQVNGSLVILHAPNLPYRYQKEKNVSIEDYY-ELLYRVFII 207
DB 127 GRFPFLETQIGPREVALTTDEKSISVVLTAPEKWKRPEDLPVSMQOITYSNLKYNSVL 186

DB 127 GRFPFLETQIGPREVALTTDEKSISVVLTAPEKWKRPEDLPVSMQOITYSNLKYNSVL 186
OY 208 NNSLEKEQKVEGAHRAVEIEALTPHSSYCVVAEIQPMLDRRSQSEERC 258
DB 187 NTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVHVESFVPGPPRAQPSEROC 236

RESULT 9

US-08-943-087-22

; Sequence 22, Application US/08943087
; Patent No. 5945511

; GENERAL INFORMATION:

; APPLICANT: Lok, Si
; APPLICANT: Kho, Choon J.
; APPLICANT: Jelmerberg, Anna C.
; APPLICANT: Adams, Robyn L.
; APPLICANT: Whitmore, Theodore E.
; APPLICANT: Farrah, Theresa M.
; TITLE OF INVENTION: CYTOKINE RECEPTOR
; NUMBER OF SEQUENCES: 60
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: ZymoGenetics, Inc.
; STREET: 1201 Eastlake Avenue East
; CITY: Seattle
; STATE: WA
; COUNTRY: USA

; ZIP: 98102
; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/943,087
; FILING DATE:
; CLASSIFICATION: 536

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/803,305
; FILING DATE: 20-FEB-1997

; ATTORNEY/AGENT INFORMATION:
; NAME: Lunn, Paul G
; REGISTRATION NUMBER: 32,743
; REFERENCE/DOCKET NUMBER: 96-24C1

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-442-6627
; TELEFAX: 206-442-6678

; TELEX:
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:

; LENGTH: 553 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FRAGMENT TYPE: internal
; US-08-943-087-22

Query Match 21.7%; Score 310; DB 2; Length 553;
Best Local Similarity 32.0%; Pred. No. 7.2e-27;
Matches 74; Conservative 33; Mismatches 90; Indels 34; Gaps 3;

OY 29 KPQRYQFQSRNFHNILOPGRALTGNSVYFVQYKIMFSCSMKSSHQKPSGCWQHISCN 88
DB 39 KPNITFLSINMKNVLOWTPPEGLQGVKVTYTVQYFI----- 75
OY 89 FPGCRTLAKYGQROWKKNKEDCWGTOELSCDLTSETSDIOEPYIGRYRAASAGSYSEWSMT 148
DB 76 -----YGQKWLKNSKCRNINRTYCDLSAETSDYEHQYAKYKAIWGTCKSKWAES 126
OY 149 PRFTPWETKIDPPVMTITQVNGSLVILHAPNLPYRYQKEKNVSIEDYY-ELLYRVFII 207
DB 127 GRFPFLETQIGPREVALTTDEKSISVVLTAPEKWKRPEDLPVSMQOITYSNLKYNSVL 186

OY 208 NNSLEKEQKVEGAHRAVEIEALTPHSSYCVVAEIIYQPMIDRRSQRSEERC 258
DB 187 NTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVHVESFVPGPPRAQPSSEKQC 236

RESULT 10
US-08-943-087-24

; Sequence 24, Application US/08943087
; Patent No. 5945511

GENERAL INFORMATION:

APPLICANT: Lok, Si
APPLICANT: Kho, Choon J.
APPLICANT: Jelmeberg, Anna C.
APPLICANT: Adams, Robyn L.
APPLICANT: Whitmore, Theodore E.
APPLICANT: Farrah, Theresa M.
TITLE OF INVENTION: CYTOKINE RECEPTOR
NUMBER OF SEQUENCES: 60
CORRESPONDENCE ADDRESS:
ADDRESSEE: ZymoGenetics, Inc.
STREET: 1201 Eastlake Avenue East
CITY: Seattle
STATE: WA
COUNTRY: USA
ZIP: 98102

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FASTSEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/943,087
FILING DATE:
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/803,305
FILING DATE: 20-FEB-1997
ATTORNEY/AGENT INFORMATION:
NAME: Lunn, Paul G
REGISTRATION NUMBER: 32,743
REFERENCE/DOCKET NUMBER: 96-24C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-442-6627
TELEFAX: 206-442-6678
TELEX:

INFORMATION FOR SEQ ID NO: 24:

SEQUENCE CHARACTERISTICS:
LENGTH: 553 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
FRAGMENT TYPE: internal
US-08-943-087-24

Query Match 21.7%; Score 310; DB 2; Length 553;
Best Local Similarity 32.0%; Pred. No. 7.2e-27;
Matches 74; Conservative 33; Mismatches 90; Indels 34; Gaps 3;

OY 29 KPQRVQFQSRNHNILQWOPGRALTGNSVYFVQYKIMFSCSMKSSHQKPSGCWQHISCN 88
DB 39 KPNITFLSINMKNVLQWTPREGLVGVKVTYTVQYFI----- 75
OY 89 FPGCRTLAKYGQROWKNKEDCWGTQELSCDLTSETSDIQEPYVGRVRAASAGSYSEWSMT 148
DB 76 -----YGQKKWLNKSECRNINRTYCDLSAETSDYEHQYAKVKAIWGTCKSKWAES 126
OY 149 PRFTPWETKIDPPVMTITQVNGSLVILHAPNLPYRYQKEKNVSIEDYY-ELLYRVFTI 207
DB 127 GRFPFLETQIGPPEVALTTDEKSIYVLTAFPEKWKRNPEDLPVSMQIYSLNLYKYNVSVL 186
OY 208 NNSLEKEQKVEGAHRAVEIEALTPHSSYCVVAEIIYQPMIDRRSQRSEERC 258
DB 187 NTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVHVESFVPGPPRAQPSSEKQC 236

DB 187 NTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVHVESFVPGPPRAQPSSEKQC 236

RESULT 11
US-08-943-087-26

; Sequence 26, Application US/08943087
; Patent No. 5945511

GENERAL INFORMATION:

APPLICANT: Lok, Si
APPLICANT: Kho, Choon J.
APPLICANT: Jelmeberg, Anna C.
APPLICANT: Adams, Robyn L.
APPLICANT: Whitmore, Theodore E.
APPLICANT: Farrah, Theresa M.
TITLE OF INVENTION: CYTOKINE RECEPTOR
NUMBER OF SEQUENCES: 60
CORRESPONDENCE ADDRESS:
ADDRESSEE: ZymoGenetics, Inc.
STREET: 1201 Eastlake Avenue East
CITY: Seattle
STATE: WA
COUNTRY: USA
ZIP: 98102

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FASTSEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/943,087
FILING DATE:
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/803,305
FILING DATE: 20-FEB-1997
ATTORNEY/AGENT INFORMATION:
NAME: Lunn, Paul G
REGISTRATION NUMBER: 32,743
REFERENCE/DOCKET NUMBER: 96-24C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-442-6627
TELEFAX: 206-442-6678
TELEX:

INFORMATION FOR SEQ ID NO: 26:

SEQUENCE CHARACTERISTICS:
LENGTH: 553 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
FRAGMENT TYPE: internal
US-08-943-087-26

Query Match 21.7%; Score 310; DB 2; Length 553;
Best Local Similarity 32.0%; Pred. No. 7.2e-27;
Matches 74; Conservative 33; Mismatches 90; Indels 34; Gaps 3;

OY 29 KPQRVQFQSRNHNILQWOPGRALTGNSVYFVQYKIMFSCSMKSSHQKPSGCWQHISCN 88
DB 39 KPNITFLSINMKNVLQWTPREGLVGVKVTYTVQYFI----- 75
OY 89 FPGCRTLAKYGQROWKNKEDCWGTQELSCDLTSETSDIQEPYVGRVRAASAGSYSEWSMT 148
DB 76 -----YGQKKWLNKSECRNINRTYCDLSAETSDYEHQYAKVKAIWGTCKSKWAES 126
OY 149 PRFTPWETKIDPPVMTITQVNGSLVILHAPNLPYRYQKEKNVSIEDYY-ELLYRVFTI 207
DB 127 GRFPFLETQIGPPEVALTTDEKSIYVLTAFPEKWKRNPEDLPVSMQIYSLNLYKYNVSVL 186
OY 208 NNSLEKEQKVEGAHRAVEIEALTPHSSYCVVAEIIYQPMIDRRSQRSEERC 258
DB 187 NTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVHVESFVPGPPRAQPSSEKQC 236


```

; Patent No. 5945511
; GENERAL INFORMATION:
; APPLICANT: Lok, Si
; APPLICANT: Kho, Choon J.
; APPLICANT: Jelmerberg, Anna C.
; APPLICANT: Adams, Robyn L.
; APPLICANT: Whitmore, Theodore E.
; APPLICANT: Farrar, Theresa M.
; TITLE OF INVENTION: CYTOKINE RECEPTOR
; NUMBER OF SEQUENCES: 60
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Zymogenetics, Inc.
; STREET: 1201 Eastlake Avenue East
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98102
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/943,087
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/803,305
; FILING DATE: 20-FEB-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Lunn, Paul G
; REGISTRATION NUMBER: 32,743
; REFERENCE/DOCKET NUMBER: 96-24C1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-442-6627
; TELEFAX: 206-442-6678
; TELEX:
; INFORMATION FOR SEQ ID NO: 32:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 553 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FRAGMENT TYPE: internal
; US-08-943-087-32

Query Match
Best Local Similarity 32.0%; Score 310; DB 2; Length 553;
Matches 74; Conservative 33; Mismatches 90; Indels 34; Gaps 3;

OY 29 KPRVQFQSRNHNILQWQGRALTGNSSVYFVQYKIMFSCSMKSSHOKPSGCWQHISCN 88
DB 39 KPRNITFLSINMKNVLTQWTPPEGLQGVKVTYVQYFI----- 75
OY 89 FPGCRTLAKYGGORQKKNKEDCWGTQELSCDLTSETSDIQEPYGRVRAASAGSYSEWSMT 148
DB 76 -----YQKKWLKSECRNINRTYCDLSAETSDYEHQYAKVKAIWGTCKSKWAES 126
OY 149 PRFTPWETKIDPYVMNITQVNGSLVILHAPNLPYRYQKEKNVSIEDY-ELLYRVFTI 207
DB 127 GRFYPLETQIGPREVALTTDEKISVLTAPKWKRNPEDELPSVMOQIYSNLKYNVSVL 186
OY 208 NNSLEKEQKVEGAHRAVEIALTPHSSYCVVAEIQPMLDRRSQRSEERC 258
DB 187 NTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVHVESFVGPDPRAQPSSEKQC 236

RESULT 15
US-08-943-087-34
; Sequence 34, Application US/08943087
; Patent No. 5945511
; GENERAL INFORMATION:

```

```

; APPLICANT: Lok, Si
; APPLICANT: Kho, Choon J.
; APPLICANT: Jelmerberg, Anna C.
; APPLICANT: Adams, Robyn L.
; APPLICANT: Whitmore, Theodore E.
; APPLICANT: Farrar, Theresa M.
; TITLE OF INVENTION: CYTOKINE RECEPTOR
; NUMBER OF SEQUENCES: 60
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Zymogenetics, Inc.
; STREET: 1201 Eastlake Avenue East
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98102
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/943,087
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/803,305
; FILING DATE: 20-FEB-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Lunn, Paul G
; REGISTRATION NUMBER: 32,743
; REFERENCE/DOCKET NUMBER: 96-24C1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-442-6627
; TELEFAX: 206-442-6678
; TELEX:
; INFORMATION FOR SEQ ID NO: 34:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 553 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FRAGMENT TYPE: internal
; US-08-943-087-34

Query Match
Best Local Similarity 32.0%; Score 310; DB 2; Length 553;
Matches 74; Conservative 33; Mismatches 90; Indels 34; Gaps 3;

OY 29 KPRVQFQSRNHNILQWQGRALTGNSSVYFVQYKIMFSCSMKSSHOKPSGCWQHISCN 88
DB 39 KPRNITFLSINMKNVLTQWTPPEGLQGVKVTYVQYFI----- 75
OY 89 FPGCRTLAKYGGORQKKNKEDCWGTQELSCDLTSETSDIQEPYGRVRAASAGSYSEWSMT 148
DB 76 -----YQKKWLKSECRNINRTYCDLSAETSDYEHQYAKVKAIWGTCKSKWAES 126
OY 149 PRFTPWETKIDPYVMNITQVNGSLVILHAPNLPYRYQKEKNVSIEDY-ELLYRVFTI 207
DB 127 GRFYPLETQIGPREVALTTDEKISVLTAPKWKRNPEDELPSVMOQIYSNLKYNVSVL 186
OY 208 NNSLEKEQKVEGAHRAVEIALTPHSSYCVVAEIQPMLDRRSQRSEERC 258
DB 187 NTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVHVESFVGPDPRAQPSSEKQC 236

Search completed: December 22, 2002, 10:15:10
Job time : 28 secs

```


GenCore version 5.1.3
Copyright (c) 1993 - 2002 Compugen Ltd.

OM protein - protein search, using sw model

Run on: December 22, 2002, 10:13:27 ; Search time 20 Seconds
(without alignments)
219.602 Million cell updates/sec

Title: US-09-964-994-2
Perfect score: 1427
Sequence: 1 MPKHCFGLGFLISFLLTGAVG.....YQPMIDRRSQRSERCVETP 262

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 106657 seqs, 16763532 residues
1 number of hits satisfying chosen parameters: 106657

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published_Applications_AA:*
1: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep:*
2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep:*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep:*
4: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep:*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep:*
6: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep:*
7: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep:*
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep:*
9: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep:*
10: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep:*
11: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep:*
12: /cgn2_6/ptodata/1/pubpaa/US10_PUBCOMB.pep:*
13: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep:*
14: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1213	85.0	231	10 US-09-728-911-2	Sequence 2, Appli
2	1213	85.0	231	10 US-09-949-192-6	Sequence 6, Appli
3	1104	77.4	210	10 US-09-728-911-13	Sequence 13, Appli
4	310	21.7	207	10 US-09-746-359A-65	Sequence 65, Appli
5	310	21.7	214	10 US-09-746-359A-63	Sequence 63, Appli
6	310	21.7	217	10 US-09-746-359A-55	Sequence 55, Appli
7	310	21.7	221	10 US-09-746-359A-12	Sequence 12, Appli
8	310	21.7	542	12 US-10-052-586-398	Sequence 398, App
9	310	21.7	547	10 US-09-746-359A-54	Sequence 54, Appli
10	310	21.7	553	10 US-09-746-359A-11	Sequence 11, Appli
11	310	21.7	553	10 US-09-949-192-7	Sequence 7, Appli
12	310	21.7	559	10 US-09-746-359A-62	Sequence 62, Appli
13	310	21.7	571	10 US-09-746-359A-53	Sequence 53, Appli
14	310	21.7	594	10 US-09-746-359A-23	Sequence 23, Appli
15	289	20.3	56	10 US-09-864-761-40289	Sequence 40289, A
16	289	20.3	56	10 US-09-864-761-47623	Sequence 47623, A
17	276	19.3	217	10 US-09-746-359A-38	Sequence 38, Appli
18	276	19.3	514	10 US-09-746-359A-39	Sequence 39, Appli
19	276	19.3	546	10 US-09-746-359A-37	Sequence 37, Appli

20	240	16.8	574	9 US-09-912-672A-2	Sequence 2, Appli
21	240	16.8	574	9 US-10-063-547-164	Sequence 164, App
22	240	16.8	574	10 US-09-728-911-25	Sequence 25, Appli
23	240	16.8	574	10 US-09-870-574-4	Sequence 4, Appli
24	240	16.8	574	12 US-10-006-867-164	Sequence 164, App
25	237	16.6	211	10 US-09-728-911-34	Sequence 34, Appli
26	237	16.6	212	9 US-09-912-672A-6	Sequence 6, Appli
27	237	16.6	560	9 US-09-912-672A-5	Sequence 5, Appli
28	237	16.6	150	10 US-09-746-359A-66	Sequence 66, Appli
29	211	14.8	295	10 US-09-103-067-20	Sequence 20, Appli
30	163	11.4	295	10 US-09-949-192-3	Sequence 3, Appli
31	159.5	11.2	308	9 US-09-912-672A-23	Sequence 23, Appli
32	157.5	11.0	353	9 US-09-912-672A-20	Sequence 20, Appli
33	155.5	10.9	219	10 US-09-355-000-7	Sequence 7, Appli
34	153.5	10.8	219	10 US-09-355-000-8	Sequence 8, Appli
35	152.5	10.7	219	10 US-09-355-000-9	Sequence 9, Appli
36	152.5	10.7	578	9 US-09-912-672A-27	Sequence 27, Appli
37	152	10.7	211	10 US-09-728-911-36	Sequence 36, Appli
38	151.5	10.6	196	10 US-09-746-359A-67	Sequence 67, Appli
39	151.5	10.6	201	9 US-09-912-672A-16	Sequence 16, Appli
40	151.5	10.6	201	10 US-09-746-359A-59	Sequence 59, Appli
41	151.5	10.6	203	10 US-09-746-359A-15	Sequence 15, Appli
42	151.5	10.6	282	9 US-09-912-672A-15	Sequence 15, Appli
43	151.5	10.6	307	10 US-09-746-359A-58	Sequence 58, Appli
44	151.5	10.6	311	9 US-09-978-295A-352	Sequence 352, App
45	151.5	10.6	311	9 US-09-992-598-183	Sequence 183, App

ALIGNMENTS

RESULT 1
US-09-728-911-2
; Sequence 2, Application US/09728911
; Patent No. US20020012669A1
; GENERAL INFORMATION:
; APPLICANT: Presnell, Scott R.
; APPLICANT: Xu, Wenfeng
; APPLICANT: Kindsvogel, Wayne
; APPLICANT: Chen, Zhi
; TITLE OR INVENTION: Human Cytokine Receptor
; FILE REFERENCE: 99-93
; CURRENT APPLICATION NUMBER: US/09/728, 911
; CURRENT FILING DATE: 2000-12-01
; PRIOR APPLICATION NUMBER: US 60/169, 049
; PRIOR FILING DATE: 1999-12-03
; PRIOR APPLICATION NUMBER: US 60/232, 219
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: US 60/244, 610
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 231
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-728-911-2

Query Match 85.0%; Score 1213; DB 10; Length 231;
Best Local Similarity 87.8%; Pred. No. 2.4e-109;
Matches 230; Conservative 0; Mismatches 0; Indels 32; Gaps 1;

QY 1 MPKHCFGLGFLISFLLTGAVGTQSTHESLKPRVQFQSRNFHNLQWQGRALTGNSVYF 60
Db 2 MPKHCFGLGFLISFLLTGAVGTQSTHESLKPRVQFQSRNFHNLQWQGRALTGNSVYF 61
QY 61 VQKIMFSCSMKSSHQKPSGCWQHISCNFPGCRTLAKYGQRQWKKNKEDCWGTQELSCDLT 120
Db 62 VQYKI-----YQQRQWKKNKEDCWGTQELSCDLT 89
QY 121 SETSDIQEPYGRVRAASAGSYSEWSMTPTFTPWETKIDPPVMNITQVNGSLVILHAP 180
Db 90 SETSDIQEPYGRVRAASAGSYSEWSMTPTFTPWETKIDPPVMNITQVNGSLVILHAP 149

QY 181 NLPYRYQKEKNVSIEDYELLRYVFIINNSLEKEQKYEGAHRAVEIEALTPHSSYCVVA 240
DB 150 NLPYRYQKEKNVSIEDYELLRYVFIINNSLEKEQKYEGAHRAVEIEALTPHSSYCVVA 209

QY 241 EITYQMLDRRSQRSEERCVEIP 262
DB 210 EITYQMLDRRSQRSEERCVEIP 231

RESULT 2

US-09-949-192-6
; Sequence 6, Application US/09949192
; Patent No. US20020142292A1
; GENERAL INFORMATION:
; APPLICANT: Parham, Christi L.
; APPLICANT: Gorman, Daniel L.
; APPLICANT: Kurata, Hirokazu
; APPLICANT: Arai, Naoko
; APPLICANT: Sana, Theodore R.
; APPLICANT: Mattson, Jeanine D.
; APPLICANT: Murphy, Erin E.
; APPLICANT: Savkoor, Chetan
; APPLICANT: Grein, Jeffery
; APPLICANT: Smith, Kathleen M.
; APPLICANT: McClanahan, Terrill K.
; TITLE OF INVENTION: MAMMALIAN GENES; RELATED REAGENTS AND METHODS
; FILE REFERENCE: DX01169K
; CURRENT APPLICATION NUMBER: US/09/949,192
; CURRENT FILING DATE: 2001-09-07
; PRIOR APPLICATION NUMBER: 60/231,267
; PRIOR FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 231
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-949-192-6

Query Match 85.0%; Score 1213; DB 10; Length 231;
Best Local Similarity 87.8%; Pred. No. 2.4e-109;
Matches 230; Conservative 0; Mismatches 0; Indels 32; Gaps 1;

QY 1 MPKHGFLGLISFLLTGVAGTQSTHESLKPQVQFQSRNHNILQWQPGRALLTGNSVYF 60
DB 2 MPKHGFLGLISFLLTGVAGTQSTHESLKPQVQFQSRNHNILQWQPGRALLTGNSVYF 61
QY 61 VQKIMFSCSMKSSHQKPSGCMQHISCNFPGCRTLAKYGQRQWKNEKDCWGTQELSCDLT 120
DB 62 VQYKI-----YGRQWKNEKDCWGTQELSCDLT 89
QY 121 SETSDIOEPYGRVRAASAGSYSEWSMTPTFTPWETKIDPPVMNITQVNGSLVILHAP 180
DB 90 SETSDIOEPYGRVRAASAGSYSEWSMTPTFTPWETKIDPPVMNITQVNGSLVILHAP 149
QY 181 NLPYRYQKEKNVSIEDYELLRYVFIINNSLEKEQKYEGAHRAVEIEALTPHSSYCVVA 240
DB 150 NLPYRYQKEKNVSIEDYELLRYVFIINNSLEKEQKYEGAHRAVEIEALTPHSSYCVVA 209
QY 241 EITYQMLDRRSQRSEERCVEIP 262
DB 210 EITYQMLDRRSQRSEERCVEIP 231

RESULT 3

US-09-728-911-13
; Sequence 13, Application US/09728911
; Patent No. US20020012669A1
; GENERAL INFORMATION:
; APPLICANT: Presnell, Scott R.
; APPLICANT: Xu, Wenfeng
; APPLICANT: Kindsvogel, Wayne

; APPLICANT: Chen, zhi
; TITLE OF INVENTION: Human Cytokine Receptor
; FILE REFERENCE: 99-93
; CURRENT APPLICATION NUMBER: US/09/728,911
; CURRENT FILING DATE: 2000-12-01
; PRIOR APPLICATION NUMBER: US 60/169,049
; PRIOR FILING DATE: 1999-12-03
; PRIOR APPLICATION NUMBER: US 60/232,219
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: US 60/244,610
; PRIOR FILING DATE: 2000-10-31
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 13
; LENGTH: 210
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-728-911-13

Query Match 77.4%; Score 1104; DB 10; Length 210;
Best Local Similarity 86.8%; Pred. No. 6.3e-99;
Matches 210; Conservative 0; Mismatches 0; Indels 32; Gaps 1;

QY 21 TQSTHESLKPQVQFQSRNHNILQWQPGRALLTGNSVYFVQKIMFSCSMKSSHQKPSG 80
DB 1 TQSTHESLKPQVQFQSRNHNILQWQPGRALLTGNSVYFVQYKI----- 45
QY 81 CWQHISCNFPGCRTLAKYGQRQWKNEKDCWGTQELSCDLTSETSDIOEPYGRVRAASAG 140
DB 46 -----YGRQWKNEKDCWGTQELSCDLTSETSDIOEPYGRVRAASAG 88
QY 141 SYSEWSMTPTFTPWETKIDPPVMNITQVNGSLVILHAPNLPYRYQKEKNVSIEDYEL 200
DB 89 SYSEWSMTPTFTPWETKIDPPVMNITQVNGSLVILHAPNLPYRYQKEKNVSIEDYEL 148
QY 201 LYRVFIINNSLEKEQKYEGAHRAVEIEALTPHSSYCVVAEITYQMLDRRSQRSEERCVE 260
DB 149 LYRVFIINNSLEKEQKYEGAHRAVEIEALTPHSSYCVVAEITYQMLDRRSQRSEERCVE 208
QY 261 IP 262
DB 209 IP 210

RESULT 4

US-09-746-359A-65
; Sequence 65, Application US/09746359A
; Patent No. US20020042366A1
; GENERAL INFORMATION:
; APPLICANT: Thompson, Penny
; APPLICANT: Foster, Donald C.
; APPLICANT: Xu, Wenfeng
; APPLICANT: Madden, Karen L.
; APPLICANT: Kelly, James D.
; APPLICANT: Sprecher, Cindy A.
; APPLICANT: Blumberg, Hal
; APPLICANT: Eagan, Maribeth A.
; APPLICANT: Jaspers, Stephen R.
; APPLICANT: Chandrasekher, Yashmin A.
; APPLICANT: No. US20020042366A1ak, Julia E.
; TITLE OF INVENTION: Method for Treating Inflammation
; FILE REFERENCE: 99-108
; CURRENT APPLICATION NUMBER: US/09/746,359A
; PRIOR APPLICATION NUMBER: 60/171,969
; PRIOR FILING DATE: 1999-12-23
; PRIOR APPLICATION NUMBER: 60/213,341
; PRIOR FILING DATE: 2000-06-22
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 65
; LENGTH: 207
; TYPE: PRT

PRIOR APPLICATION NUMBER: 60/083559
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/084366
PRIOR FILING DATE: 1998-05-05
PRIOR APPLICATION NUMBER: 60/084414
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084639
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084640
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084643
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/085573
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085579
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085580
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085582
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085700
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/086023
PRIOR FILING DATE: 1998-05-18
PRIOR APPLICATION NUMBER: 60/086392
PRIOR FILING DATE: 1998-05-22
PRIOR APPLICATION NUMBER: 60/086486
PRIOR FILING DATE: 1998-05-22
PRIOR APPLICATION NUMBER: 60/087098
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087208
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088722
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088740
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088811
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088825
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088861

PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088863
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089090
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089908

Query Match 21.7%; Score 310; DB 12; Length 542;
Best Local Similarity 32.0%; Pred. No. 4.6e-22;
Matches 74; Conservative 33; Mismatches 90; Indels 34; Gaps 3;

QY 29 KQRYVQFSRNFHNIQWOPGRALTGNSSVYFVQYKIMFSCSMKSSHQKPSGCWQHISCN 88
DB 28 KRANITFLSINMKNVLQWTPPEGVGKVTYTVQYFI----- 64
QY 89 FPGCRTLAKYGQROWKKNKEDCGTQELSCDLTSETSDIQEPYGRYRAASAGSYSEWSMT 148
DB 65 -----YQKKWLNKSECRNINRTYCDLSAETSDYEHQYAKYKAIWGTCKSKWAES 115
QY 149 PRFTPWETKIDPVMNITQVNGSLVILLHAPNLPYRYQKEKNVSIEDY-ELLYRVFII 207
DB 116 GREYFPLETQIGPREVALTTDEKSISVLLTAPEKWKRNPEDLPVSMQIYSNLKYNVSL 175
QY 208 NNSLEKEQKYVEGAHRAVEIEALTPHSSYCVVAEITQPMIDRSORSEERC 258
DB 176 NTKSNRTWSQCVTNHTLV-LTWLEPNLTLYCVHVESFVGPRAQPSSEKQC 225

RESULT 9
US-09-746-359A-54
Sequence 54, Application US/09746359A
Patent No. US20020042366A1
GENERAL INFORMATION:
APPLICANT: Thompson, Penny
APPLICANT: Foster, Donald C.
APPLICANT: Xu, Wenfeng
APPLICANT: Madden, Karen L.
APPLICANT: Kelly, James D.
APPLICANT: Sprecher, Cindy A.
APPLICANT: Blumberg, Hal
APPLICANT: Eagan, Maribeth A.
APPLICANT: Jaspers, Stephen R.
APPLICANT: Chandrasekhar, Yashmin A.
TITLE OF INVENTION: Method for Treating Inflammation
FILE REFERENCE: 99-108
CURRENT APPLICATION NUMBER: US/09/746,359A
PRIOR FILING DATE: 2001-05-21
PRIOR APPLICATION NUMBER: 60/171,969
PRIOR FILING DATE: 1999-12-23
PRIOR APPLICATION NUMBER: 60/213,341
PRIOR FILING DATE: 2000-06-22
NUMBER OF SEQ ID NOS: 72
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 54
LENGTH: 547
TYPE: PRT
ORGANISM: Homo sapiens
US-09-746-359A-54

Patent No. US20020048763A1

GENERAL INFORMATION:

APPLICANT: Penn, Sharon G.

APPLICANT: Rank, David R.

APPLICANT: Hanzel, David K.

APPLICANT: Chen, Wensheng

TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR

FILE REFERENCE: Aeomica-X-1

CURRENT FILING DATE: 2001-05-23

PRIOR APPLICATION NUMBER: US/09/864,761

PRIOR FILING DATE: 2000-02-04

PRIOR APPLICATION NUMBER: US 60/180,312

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: US 09/632,366

PRIOR FILING DATE: 2000-08-03

PRIOR APPLICATION NUMBER: GB 24263.6

PRIOR FILING DATE: 2000-10-04

PRIOR APPLICATION NUMBER: US 60/236,359

PRIOR FILING DATE: 2000-09-27

PRIOR APPLICATION NUMBER: PCT/US01/00666

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00667

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00669

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00665

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00668

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00663

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00662

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00661

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00670

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: US 60/234,687

PRIOR FILING DATE: 2000-09-21

PRIOR APPLICATION NUMBER: US 09/608,408

PRIOR FILING DATE: 2000-06-30

PRIOR APPLICATION NUMBER: US 09/774,203

PRIOR FILING DATE: 2001-01-29

NUMBER OF SEQ ID NOS: 49117

SOFTWARE: Annomax Sequence Listing Engine vers. 1.1

SEQ ID NO 40289

LENGTH: 56

TYPE: PRT

ORGANISM: Homo sapiens

FEATURE:

OTHER INFORMATION: MAP TO AL158138.1

OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 2.5

OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 2.8

OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 1.7

OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 2.5

OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 3.3

OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 2.9

OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 2.7

OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 2.3

OTHER INFORMATION: SWISSPROT HIT: 028438, EVALUATE 1.20e+00

OTHER INFORMATION: EST_HUMAN HIT: AV714177.1, EVALUATE 4.00e-26

US-09-864-761-40289

Query Match 20.3%; Score 289; DB 10; Length 56;

Best Local Similarity 100.0%; Pred. No. 2.4e-21;

Matches 56; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 158 KIDPPVMNITQVNGSLVILHAPNLPYRYQKEKNVSIEDYYELLYRVFIINNSLEK 213

|||||

Db 1 KIDPPVMNITQVNGSLVILHAPNLPYRYQKEKNVSIEDYYELLYRVFIINNSLEK 56

Search completed: December 22, 2002, 10:21:48
Job time : 22 secs

GenCore version 5.1.3
Copyright (c) 1993 - 2002 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: December 22, 2002, 10:06:17 ; Search time 80 Seconds

(without alignments)
674.804 Million cell updates/sec

Title: US-09-964-994-2

Perfect score: 1427

Sequence: 1 MPKHCFGLGFLISFLLTGAVG.....YQPMIDRRSQSRSEERCVEIP 262

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 671580 seqs, 206047115 residues

671580

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SPTREMBL_21:*
1: sp_archaea:*
2: sp_bacteria:*
3: sp_fungi:*
4: sp_human:*
5: sp_invertebrate:*
6: sp_mammal:*
7: sp_mhc:*
8: sp_organelle:*
9: sp_phage:*
10: sp_plant:*
11: sp_rodent:*
12: sp_virus:*
13: sp_vertebrate:*
14: sp_unclassified:*
15: sp_rvirus:*
16: sp_bacteriaph:*
17: sp_archaeap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	1427	100.0	263	4	Q969J5	Q969J5 homo sapien
2	1213	85.0	231	4	Q96A41	Q96A41 homo sapien
3	664	46.5	130	4	Q96QR0	Q96QR0 homo sapien
4	310	21.7	553	4	Q9UHF4	Q9UHF4 homo sapien
5	310	21.7	553	4	Q96SH8	Q96SH8 homo sapien
6	262	18.4	209	4	Q96SH7	Q96SH7 homo sapien
7	240	16.8	574	4	Q9HB22	Q9HB22 homo sapien
8	187.5	13.1	569	11	Q99ND6	Q99ND6 rattus norv
9	180.5	12.6	341	13	Q9YGC8	Q9YGC8 gallus gall
10	173.5	12.2	294	13	Q90W13	Q90W13 oncorhynch
11	155.5	10.9	569	13	Q9YHW0	Q9YHW0 gallus gall
12	152.5	10.7	442	13	Q9PVJ9	Q9PVJ9 gallus gall
13	149.5	10.5	325	4	Q9BUU4	Q9BUU4 homo sapien
14	149	10.4	351	11	Q8VHM7	Q8VHM7 mus musculu
15	136.5	9.6	557	4	Q8WT22	Q8WT22 homo sapien
16	126	8.8	294	11	Q8R3Q1	Q8R3Q1 mus musculu

17	121.5	8.5	508	13	Q9YHV9	Q9YHV9 gallus gall
18	119.5	8.4	508	13	Q9PVK0	Q9PVK0 gallus gall
19	118.5	8.3	489	4	Q9BY69	Q9BY69 homo sapien
20	115.5	8.1	332	6	Q9GK86	Q9GK86 ovis aries
21	110.5	7.7	332	11	Q63953	Q63953 mus musculu
22	108	7.6	484	4	Q14936	Q14936 homo sapien
23	101.5	7.1	239	4	Q15467	Q15467 homo sapien
24	101.5	7.1	331	4	Q9BUA0	Q9BUA0 homo sapien
25	100.5	7.0	608	6	Q9N0Y7	Q9N0Y7 monodelphis
26	95	6.7	1253	12	Q9JGK8	Q9JGK8 sagiyama vi
27	93	6.5	453	16	Q9K434	Q9K434 streptomyce
28	92.5	6.5	1155	17	Q8TP28	Q8TP28 methanosarc
29	91.5	6.4	424	11	Q91YA2	Q91YA2 mus musculu
30	88	6.2	745	10	Q94LO3	Q94LO3 oryza sativ
31	88	6.2	795	11	Q9CRF5	Q9CRF5 mus musculu
32	88	6.2	2320	5	Q9XVM9	Q9XVM9 trichomonas
33	87.5	6.1	674	13	Q90369	Q90369 coturnix co
34	87.5	6.1	675	13	Q9PSH7	Q9PSH7 gallus gall
35	87.5	6.1	2959	11	Q9JIF1	Q9JIF1 rattus norv
36	87	6.1	304	4	Q9Y5Q4	Q9Y5Q4 homo sapien
37	87	6.1	1145	12	Q87049	Q87049 semliki for
38	87	6.1	1244	12	Q88628	Q88628 chikungunya
39	87	6.1	1384	4	Q75257	Q75257 homo sapien
40	86.5	6.1	392	11	Q99KP5	Q99KP5 mus musculu
41	86.5	6.1	632	6	Q95ML5	Q95ML5 saimiri bol
42	86.5	6.1	1083	5	Q9W071	Q9W071 drosophila
43	86.5	6.1	1289	4	Q9Y2A5	Q9Y2A5 homo sapien
44	86	6.0	477	11	Q91Y85	Q91Y85 mus musculu
45	85.5	6.0	1002	15	Q91M29	Q91M29 human immun

ALIGNMENTS

RESULT 1						
Q969J5						
ID	Q969J5	PRELIMINARY:	PRT:	263	AA.	
AC	Q969J5;					
DT	01-DEC-2001 (TREMBLrel. 19, Created)					
DT	01-DEC-2001 (TREMBLrel. 19, Last sequence update)					
DT	01-MAR-2002 (TREMBLrel. 20, Last annotation update)					
DE	Soluble cytokine class II receptor, long isoform precursor					
DE	(Interleukin 22-binding protein CRF2-10L).					
GN	CRF2-S1 OR IL22BP.					
OS	Homo sapiens (Human).					
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;					
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.					
OX	NCBI_TaxID=9606;					
RN	[1]					
RP	SEQUENCE FROM N.A.					
RC	TISSUE=PLACENTA;					
RX	MEDLINE=21518574; PubMed=11607789;					
RA	Gruenberg B.H., Schoenemeyer A., Weiss B., Toschi L., Kunz S.,					
RA	Wolk K., Asadullah K., Sabat R.,					
RT	"A novel, soluble homologue of the human IL-10					
RT	preferential expression in placenta.";					
RL	Genes Immun. 2:329-334(2001).					
RN	[2]					
RP	SEQUENCE FROM N.A.					
RX	MEDLINE=21286453; PubMed=11390454;					
RA	Kotenko S.V., Izotova L.S., Mirochnitchenko O.V., Esterova E.,					
RA	Dickensheets H., Donnelly R.P., Pestka S.,					
RT	"Identification, cloning, and characterization of a novel soluble					
RT	receptor that binds IL-22 and neutralizes its activity.";					
RT	J. Immunol. 166:7096-7103(2001).					
RL	EMBL: AJ313162; CAC85635.1; -					
DR	EMBL: AY040567; AAK85715.1; -					
DR	InterPro: IPR000282; Cytok_receptor_2.					
KW	SIGNAL					
FT	CHAIN	1	21	POTENTIAL.		
FT		22	263	SOLUBLE CYTOKINE CLASS II RECEPTOR, LONG		
FT				ISOFORM.		
SO	SEQUENCE	263	AA;	30550	MW;	C96ECEC5D78AC79B CRC64;

Query Match 100.0%; Score 1427; DB 4; Length 263;
Best Local Similarity 100.0%; Pred. No. 2.4e-129;
Matches 262; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MPKHCFGLISFLLTGAGTOSTHESLKPQRVQFQSRNFHNLQWQGRALTGSSVVF 60
|||||
DB 2 MPKHCFGLISFLLTGAGTOSTHESLKPQRVQFQSRNFHNLQWQGRALTGSSVVF 61

QY 61 VQYKIMFSCSMKSSHQKPSGCWQHISCNFPGCRTLAKYGGORWKNEKDCWGTQELSCDLT 120
|||||
DB 62 VQYKIMFSCSMKSSHQKPSGCWQHISCNFPGCRTLAKYGGORWKNEKDCWGTQELSCDLT 121

QY 121 SETSDIQEPYGRVRAASAGSYSEMSMTPRFTPWMTKIDPPVMNITQVNGSLVILHAP 180
|||||
DB 122 SETSDIQEPYGRVRAASAGSYSEMSMTPRFTPWMTKIDPPVMNITQVNGSLVILHAP 181

QY 181 NLPYRYQKEKNVSIEDYELLRYVFIINNSLEKEQKYEGAHRAVEIEALTPHSSYCVVA 240
|||||
DB 182 NLPYRYQKEKNVSIEDYELLRYVFIINNSLEKEQKYEGAHRAVEIEALTPHSSYCVVA 241

QY 241 EITYQPMIDRRSQRSEERCVEIP 262
|||||
DB 242 EITYQPMIDRRSQRSEERCVEIP 263

RESULT 2
Q96A41 PRELIMINARY; PRT; 231 AA.

AC 096A41;
DT 01-DEC-2001 (TREMBLrel. 19, Created)
DT 01-DEC-2001 (TREMBLrel. 19, Last sequence update)
DT 01-MAR-2002 (TREMBLrel. 20, Last annotation update)
DE Soluble cytokine class II receptor, short isoform precursor (Interleukin-22 binding protein CRF2-10) (Class II cytokine receptor)
DE (Interleukin-22 binding protein)
DE CRF2-S1 OR IL22BP OR IL22RA2 OR IL-22BP.
GN Homo sapiens (Human).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=MAMMARY GLAND;
RX MEDLINE=21518574; PubMed=11607789;
RA Gruenberg B.H., Schoenemeyer A., Weiss B., Toschi L., Kunz S., Wolk K., Asadullah K., Sabat R.;
RA "A novel, soluble homologue of the human IL-10 receptor with preferential expression in placenta.";
RA Genes Immun. 2:329-334(2001).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=21286453; PubMed=11390454;
RA Kottenko S.V., Izotova L.S., Mirochnitchenko O.V., Esterova E., Dickensheets H., Donnelly R.P., Pestka S.;
RA "Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity.";
RA J. Immunol. 166:7096-7103(2001).
RN [3]
RP SEQUENCE FROM N.A.
RX MEDLINE=21396522; PubMed=11481447;
RA Xu W., Presnell S.R., Parrish-Novak J., Kindsvogel W., Jaspers S., Chen Z., Dillon S.R., Gao Z., Gilbert T., Madden K., Schlutsmeyer S., Yao L., Whitmore T.E., Chandrasekhar Y., Grant F.J., Maurer M., Jelinek L., Storey H., Brender T., Hammond A., Topouzis S., Clegg C.H., Foster D.C.;
RA "A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist.";
RA Proc. Natl. Acad. Sci. U.S.A. 98:9511-9516(2001).
RN [4]
RP SEQUENCE FROM N.A.
RC TISSUE=BREAST;
RA Dumoutier L., Lejeune D., Renauld J.C.;

RT "Cloning and characterization of Interleukin-22 Binding Protein (IL-22BP), a natural antagonist of IL-TIF/IL-22.";
RT Submitted (DEC-2000) to the EMBL/GenBank/DBJ databases.
RL EMBL; AJ313161; CAC85634.1; -
DR EMBL; AY040566; AAK85714.1; -
DR EMBL; AY044429; AAK91775.1; -
DR EMBL; AJ297262; CAC83097.1; -
DR InterPro; IPR000282; Cytok_receptor_2.
KW Receptor; Signal.
FT SIGNAL 1 21 POTENTIAL.
FT CHAIN 22 231 SOLUBLE CYTOKINE CLASS II RECEPTOR, SHORT
FT ISOFORM.
SQ SEQUENCE 231 AA; 26979 MW; 24A6912BFF75100F CRC64;

Query Match 85.0%; Score 1213; DB 4; Length 231;
Best Local Similarity 87.8%; Pred. No. 8.3e-109;
Matches 230; Conservative 0; Mismatches 0; Indels 32; Gaps 1;

QY 1 MPKHCFGLISFLLTGAGTOSTHESLKPQRVQFQSRNFHNLQWQGRALTGSSVVF 60
|||||
DB 2 MPKHCFGLISFLLTGAGTOSTHESLKPQRVQFQSRNFHNLQWQGRALTGSSVVF 61

QY 61 VQYKIMFSCSMKSSHQKPSGCWQHISCNFPGCRTLAKYGGORWKNEKDCWGTQELSCDLT 120
|||||
DB 62 VQYKIMFSCSMKSSHQKPSGCWQHISCNFPGCRTLAKYGGORWKNEKDCWGTQELSCDLT 120

QY 121 SETSDIQEPYGRVRAASAGSYSEMSMTPRFTPWMTKIDPPVMNITQVNGSLVILHAP 180
|||||
DB 90 SETSDIQEPYGRVRAASAGSYSEMSMTPRFTPWMTKIDPPVMNITQVNGSLVILHAP 149

QY 181 NLPYRYQKEKNVSIEDYELLRYVFIINNSLEKEQKYEGAHRAVEIEALTPHSSYCVVA 240
|||||
DB 150 NLPYRYQKEKNVSIEDYELLRYVFIINNSLEKEQKYEGAHRAVEIEALTPHSSYCVVA 209

QY 241 EITYQPMIDRRSQRSEERCVEIP 262
|||||
DB 210 EITYQPMIDRRSQRSEERCVEIP 231

RESULT 3
Q96QRO PRELIMINARY; PRT; 130 AA.

AC 096QRO;
DT 01-DEC-2001 (TREMBLrel. 19, Created)
DT 01-DEC-2001 (TREMBLrel. 19, Last sequence update)
DT 01-MAR-2002 (TREMBLrel. 20, Last annotation update)
DE Interleukin 22-binding protein CRF2-10S.
DE IL22BP.
GN Homo sapiens (Human).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=21286453; PubMed=11390454;
RA Kottenko S.V., Izotova L.S., Mirochnitchenko O.V., Esterova E., Dickensheets H., Donnelly R.P., Pestka S.;
RA "Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity.";
RA J. Immunol. 166:7096-7103(2001).
RL EMBL; AY040568; AAK85716.1; -
DR InterPro; IPR000282; Cytok_receptor_2.
SQ SEQUENCE 130 AA; 15128 MW; A165814C641F5E5B CRC64;

Query Match 46.5%; Score 664; DB 4; Length 130;
Best Local Similarity 79.5%; Pred. No. 3.2e-56;
Matches 124; Conservative 0; Mismatches 0; Indels 32; Gaps 1;

QY 1 MPKHCFGLISFLLTGAGTOSTHESLKPQRVQFQSRNFHNLQWQGRALTGSSVVF 60
|||||
DB 2 MPKHCFGLISFLLTGAGTOSTHESLKPQRVQFQSRNFHNLQWQGRALTGSSVVF 61

QY 61 VQYKIMFSCSMKSSHQKPSGCWQHISCNFPGCRTLAKYGGORWKNEKDCWGTQELSCDLT 120

Db 62 VQYKI-----YQGRQWKNKEDCWGTQELSCDLT 89

QY 121 SETSDIQEPYGRVRAASAGSYSEWSMTPRFTPMWE 156

Db 90 SETSDIQEPYGRVRAASAGSYSEWSMTPRFTPMWE 125

RESULT 4

Q9UHF4 PRELIMINARY; PRT; 553 AA.

DT 01-MAY-2000 (TREMBlrel. 13, Created)

DT 01-MAY-2000 (TREMBlrel. 13, Last sequence update)

DT 01-MAR-2002 (TREMBlrel. 20, Last annotation update)

DE Class II cytokine receptor ZCYTOR7.

GN ZCYTOR7.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

NCBI_TaxID=9606;

[1]

SEQUENCE FROM N.A.

RP Lok S., Kho C., Jelmeberg A., Adams R., Whitmore T., Farrah T.,

RA O'Hara P.;

RT "Homo sapiens cytokine receptor homolog.";

RL Submitted (OCT-1999) to the EMBL/GenBank/DBJ databases.

[2]

SEQUENCE FROM N.A.

RA Presnell S., Gilbert T., Whitmore T., Foster D., Hart C., Lehner J.,

RA Martinez T., Hoffman R., O'Hara P.;

RL Submitted (SEP-1999) to the EMBL/GenBank/DBJ databases.

DR EMBL; AF184971; AAF01320.1; -.

DR HSSP; P13726; 2HFT.

DR InterPro; IPR000282; Cytok_receptor_2.

DR InterPro; IPR001187; Tissue_factor.

DR Pfam; PF01108; Tissue_fac; 1.

KW Receptor.

SEQUENCE 553 AA; 62533 MW; 7C23C8543B114659 CRC64;

Query Match

Best Local Similarity 21.7%; Score 310; DB 4; Length 553;

Matches 74; Conservative 33; Mismatches 90; Indels 34; Gaps 3;

QY 29 KPQRVQFQSRNFHNLQWOPGRALTGNSVYFVQYKIMFSCSMKSSHQKPSGCWQHISCN 88

Db 39 KPANITFLSIMKNVLQWTPPEGLOGVKVYTVQYFI----- 75

89 FPGCRTLAKYQGRQWKNKEDCWGTQELSCDLTSETSDIQEPYGRVRAASAGSYSEWSMT 148

Db 76 -----YQGRQWKNKSECRNINRTYCDLSAETSDYEHQYAKVKAIWGTCKSKWAES 126

QY 149 PRFTPMWETKIDPVVNITQVNGSLVILHAPNLPYRQKEKNVSIEDYY-ELLYRVFTI 207

Db 127 GREYPFLETQIGPPEVALTTDEKISVVLTAPEKWKRNPEDLVPSMQQIYSNLKYNVSVL 186

QY 208 NNSLEKEQKVEGAHRAVEIEALTPHSSYCVVAEIQPMLDRRSQRSEERC 258

Db 187 NTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVHVESFVPGPPRAQPSSEKQC 236

187 NTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVHVESFVPGPPRAQPSSEKQC 236

187 NTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVHVESFVPGPPRAQPSSEKQC 236

187 NTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVHVESFVPGPPRAQPSSEKQC 236

187 NTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVHVESFVPGPPRAQPSSEKQC 236

187 NTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVHVESFVPGPPRAQPSSEKQC 236

187 NTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVHVESFVPGPPRAQPSSEKQC 236

187 NTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVHVESFVPGPPRAQPSSEKQC 236

187 NTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVHVESFVPGPPRAQPSSEKQC 236

187 NTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVHVESFVPGPPRAQPSSEKQC 236

187 NTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVHVESFVPGPPRAQPSSEKQC 236

187 NTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVHVESFVPGPPRAQPSSEKQC 236

187 NTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVHVESFVPGPPRAQPSSEKQC 236

187 NTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVHVESFVPGPPRAQPSSEKQC 236

187 NTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVHVESFVPGPPRAQPSSEKQC 236

OX NCBI_TaxID=9606;

RN [1]

RP SEQUENCE FROM N.A.

RA Griffiths C.;

RL Submitted (MAY-2001) to the EMBL/GenBank/DBJ databases.

DR EMBL; AL135902; CAC38375.1; -.

DR InterPro; IPR000282; Cytok_receptor_2.

DR InterPro; IPR003961; FN_III.

DR InterPro; IPR001187; Tissue_factor.

DR Pfam; PF01108; Tissue_fac; 1.

DR SMART; SM00060; FN3; 1.

DR Receptor.

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

DR InterPro: IPR000282; Cytok_receptor_2.
DR InterPro: IPR003961; FN_III.
DR SMART: SM00060; FN3; 1.
KW Receptor.
FT NON_TER
SQ SEQUENCE 442 AA; 49877 MW; 839EBE92170609E0 CRC64;

Query Match 10.7%; Score 152.5; DB 13; Length 442;
Best Local Similarity 22.9%; Pred. No. 2.5e-06;
Matches 62; Conservative 39; Mismatches 101; Indels 69; Gaps 12;

QY 2 PKHCFGLFLISFLLTGAGTQSTHESLKPQVQFQSRNFHNLQWPGRALTGNSV-YF 60
DB 224 PIHC-----IKTRKVNLDLCPITNVRFALNMKFYLLMDNHY---NEHVTYT 267
QY 61 VOYKIMFSCSMKSSHQKPSGCWQHISCNFPGCRTLAKYGQROWKNKEDCWGTQELSCDLT 120
DB 268 VOYLTGY--LKNLYDDYSSKWQKVS---GCENIT-----SMKCNLS 303
QY 121 SETSDIQEPYGRVRAASAGSYSEWSMTPTPTPWETKIDPPVMN-----ITQVN 170
DB 304 SVIKPTSASYFRVQAMN-EYNKSCLSK-----DVEVDPPVTNEIGPPDYKVIDSD-- 353
QY 171 GSLVILHAPNLPYRQKEKNVSIEDYELLYRVFTINNSL--EKEQKVEGAHRAVEIE 228
DB 354 ---VLHIKRTPPGPGNKMMS-DLYDFSYQILYWKNSDNEEVKMKETQTATVS 407
QY 229 ALTPHSSYCVVAEIIYQPMIDRRSQSRSEERC 259
DB 408 DLAPSTLYCVKVAQAFSEAYNKSSDFSREECI 438

RESULT 13

Q9BUU4 PRELIMINARY; PRT; 325 AA.

ID Q9BUU4; PRELIMINARY; PRT; 325 AA.
AC Q9BUU4;
DT 01-JUN-2001 (Tremblrel. 17, Created)
DT 01-JUN-2001 (Tremblrel. 17, last sequence update)
DT 01-MAR-2002 (Tremblrel. 20, last annotation update)
DE Similar to interleukin 10 receptor, beta.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=KIDNEY;
RA Strausberg R.;
SUBMITTED (JAN-2001) to the EMBL/GenBank/DBJ databases.
EMBL; BC001903; AAH01903.1; .
DR HSSP; P13726; 1TFH.
DR InterPro: IPR000282; Cytok_receptor_2.
DR InterPro: IPR003961; FN_III.
DR InterPro: IPR001187; Tissue_factor.
DR Pfam; PF01108; Tissue_fac; 1.
DR SMART; SM00060; FN3; 2.
KW Receptor.
SQ SEQUENCE 325 AA; 36995 MW; E470726619AF54C2 CRC64;

Query Match 10.5%; Score 149.5; DB 4; Length 325;
Best Local Similarity 24.1%; Pred. No. 3.4e-06;
Matches 57; Conservative 32; Mismatches 89; Indels 59; Gaps 8;

QY 30 PORVQOSRNFHNLQWPGRALTGNSVYFVQYKIMFSCSMKSSHQKPSGCWQHISC 87
DB 24 PENVPMNSVNFKNILQWESPAFAKGNLTFTAYLSYRIF----- 62
QY 88 NPGCRTLAKYGQROWKNKEDCWGTQELSCDLTSETSDIQEPYGG---RVRAASAGSYS 143
DB 63 -----QDKCMNTLTTCEDFSSLSK-----YGDHTLRYRAFAFDEHS 98
QY 144 EWSMTPPTPWETKIDPPVMNITQVNGSLVILHAPNLPYRQ--KEKNVSIEDYELL 201

DB 99 DW-VNITFCPVDDTIIGPGQVEVLADSLHMRFLAPKIENYEETWTKNV-----YNSWT 153
QY 202 YRVFTINNSLEKEQKYEGAHRAVEIEALTPHSSYCVVAEIIYQPMIDRRSQSRSEERC 258
DB 154 YNVQYWKNGTDEKFTQITPOYDEV-LRNLEPWTTCYQVYRGFLPDNRKAGWSEPPVC 209

RESULT 14

Q8VHM7 PRELIMINARY; PRT; 351 AA.

ID Q8VHM7; PRELIMINARY; PRT; 351 AA.
AC Q8VHM7;
DT 01-MAR-2002 (Tremblrel. 20, Created)
DT 01-MAR-2002 (Tremblrel. 20, last sequence update)
DT 01-JUN-2002 (Tremblrel. 21, last annotation update)
DE Interleukin 10 receptor 2 precursor.
GN IL10R2.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6;
RA Hardy M.P., Hertzog P.J., Owczarek C.M.;
RT "The genomic structure and expression patterns of the gene encoding the second chain of the murine interleukin 10 receptor, IL-10R2."
RL Submitted (OCT-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF440787; AAI40946.1; .
DR InterPro: IPR000282; Cytok_receptor_2.
DR InterPro: IPR003961; FN_III.
DR SMART; SM00060; FN3; 2.
KW Signal; Receptor.
FT SIGNAL
SQ SEQUENCE 351 AA; 40031 MW; 53102D95809AF5D0 CRC64;

Query Match 10.4%; Score 149; DB 11; Length 351;
Best Local Similarity 26.7%; Pred. No. 4.1e-06;
Matches 71; Conservative 30; Mismatches 87; Indels 78; Gaps 13;

QY 8 GFLISFLLTGAGTQSTHESLKPQVQFQSRNFHNLQWPGRALTGNSVYFVQY 63
DB 9 GWLGGFLVLPALGIMP-----PPEKVRMNSVNFKNILQWESPAFAKGNLTFTAYLSYRIF 58
QY 64 KIMFS---CSMKSSHQKPSGCWQHISCNFPGCRTLAKYGQROWKNKEDCWGTQELSCDL 119
DB 59 ESYRSFQDHCKRTASTQ-----CDF---SHLSKYGD----- 86
QY 120 TSETSDIQEPYGRVRAASAGSYSEWSMTPTPTPWETKIDPPVMNITQVNGSLVILHA 179
DB 87 -----YTVRVRAELADEHSEW-VNVTFCPVEDTIIGPEMQIESLAESLHFRSA 135
QY 180 PNLPRYQKE-----KNVSIEDYELLYRV-FIINNSLEKEQKYEGAHRAVEIEALTP 232
DB 136 PQI-----ENPETWTLKNI-----YDSWAYRVQYWKNGTNERFQVV--SPYDSEVLRLNEP 185
QY 233 HSSYCVVAEIIYQPMIDRRSQSRSEERC 258
DB 186 WTTYCIQVQGLLDQNRGTGSEWSEPIC 211

RESULT 15

Q8WTZ2 PRELIMINARY; PRT; 557 AA.

ID Q8WTZ2; PRELIMINARY; PRT; 557 AA.
AC Q8WTZ2;
DT 01-MAR-2002 (Tremblrel. 20, Created)
DT 01-MAR-2002 (Tremblrel. 20, last sequence update)
DT 01-JUN-2002 (Tremblrel. 21, last annotation update)
DE Hypothetical 63.5 kDa protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OX NCBI_TaxID=9606;
RN [1]

